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SUMMARY
Cyclic nucleotide phosphodiesterases catalyse the hydrolysis of 3*5* -
cyclic nucleotides, such as cyclic AMP and cyclic GMP, to produce 5' -  
derivatives. Multiple isozymes of this enzyme exist that differ in their 
substrate specificities, means of regulation and subcellular localisation. 
The soluble phosphodiesterases present in homogenates of both rat liver 
and rat hepatocytes have beed identified and characterised. Using a 
high resolution anion-exchange system (Mono Q) to rapidly separate 
soluble phosphodiesterases, it has been shown that five separate 
activities are present in both of these soluble fractions. On this basis, 
it was concluded that the multiplicity of phosphodiesterase species in 
liver is not due to the presence of multiple cell types in this organ.
These soluble activities were termed PDE M Q -I  to PDE M Q -V  and 
were distinguishable from one another by a number of criteria. These 
included substrate specificity, kinetic properties, sensitivity to 
Ca2+/Calmodulin or cyclic GMP, dependency on magnesium, sensitivity
to a number of reference phosphodiesterase inhibitors, molecular 
weights and chromatographic properties.
A novel phosphodiesterase activity, PDE M Q -I, was found to be 
present in both the soluble fractions of rat liver and hepatocytes. This 
activity was found to be unable to bind to Affi -  gel Blue, was 
markedly insensitive to all of the phosphodiesterase inhibitors tested, 
including the non -  selective inhibitor IBMX, expressed nearly maximal 
cyclic nucleotide hydrolysis in the absence of added magnesium, unlike
the other soluble activities, and formed a substantial proportion of the 
cyclic AMP phosphodiesterase activity in both rat liver and rat 
hepatocyte soluble fractions. It was also observed to be insensitive to 
Ca2+/Calmodulin and to cyclic GMP.
The Ca2+/Calm odulin-stim ulated phosphodiesterase (PDE M Q -II)  was 
shown to be present in both liver and hepatocytes and exhibited a 
marked selectivity for cyclic GMP as substrate. Calmodulin was found
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to stimulate this activity only in the presence of Ca2+, where up to 2.5 
fold stimulation of cyclic GMP and 5 fold stimulation of cyclic AMP 
hydrolysis could be obtained.
The cyclic GMP -  stimulated phosphodiesterase (PDE M Q -III)  was once 
again observed in both liver and hepatocytes. In liver, the cyclic AMP 
hydrolysis of this activity formed the majority of the total cyclic AMP 
phosphodiesterase activity. In hepatocytes, this was not the case, since 
the IBMX insensitive activity was more predominant. At cyclic GMP 
concentrations up to 10 pM. cyclic AMP phosphodiesterase activity was 
stimulated, up to 9 -fo ld , higher concentrations were found to be 
inhibitory.
The cyclic AM P-specific activity present in the rat liver soluble 
fraction was shown to actually consist of two activities, PDE M Q -IV  
and PDE M Q -V . These were shown to be highly selective for cyclic 
AMP as substrate and were insensitive to inhibition by micromolar 
levels of cyclic GMP, but sensitive to inhibition by ICI 63197 and 
Rolipram, which distinguishes them from the cyclic GMP -  inhibited 
cyclic AMP -  specific phosphodiesterases that have been observed in a 
number of tissues, including rat liver. Together these activities formed 
a substantial proportion of the total soluble cyclic AMP 
phosphodiesterase activity in both liver and hepatocytes.
Two membrane bound cyclic AM P-specific phosphodiesterases that are 
stimulated by hormonses such as insulin and glucagon in rat liver and 
hepatocytes are termed the ‘dense—vesicle' and 'peripheral' plasma 
membrane phosphodiesterases. Using specific antisera raised to purified 
preparations of these phosphodiesterases the tissue distribution of 
immunologically related activities was assessed by quantitative 
immunoblotting. A species of molecular weight 6 3 -k D a  corresponding 
to the presumed subunit molecular weight of the native species, was 
identified by the antisera D V -1  (an ti- 'd en se-v esic le ' PDE) in all of 
the rat tissues examined (liver, fat, kidney and heart). In contrast the 
anitsera P M -1  (anti - 'peripheral' PDE) detected a species of 52 -kD a,
2
corresponding to the subunit molecular weight of the purified liver 
enzyme, in all of these tissues. It was observed that there was a 
differential expression of these two phosphodiesterases in these tissues. 
Heart and fat exhibited a predominant expression of the ’dense-vesicle’ 
phosphodiesterase compared to liver. Expression of the
phosphodiesterase activity of this species in tissue homogenates was 
assesssed using the inhibitor ICI 118233. This was shown to be a 
reversible competitive inhibitor of cyclic AMP hydrolysis and was shown 
to be selective for inhibition of the 'dense-vesicle’ phosphodiesterase. 
A similar pattern of distribution of the 'dense-vesicle' PDE was
obtained using this assessment of activity to that obtained by Western
blotting. The ’peripheral' phosphodiesterase showed a different pattern 
of expression to that seen with the 'dense-vesicle ' phosphodiesterase, 
with highest comparative levels observed in liver and the lowest in heart 
and white adipose tissue. The differential tissue expression of the
'peripheral' PDE was not as great as that observed for the 'dense-  
vesicle' phosphodiesterase.
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ABBREVIATIONS.
NOTE: In some instances calmodulin has been spelt as Calmodulin. This 
should not be taken to imply that this represents a trade name.
Amrinone: S - a m in o -S ^ ’-b ip y rid in -b ^ lH J-o n e .
ADP: Adenosine 5’ diphosphate.
A -K inase: cyclic AMP -  dependent protein kinase.
ATP: Adenosine 5’ triphosphate.
Cilostamide (OPC—3689): N — cyclohexyl- N — methyl -  4 -  (1,2 -  
dihydro -  2 -  oxo -  6 -  quinolyloxy) bntyramide.
Cl -  914: 4,5 -  dihydro -  6 -  [4 -  ( I f f  -  imidazol - 1  -  yl)phenyl] -  3(2H ) -  
piyidazinone.
Cl -  930: 4,5 -  dihydro -  6 -  [4 -  (1H-im idazol - 1  -  yl)phenyl] -  5 -  
methyl -  3(2H) -  pryidazinone.
CaM: Calmodulin.
cAMP: 3*5’ cyclic adenosine monophospate. 
cCMP: 3’5’ cyclic cytidine monophosphate.
C G I-PD E : cyclic G M P-inhibited cyclic AMP phosphodiesterase.
cGMP: 3’5’ cyclic guanosine monophosphate.
C G S-PD E: cyclic GMP -  stimulated cyclic nucleotide 
phosphodiesterase.
D E -5 2 : D E A E -52  Cellulose.
DMSO: Dimethysulphoxide.
DPD: Rat brain Drosophila like phosphodiesterase.
DV —1: Antisera raised against the purified rat liver ’dense —vesicle' 
phosphodiesterase.
D V —PDE: 'Dense —vesicle’ high affinity cyclic AMP phosphodiesterase.
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ECTEOLA-cellulose: Epichlorohydrin Triethanolamine cellulose.
EDTA: ethylene diamine tetra acetic acid.
EGTA: ethyleneglycolbis (P -  aminoethylether)-N ,N ,N ’N ’-te tra  ace.tic 
acid.
Fenoximone (Enoximone or MDL 17,043): (1,3 -  dihydro -  4 -  methyl -  
5 -  [4 - methylthio) -  benzoyl] -  2H -  imidazol -  2 -  one.
IBMX: 3 -  isobutyl - 1  -  methylxanthine.
ICI 118233: 6 - [p- ( 3 - methylureido) pheny l]-3[2H]-pyridazinone.
ICI 58,301: 3 -a c e ta m id o -6 -m e th y l-8 -n -p ro p y l- s - t r ia z a lo  [4,3- a ]  
pyrazine.
ICI 63,197: 2 -  amino -  6 -  methyl -  5 -  oxo -  4 -  n -  propyl -  4,5 -  dihydro -  
s-triaza lo  [1,5- a ]  pyrimidine.
ICI 74,917: 6 - n  -  butyl -  2,8 -  dicarboxy -  4,10 -  dioxo -1,4,7,10 -  
tetrahydro -1 ,7  -  phenanthroline.
IIX: 1 -  isoamyl -  3 -  isobutylxanthine.
kDa: Kilodalton
8 -  MeOMIX: 1 -  methyl -  3 -  isobutyl -  8 -  methoxymethylxarithine.
Milrinone: 1,6 -  dihydro -  2 -  methyl -  6 -  oxo -  [3,4’ -  bipyridine] -  5 -  
carbonitrile.
MIX: see IBMX.
MQ: Mono Q.
MY 5445: 1 -  (3 -  Chloroanilo) -  4 -  phenylphthalazine.
NAD: Nicotinamide adenine dinculeotide.
OPC -3911: N -  cyclohexyl -  AT -  (2 -  hydroxyethyl) -  4 -  (6(1,2 -  dihydro -  
2 -  oxoquinolyloxy))butyramide.
OPC -13135: N  -  cyclohexyl—N  -  (2 — hydroxybutyl) -  5 -  (6 -1,2,3,4 -  
tetrahydro -  2 -  oxoquinolyloxy) -  butyramide.
PDE: phosphodiesterase.
PGI2: Prostaglandin I2.
PIA: N 6 -  (phenylisopropyl) -  adenosine.
P M -1 : Antisera raised to purified preparations of the rat liver 
'peripheral plasma membrane phosphodiesterase.
PM -PD E : 'Peripheral' plasma membrane high affinity cyclic A M P - 
specific phosphodiesterase.
RD1, RD2 and RD3: Rat brain phosphodiesterase homologues of 
Drosophila melanogaster dunce encoded phosphdiesterase.
R o - 15-2041: 7 - B r o m o - 1,5-d ih y d ro - 3 ,6 -dim ethyl imadazo [2,1-b ]  
Quinazoline 2(3H )-O ne.
Ro -  20 -1724: 4 -  (3 -  butoxy -  4 -  methoxybenzyl) -  2 -  imidazolidinone. 
Rolipram: 4 -  (3 -  cyclopentyloxy -  4 -  methoxyphenyl) -  2 -  pyrrolidine. 
ROS: Rod outer segment.
R O S-PD E : Rod outer segment phosphodiesterase.
SD: Standard deviation.
SEM Stanard Error of the Mean.
SDS.: Sodium dodecyl sulphate.
SD S-PA G E: Sodium dodecyl sulphate -  polyacrylamide gel 
electrophoresis.
TEMED: N,N,N',N',-tetramethylethylenediamine.
TPA: 12 -  O -  tetradecanoyl phorbol 13 -  acetate.Tris:
Tris: Tris (Hydroxyaminomethan)
W -  7: N -  (4 -  amino -  hexyl) -  5 -  chloronapthalene - 1  -  sulphonamide. 
Zaprinast (M&B 22948): 2 - 0 - propoxyphenyl - 8  -  azapurin- 6  -  one.
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CHAPTER 1.
INTRODUCTION.
INTRODUCTION
1.1: CYCLIC NUCLEOTIDES AS SECOND MESSENGERS.
Cyclic nucleotides, such as 3 '5 '-  cyclic AMP and 3*5* — cyclic 
GMP, are important molecules that are capable of regulating a diverse 
number of biological processes in cells. Cyclic AMP was first identified 
by Earl Sutherland and his co-w orkers while investigating the 
mechanism of action of epinephrine and glucagon in liver glycogen 
breakdown. They identified a heat stable molecule that was produced 
by a liver particulate fraction in response to epinephrine and glucagon. 
This factor could activate phosphorylase when added to the supernatant 
fraction (Rail, et al., 1957). Later work showed that this ’factor' was 
3*5*-cyclic AMP (Sutherland and Rail, 1960). These pioneering studies 
led on to the concept that cyclic AMP can act as a ’second messenger’ 
for a diverse array of peptide and non -  peptide hormones and 
neurotransmitters (for reviews see Pastan, 1972; Birnbaumer, 1990).
Increases in the intracellular concentration of this nucleotide in 
target cells will elicit alterations in the metabolic pathways that control 
the synthesis and degradation of important metabolites such as 
glycogen, glucose, fat and fatty acids. In addition, in some cell types, 
cyclic AMP has been implicated in the mechanism by which cells are 
stimulated to divide. Cyclic AMP thus plays a central role in the 
response of cells to external stimuli (for reviews see Pastan, 1972; 
Schacter, et al., 1988).
In 1969 Hardman and coworkers discovered 3’5’-  cyclic GMP but 
despite intensive research efforts it’s role in biological regulation 
remained elusive for a number of years (Hardman and Sutherland, 1969; 
Hardman, et al., 1971). Recent work has indicated that cyclic GMP 
plays a much more limited and specialised role in cell function than 
cyclic AMP; a role for cyclic GMP having been suggested in retinal
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function, control of vessel tone and in the action of atrial natriuretic 
factor (ANF) (for reviews of cyclic GMP action see Goldberg and 
Haddox, 1977; Tremblay, et al., 1988).
A study of the systems that are responsible for the synthesis and 
degradation of these important molecules is thus central to an 
understanding of how cells respond to such diverse stimuli as hormones, 
neurotransmitters, growth factors and light. The structures of 3*5* 
cyclic AMP and 3'5' cyclic GMP are shown in Figure 1.8.
l- l.lt Synthesis of cyclic AMP: Adenylate cyclase.
Adenylate cyclase catalyses the formation of cyclic AMP from 
ATP at the intracellular face of the plasma membrane. Both genetic 
(Livingstone, et al., 1984) and biochemical (Pfeuffer, et al., 1985; 
Smigel, 1986; Minocherhomjee, et al., 1987) evidence indicates that 
there are multiple forms of this enzyme. The Calmodulin -  sensitive 
and -  insensitive bovine brain enzymes have been purified (Pfeuffer, 
et al., 1985; Smigel, 1986) and cDNA clones isolated (Lipkin, et al., 
1989; Krupinski, et al., 1989).
The activity of adenylate cyclase can be controlled by a wide 
range of different hormones and neurotransmitters including adrenergic 
and purinergic agents and peptide hormones such as glucagon,
adrenocorticotrophic hormone (ACTH) and opiates (for review see 
Birnbaumer, et al., 1990). Such agents can either stimulate or inhibit 
adenylate cyclase so that the system is under dual control (Gilman,
1984; Birnbaumer, et ah, 1990).
Hormonal regulation is achieved by binding to appropriate 
receptors whose actions are mediated by specific guanine nucleotide
regulatory proteins (G -proteins). These are heterotrimers consisting of 
a, p and Y subunits (Northup, et al., 1980; Manning and" Gilman, 1983; 
Hildebrandt, et al., 1984). The individual G -  protein species are 
defined by the type of a -su b u n it (Manning and Gilman, 1983; 
Codina, et al., 1984), since it appears that the p subunits are either
identical or very similar between different G -p ro te in s  (Manning and
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Gilman, 1983). There are at least three Y subunits that have been 
identified, one of which is specific for transducin (YT), the remaining 
tw0> Ya an<3 Y b> appearing to be found in all populations of G -  
proteins (Hildebrandt, et al., 1985; Gierschik, et al., 1985; Evans, 
et al., 1987; Mumby, et al., 1988). The two G -  protein types 
regulating adenylate cyclase are called G s and G i5 which stimulate and 
inhibit adenylate cyclase respectively.
Stimulatory hormones bind to specific receptors located in the 
plasma membrane. Such activated stimulatory receptors interact with 
the guanine nucleotide regulatory protein Gs (in the presence of GTP) 
leading to dissociation of the otpT trimer, producing an activated a s 
subunit (containing bound GTP) and the p? dimer (Kanaho, et al., 
1984; Watkins, et al., 1985; Florio and Sternweis, 1985; Florio and 
Sternweis, 1989). It is believed that the activated a s subunit interacts 
directly with the adenylate cyclase, leading to an increase in the 
production of cyclic AMP (May, et al., 1985). The stimulatory signal is 
turned off by the intrinsic GTPase hydrolytic activity of the a s subunit, 
leading to the production of an a s subunit containing bound GDP. 
This action allows the reassociation of as with the pf dimer and the 
cycle can then be repeated in the presence of hormone.
Inhibitory hormones exert actions through Gi (Hildebrandt, 
et al., 1983), which dissociates upon activation by hormone occupied
receptor to give a* and a pf dimer (Katada, et al., 1984a; Katada,
et al., 1984c). The precise mechanism of Gi action is not understood,
although it may involve an inhibitory effect of pf on stimulatory input 
(Katada, et al., 1984b).
1.1.2: Synthesis of cyclic GMP: Guanylate cyclase.
Guanylate cyclase catalyses the formation of cyclic GMP from 
GTP (Hardman and Sutherland, 1969; Hardman, et al., 1971). Several
forms of the enzyme exist in both the soluble and particulate fractions 
of most mammalian cells (Hardman and Sutherland, 1969; Schultz, 
et al., 1969; White, et al., 1969). Cellular guanylate cyclase activity can
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be regulated by a number of different mechanisms. Which factors are 
operative depends on the particular cell type in question. The
particulate derived forms are glycoproteins and in some cells appear to
be regulated by extracellular peptides such as sperm stimulating 
peptides, e.g. resact and speract, and also by atrial natriuretic peptides 
(ANP) (Leitman, et al., 1988) and heat stable enterotoxins (STa) from 
E.Coli. (Garbers, 1989). The atrial natriuretic peptides are of particular 
interest, since their effects include vasodilation, natriuresis, and diuresis
(Inagami, 1989). Cloning and transfection studies have indicated that 
the cellular receptor for ANP and guanylate cyclase activity reside in 
the same polypeptide (Chinkers, et al., 1989) in contrast to the 
adenylate cyclase system where the cyclase and receptors are distinct
entities.
The soluble haem containing form, on the other hand, does not 
appear to be regulated by peptides, but can be stimulated by 
nitrovasodilators (Bohme, et al., 1984), unsaturated fatty acid oxidation 
products and free radicals (White, et al., 1982). The physiological
significance of this mechanism of regulation is far from clear, but it is 
likely that the enzyme serves as a substrate for endothelial cell-derived  
relaxing factor (EDRF) (Furchgott and Zawadzky, 1980), a substance 
believed by various investigators to be nitric oxide (Garbers, 1979).
Guanylate cyclase activity is present in most mammalian cells with high
activities found in platelets, lung, brain, and liver (Tremblay, et al.,
1988).
1.1.3: The role of cyclic AMP and cyclic GMP.
The role of cyclic AMP appears to be almost ubiquitous in that 
it can serve as a 'second messenger* for a wide variety of hormones and 
neurotransmitters that control the metabolic activity of cells. It's 
actions are mediated by stimulating the activity of a specific protein 
kinase, the cyclic AMP -  dependent protein kinase (A -K inase), leading 
to the phosphorylation (and consequent activation/inactivation) of a 
number of target enzymes, the precise nature of which will depend on
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the target cell in question (Woodgett and Cohen, 1984; Belfrage, et al., 
1984; Schacter, et al., 1988).
Cyclic AMP -  dependent protein kinase exists as a heterodimer 
consisting of two regulatory subunits and two catalytic subunits (R2C2) 
(for review see Taylor, 1989). The mammalian cyclic A M P-dependent 
protein kinase exists in two main isozymic forms (I and II), whose 
regulatory subunits (RI and RII) are disimilar. These species are found 
in most mammalian cells (Corbin, et al., 1975). Like most protein 
kinases, it is tightly regulated and is maintained in an inactive form 
under basal conditions (sub -  activatoiy concentrations of cyclic AMP). 
However, unlike other protein kinases, cyclic AMP binding to a distinct 
regulatory subunit (R) induces comformational changes that lead to 
dissociation of the holo-enzym e and it’s subsequent activation.
The active, dissociated catalytic subunit (C) can phosphorylate 
and thus regulate the activity of a wide variety of target proteins
(Schacter, et al., 1988). These include key enzymes involved in 
intermediary metabolism such as glycogen phosphorylase kinase (Cohen, 
1982), glycogen synthetase (Woodgett and Cohen, 1984) and 
hormone -  sensitive lipase (Belfrage, et al., 1984). This is presumed to
be the mechanism by which hormones such as glucagon, p -  adrenergic 
agonists and adrenocorticotrophic hormone (ACTH) exert their major 
effects on target cells.
Recent evidence has indicated that the cyclic AMP.R2C2 
complex may also mediate biological effects. This is because it has
been shown to act as a potent inhibitor of ATP -  Mg(II) -  dependent 
phosphoprotein phosphatase, the major phosphorylase phosphatase in 
rabbit muscle (Jurgensen, et al., 1985; Khatara, et al., 1985).
Cyclic GMP, on the other hand, appears to have a number of 
possible roles. However, many of these are ill defined. For example, 
in mammalian smooth muscle, cyclic GMP is considered to be an 
important regulator of vascular muscle tone (Ignarro and Kadowitz,
1985). Several smooth muscle relaxants including nitrogen -  oxide
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vasodilators, endothelial cell-derived  relaxing factor, and atrial 
natriuretic peptides, stimulate cyclic GMP production in vascular 
smooth muscle (Schultz, et al., 1977; Rapoport and Murad, 1983; 
Hamet, et al., 1984b). In the mammalian retina, cyclic GMP plays a 
pivotal role in the transduction of the light signal by altering the 
conductivity of sodium ion channels in the plasma membrane of rod 
outer segments (Fesenko, et al., 1985).
There are a number of cyclic GMP -  binding proteins in cells 
including a protein kinase, termed cyclic GMP -  dependent protein
kinase. This kinase has some sequence homology with the cyclic
AMP -  dependent protein kinase but has regulatory and catalytic 
domains as part of a contiguous polypeptide chain (Takio, et al., 1984). 
It’s functional significance remains however to be ascertained. Other 
cyclic G M P-binding proteins include cyclic GMP -  stimulated
phosphodiesterases. These are found in many cells including bovine 
adrenals and liver (Martins, et al., 1982; Yamamoto, et al., 1983a). 
There is also a cyclic G M P-binding phosphodiesterase which has been 
identified in platelets and lung (Hamet and Coquil, 1978; Francis,
et al., 1980).
The precise mechanism of action of cyclic GMP in eliciting 
responses in cells is thus unclear. However, the discovery of cyclic
G M P-binding proteins other than the cyclic GMP -  dependent protein 
kinase suggests that this cyclic nucleotide does not always act through a' 
phosphorylation mechanism (see for example, Hartzell and Fischmeister 
1986).
1.2: THE PHOSPHODIESTERASE ENZYME SYSTEM.
The initiation of an intracellular signal, such as the production 
of cyclic AMP, initiates a cascade of events that eventually leads to the 
covalent modification of a number of target enzymes and hence the 
cellular response. The process of signal generation is not, however, a 
unidirectional process. Once cyclic nucleotide levels have been raised in
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the cell it is necessary to terminate their action. In addition to 
desensitisation of the nucleotide cyclase system, in particular the 
adenylate cyclase system, this can be achieved by two general 
mechanisms, namely the extrusion of the cyclic nucleotide from the cell 
or the degradation of the cyclic nucleotide. Whilst, in principle, both 
of these mechanisms may be operative, it seems likely that extrusion 
only contributes about 20% to the cyclic AMP disposal observed in 
most cells (Plagemann and Erbe, 1977; Brunton and Mayer, 1979). 
However, higher levels of extrusion of cyclic GMP have been noted in 
liver slices (Tjornhammer, et al., 1983).
Degradation of cyclic nucleotides is achieved in the cell by the 
action of the cyclic nucleotide phosphodiesterase (PDE) enzyme system. 
This catalyses the hydrolysis of the 3*5' phosphodiester bond of cyclic 
nucleotides to produce 5*-A M P  derivatives (see Figure 1.1) (Butcher 
and Sutherland, 1962). Cyclic nucleotide phosphodiesterases have been 
observed in all mammalian tissues examined to date (Beavo, 1988) as 
well as in a number of non -  mammalian systems such as the yeast 
Saccharomyces cerevisiae (Sass, et al., 1986), Dictyostelium discoideum 
(Orlow, et al., 1981; Lacombe, et al., 1986), Mucor rouxii (Galvagano, 
et al., 1979) and the fruit fly Drosophila melanogaster (Davis and 
Kauvar, 1984).
1.2.1: Multiple forms of phosphodiesterase.
Phosphodiesterases exist in multiple forms (Beavo, et al., 1970; 
Thompson and Appleman, 1971; Uzunov and Weiss, 1972; Russell, 
et al., 1973; Bergstrand and Lundquist, et al., 1976; Beavo, et al., 
1982; Beavo, 1988). These differ in their physical properties, and 
distribution between soluble and particulate cell fractions. They also 
have distinct substrate specificities, kinetic characteristics, sensitivity to 
proteolysis and in some instances can be regulated by physiologically 
important molecules such as calcium, Calmodulin, cyclic GMP, 
hormones and the G -p ro te in  Transducin (Beavo, et al., 1982; Manning 
and Gilman, 1983; Yamamoto, et al., 1983a; Yamamoto, et al., 1984a;
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Manganiello, et al., 1984; Houslay, 1986; Sharma and Wang, 1986c 
Pyne, et al., 1987a).
It has been demonstrated by immunological (Mumby, et al.,
1982; Hurwitz, 1984b), pepide mapping (Takemoto, et al., 1982; Pyne 
et al., 1987a ) and molecular cloning (Charbonneau, et al., 1986; Chen, 
et al., 1986; Podgorski, et al., 1986; Sass, et al., 1986; Lacombe, 
et al., 1986; Colicelli, et al., 1989; Davis, et al., 1989; Swinnnen, 
et al., 1989; Henkel -T igges and Davis, 1990) studies that distinct 
isoforms exist and that they are, for the most part, distinct n o n -
interconvertible enzymes (Erneux, et al., 1980; Keravis, et al., 1980; 
Hurwitz, et al., 1984a).
The reaction catalysed by cyclic nucleotide phosphodiesterase
involves the breaking of a high energy phosphodiester bond in a metal 
ion -  dependent hydrolytic process. For most enzymes, the preferred 
metal cofactors are divalent cations such as Mg2+ or Mn2+, although 
other metals, such as Co2+, Ni2+, and Zn2+, can support lower
activity; Ca2+, by itself, is virtually ineffective.
It has been suggested that there are four major classes of
phosphodiesterase with different specificities for cyclic AMP and cyclic 
GMP and different allosteric regulators. Type I phosphodiesterases are 
stimulated by Ca2+ plus Calmodulin and in general have a higher
affinity for cyclic GMP than cyclic AMP (Kincaid, et al., 1984). Type 
II phosphodiesterases likewise, have a higher affinity for cyclic GMP
than for cyclic AMP but the activity toward cyclic AMP is markedly
stimulated by low (micromolar) concentrations of cyclic GMP 
(Yamamoto, et al., 1983a; Pyne et al., 1986a). Type III 
phosphodiesterases have a higher affinity for cyclic AMP than cyclic 
GMP and their activity is increased in certain cells by' hormones e.g. 
isoproteronol, glucagon, and insulin (Heyworth, et al., 1983d; 
Marchmont and Houslay, 1980b; Loten and Sneyd, 1970; Loten, et al.,
1978). Type IV phosphodiesterases are cyclic G M P-specific enzymes, 
which also have an allosteric binding site for cyclic GMP. An example
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of this class of enzyme is the one from retinal rod outer segments, 
which is activated by light via rhodopsin and the guanine nucleotide 
binding protein Transducin (Baehr, et al., 1979).
1.3: Ca2+/CALMODULIN -  STIMULATED CYCLIC NUCLEOTIDE
PHOSPHODIESTERASES.
This is found in several mammalian tissues including bovine 
heart (Hansen and Beavo, 1982; Ho, et al., 1977), bovine brain 
(Sharma, et a l ,  1980; Sharma, et al., 1984; Kincaid, et al., 1984), rat 
liver (Strewler, et al., 1983), rat pancreas (Vandermeers, et al., 1983), 
dog thyroid (Erneux, et al., 1985b), rat testis (Purvis, et al., 1981), and 
bovine lung (Sharma and Wang, 1986b). The enzyme activity is also 
found in non-m am m alian sources, for example in Neurospora Crassa 
(Tellez -  Inon, et al., 1985).
The Ca2+/C alm odulin- stimulated phosphodiesterase is an 
enzyme of relatively low abundance. Mammalian brain is the richest 
source of the enzyme, at a level of about lOmg/kg (Sharma, et al.,
1980). Mammalian heart, although the second most abundant source of 
the enzyme, contains only 10 -  20% of the levels found in brain 
(LaPorte, et al., 1979).
1.3.1: Ca2+/Calm odulin-stim ulated phosphodiesterase isozymes.
Originally, it was thought that this was an enzyme of 
approximately 60 -kD a  subunit molecular weight, which appeared to 
exist as a homodimer in the native state (Morril, et al., 1979; LaPorte, 
et al., 1979). More recent work using improved separation procedures 
has shown that multiple forms exist, both in single tissues and between 
species.
Using rapid, immuno -  affinity chromatography techniques 
(A C A P-1 monoclonal antibody) to purify the Ca2+/Calm odulin-  
stimulated phosphodiesterase from different bovine tissues (brain and 
heart), Hansen and Beavo showed that the two enzymes isolated
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differed by approximately 2 -k D a  in apparent molecular weight, 
suggesting the occurence of tissue specific forms (Hansen and Beavo, 
1982). Kincaid and co-w orkers were, however, the first to provide 
evidence for the presence of distinct isozymes in a single source. They 
identified and purified a 5 9 -k D a  species from both bovine and ovine 
brain tissue that had an isoelectric point (pi) of 5.6 and also identified 
the presence of a fraction that had a lower p i of about 5.45.
Additionally, the purified bovine and ovine 5 9 -k D a  enzymes yielded 
different a -  chymotryptic peptide -  maps, indicating that these proteins 
differed in primary sequence (Kincaid, et al., 1984).
Similar studies by Sharma and co-w orkers, also using 
monoclonal antibodies (A6, C l and A2), showed the presence of two 
distinct isozymes in bovine brain of subunit molecular weight 6 0 -k D a  
and 6 3 -k D a  (Sharma, et al., 1984). Peptide mapping of the two 
subunits, by partial proteolysis, demonstrated that the 6 0 -k D a  species 
was not derived from the 6 3 -k D a  species. Further to this, it was 
shown that the PDE could exist in several forms (a) a homodimer of 
60 -kD a (b) a heterodimer of 6 0 -k D a  and 6 3 -k D a  and (c) a
homodimer of 63-kD a. In bovine brain, the homodimers were the 
major forms encountered (Sharma, et al., 1984).
An unusual form of the enzyme exists in bovine and rabbit lung 
that appears to contain Calmodulin as an integral subunit. This is 
analagous to the way that Calmodulin exists as the 6 -subun it of 
phosphorylase kinase (Cohen, et al., 1978; Sharma and Wang, 1986b; 
Sharma and Wirch, 1979). The bovine lung enzyme is a dimeric protein 
of subunit molecular weight 5 8 -k D a  containing, in addition, two 
molecules of Calmodulin. The Calmodulin moiety cannot be 
dissociated from the phosphodiesterase, even in the presence of very 
low calcium concentrations. The enzyme is stimulated directly by
calcium, indicating that binding of Calmodulin per se, is not sufficient 
to cause stimulation of the enzyme. The enzyme shows immunological 
cross reactivity with the bovine brain 6 0 -k D a  form based on it’s ability
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to bind to an immuno -  affinity column (Cl monoclonal antibody) 
(Sharma and Wang, 1986b).
In addition, forms of the enzyme with higher subunit molecular 
weights have been reported in male mouse germ cells (Geremia, et al., 
1984), bovine brain (Shenolikar, et al., 1985) and mouse testis (Rossi, 
et al., 1988). Identification of these individual forms has, however, 
relied upon extensive purification away from other contaminating 
activities. In a few instances multiple forms of the Ca2+/C alm odulin- 
stimulated phosphodiesterase have been identified by simple ion -  
exchange chromatography. Using this procedure, multiple Calmodulin -
stimulated forms were resolved in immature rat testis whilst two forms 
could be identified in rat pancreas (Purvis, et al., 1981; Vandermeers, 
et al., 1983). The properties of the individual isozyme forms purified
to date are summarised in Table 1.1.
1.3.2: Kinetics of cyclic nucleotide hydrolysis by Ca2+/Calmodulin -
stimulated phosphodiesterase isozymes.
The kinetic properties of the Ca2+/C alm odulin- stimulated 
phosphodiesterases from a variety of tissues and species have been 
studied in a number of laboratories. Early reports on the kinetic 
characteristics of these isozymes showed a marked variation in and 
Vmax values between different studies. For example, the values 
for both cyclic AMP and cyclic GMP varied over two orders of 
magnitude among early reports. It has been suggested that such 
variation can be attributed to a number of factors: (a) The enzyme
preparations were of different purity and may have been contaminated 
with different amounts of other phosphodiesterases, (b) Different assay 
conditions were used; agents such as imadazole or ammonium ions have 
been shown to increase the activity of the Calmodulin -  stimulated
bovine brain enzyme (Ho, et al., 1976; Nair, 1966; - Cheung, 1967;
Sakai, et al., 1977). Other cations such as potassium are inhibitory 
(Davis and Daly, 1978). (c) It was not known that different isozymes
of the Ca2+/Calmodulin -  stimulated phosphodiesterase existed.
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Kinetic characteristics of both highly purified isozymes and 
homogeneous preparations have now been obtained by a number of 
groups (Ho, et al., 1976; Sharma and Wang, 1986a; Sharma and Wang, 
1986b; Hansen and Beavo, 1986; Reeves, et al., 1987; Purvis, et al.,
1981). The basic kinetic characteristics are summarised in Table 1.2. 
On the basis of kinetic criteria, the Ca2+/C alm odulin- stimulated 
phosphodiesterase isozymes may be divided into two general groups: a
group showing high affinity for cyclic GMP but low affinity for cyclic 
AMP, and a group showing high affinity for both cyclic nucleotides. 
The first group possess values for cyclic GMP and cyclic AMP in 
the ranges 5 -  20pM and 70 -2 0 0 jiM respectively, whilst the latter group 
show similar K™ values for both cyclic nucleotides in the range 1 -  
2pM. All the well characterised bovine brain and heart isozymes belong 
to the first group although, they represent different isoenzymic forms. 
Also included in this group are the purified enzymes from bovine lung 
and coronary artery and the partially purified enzymes from porcine
brain and coronary artery and one form of the rat testis enzyme. In
the second group of isozymes is the Peak I Calmodulin -  stimulated rat 
testis PDE (identified from anion -  exchange profiles of tissue extracts) 
and the testis -  specific Calmodulin -  stimulated phosphodiesterase 
purified from mouse testis.
Within each of these general groups is the potential for sub -  
groups. The four well defined bovine isozymes, all belonging to the 
first group, appear to be separable into two subgroups on the basis of 
their affinities for cyclic AMP and cyclic GMP. The 6 0 -k D a  brain,
heart and lung isozymes show almost identical kinetic properties, while
the 6 3 -k D a  brain isoenzyme has a higher Vmax for cyclic GMP than 
for cyclic AMP.
In almost all instances Calmodulin increases both the affinity 
(decrease in K*,) and the Vmax of the enzyme toward both cyclic 
nucleotides, although effects on the Vmax component alone have been 
observed. The reported fold stimulation of cyclic nucleotide hydrolysis 
in the presence of saturating levels of Calmodulin varies considerably
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but it is not known if this is an intrinsic property of the individual 
isozymes or is a consequence of different procedures used to 
isolate/purify the enzymes. It has been shown that limited proteolysis 
can reduce the extent of Ca2+/Calmodulin stimulation as a result of 
an increase in the basal enzyme activity (Tucker, et al., 1981; Kincaid, 
et al., 1985). This may partly explain the different fold stimulations 
observed in partially purified preparations but not that of purified 
preparations where the subunit molecular weight can be easily assessed.
On the basis of observations made on purified preparations of 
bovine brain phosphodiesterase, Kincaid and his co-w orkers have 
proposed a model to explain the different fold stimulations observed. 
They observed that different procedures used to isolate the enzyme 
from bovine brain produced preparations which, although they exhibited 
identical subunit size, specific activity and K^ for cyclic GMP, differed 
in the extent of stimulation by saturating levels of Ca2+/Calmodulin 
(Kincaid, et al., 1981b).
These highly purified preparations displayed a progressive loss in 
the degree of Calmodulin stimulation with an increase in basal activity. 
This loss of Ca2+/Calmodulin responsiveness did not correlate with any 
detectable proteolytic degradation of the enzyme. There was however, 
an increase in the proportion of the phosphodiesterase that existed as a 
6 0 -k D a  monomeric species and a decrease in the proportion that 
existed in the dimeric state. They also observed that the enzyme
present in freshly prepared supernatants consistently behaved as a 
monomer, but on storage could be converted to a dimer. This
conversion correlated with an increase in the extent of
Ca2+/Calmodulin stimulation. Based on these observations, it was 
proposed that the phosphodiesterase exists as .interconvertible 
monomeric and oligomeric species and that these are activated to
different extents by Ca2+/Calmodulin (Kincaid, et al., 1981b).
Using radiation inactivation to assess the subunit structure of 
the enzyme under basal and Ca2+/Calmodulin stimulated conditions,
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Kincaid and coworkers showed that the basal activity decayed with an 
apparent target size of 60-kD a, whilst the stimulated activity decayed 
with an apparent target size of 105-kD a , giving support to their other 
observations (Kincaid, et al., 1981a). The degree of activation of a 
particular preparation of the enzyme will thus depend on the relative
proportion of the two forms of the enzyme.
1.3.3: Mechanism of Calmodulin activation.
The affinity of the the bovine brain 61-k D a  and 6 3 -k D a  forms 
for Calmodulin is about InM, whilst the affinity constant for the 
bovine heart form is about 10 fold lower at O.lnM (Hansen and Beavo,
1986). Calmodulin activates the enzyme in the presence of calcium,
presumably by binding to a domain on the enzyme, and this has been 
demonstrated with purified components, indicating that the activation is 
a direct action rather than indirect (LaPorte, et al., 1979; Hansen and 
Beavo, 1982; Hansen and Beavo, 1986).
Calmodulin contains four Ca2+ binding sites which are
characteristic of the 'EF hand' structure. These sites are designated as 
I, II, III and IV in order of their location from the N -term inus. The 
crystal structure of a mammmalian Calmodulin in it’s Ca2+ bound 
state has been determined (Babu, et al., 1985). The crystalline 
Calmodulin assumes a ’dumbbell’ shape, with each lobe of the dumbbell 
containing a pair of ’EF hand' Ca2+ binding sites. The two lobes are 
connected by a long central helix and do not show any interactions. 
However, the two Ca2+ binding sites within each lobe appear to 
interact through hydrogen bonds. There appear to be two classes of 
Calmodulin binding sites with affinities differing by more than an order 
of magnitude (Seaman, 1980; Suko, et al., 1986), which corresponds 
with the existence of the two lobes. Sites III and IV, at the C -  
terminal lobe, are the high affinity sites, whilst sites I and II, at the 
N -term inal lobe, are the low affinity sites.
Calcium binding takes place in two distinct stages. At low levels 
of Ca2+ sites III and IV are occupied whilst at higher levels, sites I
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and II become occupied (Forsen, et al., 1986) The binding of Ca2+ to 
Calmodulin is a highly cooperative process within each lobe, with no 
co -  operativity between lobes, and this may allow for a very selective 
on/off switch to activate/deactivate phosphodiesterase over a very 
narrow range of Ca2+ concentrations.
The binding of calcium to Calmodulin appears to cause a 
conformational change since it becomes more resistant to proteoytic 
cleavage (Ho, et al., 1976; Liu and Cheung, 1976) and appears to be 
more susceptible to chemical modification (Wolff, et al., 1977). 
LaPorte, et al., (1980), used a number of fluorescent probes capable of
sensing exposure of hydrophobic binding sites on proteins, to show that 
binding of Ca2+ to Calmodulin results in the exposure of a domain 
with considerable hydrophobic character. Further to this, binding of
hydrophobic ligands to this domain antagonised Calmodulin -  protein 
interactions. These workers proposed that this hydrophobic domain 
may serve as the interface for the Ca2+ -dependent binding of 
Calmodulin to target proteins including the Ca2+/C alm odulin- 
stimulated phosphodiesterase (LaPorte, et al., 1980).
The binding of bovine heart and brain phosphodiesterases to 
Calmodulin in the presence of calcium may also cause a 'second'
conformational change in the Calmodulin molecule. Hansen and Beavo, 
(1986) raised a monoclonal antibody (A C C -1) directed against an
epitope on the carboxyl terminal of bovine Calmodulin. They showed 
that the ability of this antibody to bind to Calmodulin was greatly 
enhanced in the presence of bovine heart phosphodiesterase. However, 
the antibody reacted poorly with Calmodulin that was bound to heart 
or brain Calcineurin, skeletal muscle myosin light chain kinase or other 
Calmodulin binding proteins (Hansen and Beavo, -1986). This 
differential antibody reactivity toward Calmodulin -  enzyme complexes 
was taken to indicate that target proteins either induce very different 
conformations in Calmodulin and/or interact with different geometries 
relative to the antibody binding site.
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Calmodulin and Ca2+ show synergistic interactions in the 
activation of phosphodiesterase, so an increase in Calmodulin or Ca2+ 
concentration results in an increase in the apparent enzyme affinity 
towards Ca2+ or Calmodulin respectively (Brostrom and Wolff, 1974). 
The implication of this is, depending on the levels of Calmodulin, the 
Ca2+ concentrations needed for the activation of phosphodiesterase in 
different tissues may be quite different.
It has been proposed that at normal cellular Ca2+ 
concentrations phosphodiesterase and Calmodulin do not form a 
complex (Huang, et al., 1981; Cox, et al., 1981). Detailed kinetic 
studies of the purified bovine brain enzyme have indicated that four 
Ca2+ ions are required to bind to one Calmodulin molecule before 
activation can occur.
An alternative model has, however, been suggested by a number 
of workers (Blumenthal and Stull, 1980; Keller, et al., 1982; Greenlee, 
et al., 1982). In this model, Calmodulin can bind to target enzymes in 
the absence of calcium, albeit weakly, and with succesive binding of 
Ca2+ to Calmodulin, the affinity of Calmodulin toward the enzyme is 
increased. Steady state kinetic analysis of the activation of 
phosphodiesterase by Ca2+ and Calmodulin showed that the activation 
of the enzyme requires the binding of at least three and probably four 
Ca2+ ions to Calmodulin. Using crosslinking of I 125-labelled  
Calmodulin to a highly purified bovine heart enzyme, LaPorte, et al., 
(1979) were able to show that the stoichiometry of the PDE:Calmodulin 
complex to be PDE2Calmodulin2, i.e. one Calmodulin molecule per 
PDE chain. The molecular weight of the PDE:Calmodulin complex 
calculated from sedimentation and Stokes radius data has been shown 
to be consistent with this stoichiometry (Sharma, et al., 1980), although 
this has not been rigorously tested for all isozymes.
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1.3.4: Effect of proteolysis on the Ca2+/Calm odulin-stim ulated
phosphodiesterase.
The enzyme isolated from a number of sources is subject to
proteolysis. This has been observed in both crude and purified
preparations (Cheung, 1971; Tucker, et al., 1981; Kincaid, et al., 1985). 
For example, proteolysis of a bovine brain preparation of the
Calmodulin -  stimulated PDE (6 3 -k D a subunit containing isozyme)
decreased the fold stimulation of the phosphodiesterase activity in the 
presence of Ca2+/Calmodulin from a value of 80, to a value of 1. 
This correlated with an increase in the basal activity to a value equal 
to, but not exceeding, that obtained with saturating Ca2+/Calmodulin. 
This effect also correlated with a decrease in the molecular weight of
the subunit to a molecular weight of 43 -kD a. Preparations
demonstrating intermediate fold activations displayed a fragment pattern
with predominant polypeptides at 57 -kD a, 52-kD a, 4 7 -k D a , and 
42-kD a. Proteolysis with trypsin could mimic these effects producing 
a fragment of molecular weight 4 0 -k D a  (Tucker et al., 1981).
Chymotrypsin treatment of a purified preparation of the bovine 
brain form of the enzyme also had similar effects to those observed
with trypsin (Kincaid, et al., 1985). Proteolysis of the enzyme had a 
similar effect on the kinetic parameters to that of saturating
Ca2+/Calmodulin, namely, an increase in the Vmax f°r cyclic GMP 
hydrolysis with a marginal increase in the affinity (decrease in K^) for
cyclic GMP. They also observed protection toward chymotryptic
digestion in the presence of calcium and Calmodulin.
On the basis of these observations, Kincaid and co-w orkers 
have proposed a model for the structure of the Calmodulin -  stimulated 
phosphodiesterase in bovine brain. The hypothesis is that the enzyme 
can exist either in an activated or inactivated state. Each state is a
manifestation of different interactions between three structural domains 
of the enzyme: the catalytic, inhibitory and Calmodulin binding
domains. Under basal conditions, the inhibitory and catalytic domains
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undergo strong interactions, suggested to result in a low enzyme 
activity. However, the various activated forms of the enzyme result 
from a weakening or disruption of this interaction. The stimulation of 
the enzyme can thus be envisaged to involve a comformational change; 
binding of Ca2+/Calmodulin resulting in the disruption of the 
interaction between the inhibitory and catalytic domains (Kincaid,
et al., 1985).
The relationship between the Calmodulin -  binding domain and 
the inhibitory domain is unclear, but the simplest model is for 
Calmodulin to compete with the catalytic domain for binding to the 
inhibitoiy domain. In this case, the Calmodulin -  binding and inhibitory 
domains are believed to be the same or closely proximal. The 
inhibitory domain can be removed or damaged by protease action, thus 
relieving the inhibition of the catalytic activity (see Figure 1.2 for a 
diagrammatic representation). However, other workers have not
observed Ca2+/Calm odulin-dependent protection of the rat liver
enzyme from chymotrypsin-mediated activation. This model may, 
therefore, only hold true for certain forms of the enzyme (Tucker, 
et al., 1981; Moss, et al., 1978). Furthermore, it is not known whether 
the action of proteases has any significance with respect to regulation 
of the activity.
Because of the large size and unknown three-dim ensional 
structure of Calmodulin -  regulated enzymes, the precise site(s) of
interaction of Calmodulin with phosphodiesterase isozymes is at present 
unknown. One approach that has been taken in identifying potential 
Calmodulin binding sites in a Calm odulin-regulated enzyme has been 
to assess the ability of peptides (both synthetic and natural) to bind to 
Calmodulin and to compete with target enzymes for such binding (for 
review see Erickson -  Viitanen and DeGrado, 1987). ' It has been
suggested that this approach may identify sequences in proteins that 
can serve in Calmodulin binding.
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Peptides such as mellitin were found to bind to Calmodulin in a 
1:1 complex with affinities approaching those for many target enzymes 
(KD = lnM) (Comte, et al., 1983; Malencick and Anderson, 1983). 
Mellitin has been shown to possess an amphiphilic a -h e lix , a structure 
in which the hydrophobic residues are segregated from the hydrophilic 
residues along the helix, such that there results a hydrophobic patch on 
one face of the helix (Terwilliger and Eisenberg, 1982). Since 
Calmodulin also contains a hydrophobic sequence (LaPorte, et al., 
1980), it has been proposed that mellitin and other peptides bind to 
this region of Calmodulin in an amphiphilic a -h e lica l conformation 
(Erickson -  Viitanen and Degrado, 1987). In addition to the important 
role played by hydrophobic interactions, a portion of the binding 
interaction appears to derive from electrostatic interactions, as all tight 
binding peptides carry net positive charges, whereas Calmodulin is an 
acidic (negatively charged) protein.
13.5: Methods of regulation of the Ca2+/Calm odulin-stim ulated
phosphodiesterase.
In most tissues the amount of Calmodulin is in excess of the 
quantity of phosphodiesterase (Klee and Vanaman, 1982; Hansen and 
Beavo, 1986), such that the limiting factor for stimulation is the 
concentration of free calcium. The cytosolic concentrations of 
Calmodulin in heart and brain, have been estimated to be about 1.6pM 
and 22jiM respectively. Thus, it would appear that a direct regulation 
of the enzyme activity by intracellular calcium is the most likely 
method of regulation. Further evidence for such a postulate is:
(i) Stimulation of phosphodiestrase requires micromolar calcium 
concentrations that are close to physiological concentrations of 
this divalent cation (Exton, 1988).
(ii) Intracellular calcium fluctuates in response to a wide variety 
of stimuli such as vasopressin in the liver (Combettes, et al.,
1986).
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(iii) the response of the phosphodiesterase to calcium and
Calmodulin is rapid and comparable with the rapid hydrolysis of 
cyclic AMP in response to certain stimuli (Kakiuchi and Rail, 
1968)
In addition to regulation by Calmodulin, some forms of the 
enzyme can also be regulated by phosphorylation. Using in vitro 
phosphorylation, Sharma and Wang (1985) have demonstrated that the 
bovine brain 6 0 -k D a  subunit is a substrate for cyclic AMP -  dependent 
protein kinase with a maximal incorporation of 2 moles of phosphate 
per mole of subunit. This phosphorylation was accompanied by a 
2,000% decrease in the affinity of this subunit towards Calmodulin 
(Sharma and Wang, 1985; Sharma and Wang, 1986c). In contrast, 
purified 6 3 -k D a  subunit -  containing isozyme was found to be 
phosphoryiated in a Ca2+ and Calmodulin -  dependent manner, 
presumably by a Ca2+/Calmodulin dependent protein kinase (Sharma 
and Wang, 1986a; Sharma and Wang, 1986c). Phosphorylation resulted 
in the incorporation of 2 moles of phosphate per mole of subunit. 
This also led to a decrease in the affinity of the enzyme towards 
Calmodulin. The decrease observed was much smaller than that noted 
for the 6 0 -k D a  subunit (about 50%) and was also accompanied by a
small decrease in the EC50 for calcium stimulation of the enzyme 
(l.ljiM  for phosphoryiated compared to 1.9pM for n o n -  
phosphorylated). Hashimoto and co-w orkers have recently extended 
these observations on the 6 3 -k D a  subunit of phosphodiesterase and 
shown that it has a regulatory phosphorylation site(s) that is 
phosphoryiated by the auto -  phosphoryiated form of 
Ca2+/Calm odulin-dependent protein kinase II. This phosphorylation 
can be blocked by Ca2+/Calmodulin binding to the subunit 
(Hashimoto, et al., 1989).
The two phosphoryiated species could be dephosphorylated by
the calcineurin, the Ca2+/Calm odulin-dependent phosphatase (Sharma
and Wang, 1985; Sharma and Wang, 1986a). Dephosphorylation of the 
6 0 -k D a  subunit increased the enzyme’s affinity for Calmodulin (Sharma
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and Wang, 1985) reversing the effect of phosphorylation. The effect of 
dephosphorylation of the 63 -  kDa subunit was not assessed however. 
These phosphorylation reactions have not been shown to occur in vivo. 
The data supports the notion that the isozymes are distinct species and 
may play different roles in controlling the levels of cyclic AMP and 
cyclic GMP in the brain.
13.6: Role of the Ca2+/C alm odulin- stimulated phosphodiesterase.
The role of the enzyme in controlling cyclic nucleotide levels 
has been investigated in a number of tissues and cells including, 
astrocytoma cells (Evans, et al., 1984; Tanner, et al., 1986) and thyroid 
tissue (Dumont, et al., 1984; Emeux, et al., 1985b). In human 
astrocytoma cells, the decrease in cyclic AMP levels seen in response to 
muscarinic stimulation is thought to be due to Ca2+-dependent 
increases in phosphodiesterase activity (Evans, et al., 1984). It was 
presumed by these workers that the phosphodiesterase responsible was 
one of the Ca2+/C alm odulin- stimulated isozymes and that the 
increased intracellular calcium was stimulating this enzyme (Evans et al., 
1984). Some evidence to support this notion was obtained by the use 
of specific Ca2+/Calm odulin-dependent phosphodiesterase inhibitors to 
modulate the muscarinic response in these cells (Tanner, et al., 1986).
Data from Dumont and his colleagues indicate that the 
Ca2+/Calm odulin-stimulated phosphodiesterase is an important
regulator of cyclic AMP levels in thyroid tissue (Miot, et al., 1983; 
Miot, et al., 1984; Dumont et al., 1984: Emeux, et al., 1985b). In 
these studies, the potency of selective inhibitors of this enzyme, such as 
MIX, M&B 22948, 7 -B en zy l-M IX  and 8-M eO M IX , correlated well 
with the ability of these compouds to relieve the carbachol -  induced 
decrease in intracellular cyclic AMP levels; this was not true of 
inhibitors of the cyclic AM P-specific form, such as EX and R o - 2 0 -  
1724.
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13.7: Inhibitors of Ca2+/Calm odulin-stim ulated phosphodiesterase.
A large number of inhibitors of the Ca2+/C alm odulin- 
stimulated phosphodiesterase are available. On the basis of their effects 
on the enzyme reaction, the inhibitors may be divided into two general 
categories: those counteracting Calmodulin stimulation of the enzyme
and those inhibiting the enzyme reaction directly. Inhibitors in the 
first category may be further classified into three groups according to 
their mode of action. The stimulatory activity of Calmodulin is 
dependent on the binding of Ca2+; agents that interfere with calcium 
binding form the first group of inhibitors. The second group of 
inhibitors abolish Calmodulin-stimulated phosphodiesterase activity by 
binding directly to Calmodulin. The third group exert their actions by 
binding to the phosphodiesterase to block the interaction between 
Calmodulin and the enzyme (for review see Vincenzi, 1982).
Numerous inhibitors which counteract Calmodulin activation of 
the enzyme by binding to Calmodulin have been described. They are 
represented by a group of highly heterogeneous compounds including 
proteins, peptides, amines, lipids and drugs of various chemical classes. 
A protein inhibitor of Calmodulin -  stimulated phosphodiesterase was 
first described by Klee and Krinks and was later shown to be the Ca2+ 
dependent phosphatase calcineurin (Klee and Krinks, 1978). It can act 
as a Calmodulin -  stimulated phosphodiesterase inhibitor under 
conditions of limiting Calmodulin since it can compete for the activator 
Calmodulin. Other common inhibitors, which act as Calmodulin 
antagonists include, N -  (6 -  aminohexyl)- 5  -  Chloro - 1 -napthalene -  
sulphonamide (W7) (Van Belle, 1984) and a number of W7 derivatives 
(such as 5 -  Iodo -  C8 (Barton, et al., 1987)), chlorpromazine, and 
trifluoperazine (Van Belle, 1984). The strucutres of W7 _ and 5 -  Iodo -  
C8 are shown in Figure 1.7.
Using fluorescent probes such as N -  Phenyl - 1  -  napthalene 
(NPN), 9 -  anthroylcholine, 8 -  anilino - 1  -  napthalenesulphonate and 
2 —p  -  toluidnylnapthalene -  6 -  sulphonate, it was found that when Ca2+
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binds to the high affinity sites of Calmodulin it induces a 
conformational change which exposes hydrophobic groups. 
Calmodulin -  stimulated enzymes or Calmodulin antagonists have been 
suggested to bind to this hydrophobic domain (LaPorte, et al., 1980). 
The use of Calmodulin antagonists to evaluate the role of the 
Ca2+/Calm odulin-stim ulated phosphodiesterase is, however, limited 
since they do not show specificity for the Calmodulin stimulation of 
but may affect all Calmodulin -  stimulated processes.
The most common inhibitors which interfere with the binding of 
Ca2+ to Calmodulin are the Ca2+-specific chelators such as EGTA. 
This agent is commonly used to demonstrate the existence of Ca2+-  
stimulated phosphodiesterase in crude tissue extracts. Certain metal 
ions which bind at the Ca2+ binding sites of Calmodulin, but do not 
support activation, can act as inhibitors. A novel agent, 3 - ( 2 - b e n z o -  
th iazo ly -4-5 -d im ethoxy-N [3-14-(pheny lp iperid iny l) propyl] benzene 
sulphonamide (H T -7 4 ) that inhibits Ca2+ binding to Calmodulin has 
been described by Tanaka, et al., (1982)
Of much greater potential use are selective inhibitors that 
interact directly with the enzyme. These include agents such as 
vinpocetine (Hagiwara, et al., 1984), 7 -  or 8 -  alkyl substituted IBMX 
derivatives (e.g. 8 -  methoxymethyl -  IBMX) (Wells and Miller, 1988), the 
IBMX derivative 2 - 0 -  propoxyphenyl -  8 -  azapurin -  6 -  one
(M&B 22948) (Ruckstuhl, and Landry 1981; Broughton, et al., 1974) 
and HA 558 (Hidaka and Endo, 1984; Hidaka, et al., 1984). To date 
no specific inhibitors of the various Ca2+/C alm odulin- stimulated 
isozymes have been reported.
1.4: CYCLIC G M P-BIN D IN G  PHOSPHODIESTERASES,
The cyclic G M P-binding cyclic nucleotide phosphodiesterases 
are a group of enzymes that may act as cyclic GMP "receptors". They 
are distinguished from other phosphodiesterases capable of hydrolysing 
cyclic GMP by the presence of two distinct sites for cyclic GMP. One
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site functions as the catalytic site, where nucleotide hydrolysis occurs, 
the other site being a specific binding site for cyclic GMP which 
exhibits no hydrolytic activity. This is a heterogenous family of 
enzymes consisting of several subgroups, including the widely distributed 
cyclic GMP -  stimulated phosphodiesterase (Beavo, et al., 1971; Emeux,
et al., 1981), the retinal cyclic GMP phosphodiesterases (rod outer 
segment phosphodiesterases (R O S -P D E ) (Miki, et al., 1975; Baehr, 
et al., 1979; Yamazaki, et al., 1980; Gillespie and Beavo, 1989a) and 
cone phosphodiesterases (Gillespie and Beavo, 1988), and the cyclic
G M P-binding cyclic G M P-specific phosphodiesterase from rat and 
bovine lung (Hamet and Coquil, 1978; Francis, et al., 1980; Francis
and Corbin, 1988) and those from rat and human platelets (Hamet and 
Coquil, 1978; Hamet and Coqueil, 1983; Hamet, et al., 1984a; Hamet 
and Tremblay, 1988).
1.4.1: Lung and platelet cyclic G M P-binding phosphodiesterases.
This activity was first observed as a distinct entity in both
platelets and lung (Hamet and Coquil, 1978; Coquil, et al., 1980; 
Francis, et al., 1980). Later studies identified it in a number of other 
tissues, including rat liver (Coquil, et al., 1985; Strewler, et al., 1983). 
The enzyme has since been partially purified from the cytosol of rat 
platelets and rat lung (Hamet and Tremblay, 1988; Francis and Corbin, 
1988).
1.4.2: Platelet cyclic G M P-binding phosphodiesterase.
The rat platelet enzyme displays specific, high affinity, cyclic 
GMP binding (KD=353nM) and this is characteristically stimulated in 
the presence of the non -  selective phosphodiesterase inhibitor, IBMX 
(KD = 13.4nM). Cyclic G M P-binding and hydrolytic activities co ­
eluted during purification over a number of steps and it was presumed 
that the binding and hydrolytic sites were distinct entities, each 
associated with separate properties of the 176 -k D a  holoenzyme (Coquil, 
et al., 1980; Hamet, et al., 1984a; Hamet and Tremblay, 1988).
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The rat platelet enzyme has not yet been purified to 
homogeneity so the actual subunit molecular weight and composition of 
the native enzyme is unknown. However, in studies of platelet extracts, 
Walseth and coworkers reported specific [32P ]-cG M P  photoaffinity 
labelling of a platelet protein of molecular weight 93 -kD a. This has 
been suggested to be the subunit molecular weight of the enzyme 
(Walseth, et al., 1985).
The precise role the enzyme plays in cyclic GMP metabolism is 
not known, but it has been shown that the phosphodiesterase activity is 
increased in platelets exposed to IBMX and forskolin. This effect 
could be mimicked with the catalytic unit of cyclic AMP -  dependent 
protein kinase if crude material were used but not with partially 
purified preparations. (Tremblay, et al., 1985). This may imply that 
the enzyme is under the control of the cyclic AMP -  dependent protein 
kinase in the intact cell and may represent a mechanism by which 
cyclic AMP levels may modulate cyclic GMP levels in platelets and 
lung. The need for a crude preparation may also imply the presence of 
a regulatory subunit that is lost during purification.
Similarly, the role of the cyclic GMP binding site is not known. 
However it has been suggested that since the enzyme represents the
major, if not the only, cyclic GMP binding activity in platelet cytosol,
it can serve as a significant buffer for intracellular cyclic GMP (Hamet 
and Tremblay, 1988). This will, however, be dependent on the 
concentration of the enzyme in the cell.
1.4.3: Lung cyclic G M P-binding phosphodiesterase.
The rat lung enzyme is similar in many respects to the platelet 
enzyme. Again cyclic GMP binding co-purifies with the cyclic GMP 
phosphodiestrase activity (Francis and Corbin, 1988) and represents a 
substantial proportion of the cyclic GMP binding activity in adult lung 
(Mumby, et al., 1982). It has an identical molecular weight on gel
filtration to the platelet enzyme (176,000) and displays a subunit
molecular weight of approximately 9 2 -k D a  after purification, although
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other protein bands were observed by these workers in their 
preparations. However, a protein of molecular weight 9 3 -k D a  can be 
specifically labelled with [32P]-cyclic GMP in photoaffinity labelling 
experiments (Francis and Corbin, 1988; Thomas, et al., 1988). It is 
presumed, therefore, that this represents the subunit molecular weight 
and that the enzyme exists as a homodimer under native conditions.
The phosphodiesterase activity of the cyclic GMP binding 
phosphodiesterase is highly specific for cyclic GMP and only hydrolyses 
cyclic AMP at a rate which is approximately 100 times slower than the 
hydrolytic rate for cyclic GMP. The purified rat lung enzyme has a 
Km for cyclic GMP of about 5jxM (Francis, et al., 1980). 
Immunological data indicate that this activity is distinct from other 
cyclic GMP binding phosphodiestrases, such as the cyclic G M P - 
stimulated phosphodiesterase and the photoreceptor enzyme (Mumby, 
et al., 1982; Hurwitz, et al., 1984a; Hurwitz, et al., 1984b).
As for the rat platelet enzyme the function of the cyclic GMP 
binding site is not known. However, it has been proposed that the 
allosteric site may regulate the activity of the catalytic site (Hamet and 
Coquil, 1978), although direct evidence for this suggestion is lacking. 
There does however, appear to be the capability of interaction between 
the two sites based on the ability of catalytic site -  specific analogues to 
promote both [3H ]-cyclic GMP and [32P] — cyclic GMP binding. 
Furthermore, cyclic GMP bound to the enzyme, causes a large shift in 
the elution pattern of this enzyme on DEAE chromatography (elution 
at higher ionic strength). This indicates a significant increase in surface 
electronegativity, presumably due to a conformational change.
1.4.4: Retinal rod and cone photoreceptor phosphodiesterases.
Rod outer segments (ROS) from both frog and Jbovine sources 
have been shown to contain a light and GTP -  activated cyclic GMP 
phosphodiesterase (Miki, et al., 1973; Miki, et al., 1975; Baehr, et al.,
1979). The phosphodiesterase present in rod outer segments has been 
well characterised by a number of groups. Highly purified preparations
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of the membrane bound rod enzyme were first obtained from frog 
photoreceptors (Miki, et al., 1975) and later from bovine photoreceptors 
(Baehr, et al., 1979; Gillespie and Beavo, 1989a).
Recent work has shown that, as for other phosphodiesterase 
classes, isozymes of photoreceptor phosphodiesterases exist. Gillespie 
and co-w orkers have identified the presence of a soluble form of the 
bovine rod phosphodiesterase, which is distinct from the membrane
bound form (Gillespie, et al., 1989b). A cone -  specific
phosphodiesterase was first observed by Hurwitz and co-w orkers, who 
found that a 9 4 -k D a  polypeptide could be immunoprecipitated with 
the monoclonal antibody R O S -1  (Hurwitz, et al., 1984b) from a small 
peak of phosphodiesterase activity (Peak I) in anion exchange
separations of retinal extracts (Hurwitz, et al., 1985). The cone 
phosphodiesterase was purified from the soluble fraction of bovine 
retinas using cyclic GMP -  Sepharose chromatography (Gillespie and 
Beavo, 1988).
Each of the isozymes has distinct properties with respect to the 
structure and organisation of the subunits. The membrane bound rod 
enzyme appears to consist of three polypeptides of molecular weights 
88-kD a, 8 4 -k D a  and an inhibitory polypeptide of about 11 -kD a.
This small polypeptide is trypsin -  labile and h eat-stab le  and serves to 
keep the activity of the phosphodiesterase very low until it is released 
by Transducin -  GTP leading to enzyme activation (Dumler and 
Etingof, 1976; Hurley and Stryer, 1982). The native subunit structure 
of the membrane associated bovine rod photoreceptor phosphodiesterase 
has been proposed to be a l pl'^2 (Deterre, et al., 1988). Similarly, the 
soluble rod phosphodiesterase has three subunits (aso l, psol a n d ^ so l) 
which have exactly the same size as the membrane associated isozyme, 
as well as an additional 6 -subunit of molecular weight 1 5 -k D a
(Gillespie, et al., 1989b). The cone phosphodiesterase consists of a 
single type of large subunit (a’) of molecular weight 9 4 -k D a  and three
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small subunits of molecular weights, 1 1 - kDa, 13 -kD a and 15 -kD a 
(Gillespie and Beavo, 1988) but the precise stoichiometry is unknown.
Like the Ca2+/C alm odulin- stimulated isoenzymes, the
photoreceptor phosphodiesterase isoenzymes can be activated by trypsin 
(Miki, et al., 1975). Trypsin activates the photoreceptor
phosphodiesterases by proteolysing their inhibitory subunits (Hurley and 
Stryer, 1982), which have a large number of basic residues (Ovchinnikov, 
et al., 1986).
1.4.5: Kinetics of cyclic GMP hydrolysis by retinal photoreceptor
phosphodiesterases.
Trypsin -  activated rod phosphodiesterase hydrolyses cyclic GMP 
with a of 20-150pM  (Gillespie and Beavo, 1988; Sitaramayya, 
et al., 1986; Kohnken, et al., 1981). When assayed under the same 
conditions, the membrane -  associated rod phosphodiesterase, the soluble 
rod phosphodiesterase, and the cone phosphodiesterase each hydrolyse 
cyclic GMP with Km values of about 20pM. The Vmax values of both 
of the rod isoenzymes is about twice that of the cone isoenzymes
(Gillespie and Beavo, 1988; Gillespie, et al., 1989b).
1.4.6: Cyclic GMP binding properties of retinal photoreceptor
phosphodiesterases.
The frog R O S -P D E  contains cyclic GMP -  specific, high affinity 
binding sites which are discrete from the catalytic site (Yamazaki,
et al., 1980; Yamazaki, et al., 1983). Scatchard analysis suggested the 
presence of at least two classes of cyclic GMP binding site (Miki, 
et al., 1975). Several lines of evidence have been used to confirm the 
identity of these sites as separate from the catalytic sites:
(i) Limited trypsin proteolysis rapidly damages these sites leaving
the catalytic sites intact.
(ii) The non -  catalytic sites show absolute specificity for cyclic
GMP.
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(iii) IBMX stimulates binding to the non -  catalytic site and 
inhibits the catalytic activity of R O S -PD E . The situation is 
similar to the cyclic G M P-binding phosphodiesterase identified 
in platelets and lung (Hamet and Tremblay, 1988).
(iv) A heat stable inhibitory protein of R O S -P D E  activity 
markedly stimulates binding of cyclic GMP to these sites 
(Yamazaki, et al., 1982).
The purified membrane associated bovine rod phosphodiesterase 
differs from the frog R O S -P D E  since it contains endogenously bound 
cyclic GMP that occupies nearly all of the sites. Scatchard analysis of 
[3H] — cyclic GMP binding have indicated that there are also two classes 
of binding site on the phosphodiesterase. The t0 . 5 for the high affinity 
site exceeds 4h at 37°C (Gillespie and Beavo, 1989a). At 4°C, 
essentially no cyclic GMP dissociates, so that the phosphodiesterase
isolated at this temperature retains nearly two moles of cyclic GMP 
bound per mole of oligomer (Gillespie and Beavo, 1989). It has been 
suggested that these binding sites are capable of binding the majority of 
the cyclic GMP in the rod outer segment. The phosphodiesterase
concentration in bovine ROS has been estimated to be about 30pM 
(Baehr, et al., 1979; Sitaramayya, et al., 1986). It has been estimated
that there is sufficient enzyme to bind nearly all of the cyclic GMP in
rod outer segments.
The bovine cone phosphodiesterase also has two moles of n o n -  
catalytic binding sites per mole of oligomer. The affinity of these sites 
is, however, much lower than for the bovine rod isozyme (KD = llnM ) 
(Gillspie and Beavo, 1988).
1.4.7: Activation of photoreceptor phosphodiesterases.
Cyclic GMP hydrolysis by membrane -  associated rod 
phosphodiesterase can be modulated by the degree of photobleaching of 
rhodopsin (Stryer, et al., 1981). The molecular basis for activation of 
this enzyme by light appears to be a mechanism analagous to hormonal 
coupling to adenylate cyclase. Light bleaching of rhodopsin is coupled
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to the activation of the phosphodiesterase via a guanine nucleotide 
binding protein called Transducin. This G T P-binding protein is 
composed of two large polypeptides of 3 9 -k D a  (a-subun it) and 
3 6 -k D a  (p -  subunit) and a smaller subunit of molecular weight 
10 -kD a -  subunit) (Shinowaza, et al., 1980; Fung, et al., 1981). 
Light activated rhodopsin facilitates the formation of a 
Transducin -  GTP complex, which in turn elicits the dissociation of the 
complex with the release of activated a subunit. This associates with 
the phosphodiesterase, dissociating the inhibitory subunit. The 
activation process is fully reversible.
This state of activation also appears to be modified by cyclic 
nucleotide -  independent phosphorylation of rhodopsin by opsin kinase
(Kuhn, et al., 1973), though the control mechanism of the kinase is not
yet known. This cascade of events results in the rapid hydrolysis of 
cyclic GMP. It is presumed that there is a large local change in the 
concentration of cyclic GMP which is sensed by a cyclic GMP binding 
site on, or closely associated with, a cation channel (carrying primarily 
Na+) in the plasma membrane (Fesenko, et al., 1985). The channel
requires cyclic GMP to remain open and the resulting decrease allows
closing of the channel leading to the hyperpolarisation characteristics of 
vertebrate photoreceptors.
The sequence of events responsible for visual transduction in 
cones has not been established. However, it is known that there are
distinct cone opsins (Nathans, et al., 1986), transducin, (Lerea, et al.,
1986), phosphodiesterase (Hurwitz, et al., 1985; Gillespie and Beavo, 
1988) and cyclic GMP -  sensitive channels (Cobbs, et al., 1985; Haynes
and Yau, 1985). It is likely then, that a similar sequence of events 
occurs in cones.
1.4.8: The cyclic G M P-stim ulated phosphodiesterase.
This enzyme family is termed cyclic GMP -  stimulated because 
relatively low concentrations of cyclic GMP will increase the rate of
cyclic AMP hydrolysis. It represents a potentially important point of
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interaction between two second messenger systems namely cyclic AMP 
and cyclic GMP. In this respect it resembles the Ca2+/Calmodulin 
stimulated -  phosphodiesterase which impinges on Ca2+ and cyclic 
nucleotide metabolism. Under assay conditions that mimic the 
concentrations of cyclic AMP and cyclic GMP in cells, up to 50-fo ld  
increases in the rate of cyclic AMP hydrolysis can be observed (with 
cyclic GMP in the range 0.1 to 5.0jiM). Such levels of cyclic GMP
may be reached in some cells in response to atrial natriuretic factor or 
sodium nitroprusside (Hamet, et al., 1984b; Tremblay, et al., 1986).
The cyclic GMP -  stimulated phosphodiesterase (C G S - 
phosphodiesterase) has been found in several mammalian tissues,
including rat liver (Beavo, et al., 1971; Russel, et al., 1973; Terasaki 
and Appleman, 1975; Yamamoto, et al., 1983a; Pyne, et al., 1986a; 
Lavan, et al., 1989), thymocyte extracts (Franks, et al., 1979), human 
platelets (Hidaka, et al., 1976), thyroid gland (Emeux, et al., 1977) and 
adrenal medulla (Egrie, et al., 1977).
Beavo and co-w orkers (Hurwitz, et al., 1984b; Mumby, et al.,
1982) have attempted to estimate the contribution of the soluble 
enzyme in extracts from several bovine tissues. Using non -  inhibitory 
antibodies to immunoprecipitate the enzyme selectively, they estimated 
that it contributed a significant proportion of the total cyclic AMP 
hydrolysis in several bovine tissues, approximately 80% in adrenal tissue 
and liver, 60% in spleen, 40% in heart and lung and 20 -  30% in testis 
and brain, when assayed at a saturating cyclic AMP level (0.5mM).
The activity has been observed in both the soluble and
particulate fractions of mammalian cells (Beavo, et al., 1971; Moss, 
et al., 1977; Terasaki and Appleman, 1975; Pyne, et al., 1986a). The 
cytosolic form of the enzyme has been purified from a number of 
sources including rat liver (Pyne, et al., 1986a), bovine- adrenals and 
heart (Martins, et al., 1982), calf liver (Yamamoto, et al., 1983a) and 
rabbit cerebral cortex (Whalin, et al., 1988). Other cyclic GMP -  
stimulated phosphodiesterases isoenzyme forms which have been
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reported include a particulate form of the enzyme purified from rat 
liver. This has been shown to possess distinct properties from the 
soluble form also found in rat liver including different sensitivities to
certain fatty acids and different tryptic peptide maps (Pyne, et al.,
1986a). The properties of the individual forms are summarised in Table 
1.3.
The enzyme isolated from bovine sources (liver, adrenals and
heart) appears to have a subunit molecular weight of between 102 -k D a  
and 107-k D a  (Beavo, et al., 1982; Martins, et al., 1982; Yamamoto, 
et al., 1983a), whilst the rat liver enzymes have smaller subunit 
molecular weights (6 6 -6 7 -k D a ) (Pyne, et al., 1986a). Native molecular 
weight determinations indicate that all the bovine and rat forms are
similar in that they exist as dimers. However, the rabbit cerebral
cortex form may exist as a tetramer (Whalin, et al., 1988).
High affinity monoclonal antibodies have been raised against the
bovine heart enzyme. One such antibody (CGS -  2) has been used to 
identify the presence of a cyclic GMP -  stimulated phosphodiesterase in
the soluble fraction of bovine lung. This antibody did not cross react
with either the Ca2+/Calmodulin stimulated enzyme or a cyclic A M P -
specific phosphodiesterase in bovine lung. In addition it was shown 
that the cyclic GM P-stim ulated phosphodiesterase was immunologically
distinct from the MIX -  stimulated cyclic G M P-binding protein and 
also the cyclic GMP -  dependent protein kinase present in bovine lung
(Mumby, et al., 1982).
1.4.9: Kinetics of cyclic nucleotide hydrolysis for the cyclic GMP -
stimulated phosphodiesterase.
Kinetic analyses of the bovine enzymes indicate that hydrolysis 
of both cyclic AMP and cyclic GMP displays positive co -  operative 
behaviour (Martins, et al., 1982; Yamamoto, et al., 1983a). Hill 
coefficients of 1 .8-1.9 and 1.25-1.5 having been reported for cyclic 
AMP and cyclic GMP hydrolysis respectively. All the purified forms 
appear to hydrolyse cyclic GMP preferentially to cyclic AMP with K^
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values of 10-15pM  for cyclic GMP and 33-40pM  for cyclic AMP and 
with Vmax values of 120-200 units/mg for cyclic GMP and 120-170 
units/mg for cyclic AMP. The two rat liver forms differ somewhat in 
their kinetic characteristics from the bovine forms in that, whilst they 
exhibit similar values for cyclic GMP and cyclic AMP hydrolysis, 
they exhibit much lower Vmax values for the hydrolysis of these two 
substrates (4 -4 .8  units/mg and 1.6-2.1 units/mg for cyclic AMP and 
cyclic GMP hydrolysis respectively). In addition, the hydrolysis of 
cyclic GMP of the two rat liver forms does not exhibit positively co ­
operative kinetics (Pyne, et al., 1986a). This has been attributed to the 
ability of cyclic GMP to induce a loss of positive homotropic effects 
for both cyclic AMP and cyclic GMP hydrolysis in these isolated forms. 
The enzyme would thus be expected to follow Michaelis -  Menten 
kinetics, as both the regulatory and substrate sites would be occupied 
by cyclic GMP.
At micromolar concentrations of substrate and effector levels, 
cyclic GMP can stimulate cyclic AMP hydrolysis at least five fold for 
bovine adrenal and heart forms and also for the rat liver forms 
(Martins, et al., 1982; Pyne, et al., 1986a). A somewhat higher fold 
stimulation (32 fold) was obtained for the bovine liver enzyme 
(Yamamoto, et al., 1983a). In partially purified preparations of the 
soluble enzyme from rat liver, Erneux and co-w orkers reported 
between 15 and 30 fold stimulation of cyclic AMP hydrolysis (Emeux, 
et al., 1981). The apparent activation constant for cyclic GMP 
stimulation in the presence of magnesium is similar in all the purified 
forms (0.23 -  0.28pM for the rat liver forms and 0.5pM for the bovine 
liver form). Yamamoto, et al., (1983a) demonstrated that cyclic AMP 
could stimulate cyclic GMP hydrolysis at least five fold but only at 
nanomolar levels of cyclic GMP. The apparent activation constant for 
this process was shown to be approximately lOpM.
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1.4.10: Mechanism of cyclic GMP stimulation of cyclic AMP hydrolysis.
The molecular basis for activation by cyclic GMP is ill — 
understood (Beavo, et al., 1982). Using a number of cyclic nucleotide 
analogues Emeux, et al., (1981) proposed the presence of two distinct 
sites (activatory and inhibitory) in a partially purified preparation of 
soluble rat liver enzyme. The hydrolytic site was proposed to be able 
to interact with both cyclic AMP and cyclic GMP whilst the activatory 
site shows a much greater specificity for cyclic GMP. They also
observed stimulation of cyclic GMP hydrolysis by various cyclic 
nucleotide analogues and also cyclic AMP (at lOpM). The fold
stimulation observed for cyclic AMP was however much lower, (20%), 
but this probably reflects the use of a much higher cyclic GMP 
concentration (0.3pM). Indeed, Yamamoto, et al., (1983a) showed that 
stimulation of cyclic AMP hydrolysis of the bovine liver form could 
only be observed at nanomolar levels of cyclic GMP and not at all at 
0.5 pM cyclic GMP.
In accordance with these observations, Scatchard plots of cyclic 
GMP binding to the purified enzyme from bovine adrenals displayed 
curvilinear concave upward -  curves consistent with heterogeneity of sites 
(Martins, et al., 1982). Results obtained by Miot and co-w orkers 
suggested that cyclic G M P-binding activity was directly related to the 
allosteric cyclic GMP binding site (Miot, et al., 1985). Using a number 
of cyclic nucleotide analogues, Emeux and co-w orkers showed a 
perfect correlation between potencies of stimulation of cyclic AMP 
phosphodiesterase and displacement of cyclic GMP binding (Erneux, 
et al., 1985a). The cyclic GMP -  stimulated phosphodiesterase thus 
appears to be similar to the cyclic GMP -  binding phosphodiesterases in 
platelets and lung and also to the R O S -P D E  in that it also possesses a 
non -  catalytic cyclic GMP binding site distinct from the catalytic site.
1.4.11: Other effectors of the cyclic GMP -  stimulated PDE.
Yamamoto, et al., (1984a) have also observed that another 
effector binding site, specific for cis double bonded fatty acids, is
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present on the purified bovine liver enzyme. In general, they found 
that unsaturated fatty acids were inhibitory, except for myristoleic acid 
and palmitoleic acid, which increased the hydrolysis of cyclic AMP
under basal conditions. Palmitoleic acid at 10-100pM  could increase 
cyclic AMP hydrolysis by up to 50%, presumably through interaction 
with a hydrophobic domain, higher concentrations were inhibitory.
Such stimulatory effects were evident at low cyclic AMP concentrations 
where homotropic effects were minimal. Indeed, immobilisation of the 
cytosolic rat liver enzyme upon the hydrophobic matrix, hexyl agarose 
reduced the ability of cyclic GMP to stimulate cyclic AMP hydrolysis, 
suggesting an important functional role for such a novel regulatory site. 
Pyne and co-w orkers (1986a) also observed stimulation of cyclic AMP 
hydrolysis by palmitoleic acid at low concentrations and inhibition at 
higher concentrations. This effect was only observed for the cytosolic
form of the enzyme, with the particulate form being insensitive to 
palmitoleic acid under basal conditions. Under cyclic GMP stimulated 
conditions no activation was observed for either form but both forms 
were inhibited by high concentrations of this fatty acid (Pyne, et al., 
1986a).
1.4.12: Regulation and role of the cyclic GMP -  stimulated PDE.
Little is known concerning the regulation of the cyclic GMP -  
stimulated or it’s physiological role in the control of metabolism in 
intact cells. In cultured rat hepatoma cells (HTC), the levels of the
cyclic GMP -  stimulated phosphodiesterase can be decreased by 
prolonged (48-72h) treatment with dexamethasone, with little or no
effect on the ’low-Km ’ cyclic AMP phosphodiesterase activity (Ross, 
et al., 1977).
The precise role of the enzyme in controlling cyclic nucleotide 
levels is unknown but it has been suggested that insulin may activate 
this enzyme in rat liver via the intermediancy of a ’mediator’ (Pyne, 
et al., 1988). Beavo and co-w orkers demonstrated that adrenal 
glandular tissue contains the highest amount of cyclic GMP -  stimulated
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phosphodiesterase activity; in the gland itself, virtually all the cyclic
GMP -  stimulated phosphodiesterase activity is confined to the 1 -2m m
layer of the adrenal gland (Beavo, 1988). This has suggested an 
important role for the enzyme in zona glomerulosa function, i.e. 
aldostrone production and adrenal cell growth. These workers have 
suggested that agents which might increase cyclic GMP e.g. ANF (atrial 
natriuretic factor), might bring about some of their physiological effects 
by increasing cyclic AMP hydrolysis and inhibiting cyclic AMP mediated 
processes.
1.5: CYCLIC AM P-SPECIFIC PHOSPHODIESTERASES.
Initially, these were identified as activities that elute at high salt 
concentrations as the third peak of activity from DEAE -  cellulose 
columns ('PDE IIP or 'low cyclic AMP phosphodiesterase) and
show a marked preference for cyclic AMP as substrate (when assayed at 
low jxM substrate concentrations). In some instances they have been
shown to be insensitive to Ca2+/Calmodulin and insensitive or partially 
inhibited by cyclic GMP. (Weishaar, et al., 1985; Weishaar, et al.,
1986; Grady and Thomas, 1986; Gulyassy, et al., 1975; Russel, et al., 
1973; Manganiello, et al., 1984; Turnbull and Hickie, 1984). It has 
become apparent from more recent work that the cyclic A M P-specific 
class of phosphodiesterase includes a number of activities that differ
primarily in their response to cyclic GMP and also to a number of
pharmacological agents (Yamamoto, et al., 1984a; Pyne, et al., 1987; 
Whitson and Appleman, 1982; Weber and Appleman, 1982; Weishaar, 
et al., 1987a; Weishaar, et al., 1987b; Weishaar, et al., 1987c; 
Weishaar, et al., 1987d). Identification of these 'subclasses' has relied 
both upon extensive purification protocols and improved separation
methods that allow separation from the cyclic GMP -  stimulated
phosphodiesterase, an activity that could serve to mask the presence of 
these isozymes. (Yamamoto, et al., 1984a; Reeves, et al., 1987; Weber 
and Appleman, 1982). In general these isozymes have been classified
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into two groups, namely the cyclic GMP -  inhibited phosphodiesterases 
and a cyclic GMP -  insensitive class also referred to as the Rolipram -  
sensitive phosphodiesterases.
1.5.1: The cyclic GMP -  inhibited phosphodiesterase (C G I-P D E ).
This class of phosphodiesterase exhibits very characteristic 
properties including a low Km- for both cyclic AMP and cyclic GMP 
(usually submicromolar) but with a much greater Vmax for cyclic AMP 
than for cyclic GMP (4 -1 0  fold greater). For this reason they are 
deemed to be cyclic A M P-specific despite the fact that they can 
hydrolyse cyclic GMP. Characteristically, hydrolysis of cyclic AMP is 
potently inhibited by cyclic GMP with a Ki =Km indicating that the 
inhibition is competitive. They are potently inhibited by a number of 
inotropic and anti -  thrombic agents but are • relatively insensitive to 
inhibition by the phosphodiesterase inhibitors, R o - 20-1724 and 
Rolipram.
The apparent subcellular localisation of the phosphodiesterase 
varies depending on the tissue. Whereas, most of the human platelet 
C G I-P D E  appears to be cytosolic (MacPhee, et al., 1986; Grant and 
Colman, 1984), the rat adipocyte and hepatocyte enzymes both appear 
to be membrane bound (Heyworth, et al., 1983d; Loten, et al., 1978; 
Pyne, et al., 1987a; Degerman, et al., 1987). The precise organelle in 
each of these cases has not been identified, although the rat liver 
enzyme appears to be located in a unique vesicle fraction termed by 
Houslay’s group the ’dense -vesicle* (Heyworth, et al., 1983d). The 
subcellular localisation of the enzyme in a particular tissue also appears 
to depend on the species in question. In the heart, it has been shown 
that the enzyme from bovine, human and canine sources is membrane 
bound whilst in guinea pig it is soluble (Harrison, - et al., 1986b; 
Reeves, et al., 1987; Weishaar, et al., 1987a). Such differences in 
subcellular distribution may imply the existence of distinct tissue and 
species-specific isozymes of this subclass of phosphodiesterase.
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The enzyme has been identified in a l a ^  number of tissues and 
cells including rat liver and hepatocytes (Loten, et al., 1978; Whitson 
and Appleman, 1982; Pyne, et al., 1987a), adipose tissue (Saltiel and 
Steigerwalt 1986; Degerman, et al., 1987), human platelets (Umekawa, 
et al., 1984; Grant and Colman, 1984), ventricular muscle (Weishaar, 
et al., 1987a; Harrison, et al., ' 1986b; Harrison, et al., 1988) and 3 1 3 -  
L1 adipocytes (Manganiello, et al., 1983).
The cyclic GMP -  inhibited phosphodiesterase has been purified 
from a number of sources including rat liver (Whitson and Appleman, 
1982; Pyne, et al., 1987a; Boyes and Loten, 1988), rat adipose tissue 
(Saltiel and Steigerwalt, 1986c; Degerman, et al., 1987), human platelets 
(Grant and Colman, 1984; Umekawa, et al., 1984) and bovine cardiac 
muscle (Harrison, et al., 1986; Harrison, et al., 1988). The character­
istics of the purified species are summarised in Table 1.4.
1.5.2 The rat liver 'dense-vesicle* phosphodiesterase.
The rat liver enzyme (C G I-P D E  or ’dense-vesicle' 
phosphodiesterase) is membrane bound and can be released in a
catalytically active form by endogenous proteases released either by 
hypotonic shock (Loten, et al., 1978; Loten, et al., 1980; Pyne, et al., 
1987a) or by freeze -  thawing (Whitson and Appleman, 1982). The
enzyme may also be solublilised by controlled chymotrypsin action 
under isotonic conditions (Boyes and Loten, 1988). N o n -  ionic 
detergents such as Triton X -100  (Whitson and Appleman, 1982; 
Loten, 1983) or anionic detergents such as Triton Q S -9  (Loten, 1983) 
can also release the activity. Whilst the detergent solubilised form
probably reflects the holo -  enzyme, it has proved difficult to purify
since it precipitates out of solution in the absence of detergent (Loten,
1983). Consequently, all purifications of this species from rat liver have 
involved a proteolytic solubilisation from a crude membrane fraction.
The enzyme is capable of hydrolysing both cyclic AMP and 
cyclic GMP but appears to have a preference for cyclic AMP (Whitson
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and Appleman, 1982; Pyne, et al., 1987a; Boyes and Loten, 1988) and 
is not stimulated by Ca2+/Calmodulin (Whitson and Appleman, 1982).
Kinetic analysis of cyclic nucleotide hydrolysis indicates that the 
enzyme has similar high affinities (low K^) for both cyclic nucleotides 
(Kh, cyclic AMP 0.24-0.5pM, K* cyclic GMP 0.17-0.43pM) but a
much lower Vmax for cyclic GMP (5 -200  times lower). Cyclic GMP 
acts as a competitive inhibitor of cyclic AMP hydrolysis with a Ki
similar to it’s (Boyes and Loten, 1988). Whilst the values 
determined for the high affinity component of cyclic nucleotide 
hydrolysis agree between the different groups, Vmax values differ 
significantly. The highest Vmax value reported was 6.2 pmol/min/mg 
for cyclic AMP as substrate and this corresponded to a fold 
purification in excess of 100,000 over the homogenate (Boyes and 
Loten, 1988). Lower Vmax values were reported by Pyne, et al., (1987a) 
(Vmaxl 0.7 pmol/min/mg, Vmax2 0.114 pmol/min/mg) and Whitson 
and Appleman (1982), (Vmax 0.025 pmol/min/mg). In both instances, 
these correlated with much lower fold purification values (2,773 fold 
purification over the homogenate (Pyne, et al., 1986) and 178 fold 
purification over the homogenate (Whitson and Appleman, 1982).
The reasons for these discrepancies are unclear but it has been
suggested that the preparations of Pyne, et al., (1987a) and Whitson and
Appleman, (1982) were contaminated with other proteins including a 
low affinity phosphodiesterase. This was based on the observation that 
the preparations of Pyne, et al., and Whitson and Appleman both 
displayed n on -linear kinetics for cyclic AMP hydrolysis whilst those of 
Boyes and Loten displayed linear Michaelis -  Menten kinetics (Boyes and 
Loten, 1988). However, Pyne, et al., assessed purity by a number of 
different criteria including both non -  denaturing and denaturing gels 
and thermal inactivation measurements and concluded that only one 
species of phosphodiesterase was present. These differing reports may 
reflect the purification of different species of enzyme or alternatively, 
the different solubilisation procedures employed by the three groups 
may result in the release of differently ’clipped' versions of the CGI
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phosphodiesterase which may alter both the kinetic and 
chromatographic properties of the enzyme. It is well documented that 
limited proteolysis can alter the properties of certain phosphodiesterases 
including the Ca2+/C alm odulin- stimulated phosphodiesterase and the 
cyclic GMP -  stimulated phosphodiesterase (Epstein, et al., 1978; 
Tucker, et al., 1981; Kincaid, et al., 1985; Price, et al., 1987).
The reported subunit molecular weights also differ between 
different groups. Pyne, et al., (1987a) obtained a protein of molecular 
weight 57-k D a  which formed a dimer of 112-k D a  under n o n -  
denaturing conditions. An antibody (D V -1 ) raised to the purified 
protein could immunoprecipitate a larger form of the enzyme (62-k D a ) 
from cholate extracted membranes indicating that this was the native 
subunit molecular weight. Whitson and Appleman, (1982) also obtained 
a single protein band on SDS -  PAGE with a molecular weight of 67 -  
kDa whilst the preparation of Boyes and Loten, (1988) displayed a 
larger subunit molecular weight of 73-k D a  which also formed a dimer 
under non -  denaturing conditions.
1.5.3: Cyclic G M P-inhibited phosphodiesterase in other tissues.
A similar activity to the rat liver ’dense-vesicle ' 
phosphodiesterase has been identified in rat adipose tissue (Kono, 
et al., 1977; Makino, et al., 1982; Weber and Appleman, 1982; Ueda, 
et al., 1984; Osegawa, et al., 1985; Saltiel and Steigerwalt, 1986c; 
Degerman, et al., 1987). This species resembles the rat liver 'dense -  
vesicle' phosphodiesterase in a number of respects, including it’s 
activation by insulin (Kono, et al., 1975), high affinity for cyclic AMP, 
association with the P - 2  fraction, (Manganiello and Vaughan, 1973; 
Sakai, et al., 1974; Zinman and Hollenberg, 1974) and solubilisation 
by detergents or by hypotonic shock (Lovell -  Smith, et al., 1977; 
Loten, et al., 1980; Makino, et al., 1980; Makino and Kono, 1980).
Saltiel, et al., (1986c) and Degerman, et al., (1987)' have both 
purified the rat adipocyte enzyme. The former group identified a 
protein of 6 0 -k D a  molecular weight purified some 54 fold from a
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Triton X -1 0 0  extract of a crude P - 2  fraction. This appeared to have 
a much higher Km for cyclic AMP (6jxM) than the membrane bound 
form and was less sensitive to inhibition by cyclic GMP (Saltiel, et al., 
1986c). The latter group purified a protein of 64-k D a  molecular 
weight some 65,000 fold from a sonicated particulate fraction 
(Degerman, et al., 1987). The properties of the purified 
phosphodiesterase resembled the properties of the C G I-P D E  isolated
by Boyes, et al., (1988) from rat liver, in particular, linear M ichaelis- 
Menten kinetics and high affinities for both cyclic AMP and cyclic 
GMP. In addition, the Vmax values obtained for cyclic AMP 
hydrolysis are very similar between the different purified preparations 
(8.5 jimol/min/mg for the adipocyte enzyme compared to
6.2 pmol/min/mg for the rat liver enzyme). The actual substrate range 
used in determining these values was not stated by this group, so it is 
not possible to assess if the kinetics were linear due to only a narrow 
substrate concentration range being used. Linear kinetics would be 
observed if only low cyclic AMP concentrations were analysed. In 
agreement with the rat liver enzyme studies, the fat derived enzyme
also appears to form a dimer under native conditions.
The C G I-P D E  has also been purified from bovine heart (16,000 
fold) and human platelets (2,000 fold) (Harrison, et al., 1986b; Grant 
and Colman, 1984). Both enzymes hydrolysed cyclic AMP and cyclic
GMP with normal Michaelis -  Menten kinetics. For the platelet enzyme 
the Km for cyclic AMP was 0.18 pM and Vmax 3 pmol/min/mg, the
Km for cyclic GMP was 0.02pM and Vmax was 0.3 pmol/min/mg. For
the cardiac enzyme, the Km for cyclic AMP was 0.15pM and the Vmax
was 6 pmol/min/mg. The sensitivity to inhibition of cyclic AMP 
hydrolysis by cyclic GMP and several cardiotonic drugs, is similar for 
the cardiac (Harrison, et al., 1986b), platelet (Grant and Colman, 1984; 
MacPhee, et al., 1986) and adipocyte enzymes (Degerman, et al., 1987).
The platelet enzyme may also be a dimer (140-k D a) of similar if not
identical subunits (62-kD a).
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Unequivocal . identification of the native subunit molecular 
weight of the CGI -  PDE in bovine heart and human platelets has been 
achieved using monoclonal antibodies raised to the purified bovine 
heart phosphodiesterase (C G I- 2 ,  4 & 5) (Harrison, et al., 1986;
Harrison, et al., 1988) and to the platelet enzyme (Grant, et al., 1988).
The evidence indicates that the native subunit molecular weight of the 
cardiac C G I-P D E  is 110-k D a  in fresh extracts and can be readily 
degraded to 80-k D a  presumably by endogenous cardiac proteases. 
Indeed, the purified phosphodiesterase used to raise these monoclonal 
antibodies contained largely proteolysed enzyme of 80-k D a , 67-k D a  
and 60-kD a . Using a monoclonal antibody raised to the cardiac form 
of the enzyme (CGI -  5), MacPhee, et al., (1986) have shown that the 
human platelet C G I-P D E  also has a subunit molecular weight of 
110-k D a  and that the 62-k D a  form of the human platelet enzyme 
identified by Grant and Colman (1982) may represent a proteolytic
fragment. Identical results have been obtained using a monoclonal 
antibody raised to the purified platelet phosphodiesterase (Grant, et al., 
1988).
The activity of this particular species appears to be under 
hormonal control in tissues such as hepatocytes (Loten, et al., 1978; 
Heyworth, et al., 1983d; Heyworth, et al., 1984a; Bennelli, et al., 1986; 
Heyworth, et al., 1986; Gettys, et al., 1987), and adipocytes (Loten and 
Sneyd, 1970; Zinman and Hollenberg, 1974; Kono, et al., 1975;
Weber and Appleman, 1982; Degerman, et al., 1987). In platelets, it 
may act as the target for a variety of pharmacological agents that 
inhibit platelet aggregation and hence act as anti -  thrombic agents,
(Cilostamide and it’s derivatives (Umekawa, et al., 1984; MacPhee,
et al., 1986), and R o - 15-2041 (Muggli, et al., 1985; MacPhee, et al., 
1986). A number of cardiotonic agents such as Milrinone, Fenoximone
and Amrinone, which act as positive inotropes, are all potent and 
selective inhibitors of a bovine heart cyclic GMP -  inhibited 
phosphodiesterase (Harrison, et al., 1986a; Harrison, et al., 1986b).
This ability to inhibit the CGI phosphodiesterase selectively has been
49
proposed to be the mechanism by which these agents exert their
positive inotropic effects in the heart since there is a correlation 
between their ability to act as phosphodiesterase inhibitors and their
ability to produce a positive inotropic response (Harrison, et al., 1986a; 
Weishaar, et al., 1987b).
Despite the presence of several types of phosphodiesterase in 
adipocytes and hepatocytes, the C G I-P D E  may regulate a cyclic AMP 
pool important in lipolysis and glycogenolysis (Beebe, et al., 1985). 
Likewise, of several phosphodiesterases in cardiac tissue the C G I-P D E , 
which seems to be a target for several cardiotonic drugs, may serve a 
critical role in the regulation of a cyclic AMP pool important in
myocardial contractility (Harrison, et al., 1986; Weishaar, et al., 1987b). 
The possibility thus exists that these ’lo w -K ^ ' cyclic AMP
phosphodiesterases are isoenzymes involved in the regulation of discrete 
processes mediated by cyclic AMP or, perhaps of more fundamental 
importance, may be examples of specific phosphodiesterases regulating 
functional compartmentalisation of cellular cyclic nucleotide responses.
Weishaar, et al., (1987b) have suggested that functional subclasses 
of the cyclic AM P-specific phosphodiesterse exist in ventricular muscle 
and that the cyclic GMP -  inhibited subclass of phosphodiesterase is 
important in modulating the in vivo positive inotropic response to 
agents such as Imazodan, Amrinone and several other cardiotonic 
agents. They also suggest that species differences that exist in the 
cardiotonic response to Imazodan and Amrinone can be accounted for 
by differences in the intracellular localisation of the Imazodan -  sensitive 
phosphodiesterase (C G I-PD E ). In species such as the dog, where the 
ventricular C G I-P D E  is membrane bound, then this appears to 
correlate with strong inotropic responses to Imazodan. In other 
species, such as the guinea pig and the rat, where the ventricular C G I-  
PDE appears to be soluble, then responses to Imazodan are much 
weaker. These results suggest that there may indeed be distinct pools
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of cyclic AMP regulating myocardial contractility and that specific 
subclasses of phosphodiesterase may be important in regulating them.
Further evidence for distinct functional pools of cyclic AMP has 
been provided by Elks and Manganiello. They reported that in 3T3 -  
LI cells, both the non -  selective phosphodiesterase inhibitor 
Isobutylmethylxanthine (IBMX) and the inhibitor Ro -2 0  -1724, which 
is selective for a subclass of the cyclic A M P-selective 
phosphodiesterase, could enhance differentiation of the 3T 3-L 1  
fibroblasts' into adipocytes. In contrast, the inhibitor Cilostamide, 
which is selective for the cyclic GMP -  inhibited sub-class of cyclic 
AM P-specific phosphodiesterase, had no effect on differentiation. On 
this basis, they suggested that a specific pool of cyclic AMP regulated 
by the Ro -  20 -1724 -  sensitive subclass of cyclic A M P-specific 
phosphodiesterase was important in differentiation (Elks and 
Manganiello, 1985). These authors have also shown that the 
Cilostamide -  sensitive subclass of the cyclic AMP -  specific 
phosphodiesterase (C G I-P D E ) may be more important in regulating 
lipolysis than the Ro -  20 -1724 -  sensitive subclass (Elks and 
Manganiello, 1984a).
The molecular relationships between the various purified cyclic 
GMP -  inhibited enzymes remains, however, to be established; they may 
be hormone responsive isozymes which possess similar substrate binding 
sites as well as sites for a specific class of drugs and/or endogenous 
effectors such as cyclic GMP. The reported differences in properties 
between the individual purified species may be due to either tissue 
specific expression of individual C G I-  isozymes or alternatively species 
specific differences in the physical and kinetic properties of the C G I-  
PDE. Additionally, given the proteolytic sensitivity observed in this 
particular class of phosphodiesterase and the probable consequences this 
has on the properties of the enzyme, an unequivocal identification of 
the subunit molecular weight of the rat tissue forms of this enzyme is
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required to allow comparison to the bovine and human forms of this 
enzyme.
1.5.4: The Rolipram -  sensitive (or cyclic GMP —insensitive) class of
cyclic A M P-specific phosphodiesterase.
Although also capable of specifically hydrolysing cyclic AMP, 
this class of phosphodiesterase appears to differ from the cyclic GMP -  
inhibited class in a number of respects. In general a number of 
pharmacological agents can distinguish this activity from other 
phosphodiesterases such as the C G I-P D E , namely it’s sensitivity to 
R o - 20-1724 and Rolipram (Schering Z K - 62711) and it’s relative 
insenstivity to cardiotonic agents such as Cilostamide, Imazodan (C I -  
914) and M ethyl-im azodan (C l-930). In addition, cyclic AMP 
hydrolysis is insensitive to concentrations of cyclic GMP that potently 
inhibit the CGI-phosphodiesterase.
This activity has been identified in a large number of tissues 
(Schneider, et al., 1987) including calf liver (Yamamoto, et al., 1984), 
canine, human and guinea pig left ventricle (Weishaar, et al., 1987a; 
Weishaar, et al., 1987b; Reeves, et al., 1987), rat liver, (Whitson and 
Appleman, 1982; Turnbull and Hickie, 1984; Pyne, et al., 1987b) and 
rat adipocytes (Weber and Appleman 1982).
Identification of this activity has largely relied upon the ability 
to separate it from the cyclic GMP -  inhibited and cyclic GMP -  
stimulated phosphodiesterases. In calf liver, for example,
chromatography of calf liver supernatant on N6 - H 2N(CH2)S-cyclic 
AMP agarose separated the cyclic GMP -  stimulated phosphodiesterase 
from the 'lo w -K ^  cyclic AMP phosphodiesterase activity which did 
not bind to this matrix. Further chromatography, on Ultrogel A c A - 
34, separated the cyclic GMP -  inhibited phosphodiesterase from the 
cyclic GMP -  insensitive phosphodiesterase (Yamamoto, et al., 1984a). 
In canine ventricular muscle the C G I-P D E  can be effectively separated 
from the non C G I-P D E  activity, since the former is membrane bound 
whilst the latter is soluble (Weishaar, et al., 1987a). In tissues where
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the two activities reside in the same compartment (both are soluble 
activities in rat ventricle), pharmacological evidence such as biphasic 
inhibition curves for D EA E-  resolved 'PDE III' to drugs, such as 
Imazodan and R o - 20-1724 has been used to suggest the presence of 
both the C G I-P D E  and non C G I-P D E  classes (Weishaar et al.,
1987b).
1.5.5: Characteristics of purified forms of cyclic GMP -  insensitive
phosphodiesterases.
A membrane bound enzyme, which appears to belong to this 
subclass of cyclic AMP phosphodiesterase has been identified in rat 
liver plasma membranes. The enzyme behaved as a 'peripheral' protein 
associated exclusively with the plasma membrane (Marchmont and
Houslay, 1980a; Marchmont and Houslay, 1980b; Houslay and 
Marchmont, 1981) and for this reason has been termed the 'peripheral' 
plasma membrane phosphodiesterase (PM -PD E ). It can be activated 
by it’s phosphorylation which is triggered by insulin (Marchmont and 
Houslay, 1980b). It is found to be exclusively associated with the 
plasma -  membrane due to it’s binding to a specific integral membrane 
protein (Houslay and Marchmont, 1981).
The enzyme has been extensively purified from both rat liver 
plasma -  membranes (Marchmont, et al., 1981b) and a rat liver 
particulate fraction (Pyne, et al., 1986b; Houslay, et al., 1988). The 
purified enzyme from both procedures exhibited anomalous n o n -lin ea r 
kinetics with a high affinity ¥Lrnl for cyclic AMP of 0.7-0.9pM  and a
Vmaxi of 1*24 jimol/min/mg. The Hill coefficient of 0.54 indicated
apparent negative co -  operativity. Cyclic GMP acts as a poor substrate 
for the enzyme with a K™ of 120|iM and a Vmax of 0.4 pmol/min/mg. 
The IC50 for cyclic GMP inhibition of cyclic AMP hydrolysis was 
150pM at 0.4pM cyclic AMP. The enzyme was moderately inhibited by 
R o - 20-1724.
The purified enzyme had a subunit molecular weight of 52-k D a  
and appeared as a monomer on sucrose density gradient centrifugation,
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although a dimeric species could be found on molecular sieving on 
Sepharose S -  200. Tryptic peptide mapping showed it to be distinct 
from the rat brain Ca2+/Calm odulin-stim ulated enzyme and the 
bovine rod outer segment phosphodiesterase, (Takemoto, et al., 1982).
Whitson and Appleman have reported that conversion of the 'dense -  
vesicle' phosphodiesterase (C G I-P D E ) to a cyclic GMP -  insensitive 
form, with altered chromatographic properties, can occur in an extract
of rat liver membranes solubilised by freeze -  thawing. This raises the 
possibility that the 'peripheral' plasm a-m em brane phosphodiesterase 
may be derived from the 'dense-vesicle' phosphodiesterase (Whitson 
and Appleman, 1982).
A soluble, cyclic GMP -  insensitive, activity has been purified by 
Thompson, et al., (1979) from canine kidney displaying linear kinetics
toward cyclic AMP and cyclic GMP with values of 2.2pM and 
312pM respectively. Initial data indicated that the enzyme was a 
monomer of molecular weight 60-k D a . However, immunological data 
(Sarada, 1982), indicated that the 60-k D a  protein was devoid of
phosphodiesterase activity and indeed later work suggests that the
enzyme is capable of binding avidly to this 60-k D a  protein, with up to 
20pg of enzyme bound per mg of 60 -  kDa protein. A different 
purification scheme yielded approximately 60pg of protein from 27g of 
homogenate with a subunit molecular weight of 82-k D a  on S D S - 
PAGE. The relative substrate affinities are identical to the previous
report, whilst the Vmax values for cyclic AMP are somewhat higher at 
10 -20  (imol/min/mg (Thompson, et al., 1988).
The relationship between these purified species is unclear 
although it would appear that there may be both soluble and 
membrane bound enzymes within this subgroup and that these may
display distinct properties. Table 1.5 details the properties of the 
purified species as well as the properties of selected partially purified
species. There is a diversity in the subunit molecular weights reported 
for the purified enzymes. It has been proposed that limited proteolysis
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can generate phosphodiesterases of lower molecular weight that still 
retain catalytic activity (Thompson, et al., 1984).
1.6: HORMONAL REGULATION OF PDE ACTIVITY.
In addition to controlling the synthesis of 'second messengers', 
hormones may also modulate the degradation of important second 
messengers such as cyclic AMP and cyclic GMP. The activity of 
phosphodiesterase appears to be under hormonal control in a number 
of tissues including rat epididymal fat pads (Loten and Sneyd, 1970; 
Manganiello and Vaughan, 1973; Zinman and Hollenberg, 1974; 
Makino, et al., 1980; Makino and Kono, 1980; Weber and Appleman, 
1982), rat liver (House, et al., 1972; Tria, et al., 1976; Loten, et al., 
1978, Loten, et al., 1980; Marchmont and Houslay, 1980b; Heyworth, 
et al., 1983d; Keppens and De Wulf, 1984; Benelli, et al., 1986; Pyne, 
et al., 1987a), human platelets, (MacPhee, et al., 1987; MacPhee, 
et al., 1988), 1321N1 human astrocytoma cells (Tanner, et al., 1986), rat 
granulosa cells (Conti, et al., 1984), 3T 3-L 1 adipocytes (Elks, et al. 
1983a; Elks, et al., 1983b), Xenopus Oocytes (Sadler and Mailer, 1987) 
and human neutrophils, (Grady and Thomas, 1986). In addition, 
phosphodiesterase activity may be under negative control since it has 
been demonstrated that TP A treatment of hepatocytes inhibits total 
cyclic AMP phosphodiesterase activity (Irvine, et al., 1986) probably 
through a phosphorylation mechanism, although the precise identity of 
the inhibited species is unknown.
1.6.1: The anti -  lipolytic and anti -  glycogenolytic actions of insulin in
adipocytes and hepatocytes.
The polypeptide hormones insulin and glucagon are involved in 
regulating circulating metabolite levels, particularly glucose levels. The 
anabolic hormone insulin promotes glucose uptake into target tissues 
such as adipose tissue and muscle, whilst the catabolic hormone 
glucagon will promote an increase in the blood levels of glucose and 
free fatty acids by increasing the breakdown of stored glycogen in the
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liver and fat in adipose tissue. In addition, it can increase the de novo 
synthesis of glucose by promoting gluconeognesis in the liver. Insulin 
also has anti -  lipolytic actions in adipose tissue (Steinberg, et al., 1975; 
Str&lfors, et al., 1984; Jungas, et al., 1963) and anti -  glycogenolytic 
actions in liver (Denton, et al., 1981). In this respect it counteracts the 
action of glucagon in liver. The precise mechanism by which this 
occurs is uncertain but it has been suggested that these effects of
insulin are due to an ability of insulin to counteract the actions of 
cyclic AMP. Such an action may be achieved at several levels.
One potential mechanism that has been investigated is the ability
of insulin to decrease intracellular cyclic AMP levels. In adipose tissue 
and liver for example, insulin has been shown to inhibit the production 
of cyclic AMP in response to agonists (Ray, 1970; Jungas, 1966; 
Butcher, et al., 1968; Hepp, 1971). Furthermore, in isolated 
hepatocytes, insulin can also reduce cyclic AMP levels that have been 
raised by previous challenge with glucagon (Blackmore, et al., 1979; 
Heyworth, et al., 1983d; Pilkis, et al., 1975). Since there is no 
hormonal regulation of cyclic AMP export from tissues such as liver 
(Pilkis, et al., 1975), a potential mechanism that has been focussed on
is the ability of insulin to exert an effect on the activity of
phosphodiesterases.
Evidence for such a mechanism of insulin action was provided
by Beebe, et al., (1985). They showed that insulin could selectively 
antagonise the lipolytic and glycogenolytic actions of a variety of 
analogues of cyclic AMP and this correlated with the ability of these 
analogues to serve as substrates for phosphodiesterase. Insulin could 
not antagonise the action of poorly hydrolysed analogues, whilst the 
reverse was true for analogues that were good - substrates for
phosphodiesterase (Beebe, et al., 1985).
However, it has also been suggested that insulin may antagonise 
the action of cyclic AMP by affecting it’s ability to activate the cyclic
AMP -  dependent protein kinase. This model was proposed by Gabbay
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and Lardy, (1984), who showed that in hepatocytes, insulin could 
antagonise the glycogenolytic action of exogenously added cyclic AMP 
even in the presence of the phosphodiesterase inhibitors IBMX and 
Ro -2 0  -1724. Under these conditions they concluded that the effect 
of insulin could be explained by an inhibitory action of insulin on the 
cyclic AMP -  dependent protein kinase.
In isolated rat adipocytes, Wong and Loten, (1981), concluded 
that the anti -  lipolytic action of insulin could be fully accounted for 
by a decrease in cyclic AMP and that there was no change in the 
sensitivity of the protein kinase to cyclic AMP. In addition Lonnroth 
and Smith (1986) and Kather and Scheurer (1987) both concluded that
the anti -  lipolytic effect of insulin in human adipocytes requires 
phosphodiesterase activation.
Taken together, these results suggest a role for phosphodiesterase 
activation in the anti -  lipolytic and anti -  glycogenolytic actions of 
insulin.
1.6.2: Desensitisation of cells to cyclic A M P-m ediated hormones.
After chronic exposure to hormones which elevate cyclic AMP,
cells appear to be able to 'densensitise', ’dow n-regulate’, or produce a 
state 'refractoriness'. Hormones such as glucagon and p -  adrenergic 
agents appear to employ a desensitisation phenomena (Heyworth, et al., 
1984b; Murphy, et al., 1987; Bouvier, et al., 1988) involving an 
uncoupling of receptor from the adenylate cylcase. A complimentary,
negative feedback mechanism, that dampens the effect on cyclic AMP 
levels by promoting cyclic AMP disposal in response to elevated cyclic 
AMP via a phosphodiesterase activation mechanism, has been proposed 
to explain the transient nature of increases in cyclic AMP levels often
observed in stimulated hepatocytes (Corbin, et al., 1985; Heyworth, 
et al., 1983d), adipocytes (Gettys, et al., 1987) and cardiomyocytes 
(Gettys, et al., 1987).
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1.63: Hormonally regulated phosphodiesterases in rat liver.
There appears to be at least two hormonally regulated cyclic 
A M P-specific phosphodiesterases in rat liver, both of which are 
membrane bound. The 'peripheral’ plasma membrane phosphodiesterase 
(P M -PD E ) can be activated by insulin both in vitro (Tria, et al., 1976; 
Marchmont and Houslay, 1980) and in vivo (Heyworth, et al., 1983d). 
This activity belongs to the subclass of cyclic AM P-specific enzymes 
that is insensitive to cyclic GMP but sensitive to R o - 20-1724 (Pyne,
et al., 1987a).
The second activity has been termed the 'dense-vesicle ' enzyme 
(D V -PD E ), since it resides in a membrane fraction that migrates on 
the high density shoulder of the endoplasmic reticulum when 
hepatocytes are fractionated on a Percoll gradient (Heyworth, et al., 
1983d). Paradoxically, this activity can be activated in intact 
hepatocytes by both insulin and glucagon (Loten, et al., 1978;
Heyworth, et al., 1983d). The enzyme can be distinguished from the 
'peripheral' activity by a number of criteria, including the ability of 
cyclic GMP to potently inhibit cyclic AMP hydrolysis, as such, it 
belongs to the CGI subclass of cyclic AMP specific phosphodiesterases 
(Loten, et al., 1978; Pyne, et al., 1987a).
A similar activity has been identified in rat adipocytes, which is 
also membrane bound, and can be activated by insulin (Manganiello
and Vaughan, 1973; Zinman and Hollenberg, 1974), and agents that 
raise cyclic AMP such as isoproteronol (Makino and Kono, 1980), 
adrenocorticotrophin (ACTH) and methylxanthines (Pawlson, et al., 
1974). Weber and Appleman, (1982) showed that this insulin-
stimulated phosphodiesterase in rat adipose tissue was cyclic AMP -  
specific and also belonged to the cyclic GMP -  inhibited class. This 
species bears a significant resemblance to the insulin and glucagon 
stimulated 'dense-vesicle' phosphodiesterase in rat liver. Other cells 
including platelets (MacPhee, et al., 1988), differentiated 3T3 -  LI 
adipocytes (Elks, et al., 1983a: Elks, et al., 1983b) and heart (Harrison,
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et al., 1986b) also possess an activity that resembles the 'dense-vesicle' 
phopshodiesterase.
1.6.4: Insulin activation of the 'peripheral' plasm a-m em brane PDE.
Activation of the rat liver 'peripheral' plasma membrane cyclic
AMP phosphodiesterase by insulin, in isolated plasma membranes, is of 
particular interest since it undergoes an insulin -  mediated cyclic A M P - 
dependent phosphorylation (Marchmont and Houslay, 1980b), resulting 
in an increase in cyclic AMP hydrolysis. Phosphorylation of this species 
elicited a decrease in the apparent Hill coefficient for cyclic AMP from 
0.62 to 0.47 such that the activated enzyme displayed greater negative 
cooperativity (Marchmont and Houslay, 1981). The phosphorylation of 
this phosphodiesterase from rat liver plasma membranes exhibited a Ka 
for cyclic AMP and insulin of 1.6 x 10~6 and 10~10 respectively 
(Marchmont and Houslay, 1980b). Utilisation of both the high affinity
receptors for insulin and basal intracellular cyclic AMP concentrations 
suggests that the activation process is physiologically important and 
indeed it has been observed in intact hepatocytes under basal 
conditions (Heyworth, et al., 1983d), where intracellular concentrations 
of cyclic AMP are of the order of 0 .3 -  0.5pM (Exton, et al., 1973; 
Smith, et al., 1978).
The mechanism of insulin-induced activation of the enzyme is 
unclear, but the requirement for cyclic AMP in the process indicates
the involvement of the cyclic AMP -  dependent protein kinase as does 
the ability of an A -k inase  inhibitor to block both phosphorylation and 
activation (Marchmont and Houslay, 1980b). Marchmont and Houslay 
(1981) were able to purify the 'peripheral' phosphodiesterase in an 
active state from insulin-treated membranes. They concluded that the 
phosphorylation was alkali -  labile and occured on serine residues. 
However, subsequent work, using an a n ti-se ra  raised to the 'peripheral' 
plasma -  membrane phosphodiesterase to immunoprecipitate the enzyme 
after insulin challenge of intact cells, indicated that the enzyme was
phosphorylated on alkali -  stable tyrosine residues (Pyne, et al., 1989).
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It would thus appear that the mechanism whereby insulin treatment can 
lead to the phosphorylation and activation of this enzyme in broken 
membranes does not reflect that employed in intact cells.
1.6.5: Evidence for the involvement of a G -  protein in insulin’s
actions on phosphodiesterase activation.
In intact cells, the 'peripheral* plasma -  membrane 
phosphodiesterase is not activated by glucagon treatment or by agents 
which increase intracellular cyclic AMP, such as dibutyryl cyclic AMP or 
IBMX (Heyworth, et al., 1983d). It can, however, be activated by 
cholera toxin, an agent which causes the NAD+ -  dependent 
ribosylation and activation of the guanine nucleotide binding protein 
G s. This observation has been taken to imply the involvement of a 
guanine nucleotide binding protein in the insulin -  induced activation of 
the 'peripheral* plasma membrane phosphodiesterase. In support of this 
contention, guanine nucleotides have been shown to activate the insulin 
stimulated phosphodiesterase in isolated plasma membranes (Heyworth, 
et al., 1983c). A similar observation was made in both rat brain and 
adipocyte membranes where guanine nucleotides were found to
stimulate membrane bound high affinity cyclic AMP -  specific
phosphodiesterase activity (deMazancourt and Guidicelli, 1984a; 
deMazancourt and Guidicelli, 1984b). This putative G protein is
unlikely to be either G s or G i ; glucagon, an activator of G s, does not 
activate the enzyme (Heyworth, et al., 1983d) and the insulin induced 
activation is insensitive to pertussis toxin (Heyworth, et al., .1986), an 
agent that causes the uncoupling of receptor-m ediated activation of
Houslay, (1986) has proposed that a novel G -p ro te in  (Gins) 
accounts for this particular phenomenon. G ins resembles G s in that 
cholera toxin elicits NAD+ -  dependent ribosylation of both of these 
G -p ro te ins (Heyworth, et al., 1985a). This results in stimulation of 
G ins and activation of the 'peripheral' plasma membrane 
phosphodiesterase in a similar manner to toxin elicited activation of 
adenylate cyclase via Gs (Heyworth, et al., 1983d). Surprisingly, in
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intact hepatocytes, glucagon can bring about the inactivation of G ins 
through occupancy of a unique fraction of high affinity glucagon
receptors. This results in insulin being unable to activate the 
‘peripheral’ plasma membrane phosphodiesterase (Heyworth, et al. 
1983a). The occupancy of such receptors also elicits the 
densensitisation of hormonally stimulated adenylate cyclase (Heyworth, 
et al., 1983d; Wakelam, et al., 1986; Murphy, et al., 1987).
Intriguingly, adenosine and N6 -phenylisopropyl adenosine (PIA) 
reverse the modification of G ins elicited by glucagon, such that insulin 
can now trigger activation of the phosphodiesterase (Wallace, et al.,
1984). Indeed, hepatocytes that are pre -  treated with adenosine prior 
to glucagon and then insulin, express an increase in the rate of cyclic 
AMP degradation compared to control cells (Heyworth, et al., 1984). 
Phorbol esters such as 12 -  0 -  tetradecanoyl -  phorbol -1 3  -  acetate (TPA) 
mimic the action of adenosine and PIA in releasing glucagon’s block 
upon the ability of insulin to activate the ‘peripheral’ plasma -
membrane enzyme (Heyworth, et al., 1985b). As phorbol esters mimic 
diacylglycerol in activating C -K inase  (Nishizuka, 1983) these studies 
indicate that G ins maybe a substrate for phosphorylation by this kinase 
and therefore sensitive to a multitude of other hormones that may
elicit differential effects upon the ability of insulin to stimulate the 
plasma membrane phosphodiesterase.
1.6.6: Hormonal activation of the ‘dense-vesicle ' phosphodiesterase.
The ‘dense—vesicle’ phosphodiesterase can be activated by 
exposure of intact isolated hepatocytes to- insulin, glucagon or agents
that mimic cyclic AMP in activating the cyclic AMP -  dependent protein 
kinase, such as dibutyryl cyclic AMP (Loten, et al., 1978; Heyworth, 
et al., 1983d). Activation can be observed in the proteolytically 
solubilised enzyme (Loten, et al., 1978) and also in the membrane 
bound form, isolated by Percoll fractionation (Heyworth, et al., 1983d). 
The mechanisms employed by glucagon and insulin to activate the 
‘dense-vesicle' phosphodiesterase appear to be different. Glucagon has
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been proposed to mediate activation of the enzyme through an 
activation of the cyclic AMP -  dependent protein kinase by elevated 
cyclic AMP levels. Insulin cannot activate the enzyme by raising cyclic 
AMP levels since it has been shown to decrease cyclic AMP levels in 
hepatocytes (Heyworth, et al., 1983d).
The glucagon mediated activation is energy dependent since
depletion of intracellular ATP levels causes an impairment of the ability 
of glucagon to activate the enzyme (Boyes, et al., 1981; Heyworth, 
et al., 1984a). Such data have been taken to imply the involvement of 
the cyclic AMP -  dependent protein kinase in the glucagon mediated 
activation of the 'dense-vesicle1 enzyme (Loten, et al., 1978; 
Heyworth, et al., 1983d).
Kilgour, et al., (1989), showed that in isolated hepatocyte
membranes, a purified preparation of cyclic AMP -  dependent protein
kinase (A -K inase) could activate the 'dense-vesicle' phosphodiesterase 
provided that the membranes had been p re -trea ted  with MgCl2 to
activate phosphatases. This activation corresponded with the labelling 
of proteins of molecular weight 57—kDa and 51—kDa corresponding to
the proteolytically 'clipped' forms of the enzyme. Dephosphorylation 
of the enzyme, whilst necessary to enable subsequent phosphorylation 
by A -K inase, does not cause any change in activity. This has led to
the proposal that there are two regulatory sites on the enzyme which 
can be phosphorylated. One being a site for phosphorylation by A -  
kinase, which enhances enzyme activity, and the other a 'silent' site
which prevents phosphorylation and activation by A -k inase . One
suggestion is that the silent phosphorylation of this enzyme might be 
elicited by the 5 '-A M P -stim ula ted  kinase. This would be analagous 
to the situation with acetyl CoA carboxylase (Munday, et al., 1988) 
where phosphorylation by the 5 '-A M P -stim ula ted  kinase (Carling,
et al., 1987) results as a consequence of cells becoming anoxic upon 
breakage leading to an increase in 5 ' - A M P  and activation of the 
enzyme. The resultant effect is the phosphorylation of acetyl CoA 
carboxylase on a site which prevents protein kinase A from
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phosphorylating and activating this enzyme. Indeed, such an effect has
also been observed with H M G -C oA -reducatase  (Carling, et al., 1987).
The adipocyte enzyme may also be activated by phosphorylation
by cyclic AMP -  dependent protein kinase. In vitro addition of the 
catalytic subunit of cyclic AMP -  dependent protein kinase to a crude 
particulate fraction could elicit the activation of phosphodiesterase
activity (Gettys, et al., 1988). However, unlike in the hepatocyte, it 
was not necessary to first dephosphorylate the enzyme, indicating that 
different control mechanisms may exist between hepatocytes and 
adipocytes.
The observation that the proteolytically solubilised enzyme from 
adipocytes and hepatocytes is not a substrate for the cyclic AMP -  
dependent protein kinase may indicate that the putative 
phosphorylation site lies on the membrane pedicle that anchors the
enzyme to the membrane. Evidence for such an hypothesis exists for 
the adipocyte enzyme since detergent solubilised enzyme can be 
activated by addition of the purified catalytic subunit of A -K inase  
whilst the proteolytically solubilised form can not (Gettys, et al., 1988). 
Phosphorylation may alter the conformation of the enzyme leading to a 
loss of a tonic inhibition, in an analagous manner to the Calmodulin 
induced release of tonic inhibition proposed to occur for the 
Ca2+/Calm odulin-stimulated phosphodiesterase (Kincaid, et al., 1985).
The mechanism employed by insulin in activating the 'dense -  
vesicle' phosphodiesterase is unknown in detail but presumably differs 
from that of glucagon, since insulin does not raise cyclic AMP levels. 
It is likely that a membrane trafficking event is involved since 
preincubation of hepatocytes with lysosomotropic agents, such as 
NH4C1, chloroquine and methylamine and lowering of the incubation 
temperature to 22°C all blocked insulin’s activation of the enzmye 
(Heyworth, et al., 1984a).
It is well established that the insulin receptor can internalise as 
a result of insulin binding to hepatocytes (Gordon, et al., 1980;
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Denton, et al., 1981) and this may be involved in insulin ’signalling'. 
This process may be the 'membrane trafficking' event that appears to 
be required for insulin activation of the enzyme. However, results
from Benelli, et al., (1986), using in vivo administration of insulin, 
indicated that insulin receptor internalisation was not required to
activate a liver Golgi -  associated phosphodiesterase, although the 
relationship between this species and the 'peripheral' and 'dense -  
vesicle' activities is unknown. Alternatively, it is possible that it is the 
trafficking of the 'dense-vesicle' enzyme itself that is responsible for
it’s activation by insulin and indeed insulin might initiate the
translocation of the enzyme to the 'dense-vesicle’ location where it is
subsequently activated. The insulin mechanism may also involve a 
pertussis toxin substrate as pertussis toxin treatment of intact 
hepatocytes blocked the ability of insulin to activate the 'dense-vesicle ' 
phosphodiesterase but interestingly, not activation of the 'peripheral1 
phosphodiesterase. (Heyworth, et al. 1986). Such an effect has also 
been observed for insulin activation of the C G I-P D E  in 3T 3-L 1
adipocytes (Elks, et al., 1983).
1.6.7: Hormonal regulation of phosphodiesterases in other cell types.
The regulation of a cyclic GMP —inhibited phosphodiesterase
(C G I-P D E ) by agents that increase cyclic AMP levels may be a control
mechanism common to a number of other cell types. In platelets, for
example, hormones such as PGI2 and PGE1? which activate adenylate 
cyclase, are known to rapidly increase ’low -K ^ ' cyclic AMP 
phosphodiesterase activity (Alvarez, et al., 1981; Hamet, et al., 1983;
Goldberg, et al., 1984). MacPhee, et al., (1988) have shown that the
activation in vivo corresponds with phosphorylation of the 110-k D a  
subunit of the C G I-P D E  and this effect could be mimicked in vitro 
by addition of the catalytic subunit of A -  kinase, using
immunoadsorbed phosphodiesterase as substrate. Similar studies using 
an immunoadsorbed cyclic GMP -  inhibited phosphodiesterase from 
bovine heart showed that the 110-k D a  subunit of the enzyme could be 
phosphorylated in vitro by the catalytic subunit of the cyclic AMP -
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dependent protein kinase. This phosphorylation resulted in the 
activation of cyclic AMP phosphodiesterase activity, although the effect 
was small (20-50%  stimulation of activity) (Reifsnyder, et al., 1987).
1.6.8: Role for a putative third insulin-sensitive PDE in rat liver.
Although insulin can activate at least two distinct membrane 
bound phosphodiesterases, the role of these enzymes in the mechanism 
whereby insulin can decrease cyclic AMP levels that have previously 
been raised by high (lOnM) glucagon has been questioned. Using 
agents such as NH4C1 or fructose to block insulin induced activation of 
the ’dense-vesicle ' phosphodiesterase, Heyworth, et al., (1984) showed 
that insulin could still decrease cyclic AMP levels that had previously 
been raised by glucagon implying that this enzyme does not play an 
important role in this action of insulin. Under these conditions of 
prior glucagon challenge, insulin cannot activate the plasma membrane 
phosphodiesterase (Heyworth, et al., 1983).
It seems therefore that this effect of insulin is mediated by one 
or other of the multiple forms of phosphodiesterase found in the 
hepatocyte. Insulin’s activation of such a phosphodiesterase is 
presumably either extremely labile or alternatively, reversible in nature. 
Two potential candidates are the Ca2+/Calmodulin stimulated 
phosphodiesterase and the cyclic GMP -  stimulated phosphodiesterase. 
A direct activation of the former would appear to be unlikely as insulin 
antagonises the action of hormones such as vasopressin, angiotensin and 
cti -  adrenergic agonists which result in an increase in the presumptive 
activator cytosolic calcium. The latter enzyme may be activated in a 
reversible manner by the purported small increase in cyclic GMP that 
occurs when hepatocytes are exposed to insulin (Czech, 1977). These 
two enzymes may however be reversibly activated by other mechanisms. 
Pyne, et al., (1988) have shown that the cyclic GMP -  stimulated 
phosphodiesterase can be activated by a preparation of the putative 
insulin mediator (Saltiel, et al., 1986c) and it is possible that the same 
may be true of the Ca2+/Calm odulin-stim ulated phosphodiesterase.
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However, the precise nature of the 'third* insulin -  stimulated 
phosphodiesterase needs further investigation.
These observations do not however rule out a role of the
'dense-vesicle' and 'peripheral' phosphodiesterase in some of insulin’s 
actions. For example, if hepatocytes are treated with PIA before 
glucagon challenge to block glucagon’s ability to prevent the insulin 
activation of the 'peripheral' phosphodiesterase then the ability of
insulin to decrease cyclic AMP levels was nearly doubled (Heyworth, 
et al., 1984a) implying that under these conditions the 'peripheral' 
phosphodiesterase plays an important role in decreasing cyclic AMP 
levels. Thus, it would appear that under various conditions, different 
phosphodiesterases may contribute to the ability of insulin, to decrease 
cyclic AMP levels by a phosphodiesterase activation mechanism.
1.7: OTHER PHOSPHODIESTERASES.
A number of other phosphodiesterases that cannot be easily 
fitted into any of the well defined categories of phosphodiesterase have 
also been identified (and in some cases purified) by a number of
workers.
1.7.1: 5 '-N ucleotide phosphodiesterase.
A cyclic nucleotide phosphodiesterase that is not specific for 
purine or pyrimidine 3*5' cyclic phosphate has been identified and
purified by Butler and colleauges (Kelly and Butler, 1975; Kelly and 
Butler, 1977; Landt and Butler, 1978). The enzyme has been purified 
from bovine intestine and shown to hydrolyse a wide range of 
phosphoesters. In addition to the hydrolysis of nucleic acids at the 3' 
end to yield 5 ' -nucleotides, the enzyme can also cleaves NAD, ADP, 
ATP and cyclic 3 '5 '-A M P  to yield 5 '-A M P  (Kelly and Butler, 1975). 
Cyclic AMP can be hydrolysed efficiently (K^ of below lOOpM, Vmax 
of 7 pmol/min/mg). The reaction mechanism involves the participation
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of a high energy phospho -  enzyme intermediate (Landt and Butler, 
1978).
1.7.2: Cytidine 31:5' — monophosphate phosphodiesterases.
A m ulti-functional phosphodiesterase capable of hydrolysing 
both purine and pyrimidine cyclic nucleotides has been identified and 
purified from pig liver by Helfman and colleauges. The purified 
enzyme appeared to behave as a monomer of molecular weight 31,000- 
37,000 under native conditions. It lacked absolute substrate specificity, 
hydrolysing both 3 '5 '-cyclic  CMP and 3 '5 '-  cyclic AMP to a 
comparable degree, and to a lesser extent 3 '5 '-cyclic  GMP, yielding 5' 
nucleotides as products. The apparent Km for cyclic CMP (182pM) was 
higher than the apparent Km for cyclic AMP (25pM). The Vmax value 
for cCMP (4.1 pmol/min/mg) was, however, higher than the Vmax for 
cAMP (1.6 pmol/min/mg) (Helfman, et al., 1981).
Later studies showed that the enzyme could catalyse the
hydrolysis of both purine and pyrimidine cyclic 2 '3 '-nucleotides, the 
product of hydrolysis being either 2 ' -  or 3 ' -  nucleotides depending on 
the substrate. Hydrolysis of 2 '3 '-cyclic  CMP or 2 '3 '-  cyclic UMP
yielded predominantly 3 '-nucleotides. In contrast, hydrolysis of 2*3' — 
cyclic AMP produced equal amounts of 2’ -  and 3' -  derivatives, whilst 
the major product formed from 2*3' — cyclic GMP was the 2' — 
nucleotide (Helfman and Kuo, 1982).
In addition to this m ulti-functional enzyme, a
phosphodiesterase capable of hydrolysing 3 '5 '-cyclic  CMP but not
3 '5 '-cyclic  AMP or 3*5' — cyclic GMP has been identified in Leukemia 
L -1210  cells (Cheng and Bloch, 1978) and in a variety of rat tissues 
(Kuo, et al., 1978b). Highest levels of activity were identified in liver, 
kidney and intestine with much lower levels observed in skeletal muscle, 
cerebellum, aorta and blood cells. This activity clearly differed from 
the m ulti-functional enzyme since it was selective for cyclic CMP as 
substrate, exhibiting a Km of 2.4mM. In contrast, the multi -  
functional enzyme exhibited a Km of 182pM for cyclic CMP hydrolysis
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(Kuo, et al., 1978; Helfman, et al., 1981). These data would seem to
indicate then that as for other phosphodiesterase classes there is also a
multiplicity of phosphodiesterases capable of hydrolysing cyclic CMP.
1.7.3: Non -  mammalian phosphodiesterases.
The phosphodiesterases in the eukaryotes, Saccharomyces
cerevisiae (Bakers yeast), Drosophila melanogaster and Dictyostelium 
discoideum have been studied extensively by a number of groups. They 
have played an important role in recent studies on the molecular
genetics of phosphodiesterase genes.
1.7.4: Drosophila melanogaster phosphodiesterases.
Drosophila contains two major types of cyclic AMP 
phosphodiesterase, a Ca2+/Calm odulin-stim ulated form and a cyclic 
AM P-specific form (Davis and Kauvar, 1984) The Ca2+/C alm odulin- 
stimulated form is similar in properties to it’s mammalian counterparts. 
The enzyme can hydrolyse both cyclic AMP and cyclic GMP and is 
activated by trypsin treatment. However, it appears to behave as a 
monomer of subunit molecular weight 120-kD a, which distinguishes it 
from the mammalian forms of this enzyme (for review see Davis and 
Kauvar, 1984).
The cyclic AM P-specific form has been much more extensively 
studied. It appears that the cyclic AM P-specific form is implicated in 
learning and/or memory processes in Drosophila. The gene which codes 
for the Drosophila melanogaster phosphodiesterase (PDE 2) is housed at 
the dunce (dnc) locus (Chen, et al., 1986), mutations at which, produce 
progeny that show defective conditioned behaviour in several different 
situations in which associative learning is evaluated (Dudai, et al., 1976; 
Tempel, et al., 1983).
The enzyme has been estimated to have a molecular mass of 
between 35-k D a  and 70-k D a  (Davis and Kauvar, 1984). cDNA clones 
encoding the transcripts of the ducne gene have been isolated and 
sequenced (Chen, et al., 1986). The amino acid sequence predicts a
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protein of molecular weight 40-k D a  (within the estimated values) 
which has a high degree of homology with the 61-k D a  subunit of the 
bovine Ca2+/C alm odulin- stimulated isoenzyme. Within this domain 
the degree of homology between the two sequences was 42% 
(Charbonneau, et al., 1986).
1.7.4.1: Use of the Drosophila melanogaster cDNA clone to isolate 
mammalian phosphodiesterase cDNA clones.
A probe corresponding to a portion of the dunce gene was used 
to screen a rat brain cDNA library at low stringency (Davis, et al., 
1989) and isolate several indepenent cDNA clones. Sequence analysis of 
the longest cDNA clone (termed RD1) revealed that it contained an 
open reading frame which translated > into a conceptual protein of 
molecular weight 68-k D a  containing 610 amino acids. Two additional 
rat brain cDNA clones (RD2 and RD3) also isolated with the 
Drosophila probe appeared identical to RD1 over the majority of their 
lengths but showed sequence variations towards their N -term in i. These 
clones were, however, incomplete at their C -term in i so these workers 
were unable to assess sequence variations in this region. These workers 
have suggested that the three PDE clones isolated represent transcripts 
that arise by alternative splicing of messenger RNA from a single gene. 
Based on genomic blotting experiments these workers have also 
suggested the presence of at least one other rat gene homologous to 
this putative gene (Davis, et al., 1989).
An alignment of the conceptual translation sequence of RD1 
with representatives of several subfamilies of phosphodiesterase (the 
Ca+/Calm odulin-stim ulated phosphodiesterase, the cyclic G M P - 
stimulated phosphodiesterase and the a -  subunit of the retinal cyclic 
GMP phosphodiesterase (all from bovine sources) and the Drospophila 
cyclic AMP phosphodiesterase) revealed the presence of a conserved 
domain of approximately 270 amino acids. Within this region, the 
homology of RD1 with the Drosophila sequence was very high, with 
75% of the residues showing absolute identity. The degree of
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homology with the other phosphodiesterases ranged from 20-40%
identity (Davis, et al., 1989).
Swinnen and co-w orkers (Swinnen, et al., 1989) also used a 
cDNA clone encoding the Drosphila melanogaster dunce 
phosphodiesterase as a probe to screen both rat testis and rat sertoli
cell cDNA libraries. They isolated four different groups of clones, 
termed ratPDEl, ratPDE2, ratPDE3 and ratPDE4; the former two from
a rat testis library and the latter two from the rat sertoli cell library. 
All four of these clones once again contained a region of approximately 
270 amino acids where the amino acid sequence was highly conserved
between both these individual clones and between known sequences of 
the other phosphodiesterases. Within this conserved region, the four 
ratPDE clones had very similar sequences but were not identical.
However, at the amino and carboxyl termini the sequences shared little
or no homology with each other (Swinnen, et al., 1989).
The molecular weights of the presumptive proteins encoded by 
ratPDE2, ratPDE3 and ratPDE4 were estimated to be 68-k D a , 67-k D a  
and 64-k D a  respectively. In the case of the ratPDEl clone the actual 
molecular weight could not be estimated since the clone was only 
partial in length but the minimum expected molecular weight was 4 7 -  
kDa (Swinnen, et al., 1989).
These clones were used in Northern blot analyses to assess the 
cell distribution of ratPDE transcripts in the various cell types of the 
seminiferous tubule. RatPDEl and ratPDE2 identified transcripts 
mainly in germ cells whilst ratPDE3 and ratPDE4 identified transcripts
in the Sertoli cell with only faint hybridisation observed in peritubular 
and germ cell RN A  The distribution of the RNA transcripts 
corresponding to the four cDNA clones was also assessed in a number 
of different rat tissues including brain, heart, liver, kidney and testis. 
RatPDEl identified a number of major transcripts in both kidney and 
testis with only minor transcripts identified in the other tissues. 
RatPDE2, on the other hand, identified major transcripts in all the
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tissues examined except liver. All the organs tested expressed
transcripts corresponding to ratPDE4 and ratPDE3 (Swinnen, et al., 
1989).
Analysis of the entire nucleotide sequences showed that there 
was no sequence longer than 32 nucleotides in which any two of the 
four groups of cDNA clones had identical sequences. On the basis of 
this observation, and the differential expression of these transcripts in 
various cell types, these workers have proposed that these four clones 
represent transcripts from different genes rather than being derived 
from a single gene by alternative splicing (Swinnen, et al., 1989).
Using a different approach, involving complementation of a 
mutant in the yeast Saccharomyces cerevisiae, Colicelli and co -  workers 
have isolated and characterised a rat brain cDNA encoding a high
affinity cyclic AMP phosphodiesterase. This was found to be highly 
homologous to the cAMP phosphodiesterase encoded by the dunce 
locus of Drosophila melanogaster (Colicelli, et al., 1989). They have 
called the gene DPD (dunce-like phosphodiesterase). The cloned 
cDNA was capable of coding for a putative protein of molecular weight 
60-k D a  which was highly homologous to the D.melanogaster dunce 
gene product over a 252 amino acid region located in the centre of the 
rat DPD cDNA (over 80% identity). Using expression of the DPD -  
cDNA in the yeast Saccharomyces cerevisiae, these workers showed that 
the clone coded for a phosphodiesterase which had a high affinity for 
cyclic AMP (K^ of 3.5pM), was insensitive to Ca2+/Calmodulin, did
not hydrolyse cyclic GMP and was insensitive to inhibition by cyclic 
GMP. This cDNA was similar to, though distinct from, the three 
cDNAs isolated from a rat brain cDNA library by Davis, et al., (1989). 
Although these putative proteins shared over 93% identity in the 
central conserved region of the molecule this homology fell off
dramatically in the flanking regions (amino and carboxyl termini) 
(Davis, et al., 1989; Colicelli, et al., 1989).
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A comparison of the properties of the Drosophila dunce, RD1 
and DPD cDNA products revealed that whilst all three coded for high 
affinity phosphodiesterases (Km values between 2 and 4jiM) the three 
activities were different with respect to their sensitivity to 
phosphodiesterase inhibitors. Whilst both RD1 and DPD
phosphodiesterases are sensitive to inhibition by Rolipram and R o - 2 0 -  
1724, the Drosophila dunce product is much less so. All three activities 
were not found to be sensitive to inhibition by Fenoximone and cyclic 
GMP; agents which exert a selective inhibitory effect on the cyclic 
GMP -  inhibited subclass of phosphodiesterase (Henkel -T igges and 
Davis, 1990).
1.7.5: Saccharomyces cerevisiae phosphodiesterases.
The Bakers yeast Saccharomyces cerevisiae contains both ’high -  
Km’ and 'low -K m '-cyclic AMP phosphodiesterases. The 'high-K m 1 
enzyme has been purified to homogeneity and was shown to exist as a 
dirtier of similar if not identical subunits of molecular weight 43-k D a  
(Londesborough and Suoranta, 1983). It is not, however, specific for 
cyclic AMP as substrate since it can also hydrolyse cyclic GMP (Km 
values of 250jxM and 160jxM respectively) (Fujimoto, et al., 1974). This 
phosphodiesterase is unusual since it is active in the absence of added 
divalent metal cations (Fujimoto, et al., 1974). It has been shown that 
purified preparations of the enzyme contain 2.4 atoms of zinc/43,000 
subunit (Londesborough and Suoranta, 1983).
The 'low-Km' form has also been purified (Suoranta and 
Londesborough, 1984). This phosphodiesterase was found to be specific 
for cyclic AMP as substrate (Km = 0.2pM) and has a molecular weight 
of 61-k D a , although if protease inhibitors were omitted during 
purification, the active fraction contains subfragments of 45-k D a  and 
17-kD a . Like the 'high-Km', enzyme this phosphodiesterase was also 
a zinc requiring enzyme. It was apparent however, from an analysis of 
their respective amino acid compositions, that these two activities were
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distinct from one another (Londesborough and Suoranta, 1983; 
Suoranta and Londesborough, 1984).
.1.75.1: Genes for Saccharomyces cerevisiae phosphodiesterase.
The structural gene for the 'low -K ^ ' phosphodiesterase (termed 
PDE2) has been isolated by Wigler and his co-w orkers by searching for 
genomic sequences which suppress the phenotypes of the ras2val 19 
mutation when carried on a high copy number plasmid (Sass, et al.,
1986). The open reading frame contained within the PDE2 gene was 
found to be 526 amino acids long, predicting a protein product of 6 1 -  
kDa, in excellent size agreement with the purified protein (Suoranta 
and Londesborough, 1984; Sass, et al., 1986). The predicted amino 
acid sequence is homologous to other phosphodiesterases including the 
Drosophila cAMP PDE and the bovine Ca2+/C alm odulin- and cyclic 
GMP -  stimulated phosphodiesterases (Charbonneau, et al., 1986). The 
gene was shown to be capable of expressing phosphodiesterase activity 
in yeast cells and exhibited a for cyclic AMP hydrolysis of I jiM  
when partially purified preparations were analysed (Sass, et al., ,1986).
The PDE1 gene which codes for the 'high-Km* enzyme has also 
been isolated by Wigler and co-w orkers using an identical strategy to 
that employed for the 'low-Km' enzyme (Nikawa, et al., 1987). The 
clone isolated had an open reading frame of 369 amino acids, predicting 
a protein molecule of 42-kD a, in agreement with the estimates for the 
purified protein (Londesborough and Suoranta, 1983). In contrast to 
the 'low Km' phosphodiesterase, the amino acid sequence of this 
enzyme demonstrates no homology with any known phosphodiesterase 
except one, the cAMP phosphodiesterase from Dictyostelium discoideum 
(see section 1.7.6.1).
1.7.6: Dictyostelium discoideum phosphodiesterases.
In this organism, the phosphodiesterase activity is found in both 
membrane bound and extracellular forms. The extracellular form of 
the enzyme has been purified and shown to consist of two proteins of 
molecular weight 48-k D a  and 50-k D a  both of which exhibit
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phosphodiesterase activity. The enzyme appears to exist as a 
monomeric species, (Orlow, et al., 1981). This enzyme has a low 
for cyclic AMP (8pM), while the K„, for cyclic GMP is 25pM (Shapiro, 
et al., 1983). It may be converted to a high Kn, form (2mM) (Chang, 
1968) upon interaction with an inhibitor protein (Kessin, et al., 1979). 
The enzyme is unusual in that it exhibits a high isoelectric point of 
between 7.5 and 9 and unlike most other phosphodiesterases is unable 
to bind to anion -  exchange resins such as D E -5 2  (Orlow, et al., 1981).
A high molecular weight form of the enzyme (150,000-200,000), 
which has an isoelectric point of 5, can be isolated from cells. This 
activity appears to result from aggregation of the low molecular weight 
form of the enzyme with an acidic protein. The high molecular weight 
form of the enzyme can be converted to the low molecular weight 
momomer by isoelectricfocussing in the presence of 6M urea. Under 
these conditions the isoelectric point of the enzyme is shifted to that 
of the monomeric form. The two species have been shown to be 
immunologically indistinguishable from one another after urea treatment 
and to react identically with the cyclic nucleotide phosphodiesterase 
inhibitor protein (Orlow, et al., 1981; Franke and Kessin, et al., 1981).
1.7.6.1: Isolation of a cDNA encoding the extracellular 
phosphodiesterase of Dictyostelium discoideum.
The purified extracellular phosphodiesterase was used to a obtain 
partial amino acid sequence for the design of oligonucleotide probes. 
The cDNA isolated contained an open reading frame capable of coding 
for a protein of molecular weight 5 1 -k D a  (LaCombe, et al., 1986). 
The predicted amino acid sequence showed no homology with any of 
the known sequences except for the yeast PDE1 gene product which 
encodes the 'h igh -K ^ ' enzyme (LaCombe, et al., 1986; Nikawa, et al.,
1987).
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1.8: PHOSPHODIESTERASE INHIBITORS.
Inhibition of phosphodiesterase activity has been reported for
many different classes of compounds. These include inhibitors that are 
presumed to interact directly with the phosphodiesterase itself and also 
compounds that inhibit the action of phosphodiesterase effector 
molecules such as the so called 'Calmodulin antagonists' (see Section
1.3.7). In general, inhibitors of the former type may be divided into 
two classes; those that show non -  selective actions against the different
phosphodiesterase classes/isozymes and those that exhibit selectivity for 
the different forms (for review see Weishaar, et al., 1985). Examples of
the non -  selective inhibitors include papaverine, theophylline, and 3 -  
iosbutyl - 1  -  methylxanthine (IBMX) (Wells, et al., 1975). The 
structures of these non -  selective inhibitors are shown in Figure 1.3.
A number of selective phosphodiesterase inhibitors have been 
described, that appear to show selectivity for different classes of
phosphodiesterase. In general, the action of these inhibitors has been 
assessed using Peaks from anion -  exchange chromatography of tissue 
extracts. It is now clear that there are several isozymes of each of the 
individual phosphodiesterase classes which may be represented in such 
peaks. Whilst these isoenzymes may be similar they may also show
different susceptibility to inhibitors. However, the total number of 
distinct isozymes for each of the different classes has yet to be 
determined. Consequently, it has not yet proved possible to assess the 
precise isozyme distribution pattern between different tissues and/or 
species. Therefore, the actual inhibition profiles obtained will most 
likely represent an average effect on all of the individual types present. 
This fact must be borne in mind when reviewing the actions of the well 
known phosphodiesterase inhibitors against partially purified 
preparations of phosphodiesterase
1.8.1: 'P D E -P  inhibitors..
For the purposes of this introduction, the term 'PDE - 1' refers
to all of the Ca2+/Calm odulin-stim ulated isozymes as well as the
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cyclic G M P-specific phosphodiesterases. Agents that exert a selective
effect on this class of phosphodiesterase include H A -558, T C V -3B , 
(Kariya, et al. , 1982; Weishaar, et al., 1983), Zaprinast (M&B 22,948) 
and ICI 74,197 (Bergstrand, et al., 1977). Hidaka and coworkers have
shown that H A -558  and T C V -3B  exert comparable inhibitory effects 
on Calmodulin -  stimulated and basal phosphodiesterase activities
(Hidaka, et al., 1984; Hidaka and Endo, 1984). On the basis of this
difference, it has been proposed that these latter agents selectively 
inhibit the hydrolytic site on the Calmodulin -  stimulated 
phosphodiesterase rather than exerting any direct inhibitory effect on 
Calmodulin or the Calmodulin binding site on phosphodiesterase.
Bergstrand and co-w orkers showed that the anti -  allergic agents, 
Zaprinast (M&B 22948) and ICI 74,197, were selective inhibitors of a 
partially purified preparation of the Ca2+/Calm odulin-stim ulated
phosphodiesterase isolated from human lung by anion -  exchange
chromatography (Bergstrand, et al., 1978). More recently, it has
become apparent that inhibitors such as Zaprinast also show inhibitory 
action against the Ca2+/Calm odulin-insensitive cyclic GMP -  selective 
phosphodiesterase as well as the Ca2+/C alm odulin- stimulated
phosphodiesterase (isolated from human platelets and bovine coronary 
arteries respectively). The IC50s for inhibition were very similar being 
1.3[iM and 3.4 pM respectively for the two enzymes (Quade, et al., 
1984).
Hidaka and Endo (1984) showed that MY—5,445 could
distinguish between these two classes of phosphodiesterase. It potently
inhibited a cyclic GM P-specific phosphodiesterase from human 
platelets (Ki = 0.5pM) whilst exerting a lesser inhibitory effect on the 
cyclic GMP -  selective Ca2+/Calmodulin phosphodiesterase from brain 
(Ki = 9.5pM). The structures of all these inhibitors are shown in Figure 
1.4.
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1.8.2: 'P D E -IT  inhibitors.
This is generally referred to as the cyclic GMP -  stimulated
phosphodiesterase (see sections 1.4.8-1.4.12). No agents have yet been 
identified that are truly selective agents for this class of enzyme.
Whilst dipyridamole, A R - L  57 and Sulmazole (A R -L  115BS) all exert
a somewhat greater inhibitory effect on cardiac T D E -II*  than on 
'P D E -F  or 'P D E -IIF , dipyridamole inhibits 'PD E -I* and 'P D E - i r  to 
comparable degrees in platelets. (Quade, et al., 1984; Weishaar, et al., 
1986). The structures of these inhibitors are shown in Figure 1.5.
1.8.3: TDE-m * inhibitors.
This class represents the cyclic AMP -  specific phosphodiesterases 
and includes the cyclic GMP -  inhibited and cyclic GMP -  insensitive
subclasses. Much attention has focussed on developing selective 
inhibitors of these classes of phosphodiesterase, particularly the cyclic 
GMP -  inhibited form in cardiac muscle and platelets, since 'P D E -IIT  
inhibitors have been shown to possess cardiotonic and anti -  thrombic 
activities (Kariya, et al., 1982; Umekawa, et al., 1984; Muggli, et al., 
1985; MacPhee, et al., 1986; Goldenberg, et al., 1987).
1.83.1: Positive Inotropic agents.
These were originally developed to replace the cardiac glycosides, 
such as digitalis, for the treatment of congestive heart failure. The 
rational for inotropic therapy is based on the observation that the 
contractility of failing myocardium can be augmented (Dyke, et al., 
1975). Studies in animal models with myocardial dysfunction and in 
the failing human heart have suggested the existence of a residual 
myocardial contractile reserve. The cardiac glycosides have a low 
therapeutic toxic ratio and a limited inotropic potential so a number of 
new inotropic agents were developed in the hope that these agents 
would be suitable for the treatment of congestive heart failure.
Most of the available inotropic agents appear to work, at least 
partly, by increasing the amount of intracellular calcium available to
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react with contractile proteins to generate a greater force of myocardial 
contraction (Scholz, 1983). Inotropic agents exist that act as Pi -  
adrenoreceptor agonists, p2 -adrenergic agonists and phosphodiesterase 
inhibitors. All these agents will increase intracellular cyclic AMP levels. 
It is presumed that increases in intracellular cyclic AMP levels will 
stimulate the cyclic AMP -  dependent protein kinase and lead to the 
phosphorylation of proteins on the cell membrane and the intracellular 
sarcoplasmic reticulum (Tadu and Katz, 1982). These changes lead to 
an enhanced calcium flux that increases intracellular calcium, the 
intensity of actin and myosin interaction and thus the force of 
myocardial contraction.
The first non -  catechol, non -  glycoside compound described that 
could act as a positive inotrope was Amrinone (Win 40,680) (Alousi, 
et al., 1979). Other such agents include, Milrinone (Bairn, et al., 1983), 
Fenoximone (also called Enoximone or MDL 17,043) (Kariya, et al., 
1982), Piroximone (MDL 19,205) (Petein, et al., 1984), Imazodan (C I-  
914), methyl -  Imazodan (C l-930), (Bristol, et al., 1984), A R - L  57 and 
Sulmazole (A R -L  115 BS) (Pouleur, et al., 1982). Of these Amrinone, 
Milrinone, Imazodan, Methyl -  Imazodan, and Fenoximone have been 
shown to be inhibitors of cyclic AMP -  specific phosphodiesterases 
(Kariya, et al., 1982; Bristol, et al., 1984; Weishaar, et al., 1985b; 
Weishaar, et al., 1987d).
1.8.3.2: Inhibitors of platelet aggregation.
Increased levels of cyclic AMP have been shown to inhibit the 
aggregation of platelets (Salzman, 1972). Interference with cyclic AMP 
disposal has been proposed as the mechanism of action of a number of 
reference platelet aggregation inhibitors, including dipyridamole 
(Salzman, 1972; Mills and Smith, 1971; Asano, et al., 1977; Pichard,
et al., 1972). More recently, several selective phosphodiesterase 
inhibitors have been described that exert potent anti -  aggregatory
effects. Hidaka and co-w orkers have shown that Cilostamide (O P C -
3,689), which is a selective inhibitor of the cyclic GMP -  inhibited
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subclass of phosphodiesterase (Hidaka and Endo, 1984; Degerman, 
et al., 1987), inhibits platelet aggregation induced by ADP, collagen or 
archidonic acid (Hidaka, et al., 1984). A number of derivatives of 
Cilostamide such as OPC-3911, O P C - 13135 and O P C -13013 are all 
selective and potent inhibitors of the cyclic GMP -  inhibited subclass of 
cAMP specific phosphodiesterase (Degerman, et al., 1987).
1.8.3.3: Other T D E -I IP  inhibitors.
A number of other selective inhibitors of cyclic A M P-specific 
phosphodiesterases have been described and these include agents such as 
R o - 20-1724 and Rolipram (ZK 62,771) (Schwabe, et al., 1976; 
Bergstrand, et al., 1977). Two phosphodiesterase inhibitors (ICI 58 301 
and ICI 63 197) which possess potent anti-bronchoconstrictor activity 
(Davies, 1973) have also been shown to be selective inhibitors of cyclic 
AMP -  specific phosphodiesterase (Somerville, et al., 1970; Davies, 
1973). The cyclic AMP phosphodiesterase inhibitor ICI 118233 is also a 
selective inhibitor of the cyclic AMP -  specific subclass of 
phosphodiesterase. The structures of a number of selective 'P D E -III ' 
inhibitors are shown in Figure 1.6.
FIGURE 1.1:
R E A C T I O N  C A T A L Y S E D  BY CYCLTC N IJC L E O T T D E  
P H O S P H O D IE S T E R S A S E .
The reaction catalysed by cyclic nucleotide phosphodiesterase is depicted using 
3'5'-cyclic AMP as an example. The same bond is hydrolysed when 3'5'- 
cyclic GMP is the substrate producing 5'-GMP as the product.
FTGITRE 1.1
NH
CYCLIC AMP
O
OH
O"
5 '-AMP
PHOSPHODIESTERASE
NH
P— o -
OH OH
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FIGURE 1.2:
POSSIBLE ARRANGEM ENT O F H Y PO TH E TIC A L DOMAINS IN 
BO V IN E BRA IN  C a ^ /C A L M O D IJL IN -S T IM IIL A T E D  C Y C L IC  
N U C L EO T ID E PH O SPH O D IEST ER A SE .
This model was proposed by Kincaid, et al.. (1985) on the basis of the 
proteolytic sensitivity of a purified preparation of bovine brain 
Ca2+/Calmodulin-stimulated cyclic nucleotide phosphodiesterase.
FTdTTRF, 1.2
C  E
II
lOKBa 45KDa
I  B CA TA LY TIC
I=Inhibitory domain 
B=CaImoduIin binding domain
Protease Sites;
C=Site exposed in presence of Ca2 +/Calmodulin 
E=Site exposed in absence of Ca2+/CaImodulin
Adapated from Kincaid et.al. (1985)
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FIGURE 1.3:
STRUCTURE OF NON-SPECIFIC PH OSPHO DIESTERA SE 
INHIBITORS.
FIGURE 1,3
H,CO.
,OCH
Papaverine
OCH
N
R
-C H 3  T h eop h yllin e  
-iB u  IBM X
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FIGURE 1.4(a):
STRUCTURE OF SELECTIVE TDE-T* INHIBITORS.
FIGURE 1.4(a)
Et
TC V -3B
n— so:
OEt
CH
H A -558
o
HN
Zaprinast (M&B 22948)
HN
ICI 74917
n-Bu
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FIGURE 1.4(b):
STRUCTURE OF SELECTIVE 'PDF.-T' INHIBITORS.
FIGURE 1.4fb)
.ci
NH-
M Y -5445
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FIGURE 1.5:
STRUCTURE OF SELECTIVE 'PDF-TT' INHIBITORS.
FTQTIRE 1.5
r
D ipyridam ole
HgCO
//
-OCH 3  AR-L 57 
-SOCH 3  S u lm azo le
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FIGURE 1.6(a):
STRU CTU RE OF SE LE CT IV E 'PPE-ITI' IN H IBITO RS.
These agents are all cardiotonic agents that exert inotropic effects in the heart.
FTGIIRE 1.6(a)
\
Am rinone
M ilrinone
c h 3
HN
CH3S(
E noxim one
FIGURE 1.6(b):
STRUCTURE OF SELECTIVE 'PDE-III1 INHIBITORS.
These agents are all cardiotonic agents that exert inotropic effects in the heart.
FIGURE 1.6(hl
CoH
NHHN
Piroximone (MDL 19205)
H
K
-H Imazodan (CI-914)
-C H 3 methyl-Imazodan(CI-930)
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FIGURE 1.6(c):
STRUCTURE OF SELECTIVE 'PPE-ITI' INHIBITORS.
These agents exert anti-aggregatory effects in platelets
FTGTJRE 1.6(c)
,CH;
H C ilostam idefO PC -3689)
OH
I
Ph
OPC 13135
FIGURE 1.6(d):
STRUCTURE OF SELECTIVE 'PPE-HT INHIBITORS.
These agents are selective for the cyclic GMP-insensitive (Rolipram sensitive) 
subclass of phosphodiesterase
FTQTJRE 1.6(d)
NHHN
OCH
R o-20-1724
HN
Rolipram
NHCOCHg
TCI 58301
NH
ICI 63197
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FIGURE 1.6(e):
STRUCTURE OF SELECTIVE ’P P E -n r  TNHTBTTORS.
FIGURE 1.6(e)
CH3-  NH
C>0
I
NH
HN
O
TCI 118233
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FIGURE 1.7:
STRUCTURE OF CALMODULIN ANTAGONISTS.
FIGURE 1.7
ci
W -7
5-Iodo-C 8
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FIGURE 1.8:
STUCTURE OF PURINE AND PYRTMTDTNE .TS'-CYCLTC 
NUCLEOTIDES.
FIGURE 1.8
o = p
3f5f cAMP: flwrf-conformation
HN
3*5* cGMP; svn-conform ation
0 =
OH
OH
NH.
0=
OH
OH
3'5' cCMP
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TABLE 1.1:
ISOZYMES OF THE Ca2+ /C A L M O D IIL IN -S T T M IIL A T E D  
PHOSPHODIESTERASE.
References for Table 1.1
1. Morril, et al.. (1979).
2. Sharma, et al.. (1980).
3. Hansen and Beavo, (1982).
4. Sharma, et al.. (1984).
5. Hansen and Beavo, (1986).
6. Sharma.et al.. (1985).
7. Sharma and Wang, (1986a).
8. Shenolikar, et al.. (1985).
9. LaPorte, et al.. (1979).
10. Sharma and Wang, (1986b)
11. Rossi, et al.. (1988)
Molecular mass (kPa)
Simr.ce Subunit Native MaxJiM-Stim11 Reference
Bovine brain
59 126 2 (1)
58 124 15 (2)
61 N.D. N.D. (3)
61 120 4 (4,5,6)
63 126 5 (4,5,7)
74 150 2.5 (8)
Bovine heart
57 120 10 (9)
59 N.D. 10-15 (3)
Bovine lung
58 130 7 (10)
Mouse Testis
68 180 6 (11)
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TABLE 1.2:
K IN ET IC  CH A R A C TER ISTIC S OF Ca2+ /C A LM O D IJLTN - 
STIMIJLATED PHOSPHODIESTERASE.
References for Table 1.2.
1. Morril, et al.. (1979).
2. Sharma, et al.. (1986a).
3. Sharma and Wang, (1986b).
4. Shenolikar, et al.. (1985).
5. Ho, et al.. (1976).
6. Rossi, et al.. (1988).
7. Purvis, et al.. (1981).
8. Weishaar, et al.. (1986).
9. Vandermeers, et al.. (1983).
KmluMl Xmax&anfll/roiji/mg) Ca2+/CaM
Snuncs PiiDtx 
JPgyine brail)
CAMP cGMP cAMP cGME Effect Bjl
59-kDa (Pure) 150 9 - - Vmax (i)
63-kDa (Pure) 66-70 6-7 1.7 8.0 Vmax»Km (2)
61-kDa (Pure) 68 17 6 17 Vmax, Km (3)
74-kDa (Pure) 
Bovine heart
13.3 4.8 0.12 1.09 Vmax, Km (4)
(Partial) 
Bovine lunp
215,39 9 - - - (5)
(Pure) 
Mouse Testis
88 15 7.15 8.5 Vmax, Km (3)
(Pure)
F a t .Zestis
2,20 2,20 8.8 6.3 Vmax. Km (6)
I (Partial) 1 1 _ _ _ (7)
II  (Partial) 3 3 - - - (7)
III  (Partial)
.Guinea Pig 
Left Ventricle
1.5 (7)
(Partial) 0.8,43 
Bovine Coronav arterv
0.9, 53 - - - (8)
(Partial) 
Rat Pancreas
2.5, 140 3, 17 - - -  - (8)
I Pure 1,4 0.7, 10 _ _ (9)
II  Pure 5, 25 1.5,8.0 - - - (9)
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TABLE 1.3:
ISO ZY M ES OF TH E C Y C L IC  G M P-S T IM U L A T E D  
PHOSPHODIESTERASE
References for Table 1.3
1. Beavo, et al.. (1982).
2. Martins, et al.. (1982).
3. Yamamoto, et al.. (1983a).
4. Whalin, et al.. (1988).
5. Pyne, et al.. (1986a).
Property Bovine. Cardiac Calf liver Rabbit liver Rat liver
(soluble)
References 1,2 3 4 5
Molecular 
Mass (kDa)
(subunit) 102-105 105 105 66-67
(native) 204-230 200 400 134
Apparent Km 
(M-M)
cAMP 36 33 28 40
cGMP 11 15 16 25
Vmax
(pmol/min/mg)
cAMP 120 170 160 4.8
cGMP 120 200 160 1.6
Hill Coefficient
cAMP 1.9 1.5-1.8 - 1.6
cGMP 1.3 1.2-1.6 - 1.0
Ka for cGMP
(pM ) - 0.5 0.35 0.28
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TABLE 1.4:
ISOZYMES OF THE CYCLIC AMP-SPECTFIC PHOSPHO­
DIESTERASES
(a) CYCLIC GMP -INHIBITED PHOSPHODIESTERASES.
References for Table 1.4(a)
1. Degerman, et al.. (1987).
2. MacPhee, et al.. (1986).
3. Grant, et al.. (1988).
4. MacPhee, et al.. (1988).
5. Grant and Colman, (1984).
6. MacPhee, et al.. (1987).
7. Harrison, et al.. (1986b).
8. Boyes and Loten, (1987a)
9. Pyne, et al.. (1987a).
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TABLE 1.4:
TSO ZY M FS O F T H E  C Y C L IC  A M P-SPEC TFIC  P H O S P H O ­
D IE ST E R A S E S
(b) CYCLIC GMP -INSENSITIVE PHOSPHODIESTERASES.
References for Table 1.4(b)
1. Thompson, et al..(1979).
2. Thompson, et al..(19881.
3. Marchmont, et al..(T981b).
4. Conti and Swinnen, (1990)
5. Demazancourt and Guidicelli, (1988).
5. Yamamoto, et al..(T984al.
6. Weishaar, et al..(19861.
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CHAPTER 2.
MATERIALS AND METHODS.
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MATERIALS.
All chemicals used in this study were either from:
Sigma Chemical Company, (Poole, Dorset, U.K.): (o- Aminopentyl
agarose, Butyl agarose, Benzamidine hydrochoride, Chloramine T,
Coomassie Blue R -2 5 0 , Cyanogen bromide activated sepharose -  6B,
*
DEAE -  sepharose C L -6B , Dowex - 1  -  Chloride, Ethylene glycol, Snake 
venom (Ophiophagus Hannah), Isobutylmethylxanthine,
N,N,Nl,N \ -tetramethylethylene diamine (TEMED), Phenyl-
methylsulphonylfluoride (PMSF), Polyoxyethylene sorbitan monolaurate
(Tween-20), Triton -  X -100, Cyclic adenosine 3'5' monophosphate
(cyclic AMP), Cyclic guanosine 3'5' monophosphate (cyclic GMP),
Cyclic 3'5' cytidine monophosphate (cyclic CMP), dipyridamole,
Antipain, Calmodulin agarose, ethylene diamine, 6 -  chloroguanine,
Thimerosol, o -  dianisidine, Pepsin, Sephacryl S -200, Sephacryl S -300.
Boehringer (UK) Ltd., (Lewes, East Sussex, U.K.): Ammonium
persulphate, Ammonium Acetate, Bromophenol Blue, Boric Acid, 
Calcium Chloride, Sodium Deoxycholate, Magnesium Chloride, 
Acrylamide, N,N' -  methylenebisacrylamide, Magnesium Chloride, 
Potassium dihydrogen orthophosphate, Dipotassium hydrogen 
orthophosphate, Sodium Chloride, Sodium deoxycholate, Sodium 
Dodecyl Sulphate (SDS), Tris (hydroxymethylaminomethan) (Tris), 
Acrylamide.
Whatman Ltd. (Maidstone, Kent, U.K.): Diethylaminoethyl cellulose
(D E -52), 3MM filter paper.
Pharmacia Ltd., (Uppsala, Sweden): FPLC system and accessories.
May & Baker Ltd., (Dagenham, Essex, U.K.): Acetic acid,
B u ta n - l - o l ,  Isopropanol.
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Biorad Ltd., (Richmond, California, USA): A ffi-gel blue agarose,
Biorad protein assay.
Kodak Ltd., (Liverpool, U.K.): Kodak XR 320 film.
Amersham International, (Amersham Bucks U.K.): f12 51] -iodine,
[3H ]-cyclic 3’5f guanosine monophosphate, [3H ]-cyclic 3 '5’-adenosine 
monophosphate.
New England Nuclear (NEN), (Du Pont Ltd, Stevenage, Herts. U.K.):
12 s i -  Protein -A .
Schleicher and Schull, (Dassel, Germany): Nitrocellulose.
Millipore (Watford, Hertfordshire, U.K.): 0.22pm single use filters.
Amrinone and Milrinone were gifts from Sterling -  Winthrop Ltd.
(see Bristol, et al., 1984) ICI 63197 and ICI 118233 were kind gifts
from ICI Pharmaceuticals, Macclesfield, Cheshire, U.K. (see Davies, 
et al., 1973). R o - 20-1724 was a gift from Roche Products Ltd., 
Welwyn Garden City Hertfordshire U.K. M&B 22948 and Zaprinast -  
agarose were kind gifts from Pfizer Central Research, Sandwich, Kent, 
U.K.
Horseradish -  peroxidase linked antibody was donated free by the
Scottish Antibody Production Unit (Law Hospital, Carluke, Lanarkshire, 
Scotland, U.K.)
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METHODS
2.1: PREPARATION OF D O W E X -1 -  CHLORIDE.
This was prepared using a modification of the method of 
Pichard and Cheung (1976). 500g of Dowex - 1  -  Chloride (200-400
mesh, Chloride form) was placed in 5 litres of 1M NaOH and gently 
stirred for 15 minutes. The resin was then allowed to settle and the 
NaOH solution poured off and replaced with distilled water. This 
process of washing and settling was repeated until the pH of the water 
was approximately 7. The resin was then suspended in 5 litres of 1M 
HC1 and once again gently stirred for 15 minutes. The washing 
procedure was repeated until the pH of the distilled water was between 
3 and 4. The resin was then made up to a 1:1 suspension in distilled 
water and stored at 4°C.
2.2: CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ASSAY.
A two step radioassay was employed to assess cyclic AMP and
cyclic GMP phosphodiesterase activity. The assay was based upon that
described by Thompson and Appleman (1971). The principle of the 
assay is that [3H] -  labelled cyclic nucleotide ([3H ]-cN M P: on the 8 
position of the adenine or guanine ring) is incubated with the sample 
to allow hydrolysis of the 3’5‘ phosphodiester bond producing a 
[3H] 5 '-N M P  derivative. The [3H] 5 '-N M P  derivative is then 
converted to the corresponding [3H] nucleoside ([3H ] -N )  by
incubating with a source of 5 '-nucleotidase activity. -Routinely this
was provided by the snake venom isolated from Ophiophagus kannah. 
The conditions are such that complete conversion is obtained in 10 
minutes at 30° C. The final step involves the separation of 
unhydrolysed [3H ]-cN M P from [3H ]-N . This is achieved by batch 
binding of the mixture to Dowex - 1  -  Chloride. This removes any
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unhydrolysed [3H ]-cN M P from the nucleoside ([3H ]-N )  because the 
latter is uncharged.
Rutten et al., (1973) demonstrated that tissue preparations 
containing adenosine deaminase can lead to significant underestimations 
of the rate of cyclic AMP hydrolysis in the assay, because this enzyme’s 
activity converts adenosine, produced from cyclic AMP degradation, 
into inosine, which is free to bind to Dowex - 1  -  Chloride. To prevent 
such adsorption, ethanol was used in the Dowex batch binding step.
2.2.1: Phosphodiesterase assay stock solutions.
(a) lOmM cyclic AMP or cyclic GMP in 20mM T ris -H C l pH 7.4 lOmM 
MgCl2: The stock solutions were kept stored at -20°C  and were 
usually used within two months.
(b) 20mM T ris -H C l pH 7.4.
(c) Snake Venom (Ophiophagus hannah): This was prepared by 
dissolving snake venom in distilled deionised water at a concentration 
of lOmg/ml. Aliquots (1ml) were stored at -20°C  and were usually 
used within six months.
(d) Dowex - 1  -  Chloride: This was prepared as described in section 2.1 
and was stored at 4°C as a 1:1 suspension in water.
2.2.2: Phosphodiesterase assay solutions.
(a) [3H] -  cyclic AMP and [3H] -cyclic GMP: The stock solution of 
cyclic AMP or cyclic GMP was diluted in 20mM Tris -  HC1, lOmM 
MgCl2 to give the desired concentration (usually 2pM). To 10 mis of 
this solution was added 30pCi (30pl) of [3H] -  cyclic AMP or 
[3H] -  cyclic GMP.
(b) Snake Venom: This was diluted in water to give a final 
concentration of lmg/ml.
(c) D ow ex-1 -Chloride: Before use in the assay, ethanol (absolute) was 
added to give final proportions of Dowex:water:ethanol of 1:1:1.
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2.2.3: Routine assay of phosphodiesterase activity.
The final volume of the initial reaction mixture was always lOOpl 
consisting of 50pl of radiolabelled substrate in 20mM Tris -  HC1 pH 7.4,
lOmM MgCl2 mixed with 25pl of sample and 25pl of T ris -H C l pH 7.4.
The final concentration of cyclic nucleotide was usually lpM.
2.2.4: Kinetic parameters of isolated phosphodiesterases.
For determination of kinetic parameters, a slighlty altered 
protocol was adopted. Radiolabelled substrate was prepared by adding 
30pCi of stock [3H] -  substrate to 5mls of 20mM Tris -  HC1 pH 7 • 4, 
lOmM MgCl2. Reaction tubes contained 25jil of this radiolabelled
substrate (about 150,000 cpm); cold substrate (at the appropriate 
concentration) was added separately in a volume of 25pi in 20mM 
T ris-H C l pH 7.4, lOmM MgCl2 along with 25pi of sample and 25pi of 
20mM T ris-H C l pH 7.4.
2.2.5: Magnesium dependency of phosphodiesterase activity.
For determining the effect of magnesium on phophodiesterase 
activity, [3H ]-substrate  was prepared in 20mM T ris -H C l pH 7.4 only 
and 50pl added to the assay. Sample was added in 25pi and the
appropriate concentration of MgCl2 added in 25pl of T ris -H C l pH 7.4.
2.2.6: Phosphodiesterase assay: Hydrolytic step.
The reaction mixture was vortexed and incubated at 30°C for a 
time interval, usually 10 minutes, to attain the conversion of cNMP to 
5 '-N M P , and terminated by boiling for 2 minutes.
2.2.7: Phosphodiesterase assay: Conversion step.
After the reaction mixture was cooled to 4°C, 25pg (25pl) of 
snake venom was added and the cocktail vortex mixed and incubated at 
30°C for 10 minutes to attain the complete conversion of 5 '-N M P  to 
N. After this stage the tubes were once more placed on ice and 400pls 
of Dowex - 1  -  Chloride slurry (1:1:1, Dowex:water:ethanol) was added 
and left on ice for at least 15 minutes with occasional vortexing.
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Samples were then centrifuged in a Beckman microcentrifuge at full 
speed for 3 minutes to sediment the resin. A 150pi sample of the 
supernatant was then removed and counted in 4ml of Ecoscint 
scintillation fluid in a Beckman scintillation counter.
In all experiments, great care was taken to ensure that the rates 
of hydrolysis of cyclic nucleotides were linear with respect to time and 
routinely less than 10% of the substrate was hydrolysed. Blank tubes 
were prepared in all experiments containing a boiled (5 minutes) 
sample. This was especially important if the samples contained any 
salt, because it has been demonstrated that increases in ionic strength 
have the effect of reducing the binding of cyclic nucleotide to the 
Dowex resin and hence increasing the apparent amount of nucleoside in 
the supernatant leading to an overestimation of the degree of 
hydrolysis. Such effects are apparent at NaCl concentrations as low as 
0.1M.
2.3: CALCULATION OF PHOSPHODIESTERASE ACTIVITY.
A simple calculation was used to calculate the rates of cyclic 
nucleotide hydrolysis. The values obtained for the apppropriate blanks 
were subtracted from the cpm obtained with the sample and substituted 
in the following equation:
150/391.67 x pmoles of cNMP/time(mins) x cpm/total cpm.
where cpm represents the blank corrected value and pmoles of cNMP 
repesents the total picomoles of cyclic AMP/cyclic GMP in the assay. 
The total cpm value was approximately 150,000 cpm/tube but was 
determined in each experiment to allow for day to day variation in the 
counting efficiency of the scintillation counter
This calculation gives the rate of hydrolysis in pmoles of cyclic 
nucleotide hydrolysed/min. To obtain total activities in a given volume
of solution this figure was then multiplied by
104
total vol(mls)/volume assayed(mls).
Specific activities were then calculated by multiplying by
1/protein in assay(mg).
2.4: ISOLATION OF RAT O V ER  HIGH SPEED SUPERNATANT.
A liver was excised from one male Sprague -  Dawley rat (250 -  
275g), diced using a pair of scissors and rinsed several times in ice cold 
homogenising Buffer ’A' (50mM T ris-H C l pH 7.5, 0.25M Sucrose, 5mM 
Benzamidine hydrochloride, 0.2mM PMSF, 20jxM leupeptin, O.lmM 
EGTA, and O.lmM dithiothreiotol). PMSF was added immediately 
before use from a stock solution of 35 mg/ml in ethanol. The liver 
was then homogenised using 5 up/down strokes on a rotating pestle 
(setting 5) at approximately 1:4 (v/v). Great care was taken to ensure 
that the homogenate was kept cool during this procedure. The 
resultant homogenate was then passed through two layers of muslin into 
a beaker on ice. The final volume of homogenate was generally 
between 40 and 50 mis for one rat liver. All subsequent operations 
were carried out at 4°C.
The homogenate was centrifuged for 10 mins. at 706g<zv 
(Beckman JA -2 0  rotor) to obtain a low speed pellet (PI) and 
supernatant (SI). The pellet was discarded and the supernatant was 
recentrifuged (Beckman Ti -  60 rotor) at 163,570gnv for 60 mins. to 
obtain the high speed supernatant (S2) and pellet (P2). The 
supernatant was carefully decanted to avoid any fat deposits and the 
pellet discarded. An identical protocol was used for the preparation of 
high speed supernatants from other tissues such as kidney, brain, and 
adipocytes.
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2.5: ISOLATION OF A HIGH SPEED SUPERNATANT FROM
RAT HEPATOCYTES.
Hepatocytes were prepared by a method used routinely in the 
laboratory (Smith, et al., 1978; Elliot, et al., 1976; Heyworth, et al., 
1983d). Essentially, hepatocytes were prepared by collagenase digestion 
in the presence of 0.01% (w/v) Trypsin inhibitor. Isolated cells were 
washed three times in Ca2+-f re e  Krebs buffer by repeated 
resuspension and pelleting at 600rpm (MSE Centaur) for 2 minutes 
(three 80ml washes per 10ml of packed cells). Washed cells were used 
without further incubation. Cell viability was assessed by the ability of 
cells to exclude the dye Trypan Blue and was always greater than 90% 
in all preparations used. It was noted on some occasions that despite 
the ability of cells to exclude Trypan Blue, very poor yields of 
phosphodiesterase activity were obtained and that significant quantities 
of phosphodiesterase activity could be detected in the washes from the 
cells indicating that Trypan Blue was not a reliable indicator of cell 
viability with respect to maintenance of phosphodiesterase content. 
Consequently, the cellular ATP levels were also checked (see Section 
2.6); only cell preparations containing a cellular ATP content in the 
range of 9 -1 0  nmol/mg dry weight were used as valid.
Cells were homogenised in ice cold Buffer ’A' (see section 2.4) 
at 1:4 (v/v) using fifteen up/down strokes in a tight fitting pestle. The 
final volume of homogenate was approximately 40 mis. A high speed 
supernatant was then prepared exactly as for a rat liver supernatant.
2.6: MEASURING HEPATOCYTE ATP CONTENT.
Hepatocyte ATP content was determined by a firefly luciferase
assay.
2.6.1: Extraction of intracellular ATP.
The stock solutions used were;
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(a) 20% (w/v) Perchloric acid (PCA)
(b) 0.5M Triethanolamine, 2M Potassium Hydroxide (TEA/KOH).
(c) Univeral indicator (diluted 1/10 in water).
Cells were pelleted at 600rpm (MSE Centaur) for two minutes 
and the supernatant discarded. The cell pellet was resuspended in 
0.5ml of Krebs -  Heinslet and 50pl of 20% PCA were added with 
mixing. The mixture was neutralised with approximately lOOjxl of 
TEA/KOH. Neutralisation was checked by adding about 2pl of this 
extract to 1ml of 1/10 diluted universal indicator. The extract was 
centrifuged to pellet precipitated protein and the supernatant saved and 
frozen at -20°C  as lOOpl aliquots.
2.6.2: ATP Measurement: Luciferase Assay.
The stock solutions used were;
(a) 80mM M gS04
(b) lOmM KH2P 0 4 pH 7.4
(c) lOOmM Na2H A S04
These were mixed at a 1:1:1 ratio just prior to use.
(d) ATP standard solutions in KH2P 0 4 (30, 20, 10, 5 and I jiM)
(e) Luciferin/Luciferase reagent (Sigma F L E - 50 = dried lantern extract). 
This was resuspended in 5ml of water and hand homogenised and 
stored in the dark at 4°C.
(f) Glass vials were washed with NaOH and then HC1 to reduce 
photoemission.
3mls of 1:1:1 buffer were added to one glass vial and 5 pi of 
sample added and left for 15 minutes at 4°C. In the absence of 
flourescent light, 50pl of Luciferin/Luciferase was added and the sample 
counted immediately on an LKB Scintillation counter using a wide 
open channel (5-1024).
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2.7: PROTEIN DETERMINATIONS.
Protein concentrations were determined using a Bio -  Rad assay 
kit (Bradford, 1976; Spector, 1978) for soluble proteins and a modified 
Lowry assay for membrane proteins (Peterson, 1977).
2.8: SUBCELLULAR FRACTIONATION OF HEPATOCYTES.
Hepatocytes were prepared and homogenised as described for the 
preparation of high speed supernatants (Section 2.4) and were similarly 
fractionated to produce low speed PI and SI fractions. The resultant 
PI fraction was washed to release any trapped soluble activity by 
resuspending in ice cold Buffer ’A ' using 5 up/down strokes in a tight 
fitting pestle. This was centrifuged to produce a further SI and PI 
fraction. This washing procedure was repeated once more to yield 
another SI and PI fraction. This PI was the 'washed PI fraction'. The 
three SI fractions were then spun at 163,570gav (Beckman T i-6 0  rotor) 
for 60 minutes at 4°C to yield separate S2 and P2 fractions.
2.9: D E -5 2  SEPARATION OF RAT LIVER SOLUBLE PDEs.
This was performed using chromatography on the anion -  
exchange resin D E -5 2 .
2.9.1: Equilibration of the anion-exchange matrix (D E -52 ).
All operations were carried out at 4°C. Approximately lOg of 
D E -5 2  was equilibrated in 50mM T ris -H C l pH 7.5 by repeated 
resuspension and settling in the equilibration buffer. After 
approximately 2 litres of buffer had been passed onto the matrix (4 x 
500ml changes) the matrix was poured into a column (final dimensions 
3.0cm x 1.4cm). The column was then washed with a further 20 bed 
volumes (approximately lOOmls) of running buffer, Buffer 'B', (50mM 
T ris-H C l pH 7.5, 5mM benzamidine hydrochloride, 0.2mM PMSF, 2pM 
leupeptin, O.lmM EGTA, and O.lmM dithiothreitol). The column was
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considered to be equilibrated when the pH of the eluant from the 
column was exactly 7.5.
2.9.2: Separation of soluble cyclic nucleotide PDE activties.
All operations were carried out at 4°C. The column was loaded 
with the high speed supernantant prepared from rat liver homogenates 
using a peristaltic pump set at 1.5ml/min and was then washed with 
approximately 100 ml of Buffer 'B' at lml/min. Under these 
conditions >95%  of the phosphodiesterase activity (assessed at lpM  
cyclic AMP or cyclic GMP) was bound to the column. 
Phosphodiesterase activity was subsequently eluted at lm l/m in using a 
400ml linear salt gradient between 0 and 0.5M NaCl contained in Buffer 
*Bf. 4ml fractions were collected and aliquots (25pl) assayed for cyclic 
AMP and cyclic GMP phosphodiesjJ’ase activity.
2.10: ASSAY OF CALMODULIN FROM COLUMN FRACTIONS.
Fractions of column eluates from ion-exchange chromatography 
steps were boiled for 5 minutes in order to destroy any endogenous 
phosphodiesterase activity, whilst retaining heat stable Calmodulin. 
Aliquots (10pl) were assayed for their ability to stimulate a Calmodulin 
deficient preparation of Calmodulin -  stimulated phosphodiesterase (see 
Section 2.17). The assay was performed in the presence of lpM  cyclic 
GMP as substrate and lOOpM calcium. This concentration of calcium 
was found to be saturating for the buffer system used. The final 
concentration of EGTA in the assay was always 35jiM.
2.11: D E -5 2  PEAK I CHROMATOGRAPHY ON A F F I-G E L  BLUE.
Pooled fractions from Peak I of the DE -  52 chromatography 
step were made up to 5mM MgCl2 and loaded at 0.5ml/min onto a 
column of A ffi-gel blue (1.8 x 1.1cm) which had previously been 
equilibrated in Buffer 'C', (50mM T ris-H C l pH 7.5, 0.15M NaCl, 5mM 
MgCl2, 5mM Benzamidine hydrochloride, 0.2mM PMSF, 2pM leupeptin,
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O.lmM EGTA and O.lmM dithiothreitol). Total unbound protein was 
collected and the column was washed in 8 bed volumes of Buffer 'C', 
which was collected as a pooled fraction. All operations were carried 
out at 4°C.
2.12: MONO Q ANION -  EXCHANGE CHROMATOGRAPHY.
This was performed using the Pharmacia Fast Performance 
Liquid Chromatography system (FPLC).
2.12.1: Mono Q column (HR 5/5) equilibration and maintenance.
All buffers and solutions were filtered through a 0.2pm filter 
before use, to remove any particles that could clog .the resin. The 
Mono Q column was stored in 25% ethanol and was equilibrated before 
use using the programme shown in Table 2.1. The composition of 
Buffer ’A* was 50mM T ris-H C l pH 7.5, 5mM Benzamidine 
hydrochloride, 0.2mM PMSF, 2pM leupeptin, O.lmM EGTA and O.lmM 
dithiothreiotol. Buffer 'B' contained in addition 0.5M NaCl. The 
column was kept immersed in an ice jacket for the duration of the 
equilibration and the experiments. At the end of an experimental run 
the column was washed in 25ml of 1.0M NaCl in distilled deionised 
water and stored in 25% ethanol. After approximately 10 runs the
column was cleaned to remove any material bound to the matrix. The
protocol adopted was as follows:
The column was left overnight in a solution of 1 mg/ml pepsin, 
0.1M acetic acid and 0.5M NaCl at a temperature of 37°C. This
procedure removed any bound protein material. The column was rinsed 
thoroughly in water and then cleaned using a chemical 'scrubbing' 
protocol as follows:
The column was inverted and 500pl of 2M NaCl injected onto
the column and rinsed thoroughly in distilled water.
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500jil of 2M NaOH was then injected onto the column and 
rinsed with deionised water.
Finally, the column was injected with 500jxl of 75% acetic acid 
and washed overnight in 500ml of deionised water and then stored in 
25% ethanol.
2.12.2: Separation of soluble cyclic nucleotide phosphodiesterases.
High speed supernatants from rat liver (20ml containing
approximately 120 mg of protein) or hepatocytes (30ml containing 
approximately 80 mg of protein) were loaded at lm l/m in onto the 
Mono Q column and the column washed with approximately 1 bed 
volume of Buffer ’A' (see Section 2.12.1). Under these conditions 
greater than 95% of the cyclic AMP and cyclic GMP 
phosphodiesterase activity (assessed at lpM  substrate) bound to the 
column. Phosphodiesterase activity was then eluted at lm l/m in using a 
95ml gradient of NaCl (0-0 .5M ) in Buffer 'A', as is indicated in Table
3.2. Fractions of 1ml were collected on ice and 25pi aliqouts assayed 
for phosphodiesterase activity. A similar protocol was adopted for the 
separation of soluble phosphodiesterase activities from other rat tissues 
including adipose tissue, kidney and brain.
2.13: BINDING OF PDE M Q -I/P D E  M Q -II  TO A F F I-G E L  BLUE.
Pooled fractions from each of the first two peaks of the Mono 
Q column step (PDE M Q -I  and PDE M Q -II)  were each made up to 
5mM MgCl2 and individually incubated with portions of A ffi-ge l Blue. 
Affi -  gel blue was equilibrated by resuspending 100pl portions of the 
matrix in 1ml of Buffer 'A ', (50mM T ris -H C l pH 7.5, 5mM
Benzamidine hydrochloride, 0.2mM PMSF, 2pM leupeptin, O.lmM 
EGTA and O.lmM dithiothreitol) containing 5mM MgCl2 and 0.1M
NaCl, mixing briefly (5mins) and pelleted as below. This was repeated 
five times. Binding was performed by mixing 0.75ml of each peak with 
lOOpl (packed volume) of Affi -  gel Blue matrix for 30 minutes on a
ill
rotaiy mixer at 4°C. The gel was pelleted using a refrigerated 
microcentrifuge (Hettich) at full speed (14,000gav) for 1 minute and the
supernatant containing unbound material removed. The pelleted gel
was washed by adding 1ml of Buffer 'A* (50mM T ris -H C l pH 7.5,
5mM Benzamidine hydrochloride, 0.2mM PMSF, 2pM leupeptin, O.lmM 
EGTA and O.lmM dithiothreitol) containing 5mM MgCl2 and 0.1M 
NaCl, mixing for a further 10 minutes and pelleted as before. This was 
repeated once more and the two washes pooled to give a combined 
wash (2ml). Phosphodiesterase activity in both the unbound and the
wash fractions was determined. Total unbound activity was determined 
by summing the activity from the binding step with the activity 
retrieved by washing.
2.14: EFFECT OF AGENTS ON RESOLVED PDE ACTIVITIES.
Fractions were carefully pooled from the m id -po in t of peaks to 
minimise any cross contamination from neighbouring activities. For 
Mono Q resolved activities generally three of four fractions (3 or 4 mis) 
were chosen for study. For DE -  52 peaks approximately 3 fractions 
were chosen (12mls). Activities were diluted where necessary in Buffer 
'A' (50mM T ris-H C l pH 7.5, 5mM Benzamidine hydrochloride, 0.2mM 
PMSF, 2pM leupeptin, O.lmM EGTA and O.lmM dithiothreitol). In all 
instances the volume assayed was 25pi. Agents were diluted to the 
required concentration in 20mM T ris -H C l pH 7.4 and effects 
compared with tubes that received 20mM Tris alone. The final 
concentration of EGTA in the assay was always 25pM.
2.15: DETERMINATION OF IC50 VALUES FOR INHIBITORS ON
RESOLVED PHOSPHODIESTERASE ACTIVITIES.
Phosphodiesterase inhibitors were dissolved in DMSO at a stock 
concentration of 25mM and subsequently diluted in 20mM T ris -H C l 
pH 7.4 to provide a range of concentrations. In order to correct for
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the effect of DMSO on resolved phosphodiesterase activities dose 
response curves were constructed to DMSO to allow for appropriate 
corrections to be made. It was assumed that the effect of DMSO and 
the inhibitory agents were additive. IC50 values were determined at 
lpM  substrate concentration using either cyclic AMP or cyclic GMP 
and a minimum of three concentrations for insensitive forms and five 
to seven for sensitive forms.
2.16: DETERMINATION OF KINETIC PARAMETERS OF PDEs.
Peak I from the Mono Q step was subjected to a further 
chromatographic step to minimise any possible residual contamination 
from Peak II. Pooled fractions from the ion-exchange step were made 
up to 5mM MgCl2 and applied at 40 m l/hr to a column of A ffi-g e l 
Blue (2.2cm x 0.76cm) previously equilibrated in Buffer 'C* (50mM 
T ris-H C l pH 7.5, 0.15M NaCl, 5mM MgCl2, 5mM Benzamidine
hydrochloride, 0.2mM PMSF, 2pM leupeptin, O.lmM EGTA and O.lmM 
dithiothreitol). Total unbound activity was collected and the column 
washed with four 2ml washes of Buffer 'C*. Washes containing the 
majority of the phosphodiesterase activity were pooled with the 
unbound activity and used in the kinetic determinations. Peaks I I - V ,  
from the Mono Q step, were used without any further purification. 
Phosphodiesterase activity was assessed using the modified protocol 
detailed in Section 2.2.4. The final Mg2+ concentration in the kinetic 
determinations was 7.5mM. All assays were done in triplicate and great 
care was taken to ensure that the rate of hydrolysis was linear with 
respect to time and that no more than 10% of the substrate was 
hydrolysed.
2.17: GEL FILTRATION OF RESOLVED PHOSPHODIESTERASES.
The molecular weights of PDE M Q -1  and M Q -I I  were 
determined using gel filtration either on Sephacryl S -2 0 0  (PDE M Q -1 )
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or Sephacryl S -3 0 0  (PDE M Q -II) . Samples of pooled PDE M Q -I  
and PDE M Q -II  were applied to S -2 0 0  (66cm x 1.6cm) and S -3 0 0  
(83cm x 1.6cm) columns respectively. These columns had been 
previously equilibrated in 50mM T ris -H C l pH 7.4, 0.1M NaCl and 
O.lmM EGTA. Columns were run at 8 m l/hr at 4°C in this buffer and 
fractions were collected and assayed for phosphodiesterase activity. 
Columns were calibrated using proteins of known molecular weight, 
namely; cytochrome c (12,400), carbonic anhydrase (29,000), ovalbumin
(45.000), bovine serum albumin (66,000), alcohol dehydrogenase
(150.000), catalase (232,000) and ferritin (440,000). Samples of protein 
( l-2 m g ) were applied to each column and detected either by 
absorbance at 280nm (410nm for ferritin) or by Bradford analysis with 
detection at 595nm. The inner and void volumes were determined 
using e - D N P -  Lysine and B lue-D extran respectively. These were 
detected at both 610nm and 410nm respectively.
2.18: STANDARD CALMODULIN ASSAY.
Calmodulin activity was determined using a Calmodulin-  
deficient beef heart phosphodiesterase.
2.18.1: Bovine Heart Calmodulin -  deficient phosphodiesterase.
500mU of enzyme was resuspended in 2mls of 20mM T ris -H C l 
pH 7.4, 50% (v/v) glycerol and aliquoted into 50pl aliqouts each 
containing 12.5mU of enzyme activity. These were stored at -2 0 °C  
until further use.
2.18.2: Sample preparation.
Column fractions were boiled for 5 minutes to destroy any 
associated phosphodiesterase activity and spun at maximum speed in a 
microfuge to pellet any denatured protein. They were then diluted 
1/300 in 20mM T ris-H C l pH 7.4 prior to assay.
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2.18.3: Calmodulin assay.
For a standard assay, one aliquot (50jil/12.5mU) of enzyme was 
diluted in 0.575mls of 20mM T ris-H C l pH  7.4, 5mM MgCl2 to give a 
final concentration of 20 mU/ml. The assay cocktail consisted of 30jil 
of 20mM T ris -H C l pH 7.4, 50pl of enzyme (ImU), iOpl of 1.5mM 
CaCl2, 50|il of ljiM cyclic GMP (containing approximately 200,000 cpm 
of [3H] — cyclic GMP) and 10pl of sample. The final volume of the 
assay was 150pl. The final concentration of cyclic GMP was 0.33 pM,
whilst the total added CaCl2 concentration was lOOpM. Where EGTA
was present in the sample the concentration in the assay was 0.44pM. 
Phosphodiesterase activity was determined using the standard two step 
assay detailed in Section 2.2.
2.19: PURIFICATION OF CALMODULIN FROM PIG BRAIN.
2.19.1: Preparation of pig brain extract.
3 pig brains (285g) were excised from freshy killed pigs which 
had received a lethal dose of barbiturates. Brains were transported 
immediately to the laboratory on ice and were stored at -80°C  
overnight. This was accomplished within three hours of death. Brains 
were defrosted using a microwave set on ’defrost'. All subsequent 
operations were carried out at 4°C. The material was sliced using a 
scalpel blade and homogenised in 4% TCA at a final concentration of
25% (w/v) using a Waring blender.
The resulting homogenate was centrifuged at 9,470g<zv (6 x 250ml 
rotor) for 30 minutes in a Sorvall RC5B centrifuge at 4°C. The 
supernatant was discarded and the pellet resuspended in 400mls of 
T ris -C a 2+ buffer (50mM T ris-H C l, pH 7.5, 5mM CaCl2, O.lmM 
PMSF) using a polytron. The pH of the suspension' was adjusted to 
7.5 using 3M Tris base (between 10 and 20 mis were usually required). 
The suspension was stirred for 20 minutes on ice to allow renaturation 
of precipitated Calmodulin to occur. The extract was then heated to
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65°C for 10 minutes and allowed to cool to 4°C before readjusting the 
pH of the solution to 7.5.
The extract was then spun at 48,250gav for 1 hour in either 
Sorvall S S -34  or Beckman JA -2 1  rotors. The supernatant was
decanted and respun at the same speed for a further 30 minutes. The 
supernatant was once again decanted and the milky white pellet 
discarded. This extract (approximately 300mls) was used as the source 
for the purification of Calmodulin.
2.19.2: Phenyl -  Sepharose Chromatography.
The supernatant was applied to a 9ml column of Phenyl -  
Sepharose C L -4B  (3.2cm x 1.9cm) stopped with glass wool at a rate of 
2ml/min. The eluate was collected and reapplied to ensure maximal 
binding to the resin. The column was washed with T r is -C a 2+ buffer 
at approximately 1.5 ml/min followed by approximately lOOmls of 'Tris -  
Ca2+ buffer containing 0.5M NaCl until no protein was found to be 
eluting as determined by Bradford assay (see Section 2.6). Calmodulin 
was eluted from the column at a slow rate overnight (approximately 
0.2 ml/min) using T ris-E D T A  buffer (50mM T ris-H C l, pH 7.5, 2mM 
EGTA, O.lmM PMSF) and one hundred 1ml fractions were collected. 
The protein content of the fractions was determined using the Bradford 
assay.
2.19.3: Dialysis of partially purified Calmodulin.
Fractions containing Calmodulin activity (about 20mls) were 
pooled and dialysed against 15mM ammonium acetate pH 8.0 in dialysis 
tubing which had been p re-soaked  in 1% BSA solution to prevent 
adsorption of Calmodulin to the tubing. Dialysis took place at 4°C 
against 5 litres of buffer with two 5 litre changes over a 48hr period.
2.19.4: Mono Q anion -  exchange chromatography.
The dialysed Calmodulin sample was diluted to 50mls in 50mM 
T ris-H C l pH 7.4, ImM EDTA. The sample was applied at 2 ml/min 
to a Mono Q column previously equilibrated in 25mM T ris -H C l pH
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7.4, ImM EDTA. The column was washed at 1 ml/min in 25mM Tris -  
HC1 pH 7.4, ImM EDTA until the A265 was equal to zero. 
Calmodulin was eluted at 1 ml/min using a linear salt gradient between 
0 and 1M NaCl contained in 25mM T ris -H C l pH 7.4, ImM EDTA. A 
major peak of activity which coincided with protein was routinely 
observed eluting at approximately 0.35M NaCl.
2.19.5: Analysis of Calmodulin purity.
The purity of the Calmodulin preparation was determined by 
SD S-PA G E using a 3% stacking gel and a 15% resolving gel (see 
Section 2.20). Calmodulin samples were applied in Laemmli sample 
buffer containing in addition ImM EGTA or lOmM CaCl2. Gels were 
fixed and stained in Coomassie Brilliant Blue and destained as in 
section 2.21. The preparations routinely displayed a significant increase 
in mobility in the presence of calcium, a well defined property of 
Calmodulin. See Figs 2 .1-2 .3  for a typical purification. Such 
preparations were judged to be homogenous. Protein content of the 
preparations was determined by the method of Bradford (1976).
2.19.6: Dialysis of purified Calmodulin.
The purified Calmodulin preparation (5 -  lOmg in 7mls) was 
dialysed against 3 x 5  litre changes of 0.1M Sodium Borate pH 8.2, 
ImM MgCl2, 0.02mM CaCl2 at 4°C for 72 hrs. Such an extensive 
dialysis was necessary to remove the Tris buffer which will interfere 
with the coupling of the Calmodulin to the Cyanogen brom ide-  
activated Sepharose since it contains amino groups.
2.20: PREPARATION OF CALMODULIN -  SEPHAROSE.
Briefly, Calmodulin purified from porcine brain was coupled to 
Cyanogen bromide -  activated Sepharose by the method of Klee and 
Krinks (1978).
117
2.20.1: Preparation of Cyanogen bromide -  activated Sepharose.
2g of Cyanogen bromide activated -  Sepharose -  4B were swelled 
to 7.5mls on a scintered glass funnel by washing with 200mls of ImM 
HC1 under a vacuum. The swollen gel was then prewashed in 40mls of 
Coupling buffer (0.1M Sodium Borate, pH 8.2, ImM MgCl2, 0.02mM 
CaCl2).
2.20.2: Coupling step.
The dialysed Calmodulin preparation from the previous step was 
diluted 1:1 in coupling buffer and mixed with the gel slurry overnight 
at 4°C on a rotary mixer. Uncoupled Calmodulin was removed (and 
retained for analysis) and the gel washed with 200mls of Coupling 
buffer.
2.20.3: Blocking step.
The gel slurry was then resuspended in 0.5M ethanolamine pH 
8.0 and mixed at 4°C for 2 hours on a rotary mixer. The Calmodulin -  
Sepharose was then washed in 0.02M T ris-H C l, pH 8.0, ImM MgCl2. 
It was stored at 4°C in this buffer in the presence of 0.02% azide.
2.21: NON DENATURING POLYACRYLAMIDE GELS.
Electrophoresis was performed in a discontinuous gel system, 
stacking occuring at pH 6.67 and resolution occuring at pH 8.83.
2.21.1: The Resolving gel.
Tube gels (15cm x 0.45cm) which had been thoroughly cleaned 
and soaked in chromic acid were used on all occasions. The following 
buffer solutions (filtered through 0.2pm millipore filter)' were used in 
preparation of the resolving gels:
(a) Resolving gel acryalamide stock: (40%T, 2%C), (10.4% w/v 
Acrylamide, 0.266% w/v N,N,methylenebisacrylamide).
(b) Resolving gel buffer stock: (1.5M T ris-H C l, pH 8.83).
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(c) Potassium Persulphate/Riboflavin/solution: (0.06% w/v potassium
persulphate, 0.002% w/v riboflavin). This was prepared fresh just 
before use.
Resolving gels were prepared at a total monomer concentration 
of 10% acrylamide with 2% crosslinks. A  maximum of twelve gels 
could be run at any one time.
For twelve 10% polyacrylamide gels, 6ml resolving gel acrylamide 
stock, 6ml resolving gel buffer stock, 6ml freshly made potassium 
persulphate/riboflavin solution and 6ml of distilled water were mixed in 
a brown bottle on ice. The gel mix was deaerated by stirring on ice 
for 5 minutes while attached to a vacuum pump. Triton X - 100 (20% 
v/v) (240pl) and TEMED solution (10% v/v) (240jil) were added in 
order to initiate polymerisation. Gel mix (1.6ml) was added to the 
glass tubes to form gels of approximately 6cm in length. The top of 
the gels were overlayed with distilled water and photopolymerised by 
illuminating with fluorescent light at 4°C for 30 minutes. After 
polymerisation was complete, the gel surface was rinsed 2 - 3  times with 
distilled water, residual water removed by aspiration and the tubes dried 
carefully.
2.21.2: The Stacking gel.
Stock buffers used for the prepartion of stacking gels were 
filtered as before and consisted of:
(a) Stacking gel acrylamide stock: (8%C, 20%T), (6.4% w/v acrylamide, 
1.6% w/v N,N,methylenebisacrylamide).
(b) Stacking gel buffer stock: (0.244M T ris -H C l pH 6.67).
(c) Potassium Persulphate/Riboflavin/solution: (0.06% w/v potassium 
persulphate, 0.002% w/v riboflavin).
Stacking gels were prepared at a total monomer concentration of 
3.5% acrylamide with 20% bisacrylamide crosslinks. It was essential
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that the volume of the stacking gel (usually 700jxl) was at least twice 
that of the sample volume loaded onto the gel.
For twelve gels, 6ml of stacking gel acrylamide stock, 3ml of 
stacking gel buffer stock and 3ml of potassium persulphate/ribolfavin 
solution were mixed in a brown bottle on ice. The gel mix was 
deaerated before adding 120pl each of Triton X -1 0 0  (20% v/v) and 
TEMED solution (10% v/v) to initiate polymerisation. The gel mix 
(700jil) was poured into the tubes, overlaid with distilled water and 
photopolymerised as described for the resolving gel.
2.213: Anode and cathode buffers.
(a) The final composition of the anode buffer was, 0.0625M T ris -H C l 
pH 7.51.
(b) The final compostion of the cathode buffer was, 0.0426M T ris -H C l 
pH 8.90, 0.0461M glycine, 02%  (v/v) Triton X -100 .
2.21.4: Sample application to gels.
Samples were made up to 270pl with cathode buffer and a 
further 30pl of cathode buffer containing 2% (v/v) Triton X -1 0 0  and 
Amaranth dye (sufficient for the pink dye to be visible when loaded on 
the gel) added. After removal of the parafllm from the ends to the 
glass tubes and rinsing of the gel surface 2 - 3  times with distilled water, 
300pl of sample was loaded onto the gel and overlaid with cathode 
buffer containing 0.2% (v/v) Triton X -1 0 0  to the top of the tube.
2.21.5: Electrophoresis running conditions.
Electrophoresis was perfomed at 4°C using an LKB power pack 
and a twelve tube gel apparatus. Anode and cathode buffers were 
cooled to 4°C overnight. Running conditions were as follows; voltage 
was fixed at 100V whilst the dye boundary moved through the stacking 
gel (running time approximately 4 hours) and 160 -  180V while the 
boundary moved through the resolving gel. Throughout electrophoresis 
a current in excess of 0.8mA per gel was avoided if possible.
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2.21.6: Gel slicing and elution of phosphodiesterase activity.
Electrophoresis was considered to be complete when the dye 
boundary reached the end of the resolving gel. Gels were extruded 
from tubes by using a needle and syringe to force distilled water up the 
inner rim of the tube until the gel was free. The white stacking gel 
was discarded and the gel sliced into 1 -2m m  slices using a scalpel 
blade. Gel slices were incubated in lOOjil of elution buffer containing 
20mM T ris -H C l pH 7.5, O.lmM EGTA and 2mM p -  mercaptoethanol 
and shaken overnight before samples were taken for assay of 
phosphodiesterase activity.
2.22: SODIUM PODECYL SULPHATE POLYACRYLAMIDE GEL
ELECTROPHORESIS (SD S-PA G E).
2.22.1: Stock solutions.
The following stock solutions were used in all SD S-PA G E  gels:
(a) Buffer 1 (1.5M T ris -H C l pH 8.8, 0.4% (w/v) SDS)
(b) Buffer 2 (0.5M T ris -H C l pH 6.8, 0.4% (w/v) SDS)
(c) Acrylamide/Bisacrylamide (30% (w/v) Acrylamide, 0.8% (w/v)
N,N,methy lenebisacrylamide).
(d) Electrophoresis Buffer (0.025M Tris, 0.192M glycine, 0.1% (w/v)
SDS).
(e) Ammonium Persulphate solution (10% (w/v) ammonium persulphate
in water).
(f) Laemmli sample buffer (30% (w/v) urea, 5% (w/v) SDS, 50mM 
Tris -  HC1 pH 8.0, 6% (w/v) dithiothreitol (added fresh before use) and 
a trace amount of Bromophenol blue).
2.22.2: Preparation of the lower (resolving) gel.
For one 10% gel the following were mixed with stirring, 10.4mls 
of water, 7.5mls of Buffer 1, lOmls of Acrylamide :Bisacrylamide, 2mls of
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50% (v/v) glycerol, 112.5jxls of ammonium persulphate. Polymerisation 
was initiated by the addition of lOpls of TEMED. The solution was 
poured between the plates and gently overlayed with water to form an 
interface.
For one 15% resolving gel, the following volumes were mixed; 
4.4mls of water, 7.5mls of Buffer 1, 15mls of Acrylamide:Bisacrylamide, 
3mls of 50% (v/v) glycerol, 7|ils of TEMED, and 87.5pis of ammonium 
persulphate solution.
2.22.3: Preparation of the upper (stacking) gel.
For one 5% stacking gel the following were mixed with stirring, 
8.725mls of water, 3.75mls of Buffer 2, 2.525mls of
Acrylamide’.Bisacrylamide, 0.3mls of ammonium persulphate. 
Polymerisation was initiated by the addition of 10pl of TEMED. The 
gel was poured around a comb (usually 10 spaces).
3% stacking gels were used in some instances, consisting of: 
9.75mls of water, 3.75mls of Buffer 2, 1.5mls of 
Acrylamide:Bisacrylamide, 150pls of ammonium persulphate and 8pls of 
TEMED.
2.22.4: Sample preparation and application to gels.
Samples containing O.lpg-lOOpg of protein were mixed with 5 0 -  
lOOpl of Laemmli sample buffer and boiled for 5 minutes in a boiling 
water bath. P r e -  stained molecular weight markers were used in all 
preparations and contained standard proteins of molecular weights 
210-kD a, 97-kD a, 68 -kD a, 45-kD a, 2 5 -k D a , 18 -kD a and 14-kD a.
Boiled samples were applied to gels using a hamilton syringe, 
care being taken to avoid spillage of the material into adjacent wells.
2.22.5: Precipitation of samples for SD S-PA G E.
For samples that were in a very dilute solution, a precipitation 
protocol was adopted involving the use of trichloroacetic acid and 
sodium deoxycholate. The following stock solutions were used;
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(a) 2% (w/v) sodium deoxycholate
(b) 24% (w/v) trichloroacetic acid (TCA)
(c) Neutralising solution (1.0M T ris-base)
25|xl of sodium deoxycholate was added to the sample and the
volume made up to 3mls with water. 1ml of TCA was then added and
precipitation allowed to occur at room temperature for 2 minutes. The 
cloudy suspension was spun at setting 7 in a Beckman TJ -  8 centrifuge 
for 20 minutes. The supernatant was aspirated off and the tubes
inverted over tissue to remove as much of the TCA as possible. 20jil 
of T ris-B ase  was added to neutralise the pellet. The pellet was 
solubilised in Laemmli sample buffer as in Section 2.22.4. In cases 
where the Bromophenol blue indicator was yellow then further aliquots 
of T ris-B ase  were added until a blue colour was obtained.
2.22.6: Electrophoresis conditions.
Electrophoresis was performed on an LKB two gel apparatus. 
Gels were normally run at a constant current of 60mA and a voltage of 
300V for approximately 2Vi hours or until the Bromophenol Blue
tracking dye reached the end of the gel. Gels were cooled where 
possible to prevent excessive heating and consequent distortion of the 
resolved bands.
2.23: COOMASSIE BLUE STAINING OF SD S-PA G E  GELS.
SD S-PA G E gels were fixed and stained in a solution of 0.25% 
Coomassie Blue (Brilliant Blue R250 form) in 5:1:5, watenacetic 
acid:methanol, for at least one hour at room temperature. Destaining 
was performed in the same solution lacking the Coomassie Blue R250.
2.24: SILVER STAINING OF SD S-PA G E  GELS.
The method adopted was based on that of Wray, et al., (1981)
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2.24.1: Silver staining solutions.
All solutions were prepared using distilled and deionised water. 
To stain one gel the following solutions were prepared:
(a) 50% (v/v) Methanol (Bulk), 200mls
(b) Solution 'A': 20% (w/v) silver nitrate, 4mls
(c) 0.3% (w/v) sodium hydroxide, lOOmls
(d) Solution ’B': 21mls of 0.3% (w/v) sodium hydroxide solution, 1.4mls 
of 14.8M ammonium hydroxide.
(e) 1M Citric acid.
(f) Developer: 0.12 mis of 1M Citric acid and 0.25mls of 38% 
formaldehyde solution. These were mixed and the volume increased to 
500mls with distilled deionised water. This solution was prepared fresh 
just prior to use.
2.24.2: Silver staining proceedure.
SD S-PA G E  gels to be silver stained were fixed in 50%
methanol overnight (3 x 200ml changes) to fix the proteins in the gel 
and allow for the removal of glycine. Since glycerol and urea produce 
high backgrounds these were removed by transferring the methanol 
fixed gel to water and allowing it to swell. The water was changed 
several times to allow for the diffusion of urea and glycerol out of the 
gel. The use of acetic acid in the fixing procedure was avoided since
this has been shown to inhibit the silver staining reaction.
4mls of solution ’A' was added dropwise to solution 'B' with
constant stirring and the volume increased to lOOmls with water. This 
solution was used within 5 minutes The gel was placed -in this mixture 
in a clean container and left for 15 minutes on an orbital shaker.
The gel was then washed in deionised water for 1 hour at 40°C 
(4 x 200ml washes). The gel was then incubated in fresh developer 
until the , appearence of protein bands. In some instances the 
appearance of bands was enhanced by the addition of further aliquots
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of formaldehyde to the developer solution (0.25mls per 500mls). Gels 
were removed and washed extensively in water and then placed in 50% 
(v/v) methanol to stop the reaction.
2.25: DESTAINING SILVER STAINED SD S-PA G E  GELS.
2.25.1: Destaining solutions.
To destain one SD S-PA G E  gel the following reagents were
prepared;
(a) Reagent A ': A  150ml solution containing 4.9% (w/v) sodium
chloride and 4.9% (w/v) Copper (II) Sulphate. Concentrated
ammonium hydroxide was added until the precipitate that formed was
completely dissolved to give a deep blue solution.
(b) Reagent ’B': A 200 ml solution containing 43.85% (w/v) sodium
thiosulphate.
2.252: Destaining method.
Reagents fA ‘ and 'B' were mixed in equal volumes just prior to 
use. The gel was covered in this solution and gently shaken in a fume
cupboard. The gel usually destained within 5 -1 0  minutes. The gel was
then soaked in water on a shaker to remove reagents from the gel. 
This was usually performed overnight at room temperature.
2.26: AU TO-RADIOGRAPHY OF DRIED GELS.
Gels were dried down onto Whatman 3MM paper under a
vacuum at 80°C for two hours. Gels were exposed to X - r a y  film
using Kodak autoradiography cassettes fitted with intensifying screens at 
-80°C .
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2.27: IODINATTON OF CALMODULIN-STIMULATED PDE.
Samples of purified Calmodulin -  stimulated phosphodiesterase 
were prepared by the method described in Chapter 4. Iodination was 
performed using the Chloramine T method. This selectively catalyses 
the iodination of tyrosine residues (see Roholt and Pressman, (1972) 
for a general method).
2.27.1: Iodination reagents.
The following reagents were prepared:
(a) Chloramine T solution: 0.04% Chloramine T in distilled water. This 
was prepared just before use.
(b) 1M T ris -H C l pH 7.5
(c) 0.1M T ris -H C l pH 7.0
(d) Stopping Buffer (9.8mls of 0.1M T ris-H C l pH 7.0 and 200pl of p -  
mercaptoethanol).
(e) 10% (w/v) SDS solution.
(f) 50% (v/v) glycerol containing a trace of Bromophenol Blue.
2.27.2: Iodination reaction.
The sample was dialysed extensively against 50mM Tris -  HC1 pH 
7.5, 0.2mM PMSF, 5mM Benzamidine, 2pM leupeptin, O.lmM EGTA at 
4°C to remove any traces of dithiothreitol before freeze drying. All 
subsequent operations were carried out at room temperature. 22pi of 
1.0M T ris-H C l pH 7.0 was added to the lyophilised sample followed by 
8jil of 10% (w/v) SDS. The sample was thoroughly vortexed mixed to 
ensure complete resuspension of the freeze dried powder. 
Approximately 200pCi of 125I was then added followed by lOpl of 
Chloramine T solution to initiate the iodination reaction. After 2 
minutes the reaction was stopped by adding 40pl of stopping buffer. 
15jil of 50% glycerol containing Bromophenol blue was then added and 
the sample boiled for 1 minute prior to SD S-PA G E  on 10% gels with 
a 5% stacking gel. If the samples were to be subsequently analysed by
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one dimensional peptide mapping the gels were fixed in 50% (v/v)
methanol and dried down under a vacuum at 80°C for two hours.
2.28: ONE DIMENSIONAL PEPTIDE MAPPING.
This was performed by the method of Cleveland, et al., (1977).
Gel chips were excised from gels that had been fixed in 50% (v/v)
methanol. It was important to ensure that gels were not fixed in acid 
in order to prevent acid hydrolysis of the peptide bond of the protein 
during drying down at 80° C. The gel chips were rehydrated in 40pl of 
0.125M T ris-H C l pH 6.7, 0.1% SDS, lOmM dithiothreitol overnight at 
room temperature. The rehydrated sample was then removed from the 
backing paper, sliced into very small slices, and placed in the well of an 
SD S-PA G E  gel consisting of a 5% stacking gel with a 15% resolving 
gel (section 2.20). The sample was overlayed with 40pls of 0.125M
T ris-H C l pH 6.7, 10% (v/v) Glycerol and 0.1% (w/v) Bromophenol 
Blue in the presence or absence of 200ng of TPCK treated trypsin.
Gels were electrophoresed at a constant current of 60mA and a 
voltage of 300V. After the Bromophenol Blue dye front was about to 
enter the separating gel the current was switched off for 30 minutes to 
allow trypsinisation to occur. Thereafter, electrophoresis was allowed to 
continue at the above current and voltage. The gel was fixed in a 5:1:5 
mixture of watenacetic acid:methanol and dried at 80°C for two hours 
prior to autoradiography. Exposed autoradiographs were then scanned 
using a Biorad model 620 gel scanner operated by an Olivetti M21 
computer.
2.29: ISOLATION OF AN IgG FRACTION FROM RABBIT BLOOD.
Immunised rabbits were bled by puncturing of a vein in the ear. 
Routinely 20-30m ls of blood were collected at any one time. The 
blood was allowed to clot for 2 hours at 4°C. The clot was removed 
manually with gentle squeezing to remove trapped serum. The resultant
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serum was then spun at 15,000g for 15 minutes at 4°C to remove blood 
cells and any traces of blood clot. The supernatant was retained for 
further purification which was either performed immediately or at a 
later date after storage at -20°C .
The supernatant was mixed with 6g wet weight of DEAE -
Cellulose which had previously been equilibrated in equlibration buffer 
(lOmM KH2P 0 4/K 2H P 0 4 pH 7.4) at 4°C. Incubation was continued 
for 30 minutes with occasional stirring. Unbound protein containing 
the IgG fraction was separated from the DEAE -  Cellulose by filtration 
using a Buchner flask attached to a vacuum pump. An equal volume 
of equilibration buffer was then added and sufficient ammonium 
sulphate added to bring the solution to 45% saturation. The solution
was stirred on ice for 15 minutes prior to spinning at 15,000g for 15
minutes to pellet the precipitated IgG fraction. The pellet was 
resuspended in approximately 5mls of equilibration buffer and dialysed 
overnight against two 2 litre changes of equilibration buffer. The IgG 
fraction was stored as 50pl aliquots at -80°C . The purity of the
preparation was determined by SD S-PA G E  electrophoresis and always 
demonstrated significant enrichment of protein bands corresponding to 
the heavy and light chains of IgG.
2.30: WESTERN BLOTTING.
2.30.1: Western Blotting: Solutions.
(a) Transfer buffer: (0.025M T ris-H C l, 0.192M Glycine, 20% (v/v) 
methanol).
(b) Tris -  buffered saline (TBS): (20mM T ris -H C l pH 7.5, 0.5M NaCl).
(c) T ris-Tw een buffered saline (1 IB S): (20mM T ris-H C l pH 7.5, 0.5M 
NaCl, 0.05% (v/v) Tween-20).
(d) Blocking buffer: 3% (w/v) gelatin in TBS.
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2.30.2: Western Blotting: Primary antibody.
The antibody was dissolved at a suitable dilution (usually 1/200 
or 1/100) in 50 mis of TBS containing 1% (w/v) gelatin. The antibody 
was then stored in this buffer at 4°C. At this temperature the gelatin 
solidifies, so before use the buffer was placed in a 37° C water bath to 
melt. After use the antibody was made up to 0.05% (w/v) Thimerosol, 
an anti-bacterial agent, to act as a preservative. This addition was 
repeated after every use of the antibody up to a maximum of five 
times or when signals from the blot became noticeably weaker.
2.303: Western Blotting: Secondary antibody.
Horseradish peroxidase linked goat anti -  rabbt IgG was dissolved 
at a suitable dilution (usually 1/200) in TBS containing 1% (w/v) 
gelatin. This solution was treated in the same way as the primary 
antibody.
2.30.4: Western Blotting: Method.
After separation of proteins on a suitable SD S-PA G E  gel the 
proteins were transferred to nitrocellulose paper in an LKB Transphor 
apparatus at maximum current (2A) for 90 minutes at room 
temperature using a cooling apparatus. Once transfer had been 
achieved (assessed by the presence of prestained molecular weight 
markers) the nitrocellulose was blocked in lOOmls of blocking buffer for 
90 minutes at 37° C. The blocking buffer was then removed and the 
blot washed thoroughly in distilled water until all the unbound gelatin 
had been removed. The blot was then placed in the primary antibody 
solution for 12 -  18hrs at. 37°C. The antibody solution was subsequently 
removed and retained if necessary and the blot then rinsed in TBS 
followed by two 10 minute washes in TTBS and one further 10 minute 
wash in TBS. The second antibody solution was then placed on the 
blot and incubated for 2 - 3  hours at 37°C. The antibody solution was 
then removed and retained and the blot washed as above in TTBS and 
TBS. Bands were detected by adding 40 ml of lOmM T ris -H C l pH 7.4 
followed by 1ml of 1% (w/v) o -  dianisidine and finally 10pl of 30%
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(v/v) hydrogen peroxide to initiate colour development. Bands usually 
became detectable within 1 - 2  minutes. The blot was then rinsed well 
in water and dried between filter paper and stored away from light.
2.30.5: Use of 12 5I-P ro te in  A in Western Blotting.
In instances where quantification of immuno -  stained bands was
required Iodinated (x251)-P ro tein  A was used in place of horseradish 
peroxidase linked goat an ti-rab b it IgG. The antibody solution, 
containing a suitable amount of radioactivity ( 2 -5  pCi/blot), was 
prepared in 1% (w/v) gelatin in TBS, was used exactly as for the 
peroxidase linked goat an ti-rab b it IgG but was not retained for further 
use.
2.31: PREPARATION OF A  RAT O V ER  HYPOTONIC EXTRACT.
Routinely this was prepared from 5 rat livers by a slight 
modification of the method detailed in Pyne, et al., (1987a). In some 
instances a hypotonic extract was prepared from one rat liver. In such 
cases the volumes used were approximately one fifth of the ones
detailed below.
5 male Sprague -  Dawley rats (250 -  275g) were sacrificed and the 
livers excised chopped, and rinsed in TES Buffer (lOmM T ris -H C l pH
7.4, ImM EDTA, 0.25M Sucrose) on ice. All subsequent operations
were carried out at 4°C. Livers were rapidly homogenised in 8 volumes
of TES Buffer by placing in Waring blender at maximum speed for 1 
minute. This procedure was found to be much faster than hand 
homogenisation of the diced livers, which could take up to 40 minutes 
to complete for 5 rat livers. The homogenate (550mls) was filtered 
through cheese cloth and the filtrate centrifuged for 10 minutes at 
lOOOrpm in an MSE Minor Centrifuge. The supernatant (450mls) was 
removed and recentrifuged at 30,000gav, for 20 minutes in a Beckman 
J A -2 0  rotor. The pellet was gently resuspended in 300mls of TE 
Buffer (lOmM T ris-H C l pH 7.4, ImM EDTA) using a hand
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homogeniser and left at 4°C for 40 minutes. The hypotonically 
solubilised extract was then centrifuged at 48,000gav for 30 minutes. 
The supernatant (285mls) was removed and made up to lOmM MgCl2 
and recentrifuged at 48,000gav. This extra step was included because it 
was routinely observed that addition of MgCl2 caused precipitation of 
some protein. "When assayed for phosphodiesterase activity the MgCl2 
precipitated pellet contained less than 10 pmol/min of cyclic AMP PDE 
activity assessed at G.lpM cyclic AMP (0.14% of total). The 
supernatant (hypotonic extract) from this procedure was then used as 
the source of the enzyme.
2.32: PRODUCTION OF D V -1  SEPHAROSE AFFINITY RESIN.
Polyclonal antisera raised to the purified ‘dense-vesicle ' 
phosphodiesterase (DV1) by Pyne, et al., (1987a) was coupled to 
Cyanogen bromide -  activated Sepharose 4B using the following method;
0.5g of Cyanogen bromide -  activated Sepharose was swelled by 
washing in ImM HC1 (lOOmls) on a glass fibre disc. The swelled gel 
was washed in approximately 150mls of Coupling Buffer (0.1M N aH C 03 
pH 8.5, 0.5M NaCl). This produced a gel of approximately 1.75mls.
The gel was coupled to the antisera D V -1  (0.4mls containing 
0.6mg of protein) in the presence of 3.1mls of Coupling Buffer. The 
mixture was applied to a rotary mixer and coupling allowed to occur at 
room temperature for IVz hours.
The coupled gel was washed in Coupling Buffer (150mls) on a 
scintered glass filter. Unreacted sites were blocked by incubating in 
Blocking Buffer (0.1M N aH C03 pH 8.0, 0.5M NaCl, 0.1M ethanolamine) 
for 2Vi hours at room temperature. The gel was washed with 200mls of 
coupling buffer followed by 200mls of 0.1M Sodium acetate, 0.5M NaCl 
pH 4.0 and then a further 200mls of coupling buffer. The gel was 
stored at 4°C in 3.5mls of coupling buffer final pH 8.5 until use.
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The gel was equilibrated in TE Buffer (lOmM T ris -H C l pH 7.4, 
ImM EDTA) prior to use by withdrawing samples from the stroage 
buffer and resuspending in TE Buffer (0.5ml per 3.33pl of DV - 1  
sepharose matrix). The gel was pelleted at maximum speed in a 
microfuge (30 seconds) and the washing procedure repeated four more 
times.
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FIGURE 2.1:
ELUTION OF CALMODULIN ACTIVUTY FROM PHENYL
SERHABPSE,
Calmodulin activity was eluted from Phenyl-Sepharose as indicated in Section
2.29.2. Calmodulin activity was assayed by the ability of aliquots of column 
fractions to stimulate the activity of a crude preparation of Calmodulin deficient 
beeg heart phosphodiesterase (Sigma) see Section 2.18. Protein was 
determined by the method of Bradford (Section 2.7).
(□ ) Protein (A595)
( ■ )  Calmodulin activity expressed as fold stimulation of phosphodiesterase 
activity.
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FIG
URE 
2.1:
FIGURE 2.2:
ELUTION OF CALMODULIN PROTEIN FROM  MONO O 
ANION-EXCHANGE.
Calmodulin was eluted from the Mono Q anion-exchange resin using a sodium 
choride gradient between 0 and 1.0M NaCl and 95 x 1 ml fractions collected. 
Aliquots were assayed for protein by the method of Bradford (Section 2.7).
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FIGURE 2.3:
SD S-PA G E G EL OF P U R IFIE D  PO R C IN E  BRATN 
CALMODULIN.
The purified calmodulin preparation was electrophoresed on a 15% SDS-PAGE 
gel (Section 2.22) in the either the presence of 10 mM CaCl2 or 1 mM EGTA. 
The gel shows the increase in mobility observed in the presence of CaQ2.
135
CHAPTER 3.
RAT O V ER  AND RAT HEPATOCYTE 
SOLUBLE PHOSPHODIESTERASES.
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Multiple forms of cyclic nucleotide phosphodiesterase have been demonstrated in a 
wide range of tissues, including heart (Weishaar.et al...1987a: Weishaar, et al., 
1987b), adipose tissue (Weber and Appleman, 1982), liver (Heyworth, et al.. 
1983d) and brain (Thompson and Appleman, 1971). Various techniques have been 
employed in the separation of phosphodiesterase isozymes, with anion exchange 
resins such as DE-52 or DEAE-Sephacel being the most commonly employed 
techniques (Russel, et al.. 1973; Thompson and Appleman, 1971; Reeves, 
et al.. 1987; Turnbull and Hickie, 1984; Weishaar, et al.. 1987b; Hidaka and 
Asano, 1976; Grady and Thomas, 1986, Lugnier, et al.. 1986; Emeux, et al.. 
1980).
These resolved isozymes are usually analysed as pooled fractions of peaks of 
phosphodiesterase activity obtained after salt elution from the columns. Such 
resolved peaks of cyclic nucleotide phosphodiesterase activity have been 
characterised on the basis of substrate specificity, sensitivity to agents such as 
calcium and calmodulin, kinetic parameters and response to various 
phosphodiesterase inhibitors (for reviews see Beavo, et al.. 1982; Beavo, 1988). 
Studies of this nature have provided strong evidence for the existence of 
functionally distinct enzyme forms and this, in turn, raises the possibility that each 
form may have a unique role in the regulation of intracellular cyclic AMP levels.
Rat liver contains cyclic nucleotide phosphodiesterase activity in both the 
soluble and the particulate fractions. Using a Percoll fractionation procedure it has 
been shown that phosphodiesterase activity is associated with all membrane 
fractions except the lysosomes and the nucleus (Heyworth, et al.. 1983d). The 
activities in the plasma membrane fraction (Marchmont and Houslay, 1980a), the 
mitochondrial fraction (Cercek and Houslay, 1983a), and the endoplamic reticulum 
fraction (Cercek and Houslay, 1983b; Wilson and Houslay, 1983) have been 
identified and characterised.
A number of these particulate phosphodiesterase isozymes have been studied in
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some detail. These include two cyclic AMP-specific form: the 'peripheral' plasma 
membrane phosphodiesterase (Marchmont, et al.. 1981b; Pyne, et al.. 1986b; 
Pyne, et al.. 1989) and the 'dense-vesicle' phosphodiesterase (Pyne, et al.. 1987a; 
Loten, et al.. 1978; Boyes and Loten, 1988, Whitson and Applman, 1982). Both 
of these two latter enzymes have been shown to be stimulated by hormones.
In comparison to such analyses the soluble fraction of rat liver has received veiy 
little attention. A crude separation of the phosphodiesterase activity of rat liver- 
derived soluble fractions has been perfomed using DEAE-chomatography, which 
identified three peaks of phosphodiesterase activity (termed PDE I, PDE n  and PDE 
ID) based upon their order of elution (Russell, et al.. 1973)). However, studies on 
phosphodiesterases in cardiac (Weishaar, et al.. 1987a; Weishaar, et al.. 1987b; 
Weishaar, et al.. 1987c; Reeves, et al.. 1987) and adrenal tissue (Beavo, et al.. 
1982) have implied that the complement of enzyms in the soluble may be more 
complex than originally surmised from crude separations performed on DEAE- 
cellulose chromatography. Furthermore, earlier investigators have used conditions 
such as hypotonic extraction and sonication (see for example Moss, et al.. 1978; 
Turnbull and Hickie, 1984; Strada, et al.. 1981).which have been shown to 
release membrane bound phosphodiesterases into the soluble fraction (Loten, 
et al.. 1978, Loten, et al.. 1980; Pyne, et al.. 1987a; Whitson and Appleman, 
1982). Also protease inhibitors, which are essential to prevent modification of 
phosphodiesterases (Wilson and Houslay, 1983; Strada. et al.. 1981; Tucker, 
et al.. 1981; Kincaid, et al.. 1985; Price, et al.. 1987) were not added, Vith this 
in mind it was decided to undertake to resolve and characterise the cyclic nucleotide 
phosphodiesterases from the soluble fraction of rat liver prepared under isotonic 
conditions and in the presence of protease inhibitors.
Further to this,it was also decided to analyse the phosphodiesterases present in 
the soluble fraction derived from hepatocytes. Whilst most studies of this nature 
are conducted using soluble prepations prepared from whole tissue/organ
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homogenates there is always the concern that multiplicity observed is due to the 
presence of multiple cell types rather than a true reflection of the number and type of 
phosphodiesterases present. With this in mind it was also decided to analyse the 
soluble phosphodiesterase isozymes present in soluble fractions-derived from 
hepatocytes.
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3.1: CHARACTERISTICS OF RAT LIVER SUPERNATANT.
A supernatant prepared from one rat liver homogenate under 
isotonic conditions and in the presence of the protease inhibitors, 
Benzamidine, Leupeptin and PMSF (see Section 2.4), contained both 
cyclic AMP and cyclic GMP phosphodiesterase activity. At 1 pM 
substrate, these were present in approximately equal amounts since the 
ratio of cAMP:cGMP hydrolysis was 0.95 + / -  0.05 (n=3, + / “  SEM). 
At this substrate concentration, the total cyclic AMP and cyclic GMP 
phosphodiesterase activities in one rat liver were 12,968 pmol/min 
+ / -  2,128 pmol/min (n=3, + / -  SEM) and 13,804 pmol/min + / -  
2,381 pmol/min (n=3 , + /  — SEM) respectively. The average protein 
content of the supernatant prepared from one rat liver under these 
conditions was 259 mg + / -  27 mg (n=3, + / — SEM).
The supernatant was further characterised by analysing the 
response of both the cyclic AMP and cyclic GMP phosphodiesterase 
activities to Ca2+ and cyclic GMP to assess for the presence of the 
Ca2+/calm odulin- stimulated and the cyclic GM P-stim ulated/inhibited 
phosphodiesterases respectively.
Figure 3.1 shows that addition of increasing calcium 
concentrations stimulated the total cyclic AMP and cyclic GMP
phosphodiesterase activities of the rat liver supernatant. The maximal 
responses produced were, however, small in both cases. Cyclic GMP 
PDE activity was stimulated some 26.9% + / -  2% (n=5, + / -  SEM) 
and cyclic AMP PDE activity 19.3% + / -  6.35% (n=3, + / -
SEM). Stimulation occured in a dose dependent manner with maximal 
stimulation occuring between 10 pM and 50 pM added Ca2+. The
actual free calcium concentration was not calculated. Addition of 
calmodulin alone, at a saturating concentration (2 pg/ml) did not 
stimulate total cyclic GMP or cyclic AMP PDE activity (less than 1% 
stimulation) indicating the presence of endogenous calmodulin in the 
rat liver supernatant. This was later confirmed by assaying for
endogenous calmodulin activity (see Section 3.3). The addition of
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Ca2+ to a maximal level (100 pM), in the presence of 2 pg/ml of 
calmodulin, did not produce any greater stimulation of cyclic GMP 
PDE activity than that observed with Ca2+ alone. Under these 
conditions, the cyclic GMP phosphodiesterase activity was stimulated 
25% + / -  4.2% (n=3, . + / -  SEM) and cyclic AMP phosphodiesterase 
activity some 15.7% + / -  2.8% (n=3, + / -  SEM). This was taken to 
imply that the supernatant contained saturating levels of calmodulin.
Since the rat liver supernatant was prepared in the presence of 
0.1 mM EGTA, in order to chelate endogenous Ca2+, it was necessary 
to assess that this level of EGTA was sufficient for this purpose. 
Figure 3.2 shows that addition of further EGTA up to 500 pM, did not 
decrease either cyclic GMP or cyclic AMP PDE activity (activities were 
99.7% + / . -  1.7% (n = 3, + / -  SEM) and 96.5% + / -  4.6% (n=3, 
+ /  — SEM) of control cyclic GMP and cyclic AMP PDE activities 
respectively).
Rat liver contains a soluble Ca2+-activated neutral protease 
(CANP) (Takai, et al., 1977: Demartino, 1981) that is activated in the
presence of micromolar levels of calcium. It is well documented that
phosphodiesterase activity can be activated by limited proteolysis 
(Cheung, 1971; Tucker, et al., 1981; Kincaid, et al., 1985) so the 
calcium effect may be mediated by activation of the CANP. The data 
shown in Figure 3.3 indicates that the Ca2+ -m ediated activation of 
cyclic GMP PDE activity could be reversed by an addition of EGTA, 
indicating that involvement of the CANP was unlikely since it’s action 
would be irreversible. Reversibility of the Ca2+ activation of soluble 
cyclic AMP PDE activity was not performed because of the smaller 
level of stimulation observed.
These data indicated then, that there was a Ca2+-stim ulated 
cyclic nucleotide phosphodiesterase activity present in the supernatant 
extract. In addition, the cyclic GMP -  stimulated cyclic AMP PDE was 
shown to be present by the observation that cyclic AMP hydrolysis, at
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1 jiM substrate, could be stimulated by 2 pM cyclic GMP (stimulated 
levels were 273% + / -  31% (n= 3 , + / -  SEM) of control values).
3.2: D E -5 2  SEPARATION OF RAT O V ER  SOLUBLE PHOSPHO­
DIESTERASE ACTIVITY.
In order to assess the number and 'type' of phosphodiesterases 
present in the rat liver supernatant, it was decided to attempt 
separation of the individual isozymes by anion -  exchange
chromatography, a technique that has been used extensively by a 
number of other groups to identify phosphodiesterase isozymes (Russel, 
et al., 1973; Moss, et al., 1978; Turnbull and Hickie, 1984; Reeves, 
et al., 1987).
Fractionation of total rat liver supernatant phosphodiesterase 
activity, by anion-exchange chromatography on D E -5 2 , resulted in the 
resolution of three peaks of phosphodiesterase activity, when assessed at 
1 pM cyclic AMP and cyclic GMP, as shown in Figure 3.4. These are 
referred to as D E -5 2  Peaks I to III inclusive.
Peak I eluted at approximately 0.07 M NaCl and hydrolysed both 
cyclic AMP and cyclic GMP equally well at 1 jxM substrate; the 
cAMP:cGMP hydrolysis ratio for the Peak being 1.07 + / -  0.09 (n= 7 , 
+ / -  SEM).
Peak II eluted at approximately 0.16 M NaCl and also hydrolysed 
both substrates, with some selectivity for cyclic GMP, since the ratio of 
cAMPrcGMP hydrolysis for this activity was 0.35 + / -  0.12 (n = 3, + / -  
SEM).
Peak III partially co -  eluted with Peak II but appeared to be 
more selective for cyclic AMP as substrate since the cAMP:cGMP 
hydrolysis ratio was 4.16 + / -  1.74 (n=3, + / -  SEM). The actual 
yields of activity for the individual Peaks were not calculated due to 
the partial co -  elution of activities.
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The total yield of cyclic AMP and cyclic GMP PDE activities 
from the column were 84% + / -  1% (n = 6, + / -  SEM) and 92%
+ / -  2% (n=6, + / -  SEM). Extending the gradient to 0.8M NaCl did 
not elute any further activity.
3.3: RESPONSE OF D E -5 2  FRACTIONATED RAT LIVER
SOLUBLE PHOSPHODIESTERASES TO EFFECTORS.
In order to characterise the individual Peaks more fully, the
responses of both the cyclic AMP and cyclic GMP PDE components to 
saturating levels of Ca2+/calmodulin and also the response of the
cyclic AMP PDE component to 2 pM cyclic GMP were investigated. 
The responses of the individual Peaks are summarised in Table 3.1.
Peak I contained a Ca2+/calm odulin-stim ulated 
phosphodiesterase since the cyclic AMP and cyclic GMP PDE activities 
were both stimulated by these agents. The response for the cyclic
GMP PDE component of the activity was however much larger than the 
response of the cyclic AMP PDE component (110% stimulation 
compared with 32% stimulation of control activity for cyclic AMP and 
cyclic GMP respectively). Ca2+ alone did not significantly activate 
either this Peak of activity or any of the other two. This implied that 
calmodulin was dissociated from the phosphodiesterase under these 
conditions. Assays of calmodulin activity were performed and it was 
shown that calmodulin eluted as a single peak of activity from the 
D E -5 2  column at a NaCl concentration of approximately 0.3 M NaCl 
(Figure 3.4) and did not co -e lu te  with phosphodiesterase activity.
Peak II clearly contained the cyclic GMP -  stimulated 
phosphodiesterase, since cyclic AMP hydrolysis was stimulated some 6.9 
fold by 2 pM cyclic GMP. Both the cyclic AMP and cyclic GMP 
activities in , this Peak were stimulated to some extent by 
Ca2+/calmodulin (25% and 19% stimulation respectively).
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Peak in  contained a cyclic AMP PDE activity that was
unresponsive to cyclic GMP since no significant stimulation, or
inhibition, of cyclic AMP hydrolysis was observed in the presence of 
this nucleotide.
These observations showed the presence of a Ca2+/calm odulin-
stimulated PDE activity, a cyclic GMP -  stimulated PDE activity and a 
cyclic GMP -  insensitive cyclic AMP -  specific PDE activity in the
soluble fraction of rat liver.
Although Peak I clearly contained the Ca2+/calm odulin-  
stimulated phosphodiesterase activity, it was apparent that it could 
hydrolyse both cyclic AMP and cyclic GMP with nearly equal efficiency 
and that the fold stimulation of cyclic AMP hydrolysis was much less 
than for cyclic GMP hydrolysis. Evidence from a number of workers 
has indicated that most of the forms of this enzyme are more selective 
for cyclic GMP as substrate (Shenolikar, et al., 1985; Sharma and 
Wang, 1986a; Sharma and Wang, 1986b; and see Table 1.2). This 
raised the possibility that there was more than one activity present in 
Peak I.
3.4: THERMAL STABILITY OF THE CYCLIC GMP AND CYCLIC
AMP PHOSPHODIESTERASE ACTIVITIES OF D E -5 2  P E A K -I.
The thermal stabilities of the cyclic AMP and cyclic GMP PDE 
activities of Peak I were assessed at 60° C. Figure 3.5 shows that the 
cyclic AMP and cyclic GMP PDE activities decayed with kinetics 
indicative of single sites. However, the half lives for decay of activity 
were different for the two activities. Cyclic GMP PDE activity decayed
with a half life (t0<5) of 125 seconds + / -  12 seconds (n= 3 , + / -
SEM) whilst cyclic AMP PDE activity decayed with a t0 . 5 of 260
seconds + / -  15 seconds (n=3 , + / -  SEM). These results implied
that there were indeed two separate activities, which were almost 
entirely selective for cyclic AMP and cyclic GMP respectively, since the
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kinetics of decay suggested the presence of single selective activities for 
hydrolysis of these two cyclic nucleotides.
3.5: CHROMATOGRAPHY OF P E A K -I ON A F F I-G E L  BLUE.
It has been shown that bovine brain isozymes of the 
Ca2+/calm odulin- stimulated phosphodiesterase can be bound to the 
dye ligand column A ffi-gel Blue (Morril, et al., 1979; Sharma, et al., 
1980). This matrix contains the dye-ligand Cibacron Blue 3GA 
covalently coupled to either agarose or Sepharose. If both the cyclic 
AMP and cyclic GMP PDE activities of Peak I were associated with the 
Ca2+/calm odulin- stimulated phosphodiesterase then both of these 
activities should bind to this column. It was thus decided to apply 
D E -5 2  Peak I to this matrix.
Figure 3.6 shows the results of a typical experiment. 
Chromatography of D E -5 2  Peak I on A ffi-gel Blue, in the presence 
of 5 mM MgCl2, resulted in the apparent separation of the cyclic AMP 
and cyclic GMP PDE activities of Peak I. Whilst the A ffi-g e l Blue 
retained 78% + / -  10% (n=5, + / -  SEM) of the cyclic GMP PDE 
activity, only 14% + / -  10% (n = 5, + / — SEM) of the cyclic AMP
PDE activity was retained. The 'unbound' activity had a cAMP:cGMP
activity ratio of 4.29 + / — 0.34 (n = 5, + / -  SEM), which differed 
significantly from the cAMP:cGMP ratio for the Peak I activity which 
was 1.07 + / -  0.09 (n = 5, + / -  SEM)..
The amount of 'Ca2+/calm odulin- stimulated' activity was 
calculated by subtracting the PDE activity of Peak I in the absence of 
Ca2+/calmodulin from the PDE activity obtained in the presence. 
When this was performed, it was apparent that the majority of the
'Ca2+/calm odulin- stimulated' cyclic AMP and cyclic GMP PDE
activities were retained by the matrix (retentions were 97% + / — 1.34% 
(n=4, + / -  SEM) for cyclic GMP and 98% + / -  1.25% (n=3, + / -  
SEM) for cyclic GMP).
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These results indicated that the Peak I activity observed on
D E -5 2  anion -  exchange profiles actually consisted of two separate 
activities, which hydrolysed predominantly cyclic AMP and cyclic GMP 
respectively and that the Ca2+/calm odulin-stim ulated activity was 
primarily associated with the cyclic GMP PDE activity and not the
cyclic AMP PDE activity of Peak I.
An alternative explanation of the results, however, was that 
A ffi-gel Blue chromatography may have removed a factor (e.g an
enzyme subunit) whose function was to control the substrate specificity 
of the activity. In the presence of the putative 'subunit', the enzyme 
would hydrolyse both cyclic AMP and cyclic GMP and show
responsiveness to Ca2+/calmodulin and it’s absence the activity would
hydrolyse cyclic AMP selectively and show little or no 
Ca2+/calm odulin-sensitive activity. In order to address this possibility 
it was necessary to demonstrate that the cyclic GMP activity could be 
retrieved from the A ffi-gel Blue column.
3.6: ELUTION OF THE PHOSPHODIESTERASE ACTIVITY OF
P E A K -I FROM A F F I-G E L  BLUE.
A  number of attempts were made to elute the 'bound' cyclic
GMP PDE activity from the Affi-gel Blue matrix. Washing the column 
extensively in the equilibration buffer eluted only a small amount of 
the cyclic AMP and cyclic GMP PDE activities (20% + / — 3% (n = 3, 
+ / -  SEM) and 16.8% + / -  5.9% (n=3, + / -  SEM) of the total 
cyclic AMP and cyclic GMP activities were retrieved respectively (Figure 
3.6). Such eluted activity represented only 1.2% + / -  0.6% (n = 3,
+ / -  SEM) and 9% + / -  2.9% (n = 3 + / -  SEM) of the total bound
cyclic AMP and cyclic GMP 'Ca2+/calm odulin- stimulated' PDE 
activities respectively.
Batch elution experiments, from small quantities of Affi -  gel 
Blue, were performed in some instances (see Section 2.13 for general 
method). In these experiments, only binding and elution of cyclic
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GMP PDE activity was assessed. Identical binding of cyclic GMP PDE 
activity could be achieved under batch binding conditions to that 
achieved under ‘column1 conditions (see Figure 3.7 for a  typical 
experiment).
Individual portions of the matrix, containing bound 
phosphodiesterase activity, were washed in equilibration buffer (which 
contained approximately the same buffer composition as the pooled 
fractions containing Peak I phosphodiesterase namely, 50 mM T ris -H C l 
pH 7.5, 5 mM Benzamidine hydrochloride, 0.2 mM PMSF, 2 pM
Leupeptin, 0.1 mM EGTA, 0.1 mM dithiothreitol and 0.15 M NaCl) 
containing in addition 5 mM MgCl2..
Elution of bound cyclic GMP phosphodiesterase activity was 
attempted using equilibration buffer, in the presence of EDTA (in place 
of 5 mM MgCl2), in the presence of high salt and in the presence of 
high cyclic nucleotide concentrations.
Figure 3.7 summarises the elution conditions attempted to 
retrieve either bound cyclic GMP PDE activity or Ca2+/calmodulin 
stimulated cyclic GMP PDE activity from A ffi-gel Blue. The activity 
could not be eluted in 1 mM EDTA indicating that Mg2 + ions were 
not necessaiy to achieve binding of the cyclic GMP PDE activity to the 
matrix. Elution in the presence of high sodium chloride concentrations 
were also unsuccessful as was elution using high concentrations of cyclic 
GMP or cyclic AMP. In this latter instance the eluted material was 
dialysed against equilibration buffer to remove the cyclic nucleotides 
prior to assay of phosphodiesterase activity. In such instances, a 24 
hour dialysis of a 2 ml sample against 4 x 500 ml changes of 
equilibration buffer, caused the loss of approximately 29% + / ”  13.3% 
(n=3, + / -  SEM) of the cyclic GMP phosphodiesterase activity of
Peak I. This loss of activity was not sufficient to account for the low 
activities recovered from the Affi -  gel Blue indicating that the cyclic 
GMP phosphodiesterase activity had remained bound to the column,
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even in the presence of high concentrations of it’s substrates cyclic 
GMP and cyclic AMP.
3.7: MONO Q ANION-EXCHA NGE CHROMATOGRAPHY OF A
RAT O V ER  SOLUBLE FRACTION.
Since the cyclic GMP phosphodiesterase activity of Peak I could 
not be retrieved from A ffi-g e l Blue very readily, it was decided to 
attempt to separate the cyclic nucleotide phosphodiesterases
contained in the rat liver soluble fraction on the high resolution 
anion -  exchange matrix, Mono Q.
The soluble fraction from rat liver, prepared under identical 
conditions to the D E -5 2  experiments, was subjected to chromatography 
on a Mono Q anion-exchange column. Binding of the cyclic AMP 
and cyclic GMP PDE activities to the column were routinely very high; 
98% + / -  1 % (n = 10, + / -  SEM) and 97% + / -  1.7% (n = 10, + / -  
SEM) for cyclic AMP and cyclic GMP phosphodiesterase activity 
respectively.
A sodium chloride gradient was used to elute the bound 
phosphodiesterase activity. A number of preliminary experiments were 
performed to determine the shape of the gradient that gave optimal 
separation of the phosphodiesterase activities. The programme used is 
given in Table 3.2.
Figure 3.8 shows a typical profile obtained using approximately 
half the supernatant prepared from one rat liver. At 1 pM substrate, 
five major peaks of activity were eluted between 0 and 0.5 M NaCl, 
termed PDE M Q -I to PDE M Q -V  inclusive. Collectively, these 
represented 92% + / -  0.05% (n = 10, + / -  SEM) of the cyclic AMP 
PDE activity and 94% + / -  0.03% (n = 10, + /-S E M )' of the cyclic 
GMP PDE activity applied to the column. The NaCl concentration 
required to elute the PDE M Q -Peaks were 0.1 M, 0.15 M, 0.25 M, 
0.35 M and 0.5 M respectively. A small peak of cyclic AMP and cyclic 
GMP PDE activity was usually observed eluting on the shoulder of 
PDE M Q -m  but the yield of this activity was very variable so no
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studies were performed on it’s properties. PDE M Q -V  was routinely 
observed to start eluting at approximately 0.4 M NaCl but could be 
eluted as a sharper peak of activity by rapidy increasing the gradient to 
0.5 M NaCl (see Figure 3.8).
3.8: CHARACTERISATION OF RAT LIVER PDE M Q -PEAKS.
The average total cyclic AMP and cyclic GMP PDE activity 
associated with each of the individual PDE M Q -Peaks was calculated 
as was the ratio of cyclic AMP:cyclic GMP hydrolysis at 1 pM. The 
results are presented in Table 3.3.
PDE M Q -I  was shown to be capable of hydrolysing both cyclic 
AMP and cyclic GMP, although it was much more selective for cyclic 
AMP since it had a cAMPxGMP hydrolytic ratio of 5.4. This was very 
similar to the ratio for the ’unbound* fraction prepared from D E -5 2  
Peak I by A ffi-gel Blue chromatography, which was 4.3 (see Section 
3.5). Based on the average yield of activity for PDE M Q -I  it can be 
estimated that this Peak contributes approximately 23% of the total 
cyclic AMP hydrolysis observed in the rat liver supernatant.
PDE M Q -II  was highly selective for cyclic GMP as substrate 
(cAMPxGMP hydrolysis ratio of 0.13). It was estimated that this Peak 
contributed 20% of the total soluble cyclic GMP PDE activity but only 
2% of the total soluble cyclic AMP PDE activity.
The majority of the rat liver soluble cyclic AMP and cyclic 
GMP PDE activity was found to be associated with PDE MQ -  III. 
This activity could hydrolyse both cyclic nucleotides but was more 
selective for cyclic GMP since the substrate ratio was 0.46. It was 
estimated to contribute 45% of the total cyclic AMP hydrolysis and as 
much as 74% of the total cyclic GMP hydrolysis in the rat liver soluble 
fraction.
PDE M Q -IV  and PDE M Q -V  were both selective for cyclic 
AMP as a substrate (the substrate ratios were 8.98 and 10.0
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respectively). They both contributed a similar amount of the total 
cyclic AMP hydrolysis (14.3% and 16.2% respectively). Taken together, 
30% of the total cyclic AMP hydrolysis of the supernatant was provided 
by the cyclic AM P-specific class of phosphodiesterase.
The PDE M Q -Peaks were further characterised by analysing the 
response to the effectors, Ca2+/calmodulin and cyclic GMP. These 
were investigated in an anlagous manner to the analysis performed for 
the D E -5 2  Peaks (see Section 3.3). In all cases, effects were 
monitored at 1 pM substrate using either saturating levels of 
Ca2+/calmodulin (50 pM Ca2+ and 2 pg/ml calmodulin) and 2 pM 
cyclic GMP. Table 3.4 shows a summary of the response of the 
individual Peaks to these effectors.
Ca2+/calmodulin, together, stimulated the cyclic AMP and 
cyclic GMP PDE activities of PDE M Q -II  some 4.8 and 2.2 fold 
respectively. In contrast, the cyclic AMP PDE activity of PDE M Q -I  
was not significantly stimulated by these agents, however, the cyclic 
GMP PDE activity could be stimulated some 0.7 fold, although in some 
instances this stimulation was either smaller or not observed at all. It 
seemed likely that this effect was due to a small amount of co -e lu tio n  
of PDE M Q -I  and PDE M Q -II. Ca2+/calmodulin did not 
significantly stimulate the PDE activities of any of the other 
PDE M Q -Peaks indicating that PDE M Q -II  contained all of the 
soluble Ca2+/calmodulin activity. Additionally, this activity was 
selective for cyclic GMP under both basal and calmodulin stimulated 
conditions, at least at 1 pM substrate.
Cyclic GMP stimulated markedly the cyclic AMP hydrolysis of 
PDE MQ -  III (6.3 fold stimulation), confirming the presence of the 
cyclic GMP -  stimulated phosphodiesterase in the soluble fraction of rat 
liver. Both of the cyclic AM P-specific Peaks were inhibited by 2 pM 
cyclic GMP although the effects were small (10% and 17% inhibition 
for PDE M Q -IV  and PDE M Q -V  respectively).
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The observed characteristics of PDE M Q - I  and PDE M Q -II  
were consistent with the notion that there were two activities present in 
the D E -5 2  Peak I which selectively hydrolysed cyclic AMP and cyclic 
GMP respectively. Chromatography on the high resolution anion-  
exchange column, Mono Q, could apparently resolve these activities 
from each other giving rise to PDE M Q -I  and PDE M Q -II.
In order to confirm that these resolved Peaks did indeed 
correspond to the activities that would be found in D E -5 2  Peak I, it 
was decided to assess their chromatographic properties on A ffi-g e l 
Blue. It would be predicted that PDE M Q -I  would possess the same 
properties as the 'cyclic AMP' component of the D E -5 2  Peak I activity 
and hence would be unable to bind to A ffi-gel Blue. Similarly, 
PDE M Q -II  should possess the same properties as the 'cyclic GMP' 
component of the D E -5 2  activity and should thus be capable of 
binding to A ffi-gel Blue very tightly. Figure 3.9 shows the result of a 
typical experiment in which PDE M Q -I  and PDE M Q -II  were batch 
bound to A ffi-gel Blue. Whilst 99% + / -  0.47 (n = 3, + / -  SEM) of 
the cyclic GMP and 71% + / -  9.8% (n=3, + / -  SEM) of the cyclic 
AMP PDE activity of PDE M Q -II  could be bound to A ffi-g e l Blue 
only 25% + / -  5.0% (n=3, + / -  SEM) of the cyclic AMP and 44% 
+ / -  14% (n=3 , + / -  SEM) of the cyclic GMP PDE activity of 
PDE M Q -I  could be bound to A ffi-gel Blue. In a single experiment, 
nearly 100% of the 'Ca2+/calm odulin-stim ulated' cyclic AMP and 
cyclic GMP PDE activities of PDE M Q -II  were retained on this 
matrix. These results indicated that PDE MQ - 1 and PDE MQ -  II did 
indeed correspond to the cyclic AMP and cyclic GMP PDE components 
of D E -5 2  Peak I.
3.9: ELUTION OF THE C YCU C  GMP PDE ACTIVITY OF
PDE M Q -n  FROM AFFI GEL BLUE.
Attempts to elute the bound cyclic GMP PDE activity from 
Affi -  gel Blue were unsuccessful. In a single experiment, 0.75 ml of
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PDE M Q -II  containing 46 + / -  2.51 pmol/min of cyclic GMP PDE 
activity was bound to 100 jxl of A ffi-ge l Blue and elution was
attempted using a variety of elution procedures (see Section 2.13 for 
general method). The results are shown in Table 3.5.
The use of high salt (0.5 M or 1.0 M NaCl) either in the 
presence of 5 mM MgCl2 or 2 mM EDTA eluted less than 10% of the 
bound activity. Elution in the presence of Ca2+/calmodulin and 
2 mM EDTA was also ineffective (8.4% of the activty was eluted). No 
cyclic GMP PDE activity could be detected when the A ffi-g e l Blue 
was assayed for activity. These results implied that binding of
PDE M Q -II  to the dye matrix column A ffi-gel Blue was not 
dependent on the presence of Mg2+ ions. The inability to detect any 
activity on the column itself could have implied that binding of the 
enzyme had occurred via the catalytic site (or sterically near to it).
The ability of PDE M Q -I  and PDE M Q -II  to bind to A ffi-  
gel Blue in the presence of 2 mM EDTA (in place of 5 mM MgCl2) 
was also investigated. In a single experiment, the properties of these 
activities were not altered. 24% of the cyclic AMP and 21% of the 
cyclic GMP PDE activity of PDE M Q -I  were retained on A ffi-ge l 
Blue under these conditions, whilst 100% of the cyclic AMP and 92% 
of the cyclic GMP PDE activity of PDE M Q -II  were retained. In this 
experiment, 2 mM EDTA did not have any direct effect on the PDE 
activity of PDE MQ - 1 (cyclic AMP and cyclic GMP PDE activities 
were 92% and 108% of control values). The activity of PDE MQ -  II 
was inhibited slightly by 2 mM EDTA (cyclic AMP and cyclic GMP
PDE activities were 84% and 88% of control values). In the presence
of 5 mM MgCl2, the cyclic AMP and cyclic GMP PDE activities of 
PDE M Q -I  were 103% and 132% of control values, whilst for 
PDE M Q -II  the cyclic AMP and cyclic GMP PDE activities were 75% 
and 82% of control values.
Together, these results were taken to indicate that binding of 
PDE M Q -II  to A ffi-gel Blue was extremely difficut to reverse,
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presumably as a result of the high affinity of the enzyme for the dye 
ligand Cibacron Blue 3GA.
3.10: EFFECT OF CALCIUM ON MONO Q ANION -  EXCHANGE
CHROMATOGRAPHY OF RAT LIVER SUPERNATANT.
The presence of PDE M Q - I  in rat liver soluble fractions has 
not previously been observed by other workers (Russel, et al., 1973; 
Strewler, et al., 1983). This could have been related to the different 
preparation conditions employed in this study. Strewler et al., (1983) 
used CaCl2 in the homogenisation buffer. When the rat liver soluble 
fraction was prepared and chromatographed in Buffers containing 
calcium they did not observe any activity corresponding to PDE M Q -I . 
In addition, the chromatographic mobility of the Ca/calm odulin- 
sensitive form was altered in the presence of calcium. In the presence 
of calcium the activity elviUd at higher salt concentrations than in 
the presence of the calcium chelator EGTA (Strewler, et al., 1983). 
This was presumed to be due to the interaction of the 
phosphodiesterase with calmodulin. Since calmodulin is an acidic 
protein, such an interaction would be expected to increase the NaCl 
concentration required to elute the phosphodiesterase activity.
Figure 3.10(a) shows that essentially the same Mono Q profile 
was obtained when the rat liver supernatant was prepared and 
chromatographed in the presence of 100 pM CaCl2+ as in the presence 
of 100 pM EGTA. PDE M Q - I  was clearly present and in addition 
there was no evidence for a mobility shift in the Ca2+/calm odulin-  
stimulated phosphodiesterase (PDE M Q -II) . Presumably Mono Q 
chromatography was sufficient to dissociate the calmodulin:PDE 
interaction so that these migrate as independent entities.
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3.11: MONO Q AN ION-EXCHA NGE PROFILE OF RAT LIVER
SUPERNATANT ASSESSED AT lOOpM SUBSTRATE.
The Mono Q profile obtained when the phosphodiesterase assay
was performed using 100 pM substrate was clearly different to that 
obtained when the assay was performed at 1 pM substrate. Peaks 
corresponding to PDE MQ - 1, PDE MQ -  II and PDE MQ -  III were
observed, however the activities corresponding to PDE M Q -IV  and 
PDE M Q -V  were not. Importantly, no additional peaks were
observed.
3.12: INHIBITOR SENSITIVITY OF RAT O V ER  MONO Q PEAKS.
The cyclic AMP hydrolysis of the rat liver -  derived 
phosphodiesterases, PDE M Q -I  to PDE M Q -V  inclusive, were 
analaysed in response to the inhibitors IBMX, milrinone and R o - 2 0 -  
1724. IBMX is considered to be a non-specific inhibitor of 
phosphodiesterases whilst milrinone and R o - 20-1724 are considered 
selective for the cyclic A M P-specific class of phosphodiesterase (see 
Section 1.8). The structures of IBMX, milrinone and R o - 20-1724 are 
shown in Figures 1.3, 1.6(a) and 1.6(b) respectively.
3.12.1: Method for determination of IC50s.
Dose response curves were constructed at a fixed cyclic AMP
concentration of 1 pM and the % inhibition of cyclic AMP hydrolysis 
determined for each individual drug concentration. Since all the drugs 
were diluted from 25 mM stocks prepared in dimethylsuphoxide 
(DMSO) it was necessary to prepare DMSO correction curves. The 
cyclic AMP hydrolysis of each PDE M Q -P eak  was analysed in the 
presence of DMSO concentrations that corresponded to the 
concentration that would be present in a given concentration of 
inhibitor. The average effect on cyclic AMP hydrolysis was determined 
and the appropriate correction curve constructed. These curves are 
shown in the Appendix (Figure I -  V). On the assumption that the
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effects of DMSO and the inhibitor were additive, the inhibition 
obtained for each drug was corrected for the effect of DMSO.
3.12.2: IC50s for rat liver derived PDE M Q -Peaks.
Representative inhibition curves for each of the individual Peaks 
are shown in Figures 3.11-3.15 whilst Table 3.6 shows the 
concentrations of drugs required for half-m axim al inhibition of cyclic 
AMP phosphodiesterase activity (IC50) of each Peak, determined at
I pM substrate.
PDE MQ —I was found to be very insensitive to each of the
three inhibitors tested, including the non-specific phosphodiesterase
inhibitor IBMX. On this basis, this activity was termed the IB M X - 
insensitive form.
PDE M Q -II  was found to be most sensitive to inhibition by
IBMX (IC50 of 5.6 pM) and least sensitive to inhibition by R o - 2 0 -
1724 (IC50 > 500 pM). Milrinone was found to inhibit, although the 
IC50 for inhibition (145 pM) was approximately 10-fo ld  greater than
the IC50 for the two cyclic AMP -  selective Peaks.
The cyclic AMP PDE activity of PDE MQ -  III was found to be 
insensitive to both milrinone and R o - 20-1724 (in both instances the 
(IC5 o values were greater than 500 pM). IBMX was found to be 
capable of inhibition, although the IC50 for inhibition (97 pM) was at 
least 4 fold greater than for any of the other PDE M Q -Peaks.
The cyclic AMP -  selective Peaks, PDE M Q -IV  and PDE M Q - 
V, were found to be inhibited by both IBMX and milrinone with
similar sensitivities. The IC50s for IBMX action (14 pM and 11 pM 
respectively) were comparable to that for it’s action against PDE M Q -
II (IC50 of 5.6 pM). The IC50s for milrinone action against these
Peaks (10 pM and 17 pM respectively) were at least 10 fold greater than 
for any of the other Peaks. PDE M Q -IV  and PDE M Q -V  were 
found to differ markedly, however, in their response to R o - 20-1724
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with PDE M Q -IV  exhibiting poor sensitivity (IC50 190 pM) and
PDE M Q -V  showing a much greater sensitivity (IC50 1.6 pM).
3.13: SUBCELLULAR FRACTIONATION OF RAT HEPATOCYTE-
DERIVED PHOSPHODIESTERASE ACTIVITY.
\
Mammalian liver is a highly heterogenous organ containing a 
number of distinct cell types including, in addition to hepatocytes, 
Kupffer cells (Wardle, 1987). Isolated livers from freshly sacrificed 
animals will also contain substantial amounts of trapped blood. This 
is a consequence of the fact that the liver receives a substantial blood 
flow in accord with it’s central role in metabolism. Homogenates of 
rat liver will presumably contain phosphodiesterases derived from these 
multiple cell types.
It is possible to isolate hepatocytes by performing collagenase 
digestion of rat liver (Smith, et al., 1978; Elliot, et al., 1976; 
Heyworth, et al., 1983d). Such preparations are substantially enriched 
in hepatocytes and contain very little or no blood -  derived cells. Due 
to the apparently complex number of phosphodiesterase forms observed 
in the soluble fraction of rat liver and in particular, the observation 
that a novel IBMX -  insensitive phosphodiesterase is observed which has 
not been previously observed, it is possible that the multiplicity of 
phosphodiesterase forms observed may be due to the multiplicilty of 
cell types in rat liver homogenates. With this in mind, it was decided 
to assess the number and type of soluble phosphodiesterases present in 
preparations of rat hepatocytes.
3.13.1: Fractionation of rat hepatocyte -  derived phosphodiesterase 
activity.
Fractionation of hepatocytes into a ’washed' P I fraction (low 
speed pellet) and P2 and S2 fractions (high speed pellets and 
supernatants) was performed (see Section 2.8). An analysis of the 
phosphodiesterase activities contained in these fractions indicated that,
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at 1 jiM substrate, 50% of the cyclic AMP PDE activity 
(7,576 pmol/min out of 15,183 pmol/min) and 45% of the cyclic GMP 
PDE activity (11,749 pmol/min out of 26,619 pmol/min) observed in the 
homogenate were contained in the soluble fraction. The yield of cyclic 
AMP PDE activity during the fractionation procedure was 108% and for 
cyclic GMP PDE activity was 89%.
The Ca2+/calm odulin- and cyclic GMP -  sensitivity of the 
phosphodiesterase activity contained in the homogenate and the various 
fractions was assessed using saturating levels of Ca2+ (100 jiM ) and 
calmodulin (2 pg/ml) and 2 jiM cyclic GMP respectively. It was 
observed that only the soluble cyclic GMP PDE activity demonstrated 
any noticeable sensitivity to Ca2+/calmodulin (1.4 fold stimulation) 
whilst cyclic GMP -  stimulated cyclic AMP PDE activity was observed in 
both the particulate and soluble fractions. The soluble cyclic AMP 
PDE activity was stimulated approximately 3 fold. These results are 
summarised in Figure 3.16(a) and (b).
3.14: MONO Q ANION-EXCHANGE CHROMATOGRAPHY OF
RAT HEPATOCYTE-DERIVED SOLUBLE PHOSPHODIESTERASES.
Chromatography of a rat hepatocyte high speed supernatant on a 
Mono Q column, using identical experimental conditions to those used 
for rat liver supernatants, resulted in a broadly similar elution profile to 
that seen with rat liver supernatant (Figure 3.17) Again, five major 
peaks of activity were observed. An activity corresponding to 
PDE M Q -I, the IBMX -  insensitive phosphodiesterase was present and 
chromatographed in an identical position to that of the rat liver 
derived PDE M Q -I. This proved that the presence o f.th is  previously 
unobserved activity was not due to the multiplicity of cell types in rat 
liver. As with the rat liver PDE MQ -  Peaks, an analysis of the ratio of 
cyclic AMP:cyclic GMP hydrolysis at 1 pM substrate was carried out. 
The results of this analysis are summarised in Table 3.7. There were 
several noticeable differences between hepatocyte and liver derived
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activities (compare Tables 3.3 and 3.7). Firstly, a lower yield of 
phosphodiesterase activity was obtained from hepatocytes than from 
liver. On average the levels of total soluble cyclic AMP 
phosphodiesterase activity from hepatocytes was approximately one third 
of the level obtained from whole liver, whilst hepatocyte -  derived cyclic 
GMP phosphodiesterase activity was approximately 40% of the liver 
activity. Secondly, the proportion of the total activity contributed by 
each PDE M Q -P eak  was different from that observed in rat liver. 
PDE M Q—I was now observed to contribute approximately 40% of the 
total cyclic AMP PDE activity (compared with 23% in liver), whilst 
PDE M Q -III  only contributed some 10% of the cyclic AMP PDE 
activity (compared with 45% in liver). The two cyclic A M P-specific 
activities were present in approximately equal amounts, as they were in 
liver, but were now found to form almost 50% of the total cyclic AMP 
phosphodiesterase activity (compared with 30% in liver). Thirdly, the 
substrate selectivity of PDE M Q -III  was significantly different from 
that in liver; the substrate selectivity ratio for cyclic AMP 
hydrolysis:cyclic GMP hydrolysis was 0.15 + / -  0.015 in hepatocytes, 
compared to 0.46 + / -  0.06 in liver.
3.15: RESPONSE OF RAT HEPATOCYTE-DERIVED PDE M Q -
PEAKS TO EFFECTORS.
In an analagous manner to the rat liver -  derived PDE M Q - 
Peaks, an analysis of the responses of the cyclic AMP and cyclic GMP 
PDE activity to the agents Ca2+/calmodulin and to cyclic GMP was 
carried out. Once again saturating levels of Ca2+/calmodulin (100 jiM 
and 2 pg/ml respectively) and 2 jiM cyclic GMP were used to 
determine the effects. Table 3.4 summarises the responses and also 
draws a comparison between hepatocyte and liver derived forms.
3.15.1: Effectors on rat hepatocyte -  derived PDE M Q -I .
PDE M Q -I  was found to be insensitive to Ca2+/calmodulin 
when cyclic AMP was the substrate but exhibited a small sensitivity
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when cyclic GMP was the substrate (1.28 fold stimulation above control 
values). This value was smaller than the value observed with the rat 
liver peak (1.72 fold stimulation of control values). The cyclic GMP 
PDE activity was not found to be affected by 2 pM cyclic GMP.
3.15.2: Effectors on rat hepatocyte-derived PDE M Q -II.
Ca2+/calm odulin- stimulated PDE activity was found to be 
associated with PDE M Q -II, as was observed for the rat liver -  derived 
activity. Both the cyclic AMP and cyclic GMP PDE activities were 
stimulated to very similar extents to the rat liver -  derived forms. Once 
again, the fold stimulation for cyclic AMP as substrate (3.83) was 
greater than that observed with cyclic GMP as substrate (2.26).
An analysis of both the calm odulin- and Ca2+-dependence
for stimulation of cyclic GMP phosphodiesterase activity of PDE M Q - 
II was carried out, to allow comparisons to be drawn between this 
activity and previously purified and characterised forms.
Figure 3.18 shows the calmodulin dependency in the presence of 
saturating Ca2+ (100 pM), whilst Figure 3.19 shows the Ca2+
dependency in the presence of saturating calmodulin (2 pg/ml). The 
EC50 for calmodulin stimulation of cyclic GMP PDE activity was
28 ng/ml + / -  3 ng/ml (n=4, + / - ■  SEM), this corresponds to an 
EC5Q of 1.64nM + / -  0.18nM. In the absence of Ca2+, a small 
stimulation of cyclic GMP PDE activity could be observed 
(approximately 1.10-1.15 fold stimulation above controls). This 
Ca2+-independent action of calmodulin was, however, small compared 
to the fold stimulation for it’s Ca2+ -dependent action (3.3 fold). 
Ca2+ was found to be capable of stimulating the cyclic GMP PDE 
activity, but only in the presence of calmodulin. The EC50 for it’s 
action at saturating levels of calmodulin was 18.8 pM + / -  2.1 pM 
(n=3, + / -  SEM). The calmodulin stimulation of both cyclic AMP 
and cyclic GMP hydrolysis by PDE M Q -II  was inhibited by the 
calmodulin antagonist 5 -  Iodo -  C8 in a dose dependent manner as 
shown in Figures 3.59(a) and 3.59(b). The IC50 for this effect was
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13 pM + / -  3.1 pM when cyclic GMP was the substrate and 16.33 pM
+ / -  1.92 pM when the substrate was cyclic AMP. This antagonist had
no significant effect on the basal cyclic AMP and cyclic GMP 
hydrolysis up to a maximal concentration of 100 pM.
3.153: Effectors on rat hepatocyte -  derived PDE MQ -  III.
The substrate selectivity ratio of hepatocyte derived PDE MQ -  
III was different to that of the rat liver derived form (0.15 compared 
with 0.46). Despite this, the cyclic AMP hydrolytic component was 
stimulated to a very similar extent to that of the rat liver -  derived 
form (5.92 fold stimulation compared to 6.32 fold stimulation for the 
rat liver -  derived form). Further analysis of the effect of cyclic GMP 
on the cyclic AMP PDE activity of this Peak revealed that cyclic GMP 
had a biphasic effect on the cyclic AMP PDE activity (Figure 3.20). At 
1 pM cyclic AMP, low levels of cyclic GMP could stimulate the cyclic 
AMP PDE activity, with up to 10 fold stimulations observed at 10 pM 
cyclic GMP. Higher doses of cyclic GMP were capable of inhibiting 
cyclic AMP PDE activity. The EC50 for stimulation of cyclic AMP
hydrolysis was 0.466 pM + / '— 0.098 pM (n=4, + / -  SEM), whilst the 
IC50 for inhibition of cyclic AMP hydrolysis was found to be 43 pM 
+ / -  9.8 pM (n=4 , + / -  SEM).
3.15.4: Effectors on rat hepatocyte-derived PDE M Q -IV  and V.
The cyclic AMP PDE activity of the cyclic A M P-specific
activities PDE M Q -IV  and PDE M Q -V , were found to be insensitive 
to cyclic GMP at a concentration of 2 pM (Table 3.4). Further 
analysis of the effect of cyclic GMP on these two activities revealed 
that the IC50s for inhibition of cyclic AMP PDE activity were 214 pM 
+ / -  50 pM and 570 pM + / -  87 pM for PDE M Q -IV  and
PDE M Q -V  respectively (Figure 3.63 and Table 3.8) when assessed at 
1 pM substrate. This implied that these two activities belonged to the 
cyclic GMP -  insensitive subclass of cyclic A M P-specific
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phosphodiesterases (Yamamoto, et al., 1984; Pyne, et al., 1987b;
Weishaar, et al., 1987a; Weishaar, et al., 1987b).
3.16: KINETIC ANALYSIS OF RAT HEPATOCYTE -  DERIVED
PDE MQ PEAKS.
An analysis of the substrate utilisation of PDE M Q -I  to 
PDE M Q -V  was carried out in order to obtain values for cyclic 
AMP and cyclic GMP. Vmax values were also determined and in 
instances where the kinetics of hydrolysis of both substrates determined, 
a ratio of the respective Vmax values calculated.
3.16.1: Methods for determination of kinetic parameters of PDE MQ -  
Peaks.
This was performed by conservatively pooling activities from 
Peaks in order to minimise any possible contamination with 
neighbouring activities. In the case of PDE M Q -I , fractions were first 
pooled and then passed over a column of Affi -  gel Blue in the 
presence of 5 mM MgCl2. This was performed to remove any residual 
PDE activity contributed by PDE M Q -II  which binds tightly to this 
matrix (see Section 3.8 and Figure 3.9). Kinetic data were initially 
analysed by Lineweaver -  Burk analysis and and Vmax values
estimated from the plots where applicable. The estimates of the Vmax 
value were further validated by constructing both Hanes plots and 
Eadie -  Hofstee plots of the data and an average Vmax value 
determined. Hill plots were constructed using the averaged Vmax value 
and the degree of co -  operativity determined as well as an estimate of 
the Kn,. Absolute Vmax values could not be determined since the 
preparations were not pure. In instances where the Vmax values for 
both cyclic AMP and cyclic GMP were determined, . a ratio of the 
respective Vmax values was calculated (PDE M Q -I  and PDE M Q -III) . 
The results of a number of kinetic analyses are summarised in Table 3.8 
and representative plots shown in Figures 3.21-3.38.
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3.16.2: Kinetics of rat hepatocyte -  derived PDE M Q -I .
PDE M Q -I  was found to hydrolyse both cyclic AMP and cyclic 
GMP with linear kinetics, as assessed by Lineweaver -  Burk analysis 
(Figures 3.21 and 3.23 and Table 3.8). Hill plots of the kinetic data 
were also linear with slopes of 0.97 and 1.04 for cyclic AMP and cyclic 
GMP respectively, indicating that hydrolysis of these two cyclic 
nucleotides obeyed hyperbolic kinetics (Figures 3.22 and 3.24). 
Estimates of the values for both substrates determined from both 
Lineweaver-Burk plots and Hill plots were similar (Table 3.8). Cyclic 
AMP was hydrolysed with a Km of 25 pM to 31 pM and cyclic GMP 
with a Kn, of 237 jiM to 246 pM. The ratio of Vmax for cyclic 
AMP:Vmax for cyclic GMP was 1.07 + / -  0.14 (n=3, + / -  SEM).
3.16.3: Kinetics of rat hepatocyte -  derived PDE M Q -II.
PDE M Q -II  hydrolysed cyclic GMP with apparently n o n -lin e a r 
kinetics as determined by Lineweaver -  Burk analysis, with evidence of 
both high and low affinity components, (Figure 3.25). In addition, the 
kinetic data was plotted using both Hanes and E adie-H ofstee  plots 
(Figure 3.26(a) and (b)). These further confirmed the n o n -lin ea r 
kinetics' for cyclic GMP hydrolysis since they more readily showed 
evidence of apparent negative co -  operativity. The limiting values, 
deduced from Lineweaver -  Burk plots, were 1.9 pM (K ^ )  and 11 pM 
(K ^ )  respectively (Figure 3.25 and Table 3.8). The Hill plots were 
linear with slopes that were less than 1 (0.72) and gave a K,* value of 
5.1 pM for cyclic GMP hydrolysis (Figure 3.27 and Table 3.8). The
kinetics of cyclic AMP hydrolysis of PDE M Q -II  were not determined
due to the low activity observed with this cyclic nucleotide as substrate
(see Table 3.7 and Figure 3.17)
3.16.4: Kinetics of rat hepatocyte -  derived PDE M Q -III .
This activity hydrolysed both cyclic AMP and cyclic GMP with
positively cooperative kinetics. Lineweaver -  Burk plots of cyclic AMP 
hydrolysis were n on -linear (Figure 3.28). The fitted line did not 
intercept on the l/[cAMP] axis so a 'K^' value could not be
163
determined from this plot. The fitted line did, however, indicate that 
a 'lim iting '. Vmax value could be estimated, since the fitted line
'levelled' off (see inset of Figure 3.28). Hanes and Eadie — Hofstee
plots of cyclic AMP hydrolysis were also distinctly n o n -lin ear (Figure 
3.29), producing b i-p h asic  curves typical of enzymes obeying positively 
co-operative kinetics (see Whalin, et al., 1989). Hill plots for cyclic 
AMP hydrolysis were linear over the range between 10 and 90% of the 
Vmax value ( + 1 to - 1  on the y -ax is), giving an estimated K„, of 
37.7 pM for cyclic AMP hydrolysis with a Hill Coefficient of 1.62
(Table 3.8 and Figure 3.30).
Cyclic GMP was also hydrolysed with positively cooperative
kinetics. Lineweaver -  Burk analysis of this data once again showed
plots that were typical of enzymes obeying positively cooperative
kinetics. There was no intercept on the l/[cGMP] axis and the fitted 
line also 'levelled off', allowing an estimate of the Vmax value to be 
calculated (Figure 3.31 and inset of Figure 3.31). Hanes and Eadie -  
Hofstee plots were markedly n o n -lin ear and were of a veiy similar 
shape to those obtained when cyclic AMP was the substrate (Figure 
3.32). Hill plots of the data were constructed using an estimate of the 
Vmax from Lineweaver -  Burk plots and also a value from V (Velocity) 
versus log [cGMP] plots. These plots were linear and gave an estimate 
of the Kn, for cyclic GMP of 35.5 pM with a Hill coefficient of 1.22 
(Figure 3.33 and Table 3.8). The ratio of the Vmax for cyclic AMP 
hydrolysis to the Vmax for cyclic GMP hydrolysis was found to be 0.31 
+ / -  0.07 (n=4, + / -  SEM).
3.16.5 Kinetics of rat hepatocyte -  derived PDE M Q -IV .
This activity has been shown to exhibit a greater selectivity for 
cyclic AMP as substrate than for cyclic GMP (Table 3.7) so kinetic 
parameters were only determined with cyclic AMP as substrate. 
Lineweaver -  Burk plots of the kinetic data were n o n -lin e a r with 
evidence of both high and low affinity components (Figure 3.34).
Estimates of the (high -  affinity) and (low -  affinity)
164
parameters gave values of 0.8 pM and 8.0 pM respectively. When the 
data was plotted as both Eadie -  Hofstee and Hanes plots the non ­
linear nature of the kinetics was more apparent, particularly when 
Eadie -  Hofstee plots were used. Estimates of the limiting Km and 
Vmax parameters gave very similar values to those obtained from 
Lineweaver -  Burk plots (Figures 3.34, 3.35(a) and 3.35(b)). Hill plots of 
the data using an averaged Vmax value determined from the separate 
plots gave a straight line between - 1  and +1 on the y -  axis (i.e. at 
velocities between 10% and 90% of the Vmax)- The estimated Hill 
coefficient was 0.69 and the estimated Km value was 6.33 pM (Figure 
3.36 and Table 3.8).
3.16.6: Kinetics of rat hepatocyte -  derived PDE M Q -V .
As for PDE M Q -IV , this activity has been shown to exhibit a 
greater selectivity for cyclic AMP as substrate than for cyclic GMP 
(Table 3.7) so that only the kinetics of cyclic AMP hydrolysis were
determined. Lineweaver -  Burk plots of the kinetic data were linear 
giving an estimated value of 1.02 pM for cyclic AMP as substrate. 
Hill plots of the data were also linear and gave a value for the Hill 
coefficient of 1.01 with an estimated K^ value of 0.62 pM. There was, 
however, some variability in the slope of the Hill plots for this activity, 
so that in some instances, despite the apparent linearity of 
Lineweaver -  Burk plots, Hill coefficients with values below 1 were 
obtained (Figure 3.38). When this was the case, value of the Hill 
coefficient was only ever estimated to be as low as 0.8. This may have
reflected a partial coelution of PDE M Q -IV  with P D E -M Q -V ,
although this possibility could not be directly tested.
3.17: MAGNESIUM DEPENDENCY OF PDE M Q-PEAKS.
The metal ion Mg2+ is commonly employed in assays for
phosphodiesterase activity and is considered to be essential to support 
the cyclic nucleotide hydrolytic capacity of phosphodiesterases. It was 
decided to assess the dependency of the individual P D E -M Q -P e a k s  on
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Mg2+ in order to confirm this commonly held assumption. 
Phosphodiesterase assays were performed under basal conditions (i.e. in 
the absence of any other effectors) in the presence of increasing 
concentrations of magnesium and the degree of hydrolysis of cyclic 
AMP or cyclic GMP determined.
PDE MQ -  II to PDE MQ -  V inclusive were found to be almost 
entirely dependent on the addition of Mg2+ to support cyclic 
nucleotide hydrolysis. The EC50s for Mg2+ stimulation of 
phosphodiesterase activity by PDE M Q -II  to PDE M Q -V  were 
estimated from the dose response curves shown in Figures 3.39-3.41 
and summarised in Table 3.9. In the absence of Mg2+, PDE M Q -II  
exhibited a cyclic GMP phosphodiesterase activity that was 14% + / -  
1% (n=3, + / -  SEM) of the fully simulated activity, indicating that 
some Mg2 +-independent activity could be exhibited by this form. 
PDE M Q -III  and PDE M Q -V  were similar in this respect, exhibiting 
19% + / -  2% and 5% + / -  1.4% (n = 3, + /■- SEM) of fully
stimulated levels respectively. The phosphodiesterase activity of 
PDE M Q -IV  was found to be absolutely dependent on the presence of 
Mg2+, with virtually no activity observed in it’s absence.
On the other hand, PDE M Q -I  was found to be nearly fully 
active in the absence of Mg2+, although further activity could be 
stimulated in the presence of increasing concentrations of Mg2+. In 
the absence of added Mg2+, PDE M Q -I  was found to exhibit an 
activity that was 80% + / -  3% (n=3, + / -  SEM) of the maximal 
activity observed. Further to this, it was shown that the cyclic AMP 
PDE activity of PDE M Q -I  was still fully active in the presence of 
10 mM EDTA (Figure 3.39). The EC50s for Mg2+ stimulation of 
activity for PDE M Q -II, PDE M Q -IV  and PDE M Q -V  were similar 
with values of 20 pM + / -  2 pM, 50 pM + / -  7 pM and 40 pM + / -  
6 pM respectively (n=3, + / -  SEM). PDE M Q -III  exhibited a
significantly larger EC50 value of 193 pM + / -  18 pM. These results 
are summarised in Table 3.9.
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3.18: EFFECT OF INHIBITORS ON RAT HEPATOCYTE -  DERIVED
PDE M Q -PEAKS.
Given that some differences existed between the PDE MQ -  
Peaks derived from rat hepatocytes and those derived from rat liver, 
particularly with respect to PDE M Q -III , it was decided to assess the 
pharmacological characteristics of these resolved activities using an 
extended range of well characterised phosphodiesterase inhibitors. In 
addition to the inhibitors used for characterisation of the rat liver 
derived activities (IBMX, milrinone and R o - 20-1724), the
phosphodiesterase inhibitors, ICI 63197, ICI 118233, zaprinast and 
rolipram were used. ICI 63197 has been shown to exert a more 
selective inhibitory effect on a purified preparation the rat liver 
'peripheral’ plasma membrane phosphodiesterase as compared to the rat 
liver 'dense-vesicle' phosphodiesterase (Pyne, et al., 1987a). ICI 118233 
is a cardiotonic agent that specifically interacts with the cyclic G M P - 
inhibited subclass of cyclic A M P-specific phosphodiesterase, whilst 
rolipram has been shown to interact with the cyclic GMP -  insensitive 
subclass of cyclic AMP -  specific phosphodiesterase (Schwabe, et al., 
1976; Bergstrand, et al., 1977; H enkel-Tigges and Davis, et al., 1990). 
Zaprinast is a derivative of IBMX that exerts some selectivity for cyclic 
GM P-specific phosphodiesterases including at least some of the 
Ca2+/calm odulin-stim ulated isozymes (Bergstrand, et al., 1978; Quade, 
et al., 1984). The characteristics of these inhibitors are described in 
Section 1.8. The structures of ICI 118233, ICI 63197, rolipram and 
zaprinast are shown in Figures 1.6(e), 1.6(d) and 1.4(a).
The cyclic AMP phosphodiesterase activity of the individual 
PDE M Q -peaks was assessed in the presence of increasing 
concentrations of these inhibitors and- the IC50 determined in exactly 
the same manner as for the rat liver activities. Whilst cyclic AMP was 
normally used to assess the activity of the individual peaks, cyclic GMP 
was used instead in some instances. This was the case when the
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phosphodiesterase activity of PDE M Q -II  was assessed in the presence 
of ICI 118233, ICI 63197, zaprinast, and rolipram.
The IC50 values are summarised and compared- to the 
comparable values for rat liver -  derived PDE M Q -Peaks in Table 3.6. 
The data for ICI 63197 inhibition of phosphodiesterase activity are given 
in the text. Representative inhibition curves are shown in Figures 
3.42-3.53.
As for rat liver, PDE MQ - 1 was found to be insensitive to any 
of the inhibitors tested (Figures 3.42, 3.43 and 3.52). Whilst in all 
instances the IC50 values were greater than 500 jiM, this maximal
concentration of some inhibitors did produce some inhibition of 
phosphodiesterase activity. The extent of this inhibition were in the 
range 10% to 20% maximal effect when the inhibitors were IBMX,
milrinone, and R o - 20-1724. Larger effects were observed with
zaprinast and rolipram where the maximal effects were in the range 
40% to 50%.
PDE M Q -II  was found to be similar to the rat liver -  derived 
form, although it was found to be marginally more sensitive to both
milrinone and R o - 20-1724. The cyclic GMP -  selective inhibitor
zaprinast was found to inhibit the cyclic GMP PDE activity with an
IC5 o of 4.5 pM. PDE MQ -  IV showed some sensitivity to this 
inhibitor although the IC50 for inhibition in this instance was 
approximately 70 fold higher than for PDE M Q -II  (IC50 value of 
300 pM) (Figures 3.44 and 3.45). The IC50 for ICI 63197 action against 
this activity was 317 pM + / -  49 pM (n= 3 , + / -  SEM) (Figure 3.52).
PDE M Q -III  was found to be very insensitive to any of the 
inhibitors tested with only IBMX showing a very weak inhibitory 
response. The IC50 in this case was 323 pM which was some 3 fold
lower than the value for the rat liver -  derived activity (Figures 3.46 and
3.47). This difference may be related to the different substrate
selectivity of this Peak in hepatocytes compared to liver. The IC50 for
ICI 63197 action was greater than 500 pM (Figure 3.52). The maximal
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inhibition in this case was approximately 20%. It was noted that small
activatory effects could be observed in the presence of milrinone and
IBMX, rolipram and zaprinast. The magnitude of these effects were 
only in the range of 30% to 50% which is much smaller than the 
stimulation obtained in the presence of a maximal concentration of 
cyclic GMP which was about 10-fo ld  (see Figure 3.20).
The cyclic AMP -  selective activities, PDE M Q -IV  and 
PDE M Q -V , were found to be sensitive to inhibition by IBMX and 
milrinone with similar IC50 values to the rat liver -  derived forms. 
Whilst in rat liver R o - 20-1724 displayed a clear selectivity for 
PDE M Q -V  over PDE M Q -IV  (100 fold more potent) this difference 
was not as clear for the hepatocyte forms although there was still a 10
fold difference in the IC50 values (13 pM compared with 1.6 pM). ICI
118233 was not found to be inhibitory for either of these two forms or 
any of the other forms. The cyclic GMP PDE selective inhibitor 
zaprinast was found to exert only a small inhibitory effect on 
PDE M Q -IV  and none on PDE M Q -V . Both PDE M Q -IV  and
PDE M Q -V  were found to be very sensitive to rolipram with
PDE M Q -V  showing a greater sensitivity than PDE M Q -IV  (IC50 
values of 0.095 pM and 0.5 pM respectively) (Figures 3.48, 3.49, 3.50 
and 3.51). Similarly, ICI 63197 was found to be capable of inhibiting 
both PDE M Q -IV  and PDE M Q -V . The IC50 values in this instance 
were 2.1 pM + / -  0.6 (n=3 , + / -  SEM) and 6.6 pM + / -  0.3 (n = 3
+ / -  SEM) for PDE M Q -IV  and PDE M Q -V  respectively (Figure
3.53).
3.19: FURTHER CHARACTERISATION OF PDE M Q -PEA K S.
3.19.1: Further characterisation of PDE M Q -I  and PDE M Q -II .
The phosphodiesterase activities of rat hepatocyte -  derived
PDE M Q -I  and PDE M Q -II  were further characterised by determining 
the molecular weights of these activities by gel filtration on calibrated 
Sephacryl S -200  and S -3 0 0  gel filtration columns respectively (see
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Section 2.17). The calibration curves shown in Figures 3.54 and 3.57 
show that the S -2 0 0  column is suitable to separate proteins over a 
molecular weight range of 12,500 to 66,000, whilst the S -3 0 0  column is 
suitable to separate proteins over a range of 12,500 to 410,000. 
Chromatography of PDE M Q -I  on the Sephacryl S -2 0 0  column 
yielded a single peak of cyclic AMP phosphodiesterase activity that 
corresponded to a molecular weight of 3 3 -k D a  + / -  3 -k D a  (n=3, 
+ / -  SEM) (Figure 3.55). In contrast, chromatography of PDE M Q -II  
on the Sephacryl S -3 0 0  column yielded a peak of activity that had 
evidence of two closely eluting cyclic GMP phosphodiesterase activities 
(Figure 3.58). These activities were estimated to have molecular weights 
of 237-kD a + / -  13 -kD a (n = 3, + / -  SEM) and 190-kD a + / -  5 -  
kDa (n = 3, + / -  SEM) in three separate determinations. The yields 
of phosphodiesterase activity were very low in both procedures. It was 
not possible to estimate a precise value however, since the column 
profiles from both determinations were assayed for two hours instead of 
the usual ten minutes. This was performed to ensure that activity 
could be detected.
The ability of the cyclic nucleotides cyclic GMP and cyclic CMP 
to inhibit the cyclic AMP phosphodiesterase activity of PDE MQ - 1 was 
determined. Figure 3.56 shows that both of these cyclic nucleotides
were capable of inhibiting this activity although the IC50s determined
for this process were high. The IC50 for cyclic GMP was found to be 
850 pM + / -  57 pM (n= 3 , + / -  SEM), whilst the IC50 for cyclic 
CMP was found to be 413 pM + / -  27 pM (n=3, + / — SEM). The 
IC50 for this action of cyclic GMP is also shown in Table 3.9 where it 
is compared with cyclic GMP -  dependent -  inhibition of the other
phosphodiesterases.
The calmodulin antagonist, 5 - Io d o -C 8 , has been shown to be a 
relatively selective inhibitor of calmodulin stimulated bovine heart cyclic 
nucleotide phosphodiesterase (MacNeil, et al., 1988). The data shown 
in Figure 3.59 show that this calmodulin antagonist could inhibit the
Ca2+/calm odulin-stim ulated portion of the cyclic GMP and cyclic
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AMP phosphodiesterase activity of PDE M Q -II. The IC50s for this 
action of 5 - Io d o -C 8  were found to be 13 pM + / — 3.1 pM (n=3, 
+ / -  SEM) when cyclic GMP was the substrate and 16.33 pM + / -  
1.92 pM when cyclic AMP was the substrate. This antagonist had no 
significant effect on the basal cyclic AMP and cyclic GMP hydrolysis 
up to a maximal concentration of 100 pM.
3.19.2: Further characterisation of PDE M Q -IV  and PDE M Q -V .
From the data presented in Table 3.4 the cyclic AMP 
phosphodiesterase activities of PDE M Q -IV  and PDE M Q -V  were 
shown to be insensitive to inhibition by 2 pM cyclic GMP. At this 
level of cyclic GMP and a substrate concentration of 1 pM the 
maximal inhibitions observed were 19% and 23% respectively. The data 
presented in Figure 3.63 show that cyclic GMP could inhibit the cyclic 
AMP phosphodiesterase activity of PDE M Q -IV  and PDE M Q -V  with 
IC50 values of 214 pM + / -  50 pM and 570 pM + / -  87 pM 
respectively. These values are quoted in Table 3.9 which also draws a 
comparison with the effect of cyclic GMP on the other activities. This 
analysis further confirmed that these two activities were distinct from
the cyclic GMP -  inhibited subclass of cyclic A M P-specific 
phosphodiesterase.
3.20: THE SOLUBLE PHOSPHODIESTERASES IN OTHER RAT
TISSUES.
Given the large number of soluble activities that were observed
in the soluble fraction derived from both rat liver and hepatocytes, it
was decided to see if this multiplicity of phospodiesterase activities was 
also observed in the soluble fractions of other tissues. Soluble
fractions were prepared from brain, kidney and adipose tissue under 
identical conditions to those used for the preparation of hepatocyte 
and liver soluble extracts. For the case of adipocytes, the initial 
homogenisation was carried out at room temperature to avoid 
coaggulation of fats occuring. The&fter, all procedures were carried
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out at 4°C. Soluble fractions were separated using an identical gradient 
to that employed for the separation of rat liver and hepatocyte soluble 
extracts.
3.20.1: Adipose tissue soluble phosphodiesterases.
Figure 3.60 shows the Mono Q profile obtained from the rat 
adipose tissue soluble fraction. Cyclic AMP and cyclic GMP 
phosphodiesterase activities were determined at 0.1 pM substrate. Three 
peaks of phosphodiesterase activity were obtained. The first of these
eluted at 025 M NaCl and formed the vast majority of the cyclic GMP 
phosphodiesterase activity. The position of this activity was noted to
correspond with the position of the cyclic GMP -  stimulated 
phosphodiesterase (PDE M Q -III )  in rat liver and hepatocytes (see
Figures 3.8 and 3.17) and similarly could hydrolyse both cyclic AMP 
and cyclic GMP. This activity was also more selective for cyclic GMP 
as substrate than cyclic AMP as PDE M Q -III  was found to be.
Despite the similarity of the elution position to PDE M Q -III , this 
activity did not possess cyclic GMP -  stimulated phosphodiesterase
activity. 2 pM cyclic GMP stimulated this activity only 1.17 + / — 0.1 
fold (n=2, + / -  SD). In contrast, saturating levels of
Ca2+/calmodulin were noted to stimulate the cyclic GMP
phosphodiesterase activity of this peak 3.2 + / -  0.3 fold (n=2 , + / -
SD). This was taken to imply that the cyclic GMP -  stimulated
phosphodiesterase was not soluble in rat adipose tissue and that the 
Ca2+/calm odulin- stimulated phosphodiesterase was the major cyclic 
GMP phosphodiesterase present. Furthermore, this activity appeared to 
differ from the rat liver and hepatocyte -  derived PDE M Q -II  both in 
it’s elution position and in it’s substrate selectivity; the liver and 
hepatocyte activity eluted at a lower ionic strength from this column 
and was more highly selective for cyclic GMP as substrate. This 
activity was not characterised in more detail however.
Two peaks of cyclic AMP phosphodiesterase activity were also 
observed to be present. The first of these (Peak II) eluted at
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approximately 0.3 M NaCl, with some evidence of coelution with the 
cyclic GMP phosphodiesterase (Peak I). The second activity (Peak HI) 
was less abundant than Peak II and was observed to elute at 
approximately 0.4 M NaCl. Whilst, Peak in  appeared to correspond in 
position to PDE M Q -IV , Peak II did not seem to correspond to any 
of the PDE M Q -Peaks in hepatocytes although it’s position was similar 
to that of the small peak of activity that was occasionally observed to 
elute on the shoulder of PDE M Q -III  in rat liver soluble profiles. 
Whilst these activities were not characterised further, there was no 
evidence for an activity corresponding to the IBMX -  insensitive 
PDE M Q -I.
3.20.2: Brain soluble phosphodiesterases.
Mono Q chromatography of the rat brain soluble fraction 
separated a large number of phosphodiesterases. Figure 3.61 shows the 
presence of at least four such activities. Peak I eluted at approximately 
0.18 M NaCl and could hydrolyse both cyclic AMP and cyclic GMP 
with some selectivity for cyclic AMP as substrate. Peak II eluted over 
a veiy broad range of NaCl concentrations between approximately 0.2 M 
and 0.35 M NaCl. This peak hydrolysed both cyclic AMP and cyclic 
GMP and appeared to be slightly more selective for cyclic GMP. It 
was noted that the cyclic AMP and cyclic GMP phosphodiesterase 
phosphodiesterase activities, contained within this peak, did not coelute, 
with cyclic AMP elute eluting at a slightly higher NaCl concentration. 
This might imply that there was more than one phosphodiesterase 
activity present in this peak.
There were two peaks of cyclic AMP phosphodiesterase activity, 
which appeared to correspond to the positions of PDE M Q -IV  and 
PDE M Q -V  respectively. None of these activities were characterised in 
any detail
3.20.3: Kidney soluble phosphodiesterases.
Analysis of the soluble phosphodiesterases in kidney revealed the 
presence of four peaks of phosphodiesterase activity. Two of these
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were selective for cyclic GMP as substrate and two were selective for 
cyclic AMP as substrate. The profile obtained was clearly different to 
that of the rat liver and hepatocyte profiles, since there was no activity 
that corresponded to PDE M Q -I . These four activities eluted at 
0.18 M, 0.24 M, 0.31 M and 0.36 M NaCl respectively. It should be 
noted that a slightly different gradient was used to elute these activities 
so that optimal separation of activities could be achieved. Both the 
cyclic AMP and cyclic GMP phosphodiesterase activities of peak I were 
stimulated by Ca2+/calmodulin. Cyclic AMP phosphodiesterase activity 
was increased about 2.5 fold and cyclic GMP phosphodiesterase about
3.5 fold. The cyclic AMP phosphodiesterase activity of peak II was 
increased about 5 fold using 2 jiM cyclic GMP as the effector. The 
properties of the two cyclic A M P-specific phosphodiesterases were not 
examined in detail.
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FIGURE 3.1:
£JL 2+ SJJMIILAXIQM O F RAT L IV E R  SO LU BLE
PHOSPHODIESTERASE ACTIVITY.
A soluble fraction was prepared from rat liver as indicated in Section 2.4. 
Phosphodiesterase activity was assessed in the presence of increasing 
concentrations of added calcium. The basal level of EGTA was always 30jiM. 
Cyclic AMP phosphodiesterase activity is indicated by (Q) and cyclic GMP 
phosphodiesterase activity by (H  .The data is expressed in pmol/min/ml as the 
mean of triplicates ± SD. ;
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FIGURE 3.2:
EFFECT OF INCREASING EGTA ON RAT LIVER SOLUBLE 
PHOSPHODIESTERASE ACTIVITY.
A soluble fraction was prepared from rat liver as indicated in Section 2.4. 
Phosphodiesterase activity was assessed in the presence of increasing 
concentrations of added EGTA. The basal level of EGTA was always 30|iM. 
Cyclic AMP phosphodiesterase activity is indicated by O  and cyclic GMP 
phosphodiesterase activity by (■)• The data is expressed in pmol/min/ml as the 
mean of triplicates ± SD.
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FIGURE 3.3:
REVERSIBILITY OF CALCIUM EFFECT ON RAT LIVER 
SOLUBLE PHOSPHODIESTERASE ACTIVITY.
A rat liver soluble fraction was prepared as in Section 2.4. Samples were 
incubated in the absence (H) or presence (fi) (S )  of 2mM CaCl2 at 30°C for 
the times indicated. Samples were removed, diluted 1/5 in Buffer ’A' (50mM 
Tris-HCl pH 7.4, O.lmM EGTA, 5mM Benzamidine hydrochloride, 0.2mM 
PMSF, 2}iM Leupeptin, O.lmM Dithiothreitol) and 25|i.l assayed for cGMP 
phosphodiesterase activity either in the presence ( H ) (S )  or absence ( BB) of 
2mM EGTA. Results are expressed in pmol/min/ml as mean of triplicate 
determinations ± SD.
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FIGURE 3.4:
SEPARATION OF RAT LIVER SOLUBLE PH O SPH O ­
DIESTERASE ACTIVITY BY PE-52 CHROMATOGRAPHY
A soluble rat liver extract (45mls, 263mg of protein) prepared from one rat liver 
was applied to a column of DE-52 (3.1cm x 1.2cm) (prepared and equilibrated 
as in Section 2.8.1). The column was loaded and washed as in Section 2.8.2. 
Phosphodiesterase activity was eluted using a 400ml linear sodium chloride 
gradient between 0 and 0.5M NaCl contained in Buffer 'A1 (50mM Tris-HCl 
pH 7.4, O.lmM EGTA, 5mM Benzamidine hydrochloride, 0.2mM PMSF, 
2jiM Leupeptin, O.lmM Dithiothreitol) and 4ml fractions were collected. 25|il 
aliquots were removed and assayed for cyclic AMP Q  and cyclic GMP 4V 
phosphodiesterase activity at lfiM substrate. The sodium chloride gradient is 
shown as (—- ). Calmodulin activity was assayed by the protocol described in 
Section 2.9 and the peak of activity is indicated as the hatched box (nsas).
The relative yields of protein were:
Peak I-29mg
Peak II-37mg
Peak IE-11 mg
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FIGURE 3.5:
THERMAL INACTIVATION OF cAMP AND cGMP PHOSPHO­
DIESTERASE ACTIVITY OF DE-52 PEAK I AT 60°C.
Samples (25|il) of Peak I prepared by DE-52 chromatography were incubated at 
60°C for the indicated time before their removal onto ice. Phosphodiesterase 
activity was then determined at lfiM cGMP OB) and IpM cAMP (□). The 
zero time cAMP and cGMP PDE activities were 27 pmol/min/ml and 20 
pmol/min/ml respectively. Results are expressed as the log of the % of original 
activity remaining for each of the individual time points.
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FIGURE 3.6:
CHROMATOGRAPHY OF DE-52 PEAK I ON AFFI-GEL BLUE
Pooled fractions (24mls) from the DE-52 step containing 12mg of protein were 
made up to 5mM MgCl2 and applied at 0.5ml/min to a column of Affi-gel Blue 
(1.8cm x 1.1cm) previously equilibrated in Buffer ‘A1 (50mM Tris-HCl pH 
7.4, O.lmM EGTA, 5mM Benzamidine hydrochloride, 0.2mM PMSF, 2pM 
leupeptin, O.lmM Dithiothreitol) containing in addition 0.15M NaCl and 5mM 
MgCl2- The unbound fraction was collected as a pool and the column was then 
washed in 8 Bed volumes of the equilibration buffer and this was collected as a 
pool.
(a) Phosphodiesterase activity was assessed at l|iM  cAMP for basal activity 
<■) and in the presence of 2|ig/ml of Calmodulin Q  and 2|ig/ml Calmodulin 
plus 50|iM CaCl2 ® .
(b) Phosphodiesterase activity was assessed at lpM cGMP for basal activity 
(■) and in the presence of 2|ig/ml of Calmodulin Q )  and 2|ig/ml Calmodulin 
plus 50)iM CaCl2 ©
Values were determined in triplicate and are expressed in pmol/min as the mean 
± SD.
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FIGURE 3.7:
ELUTION OF CYCLIC GMP PDE ACTIVITY OF DE-52 PEAK I 
FROM AFFI-GEL BLUE.
lml aliquots of DE-52 Peak I (containing 56 pmol/min of cGMP PDE activity 
each) isolated from a rat Ever soluble fraction were made up to 5mM MgCl2 and 
incubated with lOOjil aliquots of Affi-gel Blue prepared and equilibrated as in 
Section 2.12. Incubation was for 30 minutes at 4°c on a rotary mixer. Gels 
were washed in 2 x 1ml aliquots of equilibration buffer (see Section 2.12). 
Elution of cGMP PDE activity was attempted using 2 x lml aliquots of Buffer 
A (50mM Tris-HCl pH 7.4, O.lmM EGTA, 5mM Benzamidine, 0.2mM 
PMSF, O.lmM dithiothreitol, 2|iM Leupeptin) containing the indicated 
additions.
1: Control cGMP PDE activity.
2: cGMP PDE activity eluted during wash.
3: 0.15M NaCl/lmM EDTA.
4: 0.15MNaCl/5mMMgCl2/10mMcGMP.
5: 0.15M NaCl/5mM MgC^/lOmM cAMP.
6: 0.5M NaCl/5mM MgC^.
7: 1.0M NaCl/5mM MgCL .^
lml of DE-52 Peak I contained 56 ± 3.91 pmol/min of cGMP PDE activity and 
in the presence of saturating Ca2+/CalmoduIin exhibited an activity of 156.25 
pmol/min.
Cyclic GMP phosphodiesterase activity was assessed either in the absence (HI) 
or presence of saturating levels of Ca2+/Calmodulin © ').
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FIGURE 3.8:
MONO a  ANION-EXCHANGE PROFILE OF RAT LIVER 
SOLUBLE PHOSPHODIESTERASE ACTIVITY.
Approximately half the high speed supernatant prepared from rat liver (20mls 
containing 120mg of protein) as in Section 2.4 was applied to a Mono Q 
column at lml/min (see Section 2.11). Phosphodiesterase activity was eluted 
using a sodium chloride gradient at lml/min and lml fractions collected. Cyclic 
AMP (□) and cyclic GMP (£) phosphodiesterase activity was determined at 
l|iM  substrate by assaying a 25jil aliquot of every alternate fraction. The 
phosphodiesterase activity is expressed in pmol/min. The sodium chloride 
gradient is shown as a solid line (-).
The relative yields of protein were:
PDE-MQI 1.62mg
PDE-MQII 1.14mg
PDE-MQ m  0.525mg
PDE-MQ IV 0.098mg
PDE-MQ VO.llOmg
Fraction
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FIGURE 3.9:
CHROMATOGRAPHY OF PDE MO-I AND PDE MQ-II ON AFFI-
fiEU-PU US,
PDE MQ-I and PDE MQ-II were isolated by Mono Q anion-exchange 
chromatography of a rat liver supernatant (see Section 2.11). 0.75ml aliquots 
were made up to 5mM MgCl2 and batch bound to 110|il aliquots of Affi-gel 
Blue using the method described in Section 2.12. Gels were washed in 2 x lml 
aliquots of the equilibration buffer. Washes and the unbound fraction were 
pooled to give a total unbound fraction. Phosphodiesterase activity was 
assessed at l|iM  cAMP (H) and ljiM cGMP $3). Results are expressed as 
the mean of triplicates ± SD.
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FIGURE 3.10 (a):
MONO Q ANION-EXCHANGE SEPARATION OF RAT LIVER 
SOLUBLE PDE MO-PEAKS ISOLATED IN THE PRESENCE OF 
GALCIUM.
A rat liver supernatant was prepared as in Section 2.4 except that O.lmM CaCl2 
was used in place of O.lmM EGTA in the homogenisation buffer. 20mls of the 
supernatant (147mg of protein) were applied to a Mono Q column and activity 
eluted using an identical protocol to that detailed in Section 2.11 except that 
O.lmM EGTA was replaced with O.lmM CaChin all the column elution 
buffers. Cyclic AMP Q )  and cyclic GMP ( | )  phosphodiesterase activity 
was determined at lpM substrate by assaying a 25|il aliquot of every alternate 
fraction. Phosphodiesterase activity is expressed in pmol/min/ml.
FIGURE 3.10 (b):
MONO ANIO.N^EXCHANGE_SEP_ARATION OF RAT LIVER
S.OLUPMS PDE MO-PE AKS A SSESSED..AX JQ QuM -SUBSTRATE
A soluble rat liver fraction was prepared as in Section 2.4. 20mls was applied to 
a Mono Q column and activity eluted as described in Section 2.11. lml fractions 
were collected and cyclic AMP (Q) and cyclic GMP <H) phosphodiesterase 
activity determined at lOGpM substrate. Phosphodiesterase activity is expressed 
in pmol/min/ml.
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FIGURE 3.11:
INHIBITION OF RAT LIVER PDE MQ-I BY IBMX. MILRINONE
AND Ro-20-1724.
The cAMP phosphodiesterase activity of liver-derived PDE MQ-I was assessed 
at lfiM substrate in the absence and presence of the indicated concentrations of 
the inhibitors IBMX, Milrinone and Ro-20-1724. The observed 
phosphodiesterase activities were corrected for the effect of solvent (DMSO) 
using the average correction curves shown in the Appendix (1-V). Results are 
expressed as the % of control activities (100%) ± SD for triplicate 
measurements.
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FIGURE 3.12:
IN H IB IT IO N  OF RAT LIV ER PDE M Q -II BY IBMX.
MILRINONE AND Ro-20-1724.
The cAMP phosphodiesterase activity of liver-derived PDE MQ-II was assessed 
at ljiM substrate in the absence and presence of the indicated concentrations of 
the inhibitors IBMX, Milrinone and Ro-20-1724. The observed 
phosphodiesterase activities were corrected for the effect of solvent (DMSO) 
using the average correction curves shown in the Appendix (1-V). Results are 
expressed as the % of control activities (100%) ± SD for triplicate 
measurements.
IBMX (■).
Milrinone ( 0 .
Ro-20-1724 ( 0).
% 
CO
NT
RO
L 
PH
OS
PH
OD
IE
ST
ER
AS
E 
AC
TI
VI
TY
FIGURE 3.12;
120
100
80
60
40
20
0
ZERO 100 1 0 0 010
[INHIBITOR] jiM
186
FIGURE 3.13:
IN H IB IT IO N  OF RAT I/TVER PDE MQ-TTT BY IBMX.
MILRINONE AND Ro-20-1724.
The cAMP phosphodiesterase activity of liver-derived PDE MQ-III was 
assessed at ljiM substrate in the absence and presence of the indicated 
concentrations of the inhibitors IBMX, Milrinone and Ro-20-1724. The 
observed phosphodiesterase activities were corrected for the effect of solvent 
(DMSO) using the average correction curves shown in the Appendix (1-V). 
Results are expressed as the % of control activities (100%) ± SD for triplicate 
measurements.
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FIGURE 3.14:
IN H IB ITIO N  OF RAT I,TVER PDE Mf^-TV BY IBMX.
MTERTNONE AND Ro-20-1724.
The cAMP phosphodiesterase activity of liver-derived PDE MQ-IV was 
assessed at l|iM  substrate in the absence and presence of the indicated 
concentrations of the inhibitors IBMX, Milrinone and Ro-20-1724. The 
observed phosphodiesterase activities were corrected for the effect of solvent 
(DMSO) using the average correction curves shown in the Appendix (1-V). 
Results are expressed as the % of control activities (100%) ± SD for triplicate 
measurements.
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FIGURE 3.15:
IN H IB IT IO N  OF RAT LIVER PDE MQ-V BY IBMX.
MILRINONE AND Ro-20-1724.
The cAMP phosphodiesterase activity of liver-derived PDE MQ-V was assessed 
at l|iM  substrate in the absence and presence of the indicated concentrations of 
the inhibitors IBMX, Milrinone and Ro-20-1724. The observed 
phosphodiesterase activities were corrected for the effect of solvent (DMSO) 
using the average correction curves shown in the Appendix (1-V). Results are 
expressed as the % of control activities (100%) ± SD for triplicate 
measurements.
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FIGURE 3.16:
D IS T R IB U T IO N  O F RAT H EPA TO CTY E PH O S PH O ­
DIESTERASE ACTIVITY.
Hepatocytes were prepared by coUagenase digestion from one rat (250-275g) as 
described in Section 2.5 and homogenised in approximately 50 mis of Buffer 
'A' (50mM Tris-HCl pH 7.5, 0.25M Sucrose, 5mM Benzamidine 
Hydrochloride, 0.2mM PMSF, 20}iM Leupeptin, O.lmM EGTA and O.lmM 
dithiothreitol) as detailed in Sections 2.4 and 2.5. The homogenate was spun at 
706gav for 10 minutes to produce a low speed 'pellet' (P^ and 'supernatant' 
(S1).The supernatant was retained. The pellet was 'washed' by resuspending 
in a further 40 mis of Buffer 'A' and recentrifuged to produce a further low 
speed pellet and supernatant. The supernatant was once again retained and the 
pellet was 'washed' in a further 40 mis of Buffer 'A' and centrifuged to 
produce a final 'washed' Pi fraction and a futher low speed supernatant. The 
three supernatants were centrifuged at 163,750gav to produce three high speed 
supernatants (S2) and three high speed pellets (P2).
3.16 (a): DISTRIBUTON OF RAT HEPATOCYTE cAMP 
PHOSPHODIESTERASE ACTIVITY.
The cyclic AMP phosphodiesterase activity of the individual fractions was 
assessed at l[iM substrate in the absence ( f | ) or presence of 2 p.g/ml 
Calmodulin plus 50|iM CaCl2 ®§D or 2|iM cyclic GMP (JS).
3.16 (b): DISTRIBUTON OF RAT HEPATOCYTE cGMP 
PHOSPHODIESTERASE ACTIVITY.
The cyclic GMP phosphodiesterase activity of the individual fractions was 
assessed at l|iM  substrate in the absence ( H )  or presence of 2 |ig/ml 
Calmodulin plus 50pM CaCl2 ®).
Fraction 1: Homogenate.
Fraction 2: Washed Pj’ pellet.
Fraction 3: High speed supernatant (S2).
Fraction 4: High speed pellet (P2). *
Fraction 5: High speed supernatant from first wash of Pj.
Fraction 6: High speed pellet from first wash of P1#
Fraction 7: High speed supernatant from second wash of Pj.
Fraction 8: High speed pellet from second wash of Pj
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FIGURE 3.17:
MONO Q  ANTON-EXCHANGE PROFILE OF RAT HEPATOCYTE 
SOLUBLE PHOSPHODIESTERASE ACTIVITY.
Hepatocytes, prepared by collagenase digestion of one rat liver, were 
homogenised under isotonic conditions in the presence of protease inhibitors 
(see Section 2.5). A high speed supernatant was prepared as described in 
Section 2.4. All of the supernatant prepared from one liver (containing 
approximately 80mg of protein) was applied to a Mono Q anion-exchange 
column at lml/min (see Section 2.11). Using an identical protocol to that 
adopted for elution of rat liver-derived soluble phosphodiesterase (see Section 
2.11), the phosphodiesterase activity was eluted using a sodium chloride 
gradient at lml/min and 1ml fractions were collected. Cyclic AMP (□) and 
cyclic GMP 41) PDE activity were determined at lfiM substrate by assaying a 
25|il aliquot of eveiy alternate fraction. The sodium chlorlide gradient is shown 
as (-------).
The relative yields of protein were as follows;
PDE MQ-I = 0.744mg.
PDE MQ-II = 1.944mg.
PDE MQ-III = 0.9mg.
PDE MQ-IV = 0.923mg.
PDE MQ-V = 0.12mg.
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FIGURE 3.18:
DOSE RESPONSE FOR CALMODULIN STIMULATION OF 
cGMP PHOSPHODIESTERASE ACTIVITY OF PDE MQ-II.
PDE MQ-II, prepared from a rat hepatocyte soluble fraction by Mono Q anion- 
exchange chromatography, was assayed for cGMP phosphodiesterase activity 
in the presence (■ )  or absence (□ )  of IOOjiM CaCl2- The Calmodulin 
concentration was varied between 0 and 10}ig/ml. The data is expressed in 
pmol/min/ml as the mean of triplicates ± SD.
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FIGURE 3.19:
DOSE RESPONSE FOR Ca2+ STIMULATION OF THE cGMP 
PHOSPHODIESTERASE ACTIVITY OF PDE MC^-II.
PDE MQ-II was prepared from the soluble fraction of rat hepatocytes by Mono 
Q anion-exchange chromatography. cGMP phosphodiesterase activity was 
assessed in the absence (P) and presence (■) of a saturating concentration of 
Calmodulin (2}ig/ml). The added calcium concentration was varied between 
zero and 500|iM. Results are expressed in pmol/min/ml of cGMP 
phosphodiesterase activity as the mean of triplicates ± SD.
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FIGURE 3.20:
DOSE RESPONSE FOR cGMP EFFECTS ON THE cAMP PPE 
ACTIVITY OF PDE MQ-HL
PDE MQ-m was prepared from the soluble fraction of rat hepatocytes by Mono 
Q anion-exchange chromatography. The cyclic AMP phosphodiesterase activity 
was assessed in the presence of increasing concentrations of cyclic GMP. The 
results are expressed in pmol/min/ml of cAMP phosphodiesterase activity as the 
mean of triplicate determinations ± SD.
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FIGURE 3.21:
LINEWEAVER-BURK PLOT FOR CYCLIC AMP HYDROLYSIS 
BY PDE MC^-I
The cAMP phosphodiesterase activity of PDE MQ-I was assessed over a 
substrate range of 0.5pM-100pM. The velocity of the reaction was calculated 
as pmol of cyclic AMP hydrolysed/min/ml of enzyme preparation. Lineweaver- 
Burk plots were constructed by plotting the reciprocal of the reaction velocity 
against the reciprocal of the substrate concentration. The line was fitted by least 
squares analysis. The estimated Vmax and values determined from such a 
plot were 1,052 pmol/min/ml and 24pM respectively.
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FIGURE 3.22:
HILL PLOT FOR CYCLIC AMP HYDROLYSIS BY PDE MO-I.
Kinetic data were replotted as Hill plots using a value of the Vmax estimated 
from Lineweaver-Burk plots, Hanes plots and Eadie-Hofstee plots. The 
average Vmax value was calculated to be 1390 pmol/min/ml. This value was 
used to determine the Hill plot. The slope of the Hill plot gives a value of 1.07 
for the Hill Coefficient (h). The estimated value for cAMP from this plot 
was 32|iM.
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FIGURE 3.23:
LINEWEAVER-BURK J L O T  JFOR CYCLIC GMP HYDROLYSIS 
PY PPE MQ^ -I
The cGMP phosphodiesterase activity of PDE MQ-I was assessed over a 
substrate range of 1.0pM-500|iM. The velocity of the reaction was calculated 
as pmol of cyclic GMP hydrolysed/min/ml of enzyme preparation. 
Lineweaver-Burk plots were constructed by plotting the reciprocal of the 
reaction velocity against the reciprocal of the substrate concentration. The line 
was fitted by least squares analysis. The estimated Vmax and Km values 
determined from such a plot were 2,000 pmol/min/ml and 250jiM respectively.
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FIGURE 3.24:
HILL PLOT FOR CYCLIC GMP HYDROLYSIS BY PDE MQ-L
Kinetic data were replotted as Hill plots using a value of the Vmax estimated 
from Lineweaver-Burk plots, Hanes plots and Eadie-Hofstee plots. The 
average Vmax value was calculated to be 1,775 pmol/min/ml +/- 159. This 
value was used to determine the Hill plot. The slope of the Hill plot gives a 
value of 1.01 for the Hill Coefficient (h). The estimated value from this 
plot was 282}iM.
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FIGURE 3.25:
LINEWEAVER-BURK PLOT FOR CYCLIC GMP HYDROLYSIS 
BY PDE MO-n.
The cGMP phosphodiesterase activity of PDE MQ-II was assessed over a 
substrate range of 0.1pM-100|iM. The velocity of the reaction was calculated 
as pmol of cyclic GMP hydrolysed/min/ml of enzyme preparation. 
Lineweaver-Burk plots were constructed by plotting the reciprocal of the 
reaction velocity against the reciprocal of the substrate concentration. The 
limiting Km and Vmax values estimated from this plot were, = 2.9|iM, 
Km2 -  14pM, Vmaxl = 264 pmol/min/ml and Vmax2 = 563 pmol/min/ml.
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FIGURE 3.26(a):
EAPIE-HOFSTEE PLOT FOR cGMP HYDROLYSIS BY PDE M q-II.
Kinetic data were plotted as velocity (v) against v/[cGMP]. Estimates of the 
intercepts gave the following limiting values for and Vmax.
Kmi = 1.6}iM, Km2= ll|iM
Vmax i = 200 pmol/min/ml, Vmax2 = 550 pmol/min/ml
FIGURE 3.26(b):
HANES PLOT FOR cGMP HYDROLYSIS BY PDE M q-II.
Kinetic data were plotted as [cGMP]/velocity(v) against [cGMP]. Estimates of 
the intercepts gave the following limiting values for Km and Vmax.
Kmi = l*2pM, Km2 = 8|iM
Vmaxi = 171 pmol/min/ml, VmaX2 = 510 pmol/min/ml.
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FIGURE 3.27:
HILL PLOT FOR CYCLIC GMP HYDROLYSIS BY PDE M Q JL
Kinetic data were replotted as Hill plots using the Vmax2 values estimated from 
Lineweaver-Burk plots, Hanes plots and Eadie-Hofstee plots. The average 
Vmax2 value was calculated to be 541 pmol/min/ml ± 23 (SD). This value was 
used to determine the Hill plot The slope of the Hill plot gives a value of 0.81 
for the Hill Coefficient (h). The estimated Km value from this plot was 
7.94|iM.
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FIGURE 3.28:
LINEWEAVER-BURK PLOT FOR CYCLIC AMP HYDROLYSIS 
P Y PDF M ^-U I,
The cAMP phosphodiesterase activity of PDE MQ-IH was assessed over a 
substrate range of 0.3|iM-700p,M. The velocity of the reaction was calculated 
as pmol of cyclic AMP hydrolysed/min/ml of enzyme preparation. Lineweaver- 
Burk plots were constructed by plotting the reciprocal of the reaction velocity 
against the reciprocal of the substrate concentration. The inset shows the 
Lineweaver-Burk plot at the maximal levels of cAMP. From this it was 
estimated that the Vmax value was 4,000 pmol/min/ml.
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FIGURE 3.29(a) and (b):
HANES AND EAPIE-HOFSTEE PLOT FOR CYCLIC AMP 
HYDROLYSIS BY PPE MC^-m.
Kinetic data were plotted both as (a) [cAMP]/velocity (v) against [cAMP] 
(Hanes plot) and as (b) velocity (v) against v/[cAMP] (Eadie-Hofstee plot).
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FIGURE 3.30:
HILL PLOT ANALYSIS FOR CYCLIC AMP HYDROLYSIS BY 
PPE  MQ-HL
Kinetic data were replotted as Hill plots using a Vmax value of 4000 
pmol/min/ml estimated both from Lineweaver-Burk plots, and a Velocity versus 
Log [cAMP] plot. The slope of the Hill plot gives a value of 1.44 for the Hill 
Coefficient (h). The estimated Km value from this plot was 50jjM.
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FIGURE 3.31:
LINEW EAVER-BURKPLOT FOR CYCLIC GMP HYDROLYSIS 
BY PDE MQ-III.
The cGMP phosphodiesterase activity of PDE MQ-in was assessed over a 
substrate range of 0.13|iM-200jiM. The velocity of the reaction was calculated 
as pmol of cyclic GMP hydrolysed/min/ml of enzyme preparation. 
Lineweaver-Burk plots were constructed by plotting the reciprocal of the 
reaction velocity against the reciprocal of the substrate concentration. The inset 
shows the Lineweaver Burk plot at the maximal levels of cGMP. From this it 
was estimated that the Vmax value was 8,500 pmol/min/ml.
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FIGURE 3.32(a) and (b):
HANES AND EADIE-HOFSTEE PLOT FOR CYCLIC GMP 
HYDROLYSIS BY PDE MO-m.
Kinetic data were plotted both as (a) [cGMP]/velocity (v) against [cGMP] 
(Hanes plot) and as (b) velocity (v) against v/[cGMP] (Eadie-Hofstee plot).
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FIGURE 3.33:
HILL PLOT FOR CYCLIC GMP HYDROLYSIS BY PDE MQ-m.
Kinetic data were replotted as Hill plots using a Vmax value of 4,000 
pmol/min/ml estimated both from Lineweaver-Burk plots, and a Velocity 
versus Log [cGMP] plot The slope of the Hill plot gives a value of 1.22 for 
the Hill Coefficient (h). The estimated Km value from this plot was 32|iM.
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FIGURE 3.34:
LINEWEAVER-BURK PLOT FOR CYCLIC AMP HYDROLYSIS 
BY PDE MQ-IV.
The cyclic AMP phosphodiesterase activity of PDE MQ-IV was assessed over a 
substrate range of 0.15|iM-100}iM. The velocity of the reaction was calculated 
as pmol of cyclic GMP hydrolysed/min/ml of enzyme preparation. 
Lineweaver-Burk plots were constructed by plotting the reciprocal of the 
reaction velocity against the reciprocal of the substrate concentration. The 
limiting Km and Vmax values estimated from this plot were, Kmx = 0.95pM, 
Km2 = 6.67|iM, Vmaxi = 155 pmol/min/ml and Vmax2 = 261 pmol/min/ml.
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FIGURE 3.35(a):
EADIE-HOFSTEE PLOT FOR CYCLIC AMP HYDROLYSIS BY 
PDE MQ-IV.
Kinetic data were plotted as velocity (v) against v/[cAMP]. Estimates of the 
intercepts gave the following limiting values for Km and Vmax;
Kml = 0.7|iM, Km2 = 7.2|iM
Vmaxi = 129 pmol/min/ml, Vmax2= 240 pmol/min/ml
FIGURE 3.35(b):
HANES PLOT FOR cAMP HYDROLYSIS BY PDE MQ-IV.
Kinetic data were plotted as [cAMP]/velocity(v) against [cAMP]. Estimates of 
the intercepts gave the following limiting values for Km and Vmax;
Kmi = 0.8|iM, Km2 = 8|iM
Vmaxl = 145 pmol/min/ml, Vmax2 = 266 pmol/min/ml.
[c
AM
P]
/V
 
[{x
M
.M
IN
.M
L/
PM
O
L]
 
V 
[P
M
O
L/
M
IN
/M
L]
FTOIIRE 3.35fal:
280
240
200
160
120
80
40
0
60 80 100 120 140 160 180 20020 400
V/[cAMP] [PMOL/MIN/ML/|iM]
FIGURE 3.35(b);
0.5
0.4
0.2
0.1 -
0.0
200 40 12060 80 100
[cAMP] [|iM]
209
FIGURE 3.36:
HILLJPLDJ -F.OR CYCLIC AMP HYPRQLYSIS BY TDE MQrl L
Kinetic data were replotted as Hill plots using a value of the Vmax2 estimated 
from Lineweaver-Burk plots, Hanes plots and Eadie-Hofstee plots. The 
average Vmax2 value was calculated to be 270 pmol/min/ml. This value was 
used to determine the Hill plot. The slope of the Hill plot gives a value of 0.59 
for the Hill Coefficient (h). The estimated Km value from this plot was 7.1|iM.
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FIGURE 3.37:
LINEWEAVER-BURK PLOT FOR CYCLIC AMP HYDROLYSIS
The cyclic AMP phosphodiesterase activity was assessed over a substrate range 
of 0.064pM-20jiM. The velocity of the reaction was calculated as pmol of 
cyclic AMP hydrolysed/min/ml of enzyme preparation. Lineweaver-Burk plots 
were constructed by plotting the reciprocal of the reaction velocity against the 
reciprocal of the substrate concentration. The line was fitted by least squares 
analysis. The estimated Vmax and Km values determined from such a plot were 
152 pmol/min/ml and 0.63}iM respectively.
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FIGURE 3.38:
HILL PLOT FOR CYCLIC AMP HYDROLYSIS BY PDE MO-V.
Kinetic data were replotted as Hill plots using a value of the Vmax estimated 
from Lineweaver-Buik plots, Hanes plots and Eadie-Hofstee plots. The 
average Vmax value was calculated to be 156 pmol/min/ml. This value was 
used to determine the Hill plot. The slope of the Hill plot gives a value of 0.80 
for the Hill Coefficient (h). The estimated Km value from this plot was lfiM.
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FIGURE 3.39
EFFECT OF MAGNESIUM ON PDE MO-I AND PDE M Q-II 
CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ACTIVITY.
The cAMP phosphodiesterase activity of PDE MQ-I ( O ) and cGMP 
phosphodiesterase activity of PDE MQ-II (6) were assayed at l}iM substrate 
in the absence and presence of increasing concentrations of magnesium. 
Results are expressed as the % of maximal phosphodiesterase activity observed 
± SD for triplicates. The basal activities were:
PDE MQ-I 59 pmol/min/ml
PDE MQ-II 18.55 pmol/min/ml.
EFFECT OF EDTA ON THE cAMP PHOSPHODIESTERASE 
ACTIVITY OF PPE MQrL
The cyclic AMP phosphodiesterase activity of PDE MQ-I was assayed at ljiM 
substrate in the absence and presence of increasing concentrations of EDTA (p|. 
Results are expressed as % of control activity (100%) ± SD for triplicates. The 
control activity was 54.3 pmol/min/ml.
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FIGURE 3.40
EFFECT OF MAGNESIUM ON PDE MO-III AND PDE M Q JV  
CYCLIC AMP PHOSPHODIESTERASE ACTIVITY.
The cAMP phosphodiesterase activity of PDE MQ-IV ( □ )  and cGMP 
phosphodiesterase activity of PDE MQ-in were assayed at ljiM substrate 
in the absence and presence of increasing concentrations of magnesium. 
Results are expressed as the % of maximal phosphodiesterase activity observed 
± SD for triplicates. The basal activities were:
PDE MQ-m 31 pmol/min/ml.
PDE MQ-IV 0 pmol/min/ml.
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FIGURE 3.41
EFFEC T OF MAGNESIUM ON PDE MQ-V CYCLIC AMP 
PHOSPHODIESTERASE ACTIVITY.
The cAMP phosphodiesterase activity of PDE MQ-V was assayed at l|iM  
substrate in the absence and presence of increasing concentrations of 
magnesium. The basal activity was 7.9 pmol/min/ml. Results are expressed as 
the % of maximal phosphodiesterase activity observed ± SD for triplicates.
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FIGURE 3.42:
INHIBITION OF RAT HEPATOCYTE PDE MQ-I BY IBMX.
MILRINONE AND Ro-20-1724.
The cAMP phosphodiesterase activity of hepatocyte-derived PDE MQ-I was 
assessed in the absence and presence of the indicated concentrations of the 
inhibitors IBMX, Milrinone and Ro-20-1724. The observed phosphodiesterase 
activities were corrected for the effect of solvent (DMSO) using the average 
correction curves shown in the Appendix (VI-X). Results are expressed as the 
% of control activities (100%) ± SD for triplicate measurements.
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FIGURE 3.43:
IN H IB IT IO N  OF RAT HEPATOCYTE PDE M Q -I BY
ZAPRINAST. ROLIPRAM AND ICI 118233.
The cAMP phosphodiesterase activity of hepatocyte-derived PDE MQ-I was 
assessed in the absence and presence of the indicated concentrations of the 
inhibitors Zaprinast, Rolipram and ICI 118233. The observed 
phosphodiesterase activities were corrected for the effect of solvent (DMSO) 
using the average correction curves shown in the Appendix (VI-X). Results are 
expressed as the % of control activities (100%) ± SD for triplicate 
measurements.
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FIGURE 3.44:
INHIBITION OF RAT HEPATOCYTE PDE MCfcll BY IBMX.
MILRINONE AND Ro-20-1724.
The cAMP phosphodiesterase activity of hepatocyte-derived PDE MQ-II was 
assessed in the absence and presence of the indicated concentrations of the 
inhibitors IBMX, Milrinone and Ro-20-1724. The observed phosphodiesterase 
activities were corrected for the effect of solvent (DMSO) using the average 
correction curves shown in the Appendix (VI-X). Results are expressed as the 
% of control activities (100%) ± SD for triplicate measurements.
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FIGURE 3.45:
IN H IB IT IO N  OF RAT HEPATOCYTE PDE M Q -II BY
ZAPRINAST. ROLIPRAM AND ICI 118233.
The cGMP phosphodiesterase activity of hepatocyte-derived PDE MQ-II was 
assessed in the absence and presence of the indicated concentrations of the 
inhibitors Zaprinast, Rolipram and ICI 118233. The observed 
phosphodiesterase activities were corrected for the effect of solvent (DMSO) 
using the average correction curves shown in the Appendix (VI-X). Results are 
expressed as the % of control activities (100%) ± SD for triplicate 
measurements.
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FIGURE 3.46:
INHIBITION OF RAT HEPATOCYTE PDE M Q-III BY IBMX.
MILRINONE AND Ro-20-1724.
The cAMP phosphodiesterase activity of hepatocyte-derived PDE MQ-IH was 
assessed in the absence and presence of the indicated concentrations of the 
inhibitors IBMX, Milrinone and Ro-20-1724. The observed phosphodiesterase 
activities were corrected for the effect of solvent (DMSO) using the average 
correction curves shown in the Appendix (VI-X). Results are expressed as the 
% of control activities (100%) ± SD for triplicate measurements.
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FIGURE 3.47:
IN H IB ITIO N  OF RAT HEPATOCYTE PDE M Q -III BY
ZAPRINAST. ROLIPRAM AND ICI 118233.
The cAMP phosphodiesterase activity of hepatocyte-derived PDE MQ-III was 
assessed in the absence and presence of the indicated concentrations of the 
inhibitors, Zaprinast, Rolipram and ICI 118233. The observed 
phosphodiesterase activities were corrected for the effect of solvent (DMSO) 
using the average correction curves shown in the Appendix (VI-X). Results are 
expressed as the % of control activities (100%) ± SD for triplicate 
measurements.
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FIGURE 3.48:
INHIBITION OF RAT HEPATOCYTE PDE MQ-IV BY IBMX.
MILRINONE AND Ro-20-1724.
The cAMP phosphodiesterase activity of hepatocyte-derived PDE MQ-IV was 
assessed in the absence and presence of the indicated concentrations of the 
inhibitors IBMX, Milrinone and Ro-20-1724. The observed phosphodiesterase 
activities were corrected for the effect of solvent (DMSO) using the average 
correction curves shown in the Appendix (VI-X). Results are expressed as the 
% of control activities (100%) ± SD for triplicate measurements.
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FIGURE 3.49:
IN H IB IT IO N  OF RAT HEPATOCYTE PDE M Q-IV BY
ZAPRINAST. ROLIPRAM AND ICI 118233.
The cAMP phosphodiesterase activity of hepatocyte derived PDE MQ-IV was 
assessed in the absence and presence of the indicated concentrations of the 
inhibitors Zaprinast, Rolipram and ICI 118233. The observed 
phosphodiesterase activities were corrected for the effect of solvent (DMSO) 
using the average correction curves shown in the Appendix (VI-X). Results are 
expressed as the % of control activities (100%) ± SD for triplicate 
measurements.
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FIGURE 3.50:
INHIBITION OF RAT HEPATOCYTE PDE M p-V  BY IBMX.
MILRINONE AND Ro-20-1724.
The cAMP phosphodiesterase activity of hepatocyte-derived PDE MQ-V was 
assessed in the absence and presence of the indicated concentrations of the 
inhibitors IBMX, Milrinone and Ro-20-1724. The observed phosphodiesterase 
activities were corrected for the effect of solvent (DMSO) using the average 
correction curves shown in the Appendix (VI-X). Results are expressed as the 
% of control activities (100%) ± SD for triplicate measurements.
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FIGURE 3.51:
IN H IB IT IO N  OF RAT HEPATOCYTE PDE M QjV BY
ZAPRINAST. ROLIPRAM AND ICI 118233.
The cAMP phosphodiesterase activity of hepatocyte-derived PDE MQ-V was 
assessed in the absence and presence of the indicated concentrations of the 
inhibitors Zaprinast, Rolipram and ICI 118233. The observed 
phosphodiesterase activities were corrected for the effect of solvent (DMSO) 
using the average correction curves shown in the Appendix (VI-X). Results are 
expressed as the % of control activities (100%) ± SD for triplicate 
measurements.
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FIGURE 3.52:
INHIBITION OF RAT HEPATOCYTE-DERTVED PDE MQ-I. PDE 
M O -n AND PDE M O -m  BY ICI 63197.
The phosphodiesterase activities of hepatocyte-derived PDE MQ-I, PDE MQ-II 
and PDE MQ-IH were assessed in the absence and presence of the indicated 
concentrations of ICI 63197. The observed phosphodiesterase activities were 
corrected for the effect of solvent (DMSO) using the average correction curves 
shown in the Appendix (VI-VIII). Results are expressed as the % of control 
activity (100%) ± SD for triplicate determinations.
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FIGURE 3.53:
INHIBITION OF RAT HEPATOCYTE-PERIVEP PDE MQ-IV 
AND PPE MO-V BY ICI 63197.
The phosphodiesterase activities of hepatocyte-derived PDE MQ-IV and PDE 
MQ-V were assessed in the absence and presence of the indicated concentrations 
of ICI 63197. The observed phosphodiesterase activities were corrected for the 
effect of solvent (DMSO) using the average correction curves shown in the 
Appendix (IX and X). Results are expressed as the % of control activity 
(100%) ± SD for triplicate determinations.
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FIGURE 3.54:
CALIBRATION OF SEPHACRYL S-200 GEL FILTRATION 
.C O U U M N i
A column of Sephacryl S-200 (66cm x 1.6cm) was set up and equilibrated as in 
Section 2.17. The column was calibrated by applying l-2mg of the following 
proteins; Ferritin (410,0000), Bovine Serum Albumin (66,000), Ovalbumin 
(45,000), Carbonic Anhydrase (29,000) and Cytochrome c (12,500). The 
elution volumes (Ve) of these proteins were determined. The inner volume (Vi) 
and void volume (Vo) of the column were calculated using the elution volumes 
of e-DNP-Lysine and Blue-Dextran respectively. These were estimated to be 
127 and 37mls respectively. The calibration curve was plotted as Ve/Vo against 
the log of the molecular weight. The plot yielded a straight line with a 
correlation coefficient of 0.96 over a molecular weight range of 12,500-66,000.
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FIGURE 3.55:
SEPHACRYL S-200 GEL FILTRATION OF PDE M Q J.
1 ml of rat hepatocyte-derived PDE MQ-I containing approximately 150 
pmol/min of cAMP phosphodiesterase activity was applied to a column of 
Sephacryl S-200 as detailed in Section 2.17. Activity was eluted at 8ml/hr and 
1.45 ml fractions were collected. cAMP phosphodiesterase activity was 
assayed using a 2 hour assay in place of the usual 10 minute assay. Results are 
expressed in pmol/min/ml. The value of the elution volume (Ve) was 
determined from the midpoint of the peak and using the calibration curve 
constructed for this column corresponded to a molecular weight of 27,000.
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FIGURE 3.56:
EFFECT OF cGMP AND cCMP ON RAT HEPATOCYTE PDE 
MO-1 cAMP PHOSPHODIESTERASE ACTTVTTY
The cAMP phosphodiesterase activity of PDE MQ-I was assessed at ljiM 
substrate in the absence and presence of increasing concentrations of cyclic 
GMP ( ■ )  and cyclic CMP (□ ) .  Results are expressed as the % of control 
values (100%) ± SD of triplicate determinations.
The basal (control) activities were 31.86 pmol/min/ml and 27.1 pmol/min/ml for 
the two treatments respectively.
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FIGURE 3.57:
,CALIBRATION QF—SEPBACRYL ..S -300 GEL FILTRATION 
COLUMN.
A column of Sephacryl S-300 (83cm x 1.6cm) was set up and equilibrated as in 
Section 2.17. The column was calibrated by applying l-2mg of the following 
proteins; Ferritin (410,0000), Catalase (232,000), Alchol Dehydrogenase 
(150,000), and Cytochrome c (12,500). The elution volumes (Ve) of these 
proteins were determined. The inner volume (Vi) and void volume (Vo) of the 
column were calculated using the elution volumes of e-DNP-Lysine and Blue- 
Dextran respectively. These were estimated to be 106mls and 50mls 
respectively. The calibration curve was plotted as Ve/Vo against the log of the 
molecular weight. The plot yielded a straight line with a correlation coefficient 
of 1.00 over a molecular weight range of 12,500 to 410,000.
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FIGURE 3.58:
SEPHACRYL S-300 GEL FILTRATION OFJPDE M Q JL
1.5 mis of rat hepatocyte-derived PDE MQ-II containing approximately 120 
pmol/min of cGMP phosphodiesterase activity was applied to a column of 
Sephacryl S-200 as detailed in Section 2.17. Activity was eluted at 8ml/hr and 
1.45 ml fractions were collected. cGMP phosphodiesterase activity was 
assayed using a 2 hour assay in place of the usual 10 minute assay. Results are 
expressed in pmol/min/ml. There appeared to be a shoulder observed on the 
peak of activity so two individual values of the elution volume (Ve) were 
recorded. Using the calibration curve for the S-300 column these corresponded 
to molecular weights of 220,000 and 183,000 respectively.
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FIGURE 3.59
EFFECT OF THE CALMODULIN ANTAGONIST 5-IODO-C8 ON 
BASAL AND CALMODULIN STIMULATED PDE ACTIVITY.
The cAMP and cGMP phosphodiesterase activity of PDE MQ-II was assessed 
in the presence and absence of the calmodulin antagonist 5-Iodo-C8. Basal 
phosphodiesterase activity was assessed at IOOjiM CaCl2, whilst calmodulin 
activated activity was determined in the presence of 200ng/ml of calmodulin 
plus IOOjiM CaCl2. Results are expressed as the mean of triplicates ± SD.
Panel (a) shows the effect on basal (□ ) and calmodulin stimulated (■ ) cAMP 
PDE activity.
Panel (b) shows the effect on basal (D) and calmodulin stimulated (■ ) cGMP 
PDE activity.
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FIGURE 3.60:
MONO q  ANION-EXCHANGE PROFILE OF RAT ADIPOCYTE 
SOLUBLE PHOSPHODIESTERASE ACTIVITY.
A high speed supernatant was prepared from the epididymal adipose tissue 
isolated from five rats. A modified procedure of that detailed in Section 2.4 was 
used to prepare this supernatant This involved the initial homogenisation being 
carried out at room temperature to prevent solidification of the fat. The 
supematnat (40mls)was then applied to a Mono Q column at lml/min (see 
Section 2.11). Phosphodiesterase activity was eluted using a sodium chloride 
gradient at lml/min and 1ml fractions collected. Cyclic AMP (□ ) and cyclic 
GMP (■ )  phosphodiesterase activity was determined at 0.1 pM substrate by 
assaying a 25jil aliquot of every alternate fraction. The phosphodiesterase 
activity is expressed in pmol/min.. An identical gradient was used as for the 
preparation of rat liver and hepatocyte soluble fractions (see Table 2.2)
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FIGURE 3.61:
MONO q  ANION-EXCHANGE PR O FILE OF RAT BRAIN 
SOLUBLE PHOSPHODIESTERASE ACTIVITY.
A high speed supernatant was prepared from one rat brain exactly as in Section 
2.4. This extract was then applied to a Mono Q column at lml/min (see Section 
2.11). Phosphodiesterase activity was eluted using a sodium chloride gradient 
at lml/min and 1ml fractions collected. Cyclic AMP ( □ )  and cyclic GMP 
( ■  ) phosphodiesterase activities were determined at l|iM  substrate by 
assaying a 25|il aliquot of every alternate fraction. The phosphodiesterase 
activity is expressed in pmol/min.
FRACTION 
NUM
BER
PHOSPHODIESTERASE ACTIVITY
{PMOL/MIN/ML]
235
FIG
URE 
3.61;
FIGURE 3.62:
MONO q  ANION-EXCHANGE PROFILE OF RAT KIDNEY 
SOLUBLE PHOSPHODIESTERASE ACTIVITY.
A high speed supernatant was prepared from two rat kidneys exactly as 
described for the preparation of rat liver and rat hepatocyte soluble fractions (see 
Section 2.4). This extract (40mls) was applied to a Mono Q column at lml/min 
(see Section 2.11). Phosphodiesterase activity was eluted using a sodium 
chloride gradient at lml/min and 1ml fractions collected. Cyclic AMP (□ )  
and cyclic GMP ( ■ )  phosphodiesterase activity was determined at lfiM 
substrate by assaying a 25|il aliquot of every alternate fraction. The 
phosphodiesterase activity is expressed in pmol/min.
FRACTION 
NUM
BER
PHOSPHODIESTERASE ACTIVITY
[PMOL/MIN/ML]
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FIG
URE 
3.62:
FIGURE 3.63:
IN H IB ITIO N  OF CYCLIC AMP HYDROLYSIS OF RAT 
HEPA TO CY TE-D ERIV ED  PDE M Q-IV AND PDF, MQ-V BY 
cGM P.
The cAMP phosphodiesterase activity of PDE MQ-IV and V were assessed at 
ljiM substrate in the absence and presence of increasing concentrations of 
cyclic GMP. Results are expressed as the % of control values (100%) ± SD of 
triplicate determinations.
The basal (control) activities were 48.3 pmol/min/ml and 57 pmol/min/ml for 
the two activities respectively.
(□ ) Cyclic AMP phosphodiesterase activity of PDE MQ-IV.
(■ ) Cyclic AMP phosphodiesterase activity of PDE MQ-V.
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TABLE 3.1:
EFFECT OF AGENTS ON THE CYCLIC AMP AND CYCLIC 
GMP PHOSPHODIESTERASE ACTIVITY OF PE-52 PEAKS.
The fold effects of Ca2+ (50jiM), Ca2+/Calmodulin (50|iM Ca2+ 2}ig/ml 
Calmodulin) and cyclic GMP (2jjM) on cyclic AMP and cyclic GMP hydrolysis 
were determined at ljiM substrate. Values are expressed as the mean ± SEM. 
RATIO indicates the ratio of cAMPxGMP hydrolysis determined at l|iM  
substrate and is an index of the substrate selectivity of the resolved peaks. N. A. 
ncVapplicable, n is the number of determinations.
4.16±1.74
cGM
P 
1.05±0.07 
1 
36±0.40 
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TABLE 3.2:
PROGRAMME USED FOR THE SEPARATION OF SOLUBLE
P H O S P H O D IE S T E R A S E  A C T IV IT Y  BY M ONO Q
CHROMATOGRAPHY
This Table represents the parameters that were set to obtain the sodium chloride 
gradient used for separation of soluble phosphodiesterases from both rat liver 
and rat hepatocyte soluble fractions. CONCH %B represents the % of Buffer B 
at a particular time in the gradient where 100% B represents a buffer containing 
0.5M NaCl. ML/MIN represents the speed at which the column was run. 
CM/ML indicates the chart speed. PORT SET 6.1 and 6.0 are the instructions 
for turning the fraction collector on and off respectively.
[E (MINS) PARAMETER SETTING
0 .0 CONC* %B 0 .0
0 .0 ML/MIN 1.0
0 .0 CM/ML 0 .5
0 .0 PORT SET 6 .1
35 .0 C O N C U R 40 .0
85 .0 c o n c e  %b 80 .0
88 .0 CONC^ %B 100
95 .0 CONC* %B 100
95 .0 PORT SET 6 .0
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TABLE 3.3:
YIELD OF RAT LIVER PPE MO-PEAKS I-V
The average yield of cAMP and cGMP phosphodiesterase activity, assessed at 
lpM  substrate, was calculated for each of the individual Peaks prepared from 
approximately half a rat liver supernatant and is expressed as pmol/min of 
phosphodiesterase activity ± SEM. The % of total soluble phosphodiesterase 
activity was calculated assuming the resolved peaks represented 100% of the 
applied cyclic AMP and cyclic GMP PDE activities. RATIO is the ratio of cyclic 
AMPxyclic GMP hydrolysis assessed at ljiM substrate, n is the number of 
determinations.
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TABLE 3.4:
EFFECTS OF AGENTS ON LIVER AND H EPA TO CY TE 
DERIVED PDE MO PEAKS.
The phosphodiesterase activity of pooled individual peaks was assessed at lfiM 
substrate. Final assay concentrations of Ca2+ and Calmodulin were 50|iM and 
2|ig/ml respectively, while the cyclic GMP concentration was 2|iM. An asterix 
(*) indicates that the effect of the agent was significantly different from control, 
with P < 0.05. ND indicates that while enzyme activity was too low for an 
accurate detection of small effects, no gross effects of Ca2+ and Calmodulin 
were detectable. Results are expressed as the means ± SEM, with n being the 
number of experiments. Values are fold-effects relative to control in the 
absence of agents.
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TABLE 3.5:
ELUTION OF cGMP PPE  ACTIVITY OF PDE M O-II FROM 
AFFI-GEL BLUE.
0.75ml aliquots of PDE MQ-II (containing 46 pmol/min of cGMP PDE activity 
each) isolated from a rat liver soluble fraction was made up to 5mM MgCl2 and 
incubated with 110{il aliquots of Affi-gel Blue prepared and equilibrated as in 
Section 2.12. Incubation was for 30 minutes at 4°c on a rotary mixer. Gels 
were washed in 2 x 1ml aliquots of equilibration buffer (see Section 2.12). 
Elution of cGMP PDE activity was attempted using 2 x 1ml aliquots of Buffer 
A (50mM Tris-HCl pH 7.4, O.lmM EGTA, 5mM Benzamidine, 0.2mM 
PMSF, O.lmM dithiothreitol, 2}iM Leupeptin) containing the indicated 
additions. The Ca2+/Calmodulin containing buffer contained 5jig/ml of 
Calmodulin and 500fiM CaCl2. The total applied activity was 46 pmol/min per 
0.75ml aliquot. The washes contained 4.58 ±1.13 pmol/min of cGMP PDE 
activity (10% of applied activity). The % binding of the cGMP PDE activity of 
PDE MQ-II to the matrix was 99.8%. Eluted activity is expressed both as 
pmol/min of cGMP PDE activity retrieved ± SD of triplicates and as a % of the 
total bound.
ELUTION
CONDITION
ACTIVITY % RECOVERED
[PMOL/MIN]
0.5M NaCl/5mM MgCl2 2.5710.8 5.6%
1.0M NaCl/5mM MgCl2 0 0%
2mM EDTA 1+0.16 2.22%
0.5M NaCl/2mM EDTA 2.17±0.24 4.7%
1.0M NaCl/2mM EDTA 3.8613.9 8.4%
Ca2+/Calmodulin/2mM EDTA 3.8810.21 8.4%
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TABLE 3.6:
IC ro VALUES FOR LIVER AND HEPATOCYTE PERIVEPJPDE 
MO-PEAKS
The concentration of drug causing 50% inhibition of basal cAMP or cGMP 
phosphodiesterase activity was determined at l|iM  substrate (see Section 
2.14). Results are means ± SEM with n being the number of determinations. 
All drug effects were corrected for the effect of solvent (DMSO) before 
calculation of IC5 0  values. N.I. not inhibitory at concentrations up to either 
500p,M* or 100pM+. In instances where an IC 5 0  value could not be 
determined then the % inhibition observed at the maximal drug dose is shown 
in brackets. cAMP was normally the substrate except for # which was 
cGMP.
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TABLE 3.7:
YIELD OF RAT HEPATOCYTE PDE MQ-PEAKS I-V
The average yield of cAMP and cGMP phosphodiesterase activity, assessed at 
I jiM substrate, was calculated for each of the individual Peaks prepared from 
the total hepatocyte-derived supernatant and is expressed as pmol/min of 
phosphodiesterase activity ± SEM. The % of total soluble phosphodiesterase 
activity was calculated assuming the resolved peaks represented 100% of the 
applied cyclic AMP and cyclic GMP PDE activities. RATIO is the ratio of 
cyclic AMP:cyclic GMP hydrolysis assessed at IjiM substrate, n is the number 
of determinations.
CAMP 
519±142 
22.7
(n=5) 
10.1+2.7 
cGM
P 
22±11 
0.72 
(n=3)
(n=3)
oO
EL
u
o>
o
a
ELu
o> oO o> o  oO >
s  s"O "O
3
ii
CO
CO 3
l+ iicn
cn05roi+
-vi ro— co ,—. co 
3 co 3 cn ii |+ ii lL
^  Z  3  SO coro
3
II
~vl
O  _  g  
CD 3  J
i+ a. is
~  m “  °•Vl
^  3 
■&> II l+ -
CD o
COO■vll+
CDro
ro
05
cno>
bo
o
co
co05
ro
ro
co
cn
ro
3 cn 
3  fo
*v|
3II
*sl
cnl+o
o  
3 * oo
“ ft•vj p
o
3
IICO
(J1
b■vjl+o
■o
3
o
3
3
01
“0
om
CO
c
or
ca
05 «-► ■
CD
;<
0
Q.
-u
o
m
0)
o
<
<
I ■0
I om
CO Ip i 05
05 I o|
I <
I H*| <
Ho
0)
CAO
cg;
o
33
>H
cn co
244
TABLE 3.8:
KINETIC PROPERTIES OF RAT HEP AT O C YTE-PERIVED PDE 
M % PEA K S.
Phosphodiesterase activities were resolved from rat hepatocyte high speed 
supernatants using a Mono Q column. All values quoted for PDE MQ-I were 
determined using an enzyme preparation which had been further 
chromatographed on Affi-gel Blue (see Section 2.16). Km values and Hill 
coefficients (h) were determined from Hill plots or limiting Km values (Kmi 
and Km2) from Lineweaver-Burk plots. In instances where Lineweaver-Burk 
plots were downwardly curving, and thus indicative of apparent negative 
cooperativity, the limiting values for Kmi and Km2 were obtained from their 
linear extremae. In all instances, triplicate determinations of phosphodiesterase 
activity were performed at 19 substrate concentrations (see Legends for Figures 
3.21 to 3.28 for actual range). N.A. Not applicable. N.D. Not determined.
All values are expressed as the mean ± SEM of at least three independent 
determinations.
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TABLE 3.9:
E FFEC T OF Mg2* IONS AND CYCLIC GMP ON RAT 
HEPATOCTYE-DERIVEP PDE MO-PEAKS.
Phosphodiesterase activities were resolved from rat hepatocyte high speed 
supernatants using a Mono Q column. All values for PDE MQ-I were 
determined using an enzyme preparation which had been further 
chromatographed on Affi-gel Blue (as described in Section 2.16). EC50 values 
for Mg2+ effects were determined using either lpM cyclic AMP (PDE MQ-I, 
PDE MQ-EI, PDE MQ-IV and PDE MQ-V) or l^M  cyclic GMP (PDE MQ- 
II) as substrate. All effects of cyclic GMP were determined using l|iM  cyclic 
AMP as substrate.
N.A. Not applicable. N.D. Not determined.
All values are quoted as the means of triplicate determinations ± SEM.
PEAK
I
II
III
IV
V
ECc0 Mg2* IC cqcGM P  ECgA cGMP observations
N.A.
20±2
193±18
50+7
40±6
850+57
N.D.
43±9.8
214+50
570±87
N.D.
N.A.
0.466±0.098
N.A.
N.A.
3
4
3
4
9,46
CHAPTER 3: DISCUSSION.
In most cells/tissues phosphodiesterase activity is observed in both the 
soluble and particulate fractions. A  lot of attention has been focussed 
on particulate -  derived phosphodiesterase isozymes, particularly in 
hormonally sensitive tissues such as liver and adipose tissue, due to the 
fact that these contain a number of hormone stimulated 
phosphodiesterase activities. In liver and hepatocytes, the two 
membrane bound species of phosphodiesterase that are stimulated by 
hormones such as insulin and glucagon, have been purified and 
characterised (Whitson and Appleman, 1982; Pyne, et al., 1987a; Boyes 
and Loten, 1988; Marchmont, et al., 1981b; Pyne. et al., 1986b;
Houslay, 1988). These have been termed the 'dense -vesicle ' and 
'peripheral' phosphodiesterases respectively (Heyworth, et al., 1983d; 
Marchmont, et al., 1981b; Pyne, et al., 1987a; Pyne, et al., 1986b).
These activities may play an important role both in the anti -  lipolytic 
and anti -  glycogenolytic actions of insulin as well as providing a 
negative feedback system to decrease cyclic AMP levels in hormonally
stimulated cells (Heyworth, et al., 1983d; Beebe, et al., 1985; Corbin, 
et al., 1985; Gettys, et al., 1987). Whilst much is known about the
number and type of particulate -  derived phosphodiesterases in tissues 
such as the liver and adipose tissue, relatively little is known about the 
soluble phosphodiesterases in these tissues.
The soluble fraction has been noted to contribute a significant 
proportion of the total phosphodiesterase activity in tissues and cell
types such as adipose tissue (Manganiello and Vaughan, 1973), liver
(Whitson and Appleman, 1982; Heyworth, et al., 1983d), heart
(Weishaar, et al., 1987a) and 3T 3-L 1  adipocytes (Elks and Manganiello,
1985). The aim of this study was to identify and characterise the 
soluble phosphodiesterase activities present in the soluble fraction of 
both rat liver and hepatoctyes.
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Initially, the effects of two potential regulators of 
phosphodiesterase activity, namely Ca2+ and cyclic GMP, on the total 
cyclic AMP and cyclic GMP phosphodiesterase activities observed in a 
crude rat liver soluble fraction, were determined. This is because, in 
vivo, Ca2+ is a potential regulator of the calmodulin -  sensitive 
phosphodiesterase, whilst cyclic GMP is a potential regulator of both 
the cyclic GMP -  stimulated and cyclic GMP -  inhibited 
phosphodiesterases. This was performed by assessing total 
phosphodiesterase activity of an isolated soluble fraction in the presence 
of saturating levels of Ca2+ or 2 pM cyclic GMP. This analysis 
revealed that Ca2+ could stimulate both the total cyclic AMP and the 
total cyclic GMP phosphodiesterase activity in this fraction, whilst 
cyclic GMP was also found to promote a marked stimulation of the
cyclic AMP phosphodiesterase activity. These results indicated the
presence of a Ca2+ -stim ulated phosphodiesterase activity and a cyclic
GMP -  stimulated activity.
The fold stimulations of total cyclic AMP and cyclic GMP 
phosphodiesterase activities obtained with saturating levels of Ca2+ 
were, however, small in both cases. There were three possible
explanations for the small effects observed. Firstly, that the 
Ca2+/calm odulin-stim ulated phosphodiesterase formed the majority of 
the cyclic nucleotide phosphodiesterase activity in the rat liver soluble 
fraction, but exhibited only a very small stimulation in the presence of
Ca2+. Secondly, that the levels of endogenous calmodulin in the 
preparation were too low to support maximal stimulation of 
phosphodiesterase activity, despite the presence of saturating Ca2+ 
concentrations. Lastly, that Ca2+ could stimulate the
phosphodiesterase activity of this enzyme to a much greater degree than 
that observed in the crude supernatant but that the fold stimulation 
was masked due to the presence of a number of other Ca2+-
insensitive phosphodiesterases present in the supernatant.
The second possibility was discounted by the observation that
the fold stimulations of the total cyclic AMP and cyclic GMP
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phosphodiesterase activity obtained in the presence of saturating Ca2+ 
were almost identical to those obtained when saturating calmodulin was 
included in the assays. This indicated that calmodulin levels were 
already saturating in the rat liver soluble preparation.
In order to address the first and third possibilities, it was 
necessary to separate the individual phosphodiesterase activities present 
in the rat liver soluble fraction. A number of other groups have used 
anion -  exchange chromatography on matrices such as D E -5 2  or 
D EA E-Sephacel (Thompson and Appleman, 1981; Russel, et al., 1973; 
Turnbull and Hickie, 1984; Weishaar, et al., 1986; Reeves, et al., 1987) 
to achieve this aim. In this study, I initially decided to use D E -5 2  to 
separate the individual activities. During the course of this study I 
consistenty used a substrate concentration of 1 pM to assess both cyclic 
AMP and cyclic GMP hydrolysis. For each of the individual resolved 
activities, I calculated a substrate selectivity ratio which expresses the 
ratio of cyclic AMP phosphodiesterase activity to cyclic GMP 
phosphodiesterase activity at 1 pM. This index gives an indication of 
the substrate selectivity of any individual activity but will only be 
appropriate at this concentration of cyclic nucleotide.
Three separate peaks were obtained when phosphodiesterase 
activity was eluted from the D E -5 2  column using a linear sodium 
chloride gradient (termed Peaks I to III). Peak I was found to 
hydrolyse both cyclic AMP and cyclic GMP equally well, Peak II was 
more selective for cyclic GMP, whilst Peak III was more selective for 
cyclic AMP. The individual properties of these Peaks were assessed by 
monitoring their responsiveness to saturating levels of Ca2+, 
Ca2+/calmodulin and to 2 pM cyclic GMP.
Ca2+, by itself, was not found to stimulate significantly the 
cyclic AMP or cyclic GMP phosphodiesterase activities of any of these 
three Peaks of activity. This implied that, under the conditions that 
the separation was performed (i.e. in the presence of EGTA), the 
calmodulin moiety did not associate with phosphodiesterase activity.
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When assays of calmodulin activity were performed, it was shown that 
on D E -5 2  chromatography calmodulin did indeed elute as an entity
separate from phosphodiesterase. This is consistent with the 
observations of other workers, who showed that anion -  exchange 
chromatography in the presence of EGTA is sufficient to prevent 
association of calmodulin with the Ca2+/calm odulin- stimulated 
phosphodiesterase (Ho, et al., 1977; Strewler, et al., 1983).
Using Ca2+ and calmodulin together, it was shown that Peak I 
contained a Ca2+/calm odulin-stim ulated cyclic nuclotide 
phosphodiesterase. The degree of stimulation of the cyclic GMP 
phosphodiesterase activity of Peak I by Ca2+/calmodulin was found to
be about 2 fold, which was much greater than the fold stimulation of
cyclic GMP phosphodiesterase activity observed when Ca2+ was added 
to the crude supernatant. This observation, and the ocurrence of two 
other peaks of activity that were insensitive to Ca2+/calmodulin, 
therefore explains the low 'fold -  stimulations’ of phosphodiesterase 
activity observed when Ca2+ was added to a crude soluble fraction of
rat liver.
In tissues such as bovine brain, where the Ca2+/calm odulin-  
stimulated activity contributes a significant proportion of the total 
soluble phosphodiesterase activity, the addition of Ca2+ elicits a much 
greater increase in the total cyclic nucleotide phosphodiesterase activity 
than that observed here for the rat liver soluble fraction, presumably as 
a consequence of the preponderance of this activity in this tissue 
(Sharma, et a i, 1980; Beavo, 1988).
Low (jiM) concentrations of cyclic GMP have been used by a 
number of investigators as an activator/inhibitor of cyclic AMP 
hydrolysis (Beavo, et al., 1971; Weber and Appleman, 1982; 
Yamamoto, et al., 1984a; Harrison, et al., 1986b; MacPhee, et al., 
1987). In this study I routinely used 2 pM cyclic GMP, a 
concentration that has been shown to be capable of eliciting a marked 
stimulation of the cyclic AMP phosphodiesterase activity of purified
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preparations of the cyclic GMP -  stimulated phosphodiesterase (Martins, 
et al., 1982; Yamamoto, et al., 1983a) including the rat liver soluble 
form (Pyne, et al., 1986b). This concentration of cyclic GMP will also 
cause a significant inhibition of cyclic AMP hydrolysis of purified and
partially purified preparations of the cyclic GMP -  inhibited
phosphodiesterase (Grant and Colman, 1984; Yamamoto, et al., 1984a;
Degerman, et al., 1987) including the rat liver 'dense-vesicle ' 
phosphodiesterase (Pyne, et al., 1987a; Boyes and Loten, et al., 1988).
Use of this concentration of cyclic GMP should thus allow detection of
both the cyclic GMP -  stimulated and cyclic GMP -  inhibited
phosphodiesterases. This analysis revealed that Peak II contained the 
cyclic GMP -  stimulated phosphodiesterase and Peak III a cyclic AMP -  
specific activity that was insensitive to cyclic GMP. The presence of 
these three types of activity have also been observed by other workers 
in a soluble rat liver fraction (Russel, et al., 1973; Turnbull and 
Hickie, 1984).
On closer examination it was noted that, despite the fact that 
saturating levels of Ca2+/calmodulin stimulated markedly the cyclic 
GMP hydrolysis of Peak I, these agents caused a much smaller
stimulation of cyclic AMP hydrolysis. Thermal inactivation studies 
revealed that the cyclic AMP and cyclic GMP activities in this peak
decayed with kinetics indicative of different active sites. Whilst this
observation provided an indication that the cyclic AMP and cyclic GMP 
phosphodiesterase activities contained within this peak were associated 
with different enzymes, it was also possible that these two activities
were associated with the same enzyme, with hydrolysis occurring at 
different active sites within either the same polypeptide or different 
subunits of the putative enzyme. This possibility was discounted by the 
observation that the cyclic AMP and cyclic GMP phosphodiesterase 
activities of Peak I could be separated from each other by
chromatography on the dye-ligand affinity matrix A ffi-gel Blue. In 
this instance, it was observed that the majority of the cyclic AMP
phosphodiesterase activity of Peak I did not bind to this matrix, whilst
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the majority of the cyclic GMP phosphodiesterase activity did. This 
implies that there were indeed two separate enzymic activities contained
within this peak; one predominantly hydrolysing cyclic AMP. and the
other hydrolysing cyclic GMP. It was also observed that 
Ca2+/calm odulin-stim ulated phosphodiesterase activity was capable of 
binding to the A ffi-gel Blue matrix. This was taken to imply that it 
was the species which preferentially hydrolysed cyclic GMP which was
the Ca2+/calm odulin-stim ulated enzyme.
In order to assess this by an independent methodology, I used 
chromatographic separation on a high resolution anion -  exchange 
column (Mono Q). When the rat liver soluble fraction was separated 
on this column this allowed for the separation of five peaks of
phosphodiesterase activity (termed PDE M Q -I  to PDE M Q -V ). These 
were shown to differ both in their substrate selectivity and in their 
responses to effectors such as Ca2+/calmodulin and cyclic GMP. 
These analyses revealed the presence of an a cyclic AMP -  selective, 
IBMX -  insensitive phosphodiesterase (PDE M Q -I) , a
Ca2+/calm odulin-stim ulated species (PDE M Q -II) , a cyclic G M P - 
stimulated phosphodiesterase (PDE M Q -III)  and two cyclic A M P - 
specific activities (PDE MQ IV and PDE M Q -V ) in the rat liver
soluble fraction. This was the first clear indication that the number
and type of phosphodiesterase activities contained in the rat liver 
soluble fraction was greater than the three types observed previously in 
my studies and by other workers (Russel, et al., 1973; Turnbull and 
Hickie, 1984; Moss, et aL, 1983).
PDE M Q -I  was found to predominantly hydrolyse cyclic AMP 
and bound very poorly to A ffi-gel Blue. In contrast, PDE M Q -II , 
which preferentially hydrolysed cyclic GMP, bound to" the A ffi-g e l 
Blue column and was stimulated by Ca2+/calmodulin. . The behaviour
of these two Mono Q -resolved  Peaks was analagous to the behaviour
of the cyclic AMP and cyclic GMP phosphodiesterase activities of D E -  
52 Peak I during A ffi-gel Blue chromatography. This behaviour
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strongly suggested that D E -5 2  Peak I was indeed comprised of two
separate activities.
Attempts to elute the cyclic GMP phosphodiesterase activity
from the A ffi-gel Blue matrix were unsuccessful. This was the case
when the source of the cyclic GMP phosphodiesterase activity was D E -  
52 Peak I or PDE M Q -II  (from the Mono Q column). Although 
binding to A ffi-gel Blue was usually performed in the presence of 
5 mM MgCl2, it was observed that when 5 mM MgCl2 was replaced
with 2 mM EDTA, PDE M Q -II  could still bind to A ffi-g e l Blue. 
This observation suggested that binding of this activity to Affi -  gel 
Blue could occur in the absence of added Mg2+ ions. When EDTA 
was used to elute activity that had been bound in the presence of 
MgCl2 no substantial recovery of cyclic GMP phosphodiesterase activity
was noted. Although the precise site(s) at which A ffi-g e l Blue binds
to the enzyme(s) are unknown, it has been suggested that this matrix
will bind proteins that possess a tertiary structure known as the 
'dinucleotide fold'. This structure has been observed in all nucleotide 
binding proteins for which a three dimensional structure is known 
(Thompson, et al., 1975). Morril, et al., (1979) suggested that the 
substrate binding site of the Ca2+/calm odulin- stimulated
phosphodiesterase is constructed by a N A D -binding domain similar to 
that known to form the N A D - and A TP-binding sites in several
dehydrogenases and kinases.
The dye ligand Cibacron Blue 3GA, which acts as the binding 
ligand in A ffi-ge l Blue, has been shown to be a competitive inhibitor 
of the Ca2+/calm odulin- stimulated phosphodiesterase isolated from 
bovine brain (Morril, et al., 1979). On this basis, PDE MQ -  II, which 
contains a Ca2+/calm odulin-stim ulated phosphodiesterase' activity, may 
also bind to this matrix at or near to it’s active site. Whilst no 
phosphodiesterase activity could be detected on matrix containing 
bound cyclic GMP phosphodiesterase activity, no activity could be 
eluted using high substrate concentrations (either cyclic AMP or cyclic 
GMP) which would be expected to compete with the Cibacron Blue
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3GA for the nucleotide binding site and thus allow elution of the 
enzyme activity. One possible explanation for this behaviour is that 
Cibacron Blue 3GA may act as a non-com petitive inhibitor of the 
enzyme by binding at a site distinct from the nucleotide binding site. 
Alternatively, the affinity of the A ffi-gel Blue binding site on the 
enzyme may be so high as to preclude elution by substrate competition.
The properties of this activity seemed then to be different to 
those of the bovine brain form of the enzyme and this may be related 
to the observations that distinct isozymic forms of the 
Ca2+/calm odulin- stimulated phosphodiesterase enzyme exist both 
within tissues and between species (Purvis, et al., 1981; Vandermeers, 
et al., 1983; Kincaid, et al., 1984; Sharma, et al., 1984; ‘ Sharma and 
Wang, 1986b; Sharma and Wang, 1990).
The observation that PDE M Q -I , unlike most other 
phosphodiesterase activities (Morril, et al., 1979; Marchmont, et al., 
1981b; Pyne, et al., 1986b; Pyne, et al., 1987a), is unable to bind to 
A ffi-ge l Blue, even in the presence of Mg2+, implied that this enzyme 
lacks either the appropriate dinucleotide fold or an appropriate divalent 
cation binding site. In a comparison of the inhibitor sensitivities of 
the rat liver -  derived PDE M Q -Peaks, this activity was also found to 
differ from the other soluble activities and indeed other classes of 
phosphodiesterase (Weishaar, et al., 1985b; Hidaka and Endo, 1984). It 
was found to be insensitive to the reference phosphodiesterase 
inhibitors IBMX, R o - 20-1724 and milrinone. Whilst PDE M Q -III  
was similar in showing an insensitivity to these phosphodiesterase 
inhibitors, although it did show a marginal sensitivity to IBMX, it could 
easily be distinguished from PDE M Q -I  by the ability of low (pM) 
concentrations of cyclic GMP to cause a marked stimulation of cyclic 
AMP hydrolysis, a property characteristic of the cyclic. GMP stimulated 
class of phosphodiesterase which was not shared with PDE M Q -I . On 
this basis I propose that PDE M Q - I  is a novel activity that had not 
previously been observed in the rat liver soluble fraction due to it’s
254
coelution with the Ca2+/calm odulin- stimulated cyclic GMP
phosphodiesterase.
Rat liver contains a number of phosphodiesterase activities th a t . 
are located in the particulate fraction derived from homogenates. At 
least one of these species, the 'dense-vesicle' phosphodiesterase can be 
released from it’s membrane location by the action of endogenous 
proteases (Loten, et al., 1978; Loten, et al., 1980; Pyne, et al., 1987a). 
Hypotonic conditions have been shown to cause the release of the 
membrane bound 'dense-vesicle ' phosphodiesterase due to lysis of 
lysosomes and the subsequent release of endogenous proteases (Loten, 
et al., 1978). This may also be true of other phosphodiesterase
activities including the insulin -  stimulated 'peripheral' plasma membrane 
phosphodiesterase.
If particulate phosphodiesterases are released from their
membrane location either by the action of proteases or by other
mechanisms (such as the loss of a divalent cation necessary for binding 
of a peripheral protein to a membrane) they will accumulate in the
isolated soluble fraction. Consequently, the observed activities will not 
represent true soluble proteins. I was concerned that some of the 
multiplicity of phosphodiesterases that I observed in the soluble 
fraction derived from a rat liver homogenate may have arisen as a 
result of release of species of phosphodiesterases derived from a 
particulate source. The precautions that I took to prevent this 
occurence included the preparation of the homogenate under isotonic 
conditions and the presence of protease inhibitors during 
homogenisation and all subsequent steps. EGTA was also present 
during all steps to chelate endogenous calcium and so prevent 
activation of the Ca2+-activated neutral protease, an activity that has 
been shown to be present in rat liver (Takai, et al., 1977; DeMartino, 
1981).
EGTA has long been known to cause the release of peripheral 
proteins from membrane fractions, presumably as a result of it’s ability
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to chelate divalent cations such as Ca2+. Because the soluble fractions 
were always prepared in the presence of EGTA this may have caused 
the release of peripherally localised phosphodiesterases such as the 
’peripheral’ plasma membrane phosphodiesterase. Such an artefactual 
release may be a possible explanation for the presence of the novel 
IBMX -  insensitive phosphodiesterase in the soluble fraction. When the 
soluble fraction was prepared from rat liver in the presence of 0.1 mM
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in the number and the substrate selectivities of the phosphodiesterases 
separated by Mono Q chromatography, indicating that these activities 
had not been released from membranes as the result of a Ca2+ 
chelation event.
From an analysis of the responses of the cyclic AMP hydrolysis 
catalysed by the individual PDE M Q -Peaks to the addition of 2 jiM 
cyclic GMP, it was also apparent that no activity resembling the 
membrane bound ’dense-vesicle’ phosphodiesterase (C G I-P D E ) could 
be identified. If the presence of this activity in the soluble fraction is 
used as an index of protease -  mediated release of phosphodiesterase 
activity, then it was apparent that no such event had taken place. 
Because it was only possible to assess a small number of potential 
events, the possiblity still remains, however, that some of the . activities 
observed in the soluble fraction may represent solubilised particulate 
species. This is especially true of the two cyclic AMP -  specific
activities PDE MQ -  IV and PDE MQ -  V. The inhibitor sensitivities of 
these two activities bore a significant resemblance to the ’peripheral’ 
plasma membrane phosphodiesterase, including insensitivity to cyclic 
GMP and sensitivity to the inhibitor ICI 63197 (Pyne, et al., 1986b;
Houslay, 1988). Either or both of these two activities may represent a 
solubilised form of this enzyme. However, due to the lack of a 
suitable anti - 'peripheral' PDE antisera at the time this study was 
carried out, this possiblity was not tested.
If it is assumed that each of the individual PDE M Q -P eaks
represents only a single type of phosphodiesterase activity, then it was
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apparent that the cyclic AMP and cyclic GMP phosphodiesterase 
activity of the rat liver soluble fraction is dominated by the cyclic 
GMP -  stimulated phosphodiesterase (PDE M Q -III). The novel 
IBMX -  insensitive phosphodiesterase represented about 20% of the total 
cyclic AMP phosphodiesterase activity, which was almost equal to the 
proportion contributed by the two cyclic A M P-specific 
phosphodiesterases, which together formed about 30% of the total rat 
liver -  derived cyclic AMP phosphodiesterase activity.
The Ca2+/calm odulin-stim ulated phosphodiesterase (PDE M Q - 
II) contributed about 20% of the total cyclic GMP hydrolysis, whereas 
the most of the remainder of the cyclic GMP phosphodiesterase activity 
was provided by PDE M Q -III . PDE M Q -II  contributed only about 
2% of the total cyclic AMP phosphodiesterase activity. Although five 
fold stimulation of cyclic AMP phosphodiesterase activity was obtained 
in the presence of Ca2+/calmodulin, it can be estimated that these 
agents would be unlikely to increase the total cyclic AMP hydrolysis by 
much more than 12% whilst, in contrast, cyclic GMP hydrolysis would 
be increased by about 24%. These estimated increases are very similar 
to the actual measured increases in total cyclic AMP and cyclic GMP 
phosphodiesterase activity elicited by saturating levels of Ca2+, which 
were 19% and 27% respectively.
In a similar manner, one can estimate the fold -  effect that 
would be expected if the concentration of cyclic GMP reached 2 pM in 
the rat liver -  derived soluble fraction. Such a calculation, assuming a 
fold stimulation of cyclic AMP hydrolysis of 6.3, predicts that this level 
of cyclic GMP will increase the total cyclic AMP hydrolysis by about 
3.3 fold This is similar to the level that was observed when 2 pM 
cyclic GMP was used to stimulate the total cyclic AMP 
phosphodiesterase activity of the rat liver -  derived .soluble fraction, 
which was 2.7 fold. These data would indicate that increases in cellular 
Ca2+ probably only mediate a small effect on the total rat liver 
soluble cyclic nucleotide phosphodiesterases, whilst increases in the
levels of cyclic GMP are more likely to have a profound effect on the 
total cyclic AMP phosphodiesterase activity.
Rat liver will contain a number of cell types, such as Kupffer 
cells, in addition to hepatocytes. Also, freshly excised liver will contain 
large amounts of trapped blood and, as such, homogenates of rat liver 
will presumably contain phosphodiesterases derived from these other cell 
types. I  was concerned that the multiplicity of phosphodiesterase 
isozymes observed in the soluble rat liver fraction may, in part, be 
explained by a contribution from cell types other than hepatocytes. In 
order to address this possibility I decided to prepare hepatocytes by a 
collagenase digestion method. This approach allowed me to assess the 
number and type of phosphodiesterases in soluble fractions prepared 
from homogenates of freshly prepared hepatocytes. It should be noted 
that in all instances the hepatocytes were used without further 
incubation.
When the hepatocyte -  derived soluble phosphodiesterases were 
fractionated on a Mono Q column, under identical conditions to those 
employed for the separation of soluble phosphodiesterases from the
soluble rat liver fraction, a broadly similar elution profile was observed. 
The five peaks of activity possessed very similar properties to those of 
the rat liver -  derived peaks in terms of their sensitivities to the
effectors Ca2+/calmodulin and cyclic GMP.
One noticeable difference between the two preparations occurred 
in the substrate selectivity of P D E -M Q -I I I  at 1 pM substrate. 
Whilst, in liver, this activity was marginally more selective for cyclic 
GMP over cyclic AMP, this selectivity was more pronounced in the 
hepatocyte -  derived form. Despite this difference, however, there was 
no noticeable change in the fold stimulation of cyclic AMP hydrolysis 
elicited by 2 pM cyclic GMP. It may be that this difference arises as a
result of the presence in the rat liver -  derived soluble fraction, of a
slightly different isozyme of the cyclic GMP -  stimulated
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phosphodiesterase derived from a non -  hepatocyte source which has a 
different substrate selectivity.
Whilst it is known that there are isozymes of the cyclic G M P - 
stimulated phosphodiesterase in rat liver, these appear to differ
primarily in their subcellular location (soluble versus particulate) and 
sensitivity to effectors such as fatty acids rather than in their kinetic
characteristics (Pyne, et al., 1986a). It is also possible that this
difference may arise as a result of different modifications to the cyclic
GMP -  stimulated phosphodiesterase that occured during preparation 
either of the rat liver or hepatocyte soluble fractions. Such events may 
have included partial proteolysis or the reversal of a phosphorylation 
event. It is known, for example, that partial proteolysis of this species 
in canine heart will alter it’s sensitivity to various inhibitors (Price, 
et al., 1987). Phosphorylation of this class of phosphodiesterase has 
not, however, been demonstrated to date. The answers to these
questions remain then to be determined.
It was also noted that the small peak of activity that was
occasionally found to partially coelute with rat liver -  derived 
PDE M Q -III  was never present in the Mono Q elution profiles 
obtained when the hepatocyte souble fractions were the source,
For these reasons the hepatocyte -  derived activities were 
characterised in much greater detail than the rat liver species. In
addition, no other workers have reported any work on the soluble 
phosphodiesterases of rat hepatocytes to date. In this respect, it was 
thus decided to extend the range of inhibitors used in the inhibition 
characteristics, determine the kinetic characteristics of the individual
PDE M Q -Peaks, as well as characterise a number of other parameters 
for these activities. Included in this latter category were the Mg2+-  
dependency of the various activities, as well as - the Ca2+ and 
calmodulin dependencies of PDE M Q -II  and the cyclic GMP 
dependency for stimulation of cyclic AMP hydrolysis catalysed by 
PDE M Q -III.
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PDE M Q -I  hydrolysed both cyclic nucleotides with linear 
Michaelis -  Menten kinetics, implying that there was only one enzyme 
present in this peak of phosphdodiesterase activity. This was 
substantiated by the observation that only a single peak of 
phosphodiesterase activity was observed on gel filtration analysis, 
corresponding to a protein of molecular weight 33 -kD a. The Km 
value for cyclic AMP hydrolysis (25 pM) was higher than reported
values for cyclic AMP —specific species such as the cyclic GN1P 
inhibited and cyclic GMP -  insensitive subclasses of cyclic AMP -  specific 
phosphodiesterases, which are usually in the range 0.1 pM  to 1 pM 
(Harrison, et al., 1986b; Grant, et al., 1988; Degerman, et al., 1987; 
Pyne, et al., 1987a; Boyes and Loten, et al., 1988; Marchmont, et al.,
1981b; Thompson, et al., 1988). In this respect, the Km for cyclic
AMP hydrolysis was more comparable to that of the cyclic GMP -
stimulated phosphodiesterases, although these two activities were clearly 
very different in properties. The latter would, for example, 
demonstrate cyclic GMP stimulated cyclic AMP hydrolysis, exhibit 
positively cooperative kinetics for both cyclic AMP and cyclic GMP 
hydrolysis, as well as exhibiting comparable KmS for hydrolysis o f . both 
cyclic nucleotides (Martins, et al., 1982; Yamamoto, et al., 1983a). In
comparison, cyclic GMP did not stimulate the cyclic AMP hydrolysis of 
PDE M Q -I, whilst it’s Km for cyclic GMP hydrolysis was about an 
order of magnitude larger than that for cyclic AMP.
When the Mg2+ dependency of the phosphodiesterase activity 
of PDE M Q -I  was assessed it was found that this activity expressed 
nearly full phosphodiesterase activity in the absence of added Mg2+ 
ions, although a small stimulation of activity was observed with 
increasing Mg2+ concentrations. An excess of EDTA_ (10 mM) was 
used in the assays of PDE M Q -I  phosphodiesterase activity in an 
attempt to chelate any trace amounts of Mg2 + that could potentially 
support cyclic AMP hydrolysis. When this was performed, PDE M Q -I  
was still capable of hydrolysing cyclic AMP at nearly it’s full capacity. 
In comparison, the other four hepatocyte -  derived activities were found
260
to be nearly totally dependent on the addition of added Mg2+ to 
support hydrolysis of cyclic nucleotides. This difference in behaviour 
of PDE M Q -I  implied that this activity was fundamentally different to 
the other soluble phosphodiesterases.
There are two possible explanations to account for this property 
of PDE M Q -I. The first is that, whilst other phosphodiesterases may 
require Mg2+ for binding and/or hydrolysis of cyclic nucleotides,
PDE M Q -I  can bind and hydrolyse cyclic nucleotides in the absence of 
added metal ions such as Mg2+. The second explanation is that
PDE MQ - 1 is a metallo -  enzyme that already contains a tightly bound 
metal cofactor. The observation that high concentrations of EDTA do 
not cause inhibition of cyclic AMP phosphodiesterase activity, does not 
exclude the possibility that this putative metal ion may be Mg2+. It is 
quite conceivable that the metal ion is bound to the protein in such a 
way as to exclude possible chelation by agents such as EDTA. 
Alternatively, the putative metal ion may be another metal ion such as 
Zn2+.
There are well documented examples of phosphodiesterases that 
exist as metallo -  enzymes. The high Km cyclic nucleotide 
phosphodiesterase of the yeast Saccharomyces cerevisiae contains 2.4 
atoms of zinc/43 -  kDa subunit (Londesborough and Suoranta, 1983). 
The rat liver 'peripheral' plasma membrane phosphodiesterase has also 
been shown to be a metallo -  enzyme (Londesborough, 1985). It is of 
interest to note that when the amino acid sequence of the yeast
Zn2+-containing enzyme is compared with those of several other
phosphodiesterases, including the Drosphila cyclic AMP 
phosphodiesterase and the bovine Ca2+/calm odulin-stim ulated and 
cyclic GMP -  stimulated phosphodiesterases, it bears " little or no 
sequence homology with these enzymes (Charbonneau, et al., 1986; 
Nikawa, et al., 1987; Colicelli, et al., 1989; Swinnen, et al., 1989; 
Davis, et al., 1989). It is tempting to speculate that, given the large 
number of differences in properties between the PDE M Q - I  species 
and the other soluble phosphodiesterases, this activity may be more
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related to the yeast high K„, enzyme than to any of the other classes 
of phosphodiesterase.
It has been shown by numerous other workers that several 
classes of phosphodiesterase are sensitive to proteolysis and that this 
event can lead to the production of catalytically active species that 
possess different properties to those of the ’parent' activity. This has 
been suggested to occur, for example, after trypsinisation of a soluble 
uterine phosphodiesterase (Strada, et al., 1981). The best documented 
example of this is the bovine brain Ca2+/calm odulin-stim ulated 
phosphodiesterase. Partial proteolysis of this activity produces a species 
that is insensitive to Ca2+/calmodulin and which has altered kinetic 
parameters that are similar to those of the Ca2+/calm odulin-  
stimulated enzyme (as opposed to the basal (non -  stimulated) enzyme) 
(Tucker, et al., 1981; Kincaid, et al., 1985).
Given that the monomeric size of PDE M Q -I  (33 -kD a) is 
much smaller than that of other purified phosphodiesterases such as the 
Ca2+/calm odulin-stim ulated PDE (LaPorte, et al., 1979; Kincaid, 
et al., 1981b; Sharma, et al., 1984), the cyclic GMP -  stimulated 
phosphodiesterase (Martins, et al., 1982; Yamamoto, et al., 1983a; 
Pyne, et al., 1986a) and the cyclic GMP -  inhibited phosphodiesterases 
(Harrison, et al., 1986b; Pyne, et al., 1987a; Boyes and Loten, 1988; 
Degerman, et al., 1987; Grant, et al., 1988; MacPhee, et al., 1986), it 
is conceivable that PDE M Q -I  represents a proteolysed product of 
another type of rat liver phosphodiesterase rather than an activity in 
it’s own right Molecular cloning analyses have revealed that most of 
the known phosphodiesterase sequences contain a conserved region of 
approximately 270 amino acids (Charbonneau, et al., 1986; Swinnen, 
et al., 1989; Colicelli, et al., 1989; Davis, et al., 1989). Given the 
similarity of this region between the known phosphodiesterase sequences 
it has been suggested that this region contains the active site where 
cyclic nucleotide hydrolysis takes place (Charbonneau, et al., 1986). 
Furthermore, the number of amino acids in this sequence is more than 
sufficient to encode a protein of molecular weight 33 -kD a. It is
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possible then to envisage a scenario where proteolysis of a larger 
phosphodiesterase produces a molecule that essentially contains only the 
'active site’ of the parent molecule, thus accouting for the presence of 
PDE M Q -I  in the soluble fraction.
I suggest that, on the basis of the known characteristics of 
PDE M Q -I , this is not the case and that PDE M Q -I  is an 
independent activity. Furthermore, I took precautions to avoid the 
effect of proteolysis by adding protease inhibitors during the 
preparation of the PDE MQ -  Peaks. In addition, PDE MQ - 1 is eluted 
very rapidly from the Mono Q column (within 20 minutes) so it is 
rapidly separated from the majority of other soluble proteins. It seems 
extrememly unlikely that proteolysis could produce a catalytic activity 
that is independent of added Mg2+ from a 'parent' molecule that is 
dependent on the presence of this divalent metal ion for catalysis. 
Furthermore, it’s marked inhibitor insensitivity shows that the catalytic 
activity of PDE M Q -I  differs significantly from all of the other 
phosphodiesterase species examined in this study and is therefore
unlikely to be derived from any of them. Likewise it’s inability to
bind to A ffi-ge l Blue suggests strongly that this enzyme is different in 
properties compared to other phosphodiesterases.
In support of this proposition, an enzyme that has bears a
striking resemblance to PDE M Q - I  has been purified from pig liver by 
Helfman and his colleagues (Helfman, et al., 1981). This enzyme was a 
multifunctional phosphodiesterase capable of hydrolysing both purine
and pyrimidine cyclic nucleotides. The purified enzyme behaved as a 
monomer of molecular weight 31,000 to 37,000 under native conditions. 
It lacked absolute substrate specificity hydrolysing both cyclic AMP and 
cyclic CMP and to a lesser extent cyclic GMP. The apparent for 
cyclic AMP (25 jxM) was lower than the apparent for cyclic CMP
(182 pM) but hydrolyses cyclic CMP as efficiently as cyclic AMP
because of a higher Vmax for this pyrimidine cyclic nucleotide
(Helfman, et al., 1981). This activity was also found to be insensitive
to phosphodiesterase inhibitors such as IBMX and theophylline, but was
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inhibited by increased phosphate concentrations (Kuo, et al., 1978). 
The enzyme from pig liver eluted from DEAE -  cellulose columns at 
low ionic strengths, as PDE M Q - I  does, and was found to be unable 
to bind to A ffi-gel Blue. When the enzyme was assayed in the 
absence of added Mg2+ ions it was still found to be capable of
hydrolysing nucleotides. The addition of Mg2+ stimulated the enzyme 
slightly, whilst the inclusion of EDTA as high as 20 mM had no effect 
on the activity (Helfman, et al., 1981). All these properties are
identical to the properties of PDE MQ - 1 that I measured.
Whilst I did not assess the ability of PDE M Q -I  to hydrolyse 
cyclic CMP, I did show that cyclic CMP could act as inhibitor of cyclic 
AMP hydrolysis catalysed by PDE M Q -I . If it was assumed that cyclic 
CMP acted as a competitive inhibitor, the observed IC50 for it’s action 
would be consistent with a K^ above 100 pM. It seems almost certain 
then that these two activities are one and the same enzyme.
Cyclic CMP, a pyrimidine cyclic nucleotide, has been implicated 
in playing a biological role in the control of proliferation of leukaemia 
cells. Cech and Ignarro, (1977) have shown that an enzyme system,
cytidylate cyclase, capable of synthesising cyclic CMP from CTP, is
present in normal mouse liver. Further to this, these workers 
demonstrated that cyclic CMP formation proceeds more rapidly in 
regenerating normal liver than in controls. The highest levels of 
cytidylate cyclase activity were observed in liver with lowest levels 
observed in lung (Cech and Ignarro, 1977). Whilst these observations 
indicate that one particular function of PDE M Q -I  in hepatocytes may 
be to degrade cyclic CMP that has been produced by the cytidylate 
cyclase activity, it is also apparent that this activity forms a large 
proportion of the total soluble cyclic AMP phosphodiesterase activity in 
both hepatocytes and in whole liver and this may. be an equally 
important function.
Kinetic analysis of cyclic GMP phosphodiesterase activity 
catalysed by PDE M Q - II indicated that this activity hydrolysed this
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cyclic nucleotide with apparently negatively cooperative kinetics. This 
observation could be interpreted in two ways. Either there was one
activity present in this peak which behaves with negatively cooperative
kinetics or there were two activities which behaved with linear kinetics. 
Some support for the latter possibility was obtained when PDE M Q -II  
was applied to a gel filtration column. In all instances, there was
evidence of two closely eluting activities which would be consistent with
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A Ca2 + -  insensitive cyclic GMP phosphodiesterase activity has 
been proposed to be present in the soluble fraction of rat liver
(Strewler, et al., 1983). This activity coelutes with the
Ca2+/calm odulin-stim ulated cyclic GMP phosphodiesterase on D E -5 2  
chromatography when this is performed in the presence of EGTA. If 
the separation is performed in the presence of Ca2+, in place of 
EGTA these workers observed that the Ca2+/calm odulin-stim ulated 
phosphodiesterase activity eluted at higher ionic strenghts so that it
now partially coeluted with the Peak II activity. Ho, et al., (1977) were 
the first to show that addition of Ca2+ and calmodulin to crude 
preparations of soluble calmodulin -  sensitive phosphodiesterase from 
bovine heart altered the chromatographic behaviour of the enzyme,
presumaly because of a Ca2+-dependent association with calmodulin, a 
highly acidic protein. These workers observed that this alteration in
the chromatographic properties of the Ca2+/calm odulin- stimulated 
enzyme revealed the presence of a Ca2+-insensitive activity. 
Furthermore, these workers showed that this activity did not bind to
calmodulin -  Sepaharose, whilst the Ca2+/calm odulin- sensitive activity 
did.
When the kinetics of these two cyclic GMP phosphodiesterases 
were examined by these workers (Strewler, et al., 1983), the
Ca2+/calmodulin stimulated activity was found to exhibit linear kinetics 
for cyclic GMP hydrolysis with a for cyclic GMP hydrolysis of
6,5 jiM  whilst the Ca2+-insensitive activity exhibited anomalous 
kinetics with evidence of negative cooperativity (K^ values of 1.2 pM
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and 27 pM. PDE M Q -II  has a low value of 3 pM and a high 
value of 13 pM for cyclic GMP hydrolysis. It is thus conceivable, 
based on this evidence, that the anomalous kinetics obtained for cyclic 
GMP hydrolysis catalysed by PDE M Q -II  may be explained by the
presence of these two activities.
It has long been known that partial proteolysis of the 
Ca2+/calm odulin- stimulated phosphodiesterase will produce a species 
that is no longer sensitive to Ca2+/calmodulin (Tucker, et al., 1981;
Kincaid, et al., 1985). This observation may explain the presence of 
this Ca2+—insensitive activity in the soluble fraction of rat liver. 
However, Strewler, et al., (1983) argued that the existence of this 
Ca2+-insensitive activity was not due to proteolysis of the
Ca2+/calm odulin-stim ulated enzyme since they included Leupeptin in 
all their buffers. This peptide acts a protease inhibitor and has been 
shown to inhibit proteolytic activation of a phosphodiesterase in rat 
liver homogenates (Strewler and Manganiello, 1979). On this basis, and 
the observation that the apparent molecular weight of the Ca2+-
insensitive activity (325,000) was greater than the apparent molecular 
weight of the Ca2+/calm odulin- stimulated activity (150,000), they 
considered that this activity was not derived from the 
Ca2+/calm odulin-stim ulated activity. If this is the case, then it may 
be that this activity is related to the cyclic G M P-binding cyclic
GMP -  specific phosphodiesterases that have been observed in rat lung
and platelets (Hamet and Coquil, et al., 1978; Coquil, et al., 1980;
Francis, et al., 1980; Coquil, et al., 1985), although no work has been 
done in this direction.
These same workers were also able to show that the
Ca2+/calm odulin-stim ulated activity was much more selective for
cyclic GMP than for cyclic AMP (Strewler, et al., 1983), an observation
that I noted for the PDE M Q -II  activity. The Ca2+ -insensitive 
cyclic GMP phosphodiesterase was, however, not found to be selective 
for cyclic GMP since it hydrolysed cyclic AMP with nearly equal 
efficiency at 0.5 pM substrate. It exhibited anomalous kinetics for
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both cyclic AMP and cyclic GMP hydrolysis, the apparent K^s for 
cyclic AMP hydrolysis being 15 pM and 302 pM. Since these workers 
used D E -5 2  to separate these activities, it would be expected that the 
IBMX -  insensitive activity would co -e lu te  with the Peak I activity and 
since it is insensitive to Ca2+/calmodulin would not be expected to 
show any alteration in chromatographic properties in the presence of 
Ca2+. It is my contention that the cyclic AMP phosphodiesterase 
activity of the Ca2+-insensitive species that these workers observed is 
due to the presence of the IBMX -  insensitive activity (PDE M Q -I) . 
In support of this, the low Kn, value for cyclic AMP hydrolysis 
(15 pM) is very similar to the for cyclic AMP hydrolysis catalysed
by PDE MQ - 1 (25 pM). This explanation would also explain the 
anomalous kinetics for cyclic GMP hydrolysis of this Ca2+ -insensitive
activity.
An analysis of the Ca2+ dependency for stimulation of cyclic
GMP hydrolysis by PDE M Q -II  revealed that the EC50 value was 
20 pM. This was the total concentration of calcium added to the 
assays and does not represent the actual free concentration. There 
were, however, intrinsic difficulties in estimating the actual level of free 
Ca2+ in the assays due to the presence of EGTA, a Ca2+ chelator. 
The ability of EGTA to chelate Ca2+ is critically influenced by a 
number of factors such as ionic strength, pH and the ’basal1 level of
Ca2+ contributed by contamination from buffer constituents and the 
water used to prepare these buffers. Further to this, EGTA is a very 
poor buffer of Ca2+ concentrations above 0.5 pM, which arises as a 
consequence of the relative binding affinities of the four binding sites 
for Ca2+ (Miller and Smith, 1984). The consequence of this is that 
small alterations in the total added Ca2+ can produce large changes in 
the actual free concentration of Ca2+. All these problems mean that 
the value for the estimated EC50 for Ca2+-stim ulation of PDE M Q - 
II can only be used as a rough indication of the EC50 rather than an 
absolute value. A  further complication is that Ca2+ and calmodulin 
show synergistic interactions in the activation of phosphodiesterase. An
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increase in calmodulin or Ca2+ concentration results in an increase in
the apparent enzyme affinity for towards Ca2+ or calmodulin
respectively (Brostrom and Wolff, 1974). The implication of this is 
that, depending on the level of calmodulin used to determine the EC50 
for Ca2+ stimulation of PDE M Q -II  phosphodiesterase activity, this 
will alter the value of the measured EC50.
The measured EC50 for calmodulin stimulation of PDE M Q -II, 
in the presence of a saturating Ca2+ concentration (500 pM), was 
30 ng/ml which corresponds to 1.7 nM for a monomeric protein of
17,000 molecular weight. This value compares with an affinity for the 
bovine brain 6 1 -k D a  and 6 3 -k D a  isozymes of the Ca2+/calm odulin-  
stimulated enzyme of 1 nM (Hansen and Beavo, 1986). In contrast, the 
bovine heart form has an affinity constant, which is about 10 fold 
lower at 0.1 nM (Hansen and Beavo, 1986). It would thus appear that 
the Ca2+/calm odulin-stim ulated isozyme in rat liver is very similar to 
the bovine brain enzymes with respect to it’s activation by calmodulin. 
When the calmodulin anatagonist 5 - Io d o -C 8  was used to inhibit the
phosphodiesterase activity of PDE M Q -II, it was found that it had 
virtually no inhibitory action against the basal cyclic GMP and cyclic 
AMP phosphodiesterase activity of PDE M Q -II, whilst it was capable 
of inhibiting the ’Ca2+/calm odulin- stimulated' portion of the 
phosphodiesterase activity. The observed IC50 for it’s action in the 
presence of saturating Ca2+ (100 pM) and calmodulin (0.12 pM) was 
observed to be 13 pM when cyclic GMP was the substrate and 16 pM 
when cyclic AMP was the substrate. These values are slightly greater 
than the IC50 reported for it’s action against partially purified 
preparations of the bovine heart Ca2+/calm odulin-stim ulated isozyme, 
which was 3 pM (MacNeil, et al., 1988). Whether this small difference 
is related to the occurence of isozymes of the Ca2+/calm odulin-  
stimulated phosphodiesterase is uncertain, but it is known that the 
bovine heart isozyme has a higher affinity for calmodulin than the 
bovine brain form (Hansen and Beavo, 1986).
2 6 8
When the kinetic properties of the PDE M Q -III  species were 
examined, it was found that the activity displayed anomalous positively 
cooperative kinetics for the hydrolysis of both cyclic nucleotides. On 
this basis it seemed unlikely that there were other species of 
phosphodiesterase present in this peak of activity. The estimated Km 
values for cyclic GMP and cyclic AMP were found to be very similar to 
each other (36 pM and 38 pM respectively), with cyclic AMP displaying
a more marked positively cooperative behaviour than cyclic GMP (a
larger happ). The hepatocyte -  derived activity was more selective for 
cyclic GMP than for cyclic AMP. This selectivity for cyclic GMP can
be explained by the much larger Vmax for cyclic GMP than for cyclic 
AMP.
When the properties of this rat hepatocyte -  derived activity 
were compared to those of the purified rat liver soluble and 
m em brane-bound forms of the enzyme, it was apparent that a number 
of differences existed. Firstly, the purified rat liver soluble form of the 
enzyme, whilst exhibiting similar values to PDE M Q -III  for cyclic
AMP and cyclic GMP (40 pM and 25 pM respectively), was found to 
exhibit linear kinetics for the hydrolysis of cyclic GMP (Pyne, et al., 
1986a). This has been attributed to the ability of cyclic GMP to 
induce a loss of positively cooperative kinetics for cyclic AMP 
hydrolysis. As such, these workers suggested that the reason why the
hydrolysis of cyclic GMP by the rat liver enzyme obeys Michaelis -
Menten kinetics is that under the conditions that kinetic determinations
are carried out, both the regulatory and substrate sites would be 
expected to be occupied by cyclic GMP. This did not appear to be 
the case for PDE M Q -III, which clearly displayed positively cooperative 
kinetics for hydrolysis of cyclic GMP. It should be noted that enzymes 
purified from bovine tissues have very similar values for hydrolysis 
of cyclic AMP (30 pM to 33 pM) (Martins, et al., 1982; Yamamoto,
et al., 1983a) to PDE M Q -III. The same is true of the Hill 
coefficient (happ), being 1.8 to 1.9 for the bovine enzymes, whilst 
P D E -M Q -II I  was found to have a Hill coefficient of 1.62. These
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bovine -  derived activities also exhibited positively cooperative kinetics 
for cyclic GMP hydrolysis, as PDE M Q -III  does.
The second point of difference was that the purified soluble rat
liver enzyme was inhibited by the non -  selective phosphodiesterase 
inhibitor IBMX with an IC50 of 44 pM (Pyne, et al., 1986). Whilst I 
did observe a similar IC50 for inhibition of the rat liver -  derived 
activity (97 pM), the IC50 for inhibition of the hepatocyte -  derived 
activity was much larger (323 pM). The reasons for these differences is 
not immediately apparent, but it may be related to the existence of 
distinct isozymes of the cyclic GMP -  stimulated phosphodiesterase in
cell types other than hepatocytes.
IBMX is a well establised non -  selective inhibitor of cyclic AMP 
phosphodiesterases (Weishaar, et al., 1985b; Wong and Ooi, 1985;
Wells and Miller, 1988). However, it has been shown to interact with 
both substrate and regulatory sites of cyclic GMP -  stimulated 
phosphodiesterases. Indeed, low concentrations of IBMX have been
noted as causing activation of cyclic AMP hydrolysis for the bovine 
liver enzyme (Yamamoto, et al., 1983b) and crude and highly purified 
preparations from rat liver (Erneux, et al., 1982; Pyne, et al., 1986a). 
Higher concentrations of IBMX are inhibitory. These workers have
shown that IBMX could stimulate cyclic AMP hydrolysis about 200 to 
300% at a maximal concentration of 50 pM, with inhibition of cyclic
AMP hydrolysis observed at higher concentrations of this inhibitor. 
Whilst I did observe some stimulation of cyclic AMP hydrolysis in the 
presence of IBMX at concentrations below 100 pM, the extent of this 
stimulation was much smaller with only effects up to about 30% being 
observed. The reasons for this difference in properties is not apparent.
The degree of stimulation of cyclic AMP hydrolysis of
hepatocyte -  derived PDE M Q -III  elicited by cyclic GMP was of a very 
similar magnitude to that observed for the bovine heart enzyme and 
the purified rat liver soluble and particulate enzymes (Martins, et al., 
1982; Pyne, et al., 1986a). It was, however, considerably less than the
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32-fo ld  stimulatory effect seen with the bovine liver enzyme
(Yamamoto, et al., 1983a). Nevertheless, the Ka for activation of the 
bovine liver enzyme (0.5 pM) and the purified rat liver enzymes
(0.23 pM to 0.28 pM) were very similar to that observed for the
PDE M Q -III  activity (0.47 pM).
Using the higher resolving power of Mono Q anion -  exchange
chromatography over that of the more conventional D E -5 2
chromatography, it was apparent that the one peak of cyclic A M P - 
spe cific activity observed on the latter could be separated into two
peaks on Mono Q chromatography. These two cyclic A M P-specific
activities were similar in a number of their properties including their
insensitivity to cyclic GMP and Ca2+/calmodulin. Although a small 
and statistically significant stimulation of the cyclic AMP
phosphodiesterase activity of PDE M Q -V  was observed when 
hepatocytes was the source, the stimulation was only of the order of 
20% which was much smaller than that observed for PDE M Q -I I  when 
cyclic AMP was the substrate (fold stimulation of 4.77). Further to 
this, it was not investigated if this activation was a direct effect of 
calmodulin or was mediated by some other mechanism such as the 
activation of a contaminating Ca2+-dependent protease.
When the inhibitor sensitivities of the two cyclic AMP -  specific
activities were compared, they displayed veiy similar sensitivities. They 
were both shown to be sensitive to the inhibitors IBMX, milrinone, ICI 
63197 and Rolipram. PDE M Q -V , however, showed a slightly greater
susceptibility to inhibition by Rolipram than PDE M Q -IV . Moreover, 
these two activities were shown to be the only soluble activities that 
were sensitive to rolipram. The inhibitor ICI 118233 was not found to 
be inhibitory for either of these two activities or indeed any of the 
other activities. The cyclic GMP phosphodiesterase inhibitor, Taprinast 
(M&B 22,948), was found to exert only a very weak inhibitory effect on 
PDE M Q -IV  and an even weaker effect on PDE M Q -V ; in contrast
this inhibitor selectively inhibited the cyclic GMP phosphodiesterase 
activity of PDE M Q -II, which contains the Ca2+/calm odulin-
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stimulated phosphodiesterase. PDE M Q -IV  and P D E -M Q -V  differed 
however in their sensitivity to the cyclic AMP -  specific PDE inhibitor 
R o - 20-1724. PDE M Q -V  was found to be sensitive to inhibition by 
R o - 20-1724, whilst PDE M Q -IV  was much less sensitive. This 
difference was most apparent when rat liver was the source, although it 
was still noted with hepatocyte -  derived activities.
It has been observed by a number of workers that there are 
subclasses of the cyclic A M P-specific phosphodiesterase. These have 
been broadly classified as cyclic GMP -  inhibited (Yamamoto, et al„ 
1984a; Pyne, e t al., 1987a; Whitson and Appleman, 1982; Weber and 
Appleman, 1982; Weishaar, et al., 1987a; Weishaar, et al., 1987b; 
Weishaar, et al., 1987c; Weishaar, et al., 1987d; Manganiello, et al., 
1990b) or cyclic GMP -  insensitive (or Rolipram -  sensitive) (Yamamoto, 
et al., 1984a; Weishaar, et al., 1987a; Weishaar, et al., 1987b; Reeves, 
et al., 1987; Whitson and Appleman, 1982; Pyne, et al., 1987b; Conti 
and Swinnen, 1990). The cyclic GMP -  inhiibited activities are 
characterised by the ability of low (pM) levels of cyclic GMP to elicit a 
potent inhibition of cyclic AMP hydrolysis. The cyclic G M P - 
insensitive activities possess cyclic AMP hydrolytic activities that are
much less sensitive to inhibition by cyclic GMP. These two subclasses 
of phosphodiesterase can be further distinguished from each other on 
the basis of sensitivity to drugs such as cilostamide or rolipram
(Degerman, et al., 1987; Umekawa, et al., 1984; Schneider, et al., 1987; 
Weishaar, et al., 1987a; Livi, et al., 1989). From the characteristics of 
PDE M Q -IV  and PDE M Q -V  it would seem that these activities 
belong to the cyclic GMP -  insensitive subclass of phosphodiesterase.
It has been suggested that, in addition to sensitivity to cyclic 
GMP, the inhibitor R o - 20-1724 can be used to distinguish this class 
of phosphodiesterase from the cyclic GMP -  inhibited subclass of
phosphodiesterase (Elks and Manganiello, 1985; Elks and Manganiello, 
1984a; Weishaar, et al., 1987a). The former class would exhibit 
sensitivity to R o - 20-1724, whilst the latter would be less sensitive. 
This would appear to be an oversimplification since PDE M Q -IV  and
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PDE M Q -V , although they are both clearly insensitive to inhibition by 
cyclic GMP, also show differential sensitivity to R o - 20-1724 The 
simplest interpretation of these results is that there are multiple forms 
of this type of phosphodiesterase present in hepatocytes which can be 
distinguished on the basis of their sensitivity to R o - 20-1724.
In support of this notion, recent cloning analysis has revealed 
the presence of multiple cDNA clones for cyclic A M P-specific 
phosphodiesterases. Davis, et al., (1989) isolated three cDNA clones 
from rat brain (termed RD1 to RD3) having a large degree of sequence 
homology to each other that appeared to arise as a result of 
differential splicing. A second clone has also been isolated from a rat 
brain cDNA lilbrary that differs from the RD1 clone (Colicelli, et al.,
1989). When this clone (DPD) was expressed in the yeast 
Saccharomyces cerevisiae, the enzyme encoded was shown to possess 
very similar properties to those of PDE M Q -IV  and PDE M Q -V . 
DPD encoded a high -  affinity phosphodiesterase activity (K™ of
3.5 pM) that was insensitive to Ca2+/calmodulin, insensitive to cyclic 
GMP inhibition and did not hydrolyse cyclic GMP. RD1 was also 
shown to encode a phosphodiesterase with very similar properties to the 
DPD and PDE M Q -IV  and PDE M Q -V  activities. Both RD1 and 
DPD were found to be similarly inhibited by R o - 20-1724 and 
Rolipram (Henkel-Tigges and Davis, 1990).
Swinnen, et al., (1989) also isolated a number of cDNA clones 
from rat sertoli and rat testis libraries. They termed these clones 
ratPDEl to ratPDE4 and, on the basis that they have significant 
homology with the cyclic AM P-specific phosphodiesterase from 
Drosophila melanogaster (dunce phosphodiesterase), have hypothesised 
that these will also encode high -  affinity cyclic " A M P-specific
phosphodiesterases. However, these individual clones have not yet been
expressed to determine the characteristics of the phosphodiesterases that 
they encode. These four clones appeared to be independent because, 
although very similar to each other, they differed in sequence both
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within the 'highly conserved' region and in particular at their amino 
and carboxyl terminii.
Together, these results would suggest that the number of cyclic 
AM P-specific phosphodiesterases may be far greater than originally 
suspected from a biochemical analysis. The relationship between the 
hepatocyte -  derived PDE M Q -IV  and PDE M Q -V  and these cloned 
species is however unclear at the present time but remains to be 
established.
Whilst two cyclic AMP -  specific phosphodiesterases have been 
identified in the rat hepatocyte fraction, by separation on a Mono Q 
anion -  exchange column, the actual number of activities in the soluble 
fraction may be larger than this. When the kinetics of cyclic AMP 
hydrolysis of PDE M Q -IV  and PDE M Q ^V  were examined, it was 
apparent that PDE M Q -IV  hydrolysed cyclic AMP with anomalous 
kinetics indicative of negative cooperativity. As for the PDE M Q -II  
activity, which also displayed kinetics indicative of negative 
cooperativity, this may also be explained by the presence of multiple 
cyclic AMP phosphodiesterase activities in PDE M Q -IV . One 
supporting piece of evidence for this notion comes from the 
observation that PDE M Q -IV  elutes from the Mono Q column as a 
much larger peak of activity than any of the other activities. Such a 
broad elution profile may be indicative of multiple species of cyclic 
AM P-specific phosphodiesterases which differ in their surface 
electronegativities (and presumably their primary sequence). 
Alternatively, the 'multiplicity' suggested by the broad elution profile 
may have arisen as a result of proteolysis of a single 'parent' molecule 
producing species which maintain their specificity for cyclic AMP as 
substrate but which have slightly different surface electronegativities due 
to removal of different portions of the polypeptide chain. At present 
it is not possible to assess which of these possibilities is correct.
Two high affinity, membrane -  bound cyclic AMP 
phosphodiesterases have been identified in rat liver and rat hepatocytes.
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These are the 'dense-vesicle* and 'peripheral' plasma membrane 
phosphodiesterases (Marchmont, et al., 1981b; Pyne, et al., 1987b; 
Loten, et al., 1978; Pyne, et al., 1987a; Pyne, et al., 1986b). In all the 
properties of PDE M Q -IV  and PDE M Q -V  that I examined these 
activities did not appear to be related to the .'dense-vesicle' 
phosphodiesterase. Whilst cyclic GMP can exert a potent inhibitory 
effect on the hydrolysis of cyclic AMP by the particulate rat liver 
'dense -vesicle’ cyclic AMP -  specific phosphodiesterase, the cyclic AMP 
phosphodiesterase activities of PDE M Q -IV  and PDE M Q -V  were 
relatively insensitive to inhibition by cyclic GMP. Furthermore, the 
'dense-vesicle' enzyme is also very potently inhibited by milrinone, 
whereas PDE M Q -IV  and PDE M Q -V  have IC50 values which are 
some 10-fo ld  lower.
The sensitivity of PDE M Q -IV  and PDE M Q -V  to the 
inhibitor ICI 63197 may suggest that these two activities are related to 
the 'peripheral' plasma membrane phosphodiesterase which is potently 
inhibited by this compound. It may be that these two activities 
represent soluble homologues of this membrane bound activity. It is
also conceivable that either or both of these two activities represent
solubilised form(s) of the 'peripheral' plasma membrane 
phosphodiesterase. Due to the lack of an available antisera to the
'peripheral' plasma membrane phosphodiesterase, it was not possible to
assess this possibility directly.
In summary, I have identified five soluble phosphodiesterase 
activities that are present in both the soluble fraction of rat liver and 
hepatocytes. In particular, I have identified a novel IBMX -  insensitive 
phosphodiesterase (PDE MQ - 1) that forms a substantial proportion of 
the total soluble cyclic AMP phosphodiesterase activity. " This has the
unusual property of being highly insensitive to . a number of
phosphodiesterase inhibitors including the non -  selective inhibitor 
IBMX. This suggests that caution should be applied in interpreting
whole cell cyclic AMP accumulation studies where such a compound is 
routinely used to block the hydrolysis of cyclic AMP. Indeed it has
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been shown, in hepatocytes, that even at high concentrations of IBMX, 
glucagon -  mediated increases in intracellular cyclic AMP can still be 
decreased (Heyworth, et al., 1983d).
When the soluble fractions were prepared from a number of 
other rat tissues including brain, kidney and adipocytes it was apparent 
that different elution profiles were obtained from those of rat liver. 
The kidney soluble fraction was shown to possess four activities, two of 
which were selective for cyclic GMP and two which were selective for 
cyclic AMP. The two cyclic GMP phosphodiesterases were shown to be 
stimulated by Ca2+/calmodulin and cyclic GMP respectively. However, 
these effects were not characterised by me any further. Recently work 
on these activities has been carried out in this laboratory by other 
workers (Hoey and Houslay, 1990). The two cyclic A M P-specific 
peaks were not susceptible to inhibition by cyclic GMP, and like
PDE M Q -IV  and PDE M Q -V  were susceptible to inhibition by ICI 
63197. These two activities were very similar to PDE M Q -IV  and 
PDE M Q -V  in other respects; although both sensitive to inhibition 
by R o - 20-1724 the latter activity was found to be more sensitive to 
this compound than the former. Importantly, such analyses showed
that there was no evidence for the presence of an activity 
corresponding to PDE M Q -I , which would be expected to elute at low 
ionic strength from the Mono Q column. This implies that this
activity may show a very limited tissue distribution.
The adipocyte soluble fraction was similar to that of the kidney 
profile in that again there was no evidence of the PDE M Q -I  species. 
The major cyclic GMP hydrolysing activity, although eluting at a
position similar to that of the cyclic GMP -  stimulated activity, was
shown to contain the Ca2+/calm odulin- stimulated phosphodiesterase. 
The reason for this difference in elution properties is - unknown, but it 
may suggest that this activity is a distinct member of the
Ca2+/calm odulin-stim ulated family of enzymes, a number of which 
have been identified and purified (for review see Wang and Sharma,
1990). There were also two cyclic AMP -  selective activities, one of
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which partially c o -  eluted with the Ca2+/calm odulin- stimulated
activity. The position of this activity was different to that of the
PDE MQ -  IV and PDE MQ -  V activities that were observed in rat liver 
and hepatocyte fractions. Whilst no detailed characterisation of these 
activities was carried out, this difference in elution properties may
suggest that these are distinct members of the cyclic A M P-specific 
phosphodiesterases.
The soluble fraction of rat brain contained at least four
phosphodiesterase activities. Because of a lack of time these activities 
were not characterised but once again there was no evidence of an
activity that resembled PDE M Q -I . All these observations support the 
hypothesis that this activity is restricted to a limited number of
tissue/cell types perhaps even as far as only being expressed in 
hepatocytes but this suggestion will need further analysis.
One of the interest of the laboratory that this work was carried 
out in is to identify and characterise insulin -  stimulated
phosphodiesterases. Two such membrane bound activities have been 
identified and purified to date and these are the insulin and glucagon 
stimulated 'dense-vesicle’ phosphodiesterase and the insulin -  stimulated 
'peripheral' plasma membrane phosphodiesterase. Whilst these activities 
may play a role in decreasing the intracellular levels of cyclic AMP
under certain defined conditions, it was shown by Heyworth, et al., 
(1984a) that when insulin -  induced activation of these two enzymes was 
blocked, then insulin could still promote a decrease in hepatocyte
intracellular levels that have previously been increased with glucagon. 
The ability of insulin to decrease the glucagon -  elevated intracellular 
cyclic AMP concentration was, however, still blocked by the cyclic AMP 
phosphodiesterase inhibitor IBMX (Heyworth, et al., 1984a). It seems 
therefore that the effect of insulin is mediated by one. or other of the 
multiple cyclic AMP phosphodiesterase species found in the hepatocyte 
(Thompson and Strada, 1978; Beavo, et al., 1982; Houslay, 1986;
Beavo, 1988). Using Percoll gradient analysis, Heyworth, et al., (1983d) 
have shown that insulin can stimulate the activity of only two
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phosphodiesterase and these are the membrane bound 'dense-vesicle' 
and 'peripheral' phosphodiesterases, they did not, however, observe 
stimulation of any other phosphodiesterases under these conditions.
If a 'third' insulin -  stimulated activity is present, insulin’s 
stimulation of the activity may either be readily reversible or extremely 
labile in nature. Two obvious candidates for such a reversibly activated 
cyclic AMP phosphodiesterase would be the Ca2+/calm odulin-  
stimulated phosphodiesterase or the cyclic GMP stimulated 
phosphodiesterase since these are regulated in a reversible manner by
Ca2+ and cyclic GMP respectively. In this chapter, the rat hepatocyte 
Ca2+/calmodulin—stimulated phosphodiesterase has been shown to be 
soluble, as it is in other tissues, and it can be stimulated Ca2+ in the 
presence of calmodulin. It has been proposed that increases in 
intracellular Ca2+ may be a key element in the mechanism of action
of insulin (Clausen, 1975; Kissebah, et al., 1975), particularly in 
adipocytes and muscle. This hypothesis, whilst having the strength that 
it may explain the activation of mitochondrial pyruvate dehydrogenase
(pyruvate dehydrogenase phosphate phosphatase is activated by Ca2+)
(Denton, et al., 1972; Denton, 1981), has the disadvantage that a rise 
in cytoplasmic Ca2+ could bring about any of the cytoplasmic effects
of insulin. Indeed, it has been pointed out that such a rise would be 
expected to bring about a range of effects that are not characteristic of 
insulin. This would include an increase in glycogen breakdown in liver 
due to the activation of phosphorylase kinase (Denton, 1981). Further, 
in rat liver, insulin opposes the effects of phenylephrine on glycogen
breakdown and gluconeogenesis; effects which are widely considered to 
be brought about by increases in intracellular Ca2+ (Exton, 1980; 
Blackmore, et al., 1979; Hems, 1980). Consequently, insulin -  induced 
activation of this activity, at least by an increase in cytoplasmic Ca2+
in hepatocytes, would seem to be unlikely. Further to this, in
hepatocytes, this activity has been shown to be more selective for cyclic 
GMP as substrate, than cyclic AMP and even under fully activated
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conditions, Ca2+ would be likely to increase soluble cyclic AMP 
phosphodiesterase activity only very slightly.
Another possibility is that the purported small increase in cyclic 
GMP concentration that occurs on exposure of hepatocytes to insulin 
(Czech, 1977), might activate the cyclic GMP -  stimulated 
phosphodiesterase that occurs both in the cytosol and particulate
fraction of hepatocytes (Pyne, et al., 1986a). This would appear to be 
a more likely prospect given the preponderance of this activity in both 
the soluble and particulate fractions of rat liver (Pyne, et al., 1986a). 
Although this activity was not found to be as predominant in the 
hepatocyte soluble fraction as it was in the rat liver soluble fraction,
cyclic GMP can still produce a very marked increase in total soluble
cyclic AMP phosphodiesterase activity. Whilst insulin can increase 
cyclic GMP levels in hepatocytes (Czech, 1977), it is not certain if 
cyclic GMP can attain concentrations that are sufficient to stimulate
the activity of this enzyme following insulin challenge. It is thus
/ . . .
conceivable that insulin may activate this7 putative third insulin-
sensitive phosphodiesterase by means of a mechanism other than an 
increase in cyclic GMP.
Reports from a number of laboratories have suggested that 
insulin acts on target cells to potentiate the release from plasma 
membranes of soluble 'mediators' within the target cell (Lamer, et al., 
1979; Parker, et al., 1982; Saltiel, et al., 1981). Such species mimic 
some of the effects of insulin on target cells such as the activation of 
pyruvate dehydrogenase (Saltiel, et al., 1981; Parker, et al., 1982; 
Lamer, et al., 1979) and 'lo w -K J  cyclic AMP phosphodiesterase 
(Parker, et al., 1982; Saltiel and Cuatrecasas, 1986a; Saltiel, et al., 
1986b). The chemical nature of this mediator is not well defined but 
(1: may actually consist of a number of different compounds that may be
i
peptide in nature (Larner, et al., 1979) or consist of a complex 
carbohydrate -  phosphate substances containing inositol and glucosamine 
(Saltiel and Cuatrecasas, 1986a; Saltiel, et al., 1986b). An insulin 
mediator mimics some of the effects of the short term effects of
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insulin, particularly with respect to activation of mitochondrial pyruvate 
dehydrogenase (Larner, et al., 1979; Saltiel, et al., 1981; Parker, et al., 
1982) and a high affinity 'lo w -K ^ ' cyclic AMP phosphodiesterase 
(Parker, et al., 1982; Saltiel and Cuatrecasas, et al., 1986a; Saltiel, 
et al., 1986b). The mediator substance isolated by Saltiel and 
Cuatrecasas actually consists of two complex carbohydrate substances 
that are produced on exposure of isolated hepatic membranes to insulin 
(Saltiel and Cuatrecasas, 1986a). Intriguingly, these workers showed that 
they could mimic the release of the ‘mediator’ by treating liver plasma 
membranes with a highly purified preparation of phosphatidylinositol -  
specific phospholipase C. In order to assay ‘mediator’ activity, these 
workers used a crude adipocyte membrane preparation containing a 
high -  affinity cyclic AMP phosphodiesterase. The exact nature and 
mechanism of activation of this 'mediator* -  sensitive phosphodiesterase 
is unclear. However, the mechanism by which insulin activates the 
cyclic GMP -  inhibited ('dense-vesicle ') PDE appears to involve an 
event that is persistent in nature (Loten, et al., 1978; Loten^ et al., 
1980), which is inconsistent with a simple interaction of the mediator 
with this phosphodiesterase.
The possibility thus exists that, if a third insulin -  sensitive 
phosphodiesterase is present in hepatocytes, it may be activated by this 
mediator preparation by means of a direct interaction between the 
'mediator' and the phosphodiesterase. Such a direct interaction 
between the soluble mediator and the PDE would thus be expected to 
be diluted out during Percoll fractionation explaining the lack of 
evidence of a third insulin -  sensitive phosphodiesterase by this 
technique (Hetworth, et al , 1983d).
This hypothesis, allows one to speculate that any of the 
phosphodiesterase species present in hepatocytes may be activated by 
this 'mediator'. In support of this, Pyne and Houslay (1988) have 
shown that a 'mediator' preparation from rat hepatocytes achieved a 
reversible and dose -  dependent activation of a purified preparation of 
the cyclic GMP -  stimulated phosphodiesterase from both the soluble
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and particulate fraction. In contrast, the 'mediator' preparation had no 
effect on the activity of apparently homogenous preparations of the 
'dense-vesicle' PDE and the 'peripheral' plasma membrane PDE (Pyne 
and Houslay, 1988).
Whilst this evidence may suggest that the third insulin sensitive 
phosphodiesterase is the cyclic GMP -  stimulated phosphodiesterase, it 
does not preclude the possibility that in vivo other phosphodiesterases 
may be the target. Two good candidates for such a species are the
soluble PDE M Q -IV  and PDE M Q -V . These contribute a significant 
proportion of the total soluble cyclic AMP phosphodiesterase in 
hepatocytes and in addition are specific for cyclic AMP as substrate. 
This is important since it has been shown that insulin can increase 
cyclic GMP levels in hepatocytes rather than decrease them. Activation 
of a cyclic GMP phosphodiesterase such as the Ca2+/calmodulin — 
stimulated phosphodiesterase or the cyclic GMP -  stimulated 
phosphodiesterase by this 'mediator' preparation would thus be expected 
to decrease cyclic GMP levels following insulin challenge rather than 
increase them. This is especially true of the cyclic GMP -  stimulated 
phosphodiesterase which has been shown in this study to form a very 
large proportion of the total soluble cyclic GMP phosphodiesterase 
activity as well as a large proportion of the membrane bound cyclic 
GMP phosphodiesterase activity (Pyne, et al., 1986a).
Given the substrate specificity of the Ca2+/calmodulin — 
stimulated phosphodiesterase in hepatocytes it would seem unlikely that 
this activity could act as an insulin-stim ulated cyclic AMP 
phosphodiesterase. This also discounts the possibility that Ca2+ could 
conceivably act as an insulin 'mediator' in this action of insulin. 
Whilst PDE M Q -I  has the necessary capacity to hydrolyse cyclic AMP, 
and also forms a significant proportion of the total soluble cyclic AMP 
phosphodiesterase activity, it is also unlikely to be a target for insulin 
stimulation in hepatocytes. This is based on the observation that the 
ability of insulin to decrease cyclic AMP levels is inhibited by the 
phosphodiesterase inhibitor IBMX (Heyworth, et al., 1983d), implying
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that this insulin stimulated phosphodiesterase is sensitive to IBMX, 
which PDE M Q -I  is not.
2 8 2
CHAPTER 4.
THE HORM ONE-SENSITIVE ’PERIPHERAL AND 
'DENSE-VESICLE' PHOSPHODIESTERASES.
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Challenge of cells with either insulin or hormones which activate
adenylate cyclase has been shown to enhance cyclic AMP
phosphodiesterase activity (Appleman, et al., 1973; Thompson, et al., 
1973; Houslay, 1986; Kono, et al., 1975). In hepatocytes, there appear
to - be at least three specific high -  affinity cyclic AMP
phosphodiesterases, whose activities are under rapid reversible regulation 
by hormones (Heyworth, et al., 1983d; Houslay, 1986). Two of these 
activities have been purified from rat liver. These enzymes, the 
'dense-vesicle* phosphodiesterase and the 'peripheral' plasma membrane 
phosphodiesterase have been shown to differ in their physical 
properties, thermal stability, kinetics of degradation of cyclic AMP and
cyclic GMP, inhibitor sensitivities, 125I-lab e lled  tryptic peptide maps 
and in the ability of cyclic GMP to inhibit the hydrolysis of cyclic 
AMP (Marchmont, et al., 1981b; Pyne, et al., 1987a, Pyne, et al., 
1986b). The 'peripheral' plasma membrane phosphodiesterase can be 
stimulated by insulin through a process that involves phosphorylation
(Marchmont and Houslay, 1980b; Marchmont and Houslay, 1981a; 
Pyne, et al., 1989). Activation of this enzyme by insulin can be
blocked by p re-trea tm en t of hepatocytes with glucagon (Heyworth, 
et al., 1983d; Heyworth, et al., 1984a).
The other insulin activated enzyme is the 'dense-vesicle '
phosphodiesterase (Heyworth, et al., 1983d; Pyne, et al., 1987a), whose 
activity is rapidly increased when hepatocytes are treated with either 
insulin or glucagon (Loten, et al., 1978; Loten, et al., 1980;
Heyworth,1 et al., 1983d, Pyne, et al., 1987a). Glucagon has been
suggested to exert it’s effect on this enzyme through a mechanism 
involving cyclic AMP -  dependent phosphorylation (Heyworth, et al., 
1983d, Houslay, 1986; Kilgour, et al., 1989).. This mechanism seems to
be quite distinct from the mechanism, as yet unidentified, by which 
insulin activates this enzyme (Heyworth, et al., 1984a).
These different methods of regulation may imply that these 
enzymes have specific functional roles in hepatocytes. It was of 
interest then to determine if these activities were specifically expressed
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in liver/hepatocytes or if they exhibited a wider tissue distribution. 
The aim of this section of work was to assess for the presence of these 
two hormonally regulated enzymes in tissues other than liver. Specific
anti -  sera were availabe that had previously been raised to purified
preparations of the 'dense-vesicle ' phosphodiesterase (Pyne, et al., 
1987a) and the 'peripheral' phosphodiesterase (Pyne, et al., 1986b). 
These were termed D V -1  and P M -1  respectively.
The amount of the antisera D V -1  and P M -1  were limited at 
the time this study was initiated so an attempt was made to purify the 
'dense-vesicle' phosphodiesterase in order to allow for the production 
of more a n ti-se ra  to this enzyme.
Some portions of this work were carried out in collaboration
with Dr. Nigel Pyne and Dr. Neil Anderson who were responsible for
the production of the antisera DV1.
2 8 5
4.1: THE ANTISERA D V -1  AND P M -1 .
The polyclonal antisera D V -1  and P M -1  have been raised 
against purified preparations of the 'dense-vesicle1 and 'peripheral' 
plasma membrane phosphodiesterases respectively (D V -P D E  and P M - 
PDE) in previous work in this laboratory (Pyne, et al., 1987a; Houslay, 
et al., 1988).
Using Western blotting, D V -1  could recognise the 5 7 -k D a  
subunit of the purified protein. Immunoprecipitation of a hypotonic 
extract of rat liver membranes using the antisera D V -1  identifies a 
57 -  kDa protein. A larger form of the enzyme could be identified 
from immunoprecipitates of sodium cholate extracts of liver membranes 
that has a molecular weight of 62/63-k D a . Hypotonic extraction of 
rat liver membranes has been shown to proteolytically release the 
'dense-vesicle ' PDE from the membrane due to the action of
endogenous proteases (Loten, et al., 1978; Loten, et al., 1980; Pyne,
et al., 1987a). /  This release is inhibited by a variety of protease 
inhibitors, including Benzamidine (Loten, et al., 1978). Cholate 
extraction in the presence of the protease inhibitors Benzamidine and
PMSF, should therefore, solublise but prevent proteolytic cleavage of 
the enzyme.
Based on these observations, the 5 7 -k D a  species presumably 
reflects the proteolysed form of the enzyme whilst the 62-k D a  protein 
is probably the native subunit molecular weight. The 63-k D a  protein 
has been proposed to be a precursor of the enzyme although the 
evidence for this is lacking (Pyne,. et al., 1987a). The antisera PM - 1  
recognises a 52-k D a  protein on Western Blots of liver membranes
(Houslay, et al., 1988).
In order to confirm that the D V -1  antibody could recognise 
'dense-vesicle1 phosphodiesterase activity, experiments were performed 
to assess if the antibody could remove cyclic AMP phosphodiesterase 
activity from a hypotonic extract prepared from rat liver. An antibody 
affinity column (DV- 1  - Sepharose) was prepared by coupling D V -1  to
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Cyanogen bromide -  activated Sepharose. Figure 4.1 shows that the 
column could remove cyclic AMP phosphodiesterse activity from a 
hypotonic extract. The activity appeared to be bound specifically to 
the matrix since washing in high salt removed only a small amount of 
the retained activity (5.3% -8.2%  range).
The maximal phosphodiesterase activity removed from the 
hypotonic extract by DV - 1  -  Sepharose was approximately 3.5 
pmol/min/33jil of gel matrix corresponding to a column capacity of 
107 pmol/min/ml of gel matrix. Removal of the cyclic AMP 
phosphodiesterase activity from the hypotonic extract caused a change 
in the response of the extract to cyclic GMP. The extract’s cyclic 
AMP phosphodiesterase activity was inhibited approximately 55% by 
cyclic GMP. At incubation levels below the capacity of the column, 
removal of cyclic AMP phosphodiesterase activity produced an extract 
whose cyclic AMP phosphodiesterase activity was stimulated some 45% 
by cyclic GMP. As the amount of enzyme applied to the column 
increased towards, and then exceeded, the capacity of the column, the 
response to cyclic GMP of the cyclic AMP PDE activity remaining in 
the extract approached that of the hypotonic extract itself indicating 
that D V -P D E  activity remained unbound to the affinity resin.
An attempt was made to remove the enzyme from the affinity 
matrix. Elution was assessed by iodination of the eluted proteins 
followed by fractionation on an SD S-PA G E  gel. The interaction of 
the 'dense-vesicle' enzyme with the antibody appeared to be very 
strong since only under extreme conditions could activity be eluted. 
Figure 4.2 shows that only in the presence of 3.5M MgCl2 or 8M urea 
could protein be removed from the affinity gel. Incubation in ImM 
cyclic AM P/lmM  cyclic GMP and 1% sodium cholate was ineffective. 
Two major polypeptides of 5 7 -k D a  and 51-k D a  were identified, that 
corresponded to the molecular weights of the purified 'clipped' form of 
the 'dense-vesicle ' phosphodiesterase (Pyne, et al., 1987a).
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This data confirmed that the D V -1  antibody was capable of 
recognising the 'dense-vesicle' phosphodiesterase. A similar study using 
the antisera P M -1  was precluded due to the limited amount of the 
antisera available.
- It was decided to assess the tissue distribution of these two
hormonally regulated in phosphodiesterases using the specific a n ti-se ra  
D V -1  and P M -1  to quantitate the enzyme in tissue homogenates.
4.2: TISSUE DISTRIBUTION OF THE HORMONE -  SENSITIVE
'DENSE-VESICLE' AND PERIPHERAL PLASMA MEMBRANE PDEs.
The relative distribution of the 'dense-vesicle ' and 'peripheral' 
phosphodiesterases was then assessed in several rat tissues namely, liver, 
heart, white adipose tissue and kidney.
4.2.1: Methods.
In order to address the problem of differential extraction and
proteolysis it was decided to adopt a protocol whereby tissues were 
rapidly isolated from freshly sacrificed rats. All tissues were diced 
rapidly at 4°C; white adipose tissue, liver, and kidney were 
homogenised directly whilst heart tissue was further disrupted using a
Polytron. Homogenates were prepared rapidly under isotonic conditions 
in the presence of the protease inhibitors Benzamidine, PMSF and
Leupeptin, as detailed in Section 2.4 for the preparation of 
homogenates from rat liver. A given volume of komogenate was then 
solubilised directly in an equal volume of Laemmli sample buffer by 
boiling for 5 minutes (see Section 2.22.1). Total homogenate protein 
was then determined and the required volume of the solubilised extracts 
determined to provide 50pg of total protein calculated.
4.2.2: Immunoblotting of DV and PM PDEs in rat tissues.
The 'dense-vesicle' and 'peripheral' phosphodiesterases were 
expressed in all the tissues examined. Figure 4.3 shows that 
immunoblot analysis of homogenates of liver, heart, white adipose tissue
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and kidney identified a single major band at 52-k D a  with antiserum 
P M -1 , corresponding to the molecular weight of the purified 
’peripheral' plasma membrane phosphodiesterase (P M -P D E ) and a 
63-k D a  band with antiserum D V -1  corresponding to the presumed 
molecular weight of the native 'dense-vesicle ' phosphodiesterase 
(D V -PD E ).
Using equal amounts of protein (50jig), it was apparent from the 
degree of staining from the peroxidase stained immunoblots, that the 
distribution of these two enzymes in the various tissues was not the 
same. It was thus decided to quantitate the amount of these two 
enzymes in each of these tissues by using the specific antibodies and 
12 5I -P ro te in -A .
Standard curves were constructed using purified protein 
previously prepared by the method of Pyne, et al., (1987a) for the 
'dense-vesicle' phosphodiesterase and the method of Pyne, et al., 
(1986b) for the 'peripheral' phosphodiesterase. Blots were probed with 
antisera P M -1  or D V -1  and then with 12 5I -P ro te in -A . The
standard curves are shown in Figures 4.4 and 4.5. They were linear and 
exhibited slopes that were slightly greater than 1.
Table 4.1 shows that using this procedure, it was 4lso apparent 5
that the distribution of these enzymes in the tissues examined was not 
the same. It was found that whilst liver and kidney expressed
approximately equal amounts of the D V -P D E  (0.15 and 0.14 pg/mg of 
homogenate respectively), heart and white adipose tissue were found to 
express much higher levels (0.75 and 0.48 jig/mg of homogenate 
respectively). Using these results one can estimate the total amount of 
the 'dense-vesicle' phosphodiesterase in one rat liver. In a 250 -  275g 
rat, one liver has been shown to contain approximately 300 mg of 
protein in the homogenate (Pyne, et al., 1987a). This corresponds to a 
total amount of 'dense-vesicle' phosphodiesterase of 45 pg per liver. In 
a purification of the 'dense-vesicle ' phosphodiesterase the yield from
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three rat livers was approximately 30pg of protein, which would indicate 
that these estimates of total enzyme levels are approximately correct.
The distribution of the P M -P D E  amongst the tissues also 
differed but not as markedly as for the D V -P D E . Kidney, heart and 
white- adipose tissue all exhibited very similar levels of the P M -P D E  
(0.12, 0.11 and 0.11 pg/mg of homogenate), whilst liver contained
slightly higher levels (0.15 pg/mg of homogenate).
This analysis indicated that there were distinct tissue 
distributions of the D V -P D E  and the P M -P D E  in rat tissues. 
However, it cannot be concluded that because a tissue expresses an 
enzyme, that enzyme is active. It is always possible that the enzyme 
may be inactivated or that it may be sequestered in a cellular 
compartment so that it’s activity is latent. In order to address this 
question it was decided to estimate the total contribution of the 
'dense-vesicle’ phosphodiesterase to the total homogenate cyclic AMP 
phosphodiesterase activity.
4.3: USE OF ICI 118233 TO ASSESS TISSUE DISTRIBUTION OF
THE ’D ENSE-V ESICLE’ PHOSPHODIESTERASE.
Results presented in Chapter 3 and from previous work in this 
laboratory have shown that the phosphodiesterase inhibitor ICI 118233 is 
a specific and potent inhibitor of the ’dense-vesicle’ phosphodiesterase. 
It has little or no inhibitory action against the ‘peripheral’ plama 
membrane phosphodiesterase, both the plasma membrane and cytosolic 
forms of the cyclic GMP -  stimulated phosphodiesterase, the soluble 
Ca2+/Calm odulin- stimulated phosphodiesterase, the soluble IB M X - 
insensitive phosphodiesterase, or the two soluble high affinity cyclic 
AM P-specific phosphodiesterases. Using this specific reagent, it was 
decided to assess the relative contribution of the ’dense-vesicle1 PDE 
activity in total homogenates from liver, kidney, white adipose tissue 
and heart.
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4.3.1: Characterisation of ICI 118233 inhibition of 'dense-vesicle1
cyclic AMP phosphodiesterase activity.
Further characterisation of the action of ICI 118233 against the 
D V -P D E  was carried out by analysis of the IC50 curves for inhibition 
of the DV -  PDE cyclic AMP PDE activity, followed by a calculation- of 
the Ki value for ICI 118233. When assayed over a highly extended 
concentration range, the 'dense-vesicle ' enzyme displays evidence of 
apparent negative co-operativity (Pyne, et al., 1987a). Analysis of 
inhibition was thus performed at low substrate concentrations (0.1 -  
I.OjjM  cyclic AMP), which allowed the 'high -  affinity' component of it’s 
activity to be followed.
To carry this out, a partially purified preparation of the 
D V -P D E  was first prepared from hypotonic extracts by Mono Q 
chromatography (M Q -D V -P D E  see Section 4. ). Firstly, the IC50 f o r ' 
inhibition of cyclic AMP hydrolysis by cyclic GMP was determined at a 
substrate concentration of 0.1 pM cyclic AMP. Figure 4.6 shows a 
typical inhibition curve for inhibition of cyclic AMP hydrolysis by cyclic 
GMP. From this, the estimated IC50 for cyclic GMP inhibition of 
cyclic AMP hydrolysis was 2.8pM + / -  0.7pM ( + / -  SEM, n = 3 ). This 
figure compares well with the value for the IC50 for cyclic GMP 
inhibition of cyclic AMP hydrolysis obtained for the purified enzyme, 
which was 2pM at lpM  cyclic AMP substrate concentration (Pyne, 
et al., 1987a). The inhibition curve obtained was monophasic and 
almost complete inhibition was observed at high levels of cyclic GMP. 
Based on these observations it was concluded that the partially purified 
prepartion (M Q -D V -P D E ) was sufficiently enriched in the 'dense-  
vesicle' PDE activity (C G I-P D E  activity) to be of use in determining 
both the IC50 and the Ki for inhibition of the D V -P D E  by ICI 
118233.
Figure 4.7 shows a typical estimate of the IC50 for inhibition of 
cyclic AMP hydrolysis by ICI 118233 at 0.1 pM cyclic AMP. Under
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these conditions, the estimated IC50 for ICI 118233 action was 3.0pM
+ / -  0.6pM ( + / -  SEM, n = 3).
Lineweaver -  Burk plots of cyclic AMP hydrolysis for M Q -D V -  
PDE were constructed by analysing the kinetics of cyclic AMP
hydrolysis between O.lpM and lpM . A typical analysis is shown in 
Figure 4.8 where apparently linear Lineweaver -  Burk plots were obtained 
for the activity of the enzyme. Under these conditions the estimated 
K,,, for cyclic AMP was 0.5pM + / -  0.17pM ( + / -  SEM, n = 4). In
the presence o f increasing concentrations of ICI 118233, the
Lineweaver -  Burk plots remained linear and inhibition obtained was 
apparently competitive since the lines intercepted at the same point on 
the 1/v axis. Analysis of the ICI 118233 inhibition data by replotting 
the slope of the Lineweaver -  Burk plot against ICI 118233 concentration 
(Figure 4.9) showed that the value for inhibition of cyclic AMP 
hydrolysis was 3.8pM + /-1 .2 p M  ' ( + / -  SEM, n = 4). Since the
estimated K,,, for cyclic AMP hydrolysis for the 'high affinity1 
component of the enzyme (0.5 pM) agreed well with the value for the 
purified enzyme (0.3pM) (Pyne, et al., 1987a), this further confirmed 
the validity of using a partially purified preparation of the 'dense-
vesicle* phosphodiesterase for these analyses.
4.3.2: 'D ense-vesicle' PDE activity in rat tissues assessed using the
selective inhibitor ICI 118233.
From the IC50 data it was decided to use a maximally effective
dose of ICI 118233 (lOOpM) to allow for an assessment of the
contribution this enzyme makes to total homogenate cyclic AMP 
hydrolysis. In these experiments, homogenates were prepared as for
blotting experiments but were assayed immediately for cyclic AMP 
phosphodiesterase activity at O.lpM cyclic AMP. From the % 
inhibition of homogenate PDE activity obtained with lOOpM ICI 118233 
it was possible to estimate the specific activity of the D V -P D E  activity 
in each of the tissues. Table 4.2 shows the results expressed in 
pmol/min/mg of homogenate. Calculation of the tissue distribution
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ratio (TD ratio) reveals that the pattern of expression corresponds well 
with that obtained using immunoblotting analysis. Heart and white 
adipose tissue once again expressed the highest relative amount of 
D V -P D E  activity with lower levels of activity observed in liver and 
kidney.
Using both the values for the amount of D V -P D E  protein and 
the activity of the D V -P D E  an estimated specific activity of the 
D V -P D E  in each of the tissues was calculated. The values were 
different in each of the tissues examined, the highest value obtained 
was 7857 pmol/min/mg in kidney and the lowest in heart, 3466 
pmol/min/mg. The value for the liver enzyme was 5333 pmol/min/mg 
which is about 30% of the specific activity of the purified 'clipped1 
form of the enzyme (17,503 pmol/min/mg) (Pyne, et al., 1987a).
Although there are potent inhibitors of the 'peripheral' plasma 
membrane phosphodiesterase, e.g. ICI 63 197 (Houslay, et al., 1988), this 
compound iff also an effective inhibitor of the 'dense-vesicle ' 
phosphodiesterase (Pyne, et al., 1987a) and also of the two soluble high 
affinity cyclic AMP phosphodiesterases (see Chapter 3). Consequently a 
comparable study for the 'peripheral' plasma membrane 
phosphodiesterase was not possible.
4.4: PURIFICATION OF RAT LIVER 'D ENSE-V ESICLE' PDE.
Because of the limited amount of the antibody D V -1 , several 
attempts were made to purify the enzyme from rat liver using 
previously published methods developed by Pyne, et al., (1987a) with an 
aim to produce more antisera. Two methods were available to purify 
the hypotonically extracted enzyme, the Guanine -  Sepharose method 
and the A ffi-gel Blue method.
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4.5: THE GUANINE -  SEPHAROSE METHOD.
This involves the production of a hypotonic extract of liver
membranes which contains the proteolytically solubilised enzyme (Pyne, 
et al., 1987a; Loten, et al., 1978; Loten, et al., 1980). The hypotonic 
extract is then applied to an anion -  exchange column (ECTEOLA 
cell ulose). Activity is batch eluted with high salt and the sample
diluted and applied to a hydrophobic column ( -A m in o -p en ty l
Agarose). Activity is again batch eluted with high salt and the sample 
desalted by passage through a desalting column (Sephadex G -2 5 ) . The 
sample is finally applied to a column of Guanine -  sepharose (Whitson 
and Appleman, 1982) and again eluted with salt. This procedure is
referred to as the Guanine -  Sepharose method.
4.5.1: Preparation of a hypotonic extract from rat liver.
A hyp tonic extract was prepared from three rat livers by the 
method described in Pyne, et al., (1987a). In five different 
preparations, from three rat livers, the total yield of activity was some 
31% + / -  1.35% (n= 5 + / -  SEM) of the minimum expected value 
quoted in Pyne, et al., (1987a). Whilst the cyclic AMP 
phosphodiesterase activity was very much lower than expected, the 
yields of protein were very similar (182mg + / .— 12.5mg, n = 5 , + /  —
SEM). The cyclic AMP phosphodiesterase activity was inhibited by
IOjxM  cyclic GMP some 28% + / -  4%  (n= 5 , + / -  SEM). A  typical 
purification attempt is described below.
4.5.2: Purification steps for the Guanine -  Sepharose method.
Application of the extract to the anion -  exchanger ECTEOLA 
cellulose resulted in the binding of 97% of the cyclic AMP PDE
activity. This activity remained bound during the washing procedure 
(6.2% of the cyclic AMP PDE activity eluted). Batch elution using
0.4M sodium chloride eluted some 38% of the cyclic AMP PDE activity 
as a single peak of activity that was inhibited some 55% by cyclic GMP 
(Figure 4.10). Passage of this activity over the matrix, W -
amino pentyl agarose, resulted in the binding of 98% of the activity
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with less than 1% eluted during the washing procedure. Batch elution 
with 0.5M NaCl, resulted in the elution of a single peak of PDE
activity that contained cyclic GMP -  inhibited cyclic AMP PDE activity 
(67% inhibition) (Figure 4.11). Desalting of the extract on a Sephadex 
G -2 5  column eluted a single peak of activity that was inhibited some 
80% by cyclic GMP (Figure 4.12). Guanine -  Sepharose chromatography 
produced a single peak of activity that was inhibited some 75% by
cyclic GMP (Figure 4.13). The final specific activity was 
675 pmol/min/mg with a 0.8% yield and fold purification of 131. The 
results are summarised in Table 4.4. An analysis of the purified
product by SD S-PA G E analysis revealed the presence of three major
polypeptides at 68-kD a, 61-k D a  and 55-kD a. The preparation was 
not, however, pure since a large number of other minor staining bands 
were present (Figure 4.14). The published procedure yields bands at 
5 7 -k D a  and 51-k D a .
These results were typical of preparations prepared at least five 
times. The average yield was 1.31% + / -  0.41% (n= 5 , + / -  SEM) 
and the average specific activity was 361 pmol/min/mg ■+/— 128
pmol/min/mg (n=5, + / -  SEM). These results differed markedly from 
the published procedure which produced a preparation with a yield of 
18% and a specific activity of 17,500 pmol/min/mg
A closer examination of the preparation procedure identified 
three specific areas that contributed to the low yield. The first of 
these was the low yield of cyclic AMP phosphodiesterase activity in the 
hypotonic extract which was some 31% of the expected value.
The second was the efficiency of the individual chromatographic 
steps. Analysis of the yields from the individual steps was performed 
by calculating the phosphodiesterase activity eluted from columns in the 
individual fractions prior to pooling of active fractions. The specific 
yields of the columns were calculated and are presented in Table 4.3. 
In five different preparations, the ECTEOLA cellulose and -  am ino-  
pentyl agarose columns routinely gave low yields of applied activity.
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The Sephadex G -2 5  step gave very variable yields of activity (20% - 
100% recovery). The guanine -  Sepharose step was highly efficient with 
yields of between 68 and 100%.
The third factor was the stability of the enzyme at the various
stages. It was observed that during a 24 hour period at 4°C the total
cyclic AMP phosphodiesterase activity was very stable during the first
two steps but was found to be markedly unstable after the Sephadex 
G -2 5  and, guanine -  Sepharose steps (Table 4.3). Decay of activity 
after the final stage could be as marked as 70% within a 24 hour 
period at 4°C.
4.6: THE A F F I-G E L  BLUE METHOD.
Given the low yields of activity produced from this procedure it 
was decided to attempt the purification by the alternative method using 
A ffi-gel Blue. This method involves the application of the hypotonic 
extract to an A ffi-gel Blue column in the presence of magnesium and 
elution using the magnesium chelator EDTA. The eluted activity is 
then applied to a second column of A ffi-ge l Blue and eluted by 
substrate elution with cyclic AMP which is then removed from the 
enzyme by chromatography on DEAE -  Sepharose C L -6B . A typical 
purification attempt is described below.
4.6.1: Hypotonic extract production.
The hypotonic extract was prepared from five rat livers by a 
modification of the method described in Pyne, et al., (1987a) (see 
Section 2.31). The modifications introduced included homogenisation 
of the diced rat livers in a Waring Blender (to significantly improve on 
both the speed of preparation and the yield of activity) (see Section 
2.31) and the introduction of a second high speed spin at 48,000gav 
after addition of of MgCl2 to the hypotonic extract. This was 
introduced because it was routinely observed that addition of MgCl2 
caused the precipitation of protein from the hypotonic extract. When
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assayed for phosphodiesterase activity this pellet contained less than
0.2% of the total cyclic AMP PDE activity in the hypotonic extract.
4.6.2: Characteristics of the rat liver hypotonic extract.
In order to assess if these modifications altered the properties of 
the hypotonic extract the characteristics of the preparation were 
examined. In a typical preparation from five rat livers the hypotonic 
extract contained 6,853 pmol/min of cyclic AMP PDE activity with a 
specific activity of 14.6 pmol/min/mg which agreed well with the 
published value of 18.9-28 pmol/min/mg (Pyne, et al., 1987a) and 
represented a significant improvement on the original extraction
procedure. The extract demonstrated significant inhibition of cyclic
AMP PDE activity in the presence of lOpM cyclic GMP; the activity 
was reduced some 54% to 3,833 pmol/min. Since rat liver contains a
number of cyclic GMP -  insensitive and cyclic GMP -  stimulated cyclic 
AMP PDE activities it is often difficult to observe the activity of the 
’dense-vesicle' PDE unless one has a significantly enriched preparation 
of the enzyme. Based on these observations it was concluded that the 
preparation of the hypotonic extract was significantly enriched in 
'dense-vesicle' phosphodiesterase activity.
4.6.3: Chromatography of the hypotonic extract on A ffi-g e l Blue.
In contrast to previously published results, chromatography of 
the hypotonic extract on A ffi-g e l Blue in the presence of protease 
inhibitors resulted in little binding of total cyclic AMP PDE activity. 
Figure 4.15 shows that of the 6,853 pmol/min of total cyclic AMP PDE 
activity applied to an A ffi-ge l Blue column, 67% (4,558 pmol/min) 
eluted in the breakthrough fraction. A further 29% (1,995 pmol/min) 
eluted during the extended washing procedure. The cyclic AMP PDE 
activity of both the breakthrough fraction and the wash fraction were 
inhibited by cyclic GMP (61% and 46% respectively). Unexpectedly, 
phosphodiesterase activity was observed eluting in an EDTA dependent 
manner, as is shown in Figure 4.16. This represented 1,400 pmol/min 
of cyclic AMP PDE activity (20% of activity applied). However, this
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activity was not inhibited by IOjiM cyclic GMP implying the existence 
of a cyclic GMP -  insensitive phosphodiesterase activity in the hypotonic 
extract.
This result was observed routinely using both the same batch of 
A ffi-gel Blue and also other batches. Figure 4.17 shows the result„of 
a typical experiment in which the ability of a variety of batches of 
A ffi-gel Blue to bind D V -P D E  activity was assessed. The conditions 
of the experiment were deliberately chosen so that the ratio of protein 
to gel matrix (4.3 mg/m1 of gel matrix) was significantly greater than 
the ratio that would be found in the conventional purification 
procedure (about 50 mg/ml of gel matrix). This was done to bias the 
experiment in favour of binding. The results clearly showed that the 
enzyme activity did not bind significantly to any of the batches of 
A ffi-gel Blue that were screened (less than 10% of total applied).
4.6.4: D E -5 2  chromatography of the Hypotonic extract.
In order to increase the specific activity of the 'dense-vesicle* 
preparation, before chromatography on A ffi-gel Blue, it was decided to 
perform ion-exchange chromatography. A hypotonic extract was 
prepared from 5 rat livers and applied to a column of D E -5 2 . This 
column was chosen in preference to ECTEOLA—cellulose since this had 
usually given low yields of activity. The column was developed using a 
linear NaCl gradient betweem 0 and G.55M NaCl. The elution profile 
shown in Figure 4.18 indicated that there was a single major peak of 
cyclic AMP PDE activity eluting at approximately 0.275M NaCl. The 
responses of the ascending and descending limbs to cyclic GMP were 
however different. The ascending limb was clearly insensitive to cyclic 
GMP action whilst the descending limb was clearly inhibited by cyclic 
GMP. The implication of this was that there were two major cyclic 
AMP phosphodiesterases in the hypotonic extract that differed in their 
response to cyclic GMP, namely a cyclic GMP -  insensitive activity and 
a cyclic GMP -  inhibited activity (the 'dense-vesicle ' phosphodiesterase).
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No further activity was found to elute when the gradient was extended 
to 1.0M NaCl.
Fractions from the D E -5 2  column, containing the 'dense -  
vesicle' activity, when pooled, contained 1,880 pmol/min of cyclic AMP 
PDE - activity. This represented a 39% yield of activity over the 
hypotonic extract. The specific activity of the preparation was 
increased nearly 7.5 fold from 27.7 pmol/min/mg to 204 pmol/min/mg. 
Clyclic GMP inhibited cyclic AMP PDE v activity by nearly 75%, 
compared to 49% in the hypotonic extract, indicating further
enrichment of the DV -  PDE activity. Dialysis of the D V -  PDE
preparation against 3 x 2  litre changes of TM Buffer for 12 hours
resulted in the loss of 15% of the activity with no change in the %
inhibition by cyclic GMP.
4.6.5: Chromatography of D E -5 2  purified enzyme on A ffi-g e l Blue.
A small sample (2mls) of the dialysed extract was set aside to 
assess the stability properties of the enzyme. Application of the 
remainder of the extract (58mls) to a larger column of A ffi-g e l Blue 
(18mls) and at a much slower rate (0.2 ml/min) resulted in the binding 
of the PDE activity to A ffi-gel Blue. 8% of the activity was found in 
the breakthrough fraction whilst less than 1% was found in the wash. 
However, application of the ED TA -containing elution buffer resulted 
in the elution of less than 2% of the activity applied, as is shown in 
Figure 4.19. The total yield of protein was approximately 200jig, giving 
a final specific activity of 200 pmol/min/mg. This was identical to the 
specific activity of the enzyme preparation at the D E -5 2  stage 
indicating that no significant purification had been obtained.
The possibility that the enzyme activity had decayed during this 
procedure was excluded by the experiment shown in Figure 4.20(a). 
Dialysed enzyme from the D E -5 2  step, when incubated in the presence 
and absence of 2mM p -  mercaptoethanol, demonstrated a time 
dependent decay in activity over a 48 hour period. Enzyme incubated 
in the presence of p -  Mercaptoethanol exhibited a loss of 55% of the
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initial activity whilst that incubated in the absence of of p — 
mercaptoethanol showed only a loss of 33%. The time course of these 
effects were however different. The loss of activity for the enzyme 
without. P -  Mercaptoethanol was more rapid while the loss for the 
enzyme in p -  Mercaptoethanol was much slower in onset. The %
inhibition of the samples however remained high (60-80%  range) 
Figure 4.20(b). However, these losses of activity were not sufficient to 
account for the apparent loss of activity on the A ffi-gel Blue column.
4.7: TOWARDS AN ALTERNATIVE PURIFICATION PROTOCOL.
Given the problems I found working with such procedures, I 
decided to investigate the possibility that various compounds could be 
used as an alternative ‘affinity1 step. As a first step towards this, it
was necessary to assess if interaction with the various compounds was 
reversible and that these compounds could be readily removed from the 
enzyme. The rationale behind this is that in order for an affinity step 
to be effective, ligand dependent elution needs to be achieved. If this 
is possible, then in order to assay the activity, the eluting ligand needs 
to be removed from the enzyme.
Hypotonic extracts can be prepared that demonstrate significant 
inhibition of cyclic AMP PDE activity in response to cyclic GMP. 
’D ense-vesicle1 PDE activity could be partially separated from a non 
cyclic GMP inhibited PDE activity on D E -5 2  but this procedure was 
rather slow and the resolution incomplete. It was thus decided to
attempt to resolve the hypotonic extract phosphodiesterases on a Mono 
Q anion -  exchange column.
4.7.1: Separation of hypotonic extract cyclic nucleotide PDE activity by
Mono Q anion-exchange chromatography.
In a typical experiment, a hypotonic extract isolated from one
rat liver contained 964 pmol/min of cyclic AMP PDE activity assessed 
at 0.1 pM cyclic AMP. The cyclic AMP PDE activity of this extract was
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inhibited 50% by IOjjM  cyclic GMP. Chromatography was performed 
on a Mono Q column using an identical gradient to that employed for 
the separation of soluble cyclic nucleotide phosphodiesterase (see 
Chapter 3: Table 3.2). Figure 4.21 shows the elution profile obtained
when assaying for both cyclic AMP and cyclic GMP at 0.1 pM substrate. 
In addition, cyclic AMP hydrolysis was assessed in the presence of 2pM 
cyclic GMP. This concentration of cyclic GMP was chosen so that 
both activation and inhibition of cyclic AMP hydrolysis could be 
followed more easily. At least 6 peaks of activity could be readily 
resolved by this technique.
Peaks I and II hydrolysed cyclic AMP preferentially, whilst Peak 
III hydrolysed cyclic GMP preferentially. The precise identity of these 
activities with respect to known activities was not determined. Peak IV 
clearly contained the cyclic GMP -  stimulated phosphodiesterase activity. 
Peak V hydrolysed cyclic AMP almost exclusively but it’s activity was 
not affected by cyclic GMP. Peak VI hydrolysed both cyclic AMP and 
cyclic GMP. Inhibition of cyclic AMP hydrolysis by cyclic GMP could 
be observed in fractions either side of the midpoint of the peak 
(fraction 91). No inhibition was observed in fraction 91 itself. 
Fraction 91 also exhibited a large amount of cyclic GMP hydrolytic 
activity. These results were observed in three instances where nearly 
identical profiles were obtained.
The activities quoted are calculated on the assumption of 
linearity of the assay. However, the assay has been shown to be linear 
up to 20% hydrolysis but after this limit it is difficult to accurately 
assess the actual hydrolytic rate. Based on this knowledge, the simplest 
interpretation of these results was that the 'dense-vesic le1 
phosphodiesterase is contained in Peak VI and had eluted from the 
Mono Q column in a concentrated form so that inhibition of cyclic 
AMP hydrolysis was not easily detected. This interpretation was 
supported by the fact that significant amounts of cyclic GMP PDE 
activity can be detected in the peak. This enzyme has been shown to
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hydrolyse cyclic GMP (Whitson and Appleman, 1982; Pyne, et al., 
1987a)
Although the cyclic GMP -  insensitive and -inhibited  forms of 
cyclic AMP PDE could be resolved by Mono Q chromatography using 
this gradient, a better separation could be achieved using an extended 
gradient between 0.3 and 0.5M NaCl. This is shown in Figure 4.22. 
This clearly showed the resolution of the cyclic GMP -  insensitive form 
of cyclic AMP phosphodiesterase from the cyclic GMP -  inhibited 
'dense-vesicle ' phosphodiesterase. The cyclic AMP phosphodiesterase 
activity of the D V -P D E  was potently inhibited by 10pM cyclic GMP.
4.7.2 Characterisation of the Mono Q purified 'dense-vesicle* 
phosphodiesterase (MQ -  DV -  PDE).
The preparation was characterised in terms of kinetics of cyclic 
AMP hydrolysis, and inhibition by ICI 118233 and cyclic GMP. These 
results are shown in Figures 4 .6-4 .9 . The results indicated that the 
preparation was sufficiently separated from other phosphodiesterases to 
be of use in screening for alternative affinity columns.
4.7.3: Reversibility of inhibition of the 'dense-vesicle* PDE by various
inhibitors.
In order to assess this, M Q -D V -P D E  was mixed with inhibitors 
at a final concentration of lOOpM. Figure 4.23 shows the results of a 
typical experiment. Incubation of the D V -P D E  preparation in lOOpM 
of the inhibitors, cyclic GMP, IBMX, and ICI 118233, resulted in 
inhibition of the activity to 0.01%, 2.5% and 23% of control values 
respectively. Dialysis of control enzyme, incubated in TMB Buffer 
alone, caused the loss of approximately 30% of the activity. Dialysis 
caused the return of activity to 87%, 72% and 89% of control values 
for cyclic GMP, IBMX and ICI 118233 incubated enzymes respectively. 
The dialysed samples were all potently inhibited by IOjiM cyclic GMP. 
The data thus indicated that cyclic GMP, IBMX and ICI 118233 act as 
reverible inhibitors of the 'd en se-v esic le '-P D E  and can be removed 
effectively by a simple dialysis protocol.
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FIGURE 4.1:
BINDNGOF cAMP PHOSPHODIESTERASE ACTIVITY FROM A 
RAT LIVER HYPOTONIC EXTRACT TO DV-1-SEPHAROSE.
DV-l-Sepharose was prepared and equilibrated as in Section 2.32. Five 3.33pl 
aliquots of the gel were incubated with increasing amounts of a rat liver 
hypotonic extract in eppendorf tubes on a rotary mixer at 4°C for 30 minutes. 
The gel was pelleted and the unbound fraction retained. Gels were washed in 2 
x 1ml aliquots of TE Buffer (lOmM Tris-HCl pH 7.4, lmM EDTA) followed 
by 2 x 1ml aliquots of TE Buffer/0.5M NaCl and finally in 2 x 1ml aliquots of 
TE Buffer. Washes were pooled and assayed for cAMP phosphodiesterase 
activity. The amount of activity bound to the column was estimated by 
substracting the unbound activities from the total applied. The activity 
remaining unbound was assayed for cAMP phosphodiesterase activity in the 
presence and absence of IOjiM cGMP and the ratio +/- calculated. The data is 
plotted as the estimated cAMP PDE activity bound against the total activity 
applied.
( I )  Cyclic AMP phosphodiesterase activity bound
(D) +/■ ratio for unbound cyclic AMP phosphodiesterase activity.
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FIGURE 4.2:
ELU TION OF fDENSE-V ESICLEf PHOSPHODIESTERASE 
PROTEIN FROM DV-1-SEPHAROSE
600|il aliquots of Hypotonic extract containing 8.2 pmol/min of cAMP 
phosphodiesterase activity were bound to 3.33|il aliquots of DVl-Sepharose 
and gels washed as before (see legend for Figure 5.1). The average bound 
activity was 3.2 pmol/min ± 0.3 (39%). Elution of bound material was 
attempted by incubating gels for 20 minutes at 4°C in :
1. 500|ilof3.5MMgCl2
2. 200|il of ImM cAMP/lmM cGMP
3. 200|il of 1% (w/v) sodium cholate
4. 500}il of 8M urea.
Solubilised samples were removed and dialysed against 4 x 0.5 litre changes of 
TE Buffer (lOmM Tris-HCl pH 7.4, ImM EDTA). Samples were freeze-dried 
and iodinated with 200|iCi of 125I (see Section 2.20 for general method). 
Iodinated proteins were analysed by a 10% SDS-PAGE gel.
Lane 1: 3.5MMgCl2 
Lane 2: ImM cAMP/lmM cGMP 
Lane 3: l%(w/v) sodium cholate 
Lane 4: 8MUrea
5 7  k D a  
5 1  k D a
*
T r a c k  1 2  3  14
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FIGURE 4.3:
IMMUNOBLOTTING OF RAT TISSUES WITH ANTISERA PM-I 
AND DV-1
LANE 1: OVER 
LANE 2: KIDNEY 
LANE 3: HEART
LANE 4: WHITE ADIPOSE TISSUE 
LANE 5: LIVER 
LANE 6: KIDNEY 
LANE 7: HEART
LANE 8: WHITE ADIPOSE TISSUE
Gels were loaded with equal amounts of protein (50|ig) and blotting performed 
as in Section 2.30. Lanes 1-4 were blotted with antibody OVi at a dilution of 
1/100. Lanes 5-8 were blotted with antibody jPfVl at a diluton of 1/100. Blots 
were developed with horseradish peroxidase stain using o-dianisidine as 
substrate
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FIGURE 4.4:
STANDARD CURVE FOR IM M U N O B LO TTIN G  W ITH  
ANTISERA PM -1.
Purified 'peripheral' plasma membrane phosphodiesterase (2.5ng-45ng) 
containing 52-kDa subunit was solubilised in Laemmli sample buffer and 
fractionated on a 10% SDS-PAGE gel with a 5% stacking gel (see Section 
2.22). Western blotting was performed according to section 2.30 and the blot 
probed with 2|iCi of 125I-Protein-A. This was used so that the immunostained 
bands could be excised and counted in a y-counter. In order to reduce the 
background sufficiently, it was found necessary to wash the blots in Tris- 
Tween buffered saline (20mM Tris-HCl pH 7.4, 0.5M NaCl, 0.05% (v/v) 
Tween-20. Immunostained bands were excised and counted and corrected for a 
background of approximately 50cpm.
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FIGURE 4.5:
STANDARD CURVE FOR IM M U N O BLO TTIN G  W ITH  
ANTISERA PV-1.
Purified 'dense-vesicle' phosphodiesterase (2.5ng-45ng) containing 63-kDa 
subunit was solubilised in Laemmli sample buffer and fractionated on a 10% 
SDS-PAGE gel with a 5% stacking gel (see section 2.22). Western blotting 
was performed according to Section 2.30 and the blot probed with 2|iCi of 
125I-Protein-A. This was used so that the immunostained bands could be
excised and counted in a y-counter. In order to reduce the background 
sufficiently, it was found necessary to wash the blots in Tris-Tween buffered 
saline (20mM Tris-HCl pH 7.4, 0.5M NaCl, 0.05% (v/v) Tween-20. Bands 
were excised and counted and corrected for a background of approximately 
50cpm.
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FIGURE 4.6:
INHIBITION OF THE C Y C U O _^M P PHOSPHODIESTERASE 
ACTIVITY OF A PARTIALLY PURIFIED PREPARATION OF 
THE 'DENSE-VESICLE* PHOSPHODIESTERASE BY cGMP.
A partially purified preparation of 'dense-vesicle’ PDE was isolated by Mono Q 
anion-exchange chromatography from a hypotonic extract prepared from one rat 
liver. Fractions were pooled and diluted to a suitable concentration in TMB 
buffer. Cyclic AMP phosphodiesterase activity was assessed at 0.1 jiM cAMP 
in the presence of increasing concentrations of cGMP (0-500{iM). The data 
shown is a single representative experiment with triplicate determinations (± 
SD).
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FIGURE 4.7:
INHIBITION OF THE CYCLIC AMP PHOSPHODIESTERASE 
ACTIVITY OF A PARTIALLY PURIFIED PREPARATION OF 
THE DENSE-VESICLE* PH OSPHODIESTERASE BY IC I 
118233.
A partially purified preparation of ’dense-vesicle’ PDE was isolated by Mono Q 
anion-exchange chromatography from a hypotonic extract prepared from one rat 
liver. Fractions were pooled and diluted to a suitable concentration in TMB 
buffer. Cyclic AMP phosphodiesterase activity was assessed at 0.1 |iM cAMP 
in the presence of increasing concentrations of ICI 118233 (0-100pM). The 
data is shown as the mean of triplicate determinations ± SD.
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FIGURE 4.8:
KINETIC ANALYSIS OF IC I 118233 INHIBITION OF cAMP 
HYDROLYSIS BY THE RAT LIV ER ’DENSE-VESICLE* 
PHOSPHODIESTERASE.
Cyclic AMP hydrolysis of a partially purified preparation of the ’dense-vesicle' 
phosphodiesterase (MQ-DV-PDE) was analysed over the substrate range 0.1- 
l.OjiM in the absence and presence of increasing concentrations of the ICI 
118233 inhibitor. Kinetics were analysed by Lineweaver-Burk plots of the 
reciprocal of the rate of cyclic AMP hydrolysis against the reciprocal of cyclic 
AMP substrate concentration. All points were determined in triplicate.
(4) OjiM ICI 118233
Q  lpM ICI 118233
ft) IOjiMICI 118233.
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FIGURE 4.9:
DETERMINATION OF THE Ki FOR ICI 118233 INHIBITION OF 
CYCLIC AMP HYDROLYSIS OF THE ’DENSE-V ESICLE' 
PHOSPHODIESTERASE.
The slope of the Lineweaver-Burk plot in Figure 5.6 was measured and plotted 
against the ICI 118233 concentration (pM). The straight line obtained had a 
correlation coefficient of 0.986. The intercept on the x-axis gave the Ki. In this 
typical experiment it was 4. lpM.
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FIGURE 4.10:
C H R O M A TO G R A PH Y  O F HYPOTONIC EXTRACT ON
ECTEOLA CELLULOSE.
70mls of hypotonic extract (195mg of protein) was applied to an ECTEOLA 
cellulose column (7.5 x 2.5 cm) at 0.5ml/min. The gel was washed with 
Buffer A (lOmM Tris-HCl, pH 7.4, ImM MgCl2, 2mM Benzamidine, O.lmM 
PMSF) at 1.5ml/min (350mls) and then with Buffer A containing 0.15M NaCl 
and 20% ethylene glycol (250mls). Bound phosphodiesterase activity was 
batch eluted at 1.5ml/min in Buffer A containing 0.4M NaCl and 36 x 2.5ml 
fractions were collected. cAMP phosphodiesterase activity was assessed at 
0.1 fiM cAMP in the presence Q  and absenceflpfr of IOjiMcGMP. Fractions 
containing activity were pooled and diluted 1:1 with Buffer A.
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FIGURE 4.11:
ELUTION OF cAMP PHOSPHODIESTERASE ACTIVITY FROM 
co-AMINO-PENTYL AGAROSE.
Fractions containing activity from the ECTEOLA cellulose step (80mls, 
containing 6.5mg of protein) were pooled and applied to a column of co-amino- 
pentyl agarose (3.1 x 1.3 cm) at 0.4ml/min. The column was washed at 
1.5ml/min with 90mls of Buffer A (lOmM Tris-HCl pH 7.4, ImM MgCl2, 
2mM Benzamidine, O.lmM PMSF), followed by 130mls of Buffer A 
containing 0.275M NaCl/20% ethylene glycol at 1.2ml/min. cAMP 
phosphodiesterase activity was batch eluted using Buffer A containing 0.5M 
NaCl/20% ethylene glycol. 15 x 3 ml fractions were collected and cAMP 
phosphodiesterase activity assayed in the presence (Q) and absence (ft) of 
10}iM cGMP.
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FIGURE 4.12:
ELUTION OF cAMP PHOSPHODIESTERASE ACTIVITY FROM 
SEPHADEX G-25.
Fractions (18mls containing 150jig of protein) containing cAMP 
phosphodiesterase activity were applied to a column of Sephadex G-25 (2.5 x 
19 cm) and eluted in Buffer A (lOmM Tris-HCL, pH 7.4, ImM MgCl2, 2mM 
Benzamidine, O.lmM PMSF) at a rate of 1.2ml/min. 3ml fractions collected 
from the start of loading. cAMP phosphodiesterase activity was assayed at 
O.lpMcAMP in the presence Q  and absence OH) oflOpMcGMP.
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FIGURE 4.13:
ELUTION OF cAMP PHOSPHODIESTERASE ACTIVITY FROM 
GUANINE SEPHAROSE.
Fractions containing phosphodiesterase activity (15mls, 110jig of protein) were 
pooled and applied to a column of guanine-Sepharose (0.4 x 3 cm) at 
0.3ml/min and washed in 48 mis of Buffer A (lOmM Tris-HCL, pH 7.4, ImM 
MgCl2, 2mM Benzamidine, O.lmM PMSF) followed by 15 mis of Buffer A 
containing 50mM NaCl. cAMP phosphodiesterase activity was eluted using 
Buffer A containing 0.4M NaCl/20% ethylene glycol. cAMP 
phosphodiesterase activity was assessed in the presence Q  and absence (■) 
of 10|iM cGMP. 'High activity' fractions (7-9) were pooled separately from 
'low-activity' fractions (10-13). The individual yields of protein were 5jig and 
7(ig resepectively.
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FIGURE 4.14:
SPS-PAGE ANALYSIS OF PURIFIED ’DENSE -VESICLE1 
PH OSPHO DIESTERA SE ISOLATED BY THE GUANINE- 
SEPHAROSE METHOD.
Samples of a purified preparation of the 'dense-vesicle' phosphodiesterase 
isolated by the Guanine-sepharose method were fractionated on a 10% SDS- 
PAGE gel with a 5% stacking gel (see Section 2.21). The Gel was stained in 
Coomassie Blue and destained as in Section 2.22.
LANE 1: Molecular Weight markers 
LANE 2: Blank
LANE 3: 1.3|ig of "low activity" shoulder from Guanine- 
Sepharose 
LANE 4: Blank 
LANE 5: Blank
LANE 6: 1.3jig of "high activity" shoulder from Guanine- 
Sepharose.
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FIGURE 4.15:
CHROMATOGRAPHY OF RAT LIVER HYPOTONIC EXTRACT 
ON AFFI-GEL BLUE.
A hypotonic extract was prepard from five rat livers and applied to an 8ml 
column of Affi-gel Blue (5 x 1.4cm) at lml/min and the breakthrough fraction 
collected as a pool. The column was washed in 48 Bed volumes of TMB 
Buffer (lOmM Tris-HCl pH 7.4,5mM MgCl2 and the wash collected as a pool. 
cAMP phosphodiesterase activity was assayed in the absence (H) or presence 
(j§8) of 10}iM cGMP. All assays were performed in triplicate and are shown as 
the mean ± SD.
The relative yields of protein were:
Hypotonic extract - 379mg.
Breakthrough - 214mg.
Wash - 75mg.
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FIGURE 4.16:
ELUTION OF cAMP PHOSPHODIESTERASE ACTIVITY FROM 
AFFI-GEL BLUE.
Elution was initiated at lml/min using 200mls of lOmM Tris-HCl/lmM EDTA 
pH 7.4. Fractions of 4ml were collected and assayed for cAMP 
phosphodiesterase activity at 0.1 jiM cAMP in the presence (Q) and absence 
m  of IOjiM cGMP. Activity is expressed as pmol/min/4ml.
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FIGURE 4.17:
SCREENING OF AFFI-GEL BLUE BATCHES FOR BINDING 
OF ’DENSE-VESICLE* PHOSPHODIESTERASE.
lOOjil portions of Affi-gel Blue were equilibrated in TMB buffer (lOmM Tris- 
HC1 pH 7.5, 5mM M gC l^m M  p-mercaptoethanol) (see section 2.12 for 
general method). 1ml samples of hypotonic extract (0.43mg protein and 
9.85pmol/min of cAMP PDE activity) were made up to lOmM MgCl2 and 
incubated with lOOjil portions of the equilibrated matrix and mixed on a rotary 
mixer at 4°c for 30 minutes. The gel was pelletted using a refrigerated 
microfuge (Hettich) at full speed (14,000gav) for 1 minute. The supernatant 
containing unbound material was removed and the matrix washed in 2 x 0.5 ml 
aliquots of TMB buffer and elution attempted in 2 x 0.5 aliquots of TEM buffer 
(lOmM Tris-HCl pH 7.5, ImM EDTA, 2mM p-mercaptoethanol).
cAMP phosphodiesterase activity was assessed at 0.1 jiM cAMP for the 
breakthrough fraction (HD wash fraction (H) and eluted fraction (S). All 
assays were perfomed in triplicate and are presented as the mean ± SD.
1: Affi-gel Blue (BioRad) 100-200 mesh (wet) 15-100}! Batch 1
2: Affi-gel Blue (BioRad) 100-200 mesh (wet) 15-lOOji Batch 2
3: Affi-gel Blue (BioRad) 100-200 mesh (wet) 15-100|i Batch 3
4: Cibracon Blue 3GA-agarose (Sigma) Type 300 containing 0.4 pmoles of 
dye per ml of gel
5: Cibracon Blue 3GA-agarose (Sigma) Type 1000 containing 1.1 pmoles of 
dye per ml of gel
6: Cibracon Blue 3GA-agarose (Sigma) Type 3000 containing 5.3 pmoles of 
dye per ml of gel
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FIGURE 4.18:
ION EXCHANGE CHROMATOGRAPHY OF RAT LIVER
HYPOTONIC EXTRACT ON PE-52
DE-52 resin was pepared as in Section 2.8.1 and equilibrated in TMB buffer 
(lOmM Tris-HCl pH 7.5,5mM MgCl2,2mM P-mercaptoethanol). A rat liver 
hypotonic extract in lOmM MgQ2 (202mls) containing 174 mg of protein was 
applied at 1.35ml/min to a DE-52 column (6 x 2.4) and washed in TMB Buffer 
(300mls) at lml/min. Activity was eluted using a 400ml linear NaCl gradient 
between 0 and 0.55M contained in TMB buffer and 4 ml fractions collected. 
Cyclic AMP phosphodiesterase activity was assessed at 0.1 fiM cAMP in the 
presence O  and absence ®  of IOjiM  cGMP.
The hypotonic extract contained 4820 pmol/min of cAMP PDE activity. The 
breakthrough fraction contained 71pmol/min and the wash fraction 131 
pmol/min.
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FIGURE 4.19:
ELUTION OF cAMP PHOSPHODIESTERASE ACTIVITY FROM 
AFFI-GEL BLUE.
Fractions from the DE-52 step (60mls, 9.2mg of protein) were dialysed at 4°c 
against 3 x 2  litre changes of TM Buffer (lOmM Tris-HCl pH 7.5) to remove 
sodium chloride. The dialysed sample was made up to 2mM p-mercaptoethanol 
and applied to a column of Affi-gel Blue (6.4 x 1.8cm) that had previously been 
equilibrated in TMB Buffer. The breakthrough fraction was collected and the 
column washed in TMB buffer (360mls). Elution of cyclic AMP 
phosphodiesterase activity was initiated using 200mls of TEM Buffer (lOmM 
Tris-HCl pH 7.5, ImM EDTA, 2mM (3-mercaptoethanol) at 0.2ml/min and 50 
x 4ml fractions were collected. Cyclic AMP phosphodiesterase activity was 
assessed at 0.1 jiM cAMP in the presence (Q) and absence (■ ) of IOjiM 
cGMP. Pooled fractions contained 200{ig of protein.
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FIGURE 4.20(a):
STABILITY OF cAMP PHOSPHODIESTERASE ACTIVITY OF 
THE 'DENSE-VESICLE1 PDE.
A partially purified preparation of the 'dense-vesicle' PDE (from the DE-52 
step) was incubated at 4°C in the presence ® ) and absence (ID of 2mM |3- 
mercaptoethanol for the times indicated before aliquots of enzyme were 
removed for assay of cAMP PDE activity.
FIGURE 5.20(b):
STABILITY OF THE CYCLIC GMP INHIBITED cAMP PDE 
A C I I Y I E i L O F  J B E  ,P .E N S E :y m C L E l P I > . E ,
A partially purified preparation of the 'dense-vesicle' PDE (from the DE-52 
step) was incubated at 4°C in the presence ® ) and absence (B) of 2mM (3- 
mercaptoethanol for the times indicated before aliquots of enzyme were 
removed for assay of cAMP PDE activity in the presence of 2}iM cGMP.
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FIGURE 4.21:
SEPARATION OF RAT LIVER HYPOTONIC EXTRACT
PHOSPHODIESTER ASES —USING M ONO ANION-
EXCHANGE CHROMATOGRAPHY.
The hypotonic extract from one rat liver (80mg of protein) was applied to a 
Mono Q column (HR 5/5) and PDE activity eluted using an identical 95 ml 
gradient to the one used for separation of soluble phosphodiesterases (see Table 
3.2). 1ml fractions were collected and 25{il aliquots were assayed for cAMP 
PDE activity (fl), cGMP PDE activity (O ) and cAMP PDE activity in the 
presence of 2|iM cGMP (Q). Results are expressed as pmol/min/ml.
The hypotonic extract contained 964pmol/min of cAMP PDE activity. The yield 
of cAMP PDE activity was 83% and for cGMP PDE activity was 81%.
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FIGURE 4.22:
CHROM ATOGRAPHY OF A RAT LIVER H Y PO TO N IC 
EX TR A C T ON MONO ION EXCHANGE USING AN 
EXTENDED GRADIENT
A hypotonic extract from one rat liver (120mg of protein) was applied to a 
Mono Q column and activity was eluted using a NaCl gradient contained in 
TMB Buffer (lOmM Tris-HCl, pH 7.4, 5mM MgCl2, 2mM (3- 
mercaptoethanol) (see Table 5.5). 1ml fractions were collected and 25|il 
aliquots assayed for cAMP phosphodiesterase activity assessed at 0.1 jiM cAMP 
in the presence Q )  and absence (D  of 10|iM cGMP. The figure shows the 
cAMP phosphodiesterase activity eluted over 0.3-0.5M NaCl. Results are 
expressed as pmol/min/ml.
The hypotonic extract contained 768 pmo/min of cAMP PDE activity.
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FIGURE 4.23:
REVERSIBILITY OF THE INHIBITION OF THE 'DENSE- 
VESICLE' PHOSPHODIESTERASE ELICITED BY VARIOUS 
INHIBITORS.
Partially purified 'dense-vesicle1 phosphodiesterase prepared using Mono Q 
chromatography was incubated either in TMB Buffer (lOmM Tris-HCl pH 7.4, 
5mM MgCl2,2mM P-mercaptoethanol) or lOOjiM of each of cGMP, IBMX, or 
ICI 118233 in TMB buffer. Samples were assayed for phosphodiesterase 
activity before (fH) or after dialysis in the presence (Q) and absence (23) of 
IOjiM cGMP. The data show a typical experiment performed three times. 
Results are shown as the mean ± SD.
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TABLE 4.1:
USE OF ANTISERA DV-I AND PM -I TO ASSESS THE 
DISTRIBU TIO N OF THE 'D EN SE-V ESICLE ' fDVl AND 
'PERIPH ERA L' PLASMA MEMBRANE (PM! CYCLIC AMP 
PHOSPHODIESTERASES IN RAT TISSUES.
Results are expressed as the average (± SEM) of three separate experiments. 
Tissue distribution (TD) ratio is calculated by dividing the [lg of of DV-PDE/mg 
of homogenate in one tissue by the pg of DV-PDE/mg of homogenate in liver.
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TABLE 4.2:
USE OF THE SELECTIVE PDE INHIBITOR IC I 118233 TO
ASSESS THE DISTRIBUTION OF THE ’DENSE-VESICLE* 
CYCLIC AMP PHOSPHODIESTERASE ACTIVITY IN RAT 
TISSU ES.
Results are expressed as the average (± SEM) of three separate experiments. 
Tissue distribution (TD) ratio is calculated by dividing the DV-PDE activity/mg 
of tissue by the DV-PDE activity/mg in liver.
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TABLE 4.3:
R E C O V E R Y ____ M m . ____ S T A B I L I T Y  O F  c A M P
PHOSPHODIESTERASE ACTIVITY DURING PURIFICATION 
BY THE GUANINE SEPHAROSE METHOD
(a) The % of cyclic AMP phosphodiesterase activity retrieved from individual 
columns was determined by assaying a sample of the extract before 
chromatography along with a sample of the pooled fraction from the particular 
steps indicated. Assays were performed at the same time.
(b) The % of cAMP phosphodiesterase activity remaining over approximately a 
24 hour period at 4°C was assessed at individual stages of the purification by 
assaying the pooled samples prior to a chromatographic step and then again 24 
hours later. Results are expressed as the % of activity remaining
COLUMN YIELDS ASSESSED OVER FIVE PREPARATIONS
1 2 3 4 5
STEP % ACTIVITY RETRIEVED
ECTEOLA 37% 29% 28% 38% 18%
co-APA 19% 16% 38% 20% 22%
Sephadex 100% 20% 66% 34% 67%
Guanine 68% 94% 87% 100% 100%
DECAY OF ACTIVITY AT 4°£_ FOR FIVE PREPARATIONS
1
PREPARATION 
2 3 4 5
STEP % ACTIVITY REMAINING
ECTEOLA 100% 100% 100% 100% 100%
co-APA 91% 100% 89% 100% 100%
Sephadex 30% 100% 30% 30% 100%
Guanine 70% 50% 60% 45% 30%
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TABLE 4.4:
PU R IFIC A TIO N  OF THE 'D EN SE-V ESICLE1 PH O SPH O ­
DIESTERASE BY THE GUANINE SEPHAROSE METHOD
All activities were determined at 0.1 pM cAMP as substrate in the absence (-) or 
presence of IOjiM cGMP (+).
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CHAPTER 4: DISUSSION
Cyclic nucleotide phosphodiesterases are known to exist in multiple 
forms in mammalian tissues (Wells and Hardman, 1977; Thompson and 
Strada, 1978; Beavo, et al., 1982; Beavo, 1988). It appears from
peptide mapping (Takemoto, et al., 1982) and immunological studies 
(Mumby, et al., 1982; Pyne, et al., 1987a; Harrison, et al., 1986b;
Sharma, et al., 1984) that distinct classes of phosphodiesterase exist. 
These include the Ca2+/C alm odulin- stimulated phosphodiesterases
(Beavo, 1988; Wang, et al., 1990), cyclic GMP -  stimulated 
phosphodiesterases (Beavo, 1988; Manganiello, et al., 1990b) and cyclic 
A M P-specific phosphodiesterases (Beavo, 1988; Beavo, 1990; Conti 
and Swinnen, 1990; Manganiello, et al., 1990a). The observations that 
the activities of specific isozymes are under different control 
mechanisms suggests that various forms have particular functional roles 
within the cell (Evans, et al., 1984; Tanner, et al., 1986; Hamet and
Tremblay, 1988; Pyne and Housaly, 1988; Beavo, 1988; Corbin, et al., 
1985; Heyworth, et al., 1983d; Heyworth, et al., 1984a). As such, one 
might expect that each tissue will exhibit a particular complement of 
phosphodiesterases isozymes. This is certainly true of phospho­
diesterases such as the light activated cyclic GMP phosphodiesterase,
which is only expressed in the retina (Baehr, et al., 1979; Gillespie and 
Beavo, 1989).
Further to this, it is now apparent from immunological, cloning 
and purification studies, that isozymes of phosphodiesterases exist 
within each of the major classes of phosphodiesterase. For example, it 
has been shown that there are distinct isozymes of the 
Ca2+/Calm odulin-stim ulated PDE (Sharma, et al., 1984; Kincaid, 
et al., 1984; Wang, et al., 1990), the retinal phosphodiesterases
(Gillespie, et al., 1989b; Gillespie, 1990), cyclic GMP -  stimulated
phosphodiesterases (Pyne, et al., 1986b; Manganiello, et al., 1990a), the
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cyclic AM P-specific phosphodiesterases (Weber and Appleman, 1982; 
Weishaar, et al., 1987a; Manganiello, et al., 1990b; Davis, 1990, Conti 
and Swinnen, 1990;, Degerman, et al., 1987;, Grant, et al., 1988; Davis, 
et al., 1989; Swinnen, et al., 1989; Collicelli, et al., 1989; H enkel-  
Tigges and Davis, 1990). For the case of the cyclic A M P-specific 
phosphodiesterases, it has been shown that the tissue distribution of 
mRNA species homologous to four independent cDNA clones (that 
have been presumed to encode cyclic AM P-specific phosphodiesterases) 
is different between brain, heart, kidney and testis (Swinnen, et al., 
1989).
In initial studies on the isozymes of phosphodiesterase, 
identification of multiplicity has relied upon the ability to resolve 
individual activities from one another (Beavo, et al., 1982; Appleman, 
et al., 1973; Thompson and Appleman, 1971; Thompson and Strada, 
1978). This necessarily involves the homogenisation of the tissue and in 
some cases can involve quite lengthy separation procedures. The 
conclusions based on such analyses are limited by the resolving power 
of the technique employed (such as D E -5 2  resin) as well as problems 
of differential extraction of various enzymes, solubilisation of membrane 
bound activities and susceptibility to degradation by proteolysis during 
extraction and purification procedures. It is well documented that 
species such as the Ca2+/C alm odulin- stimulated phosphodiesterase 
(Cheung, 1971; Tucker, et al., 1981; Kincaid, et al., 1985) and the 
cyclic GMP -  inhibited phosphodiesterase (Harrison, et al., 1986b; 
Grant and Colman, 1984, Grant, et al., 1988; Pyne, et al., 1987a; 
Loten, et al., 1978; Loten, et al., 1980) are susceptible to proteolysis. 
In order to address this problem it was decided to assess the expression 
of phosphodiesterase in tissues using immunoblotting of freshly 
prepared tissue homogenates. In this case, a technique was employed 
where tissues were disrupted rapidly in a medium containing protease 
inhibitors, and then boiled in SDS sample buffer and subjected to 
SDS/PAGE. with detection of specific isozymes by quantitative
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immunoblotting with specific anti -  sera. This approach also overcomes 
the problems of differential extraction.
This study focussed on two high -  affinity cyclic A M P-specific 
phosphodiesterases that have previously been purified from rat liver by 
this laboratory. In rat hepatocytes, these two activities, the 'dense -  
vesicle' and 'peripheral' phosphodiesterases are stimulated by insulin, 
whilst the former is also stimulated by glucagon (Heyworth, et al., 
1983d).
The 'peripheral' plasma membrane enzyme is a 5 2 -k D a  
monomeric species which can be detected with the polyclonal antibody 
PM1 (Pyne, et al., 1986b, Houslay, et al., 1988). The 'dense-vesicle ' 
enzyme possesses a native subunit of 63 -kD a, which can be detected 
specifically with antibody DV1 in cholate extracts of membranes (Pyne, 
et al., 1987a). This activity can be released from it’s membrane 
environment by proteolytic cleavage (Loten, et al., 1978; Loten, et al., 
1980; Pyne, et al., 1987a). This can be achieved either by an 
endogenous sulphydryl protease, relesed from lysosomes by hypotonic 
shock procedures (Loten, et al., 1978; Loten, et al., 1980; Pyne, et al., 
1987a) or by addition of exogenous protease such as chymotrypsin
(Boyes and Loten, 1988). Cleavage by endogenous proteases ('hypotonic 
shock') releases an activity of 5 7 -k D a  presumably by cleavage of an 
anchoring peptide. Purified preparations containing this 5 7 -k D a  
species also show evidence of a smaller form of the enzyme of
molecular weight 5 1 -k D a  (Pyne, et al., 1987a). Such preparations have 
been used to prepare the antisera DV1.
When the antisera DV1 was covalently coupled to Sepharose, it
was shown it could remove cyclic GMP -  inhibited phosphodiesterase 
activity from a hypotonic extract. Inhibition of cyclic AMP hydrolysis
is by pM concentrations of cyclic GMP is a characteristic property of 
this enzyme (Loten, et al., 1978; Weber and Appleman, 1982; Pyne, 
et al., 1987a; Degerman, et al., 1987; Grant and Colman, 1988). It 
could not remove all the cyclic AMP phosphodiesterase activity
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however. This could have indicated that the immunoaffinity matrix had 
a limited capacity for this activity. However, when the 
phosphodiesterases present in the hypotonic extract were examined by 
separation on a high resolution anion -  exchange matrix (Mono Q), it 
was apparent that there were other phosphodiesterases present in the 
extract. When assayed at 0.1 pM cyclic AMP and cyclic GMP it was 
shown that there were two cyclic AMP -  specific activities in the extract 
which formed most of the cyclic AMP phosphodiesterase activity and 
were present in approximately equal amounts. However, Loten, et al., 
(1978) showed by chromatography on the anion -  exchange resin 
ECTEOLA cellulose, that there was only one major peak of cyclic AMP 
phosphodiesterase activity present in the hypotonic extract prepared 
under identical conditions. From the work presented in Chapter 3 of 
this thesis, showing the limitations of such anion -  exchange resins over 
that of Mono Q separations, it is probable that the one peak of cyclic 
AMP phosphodiesterase activity that they observed on ECTEOLA 
cellulose probably represents coelution of these two activities. In 
support of this proposal, these workers observed that this activity 
possessed n o n -lin ear kinetics indicative of the presence of two 
activities (Loten, et al., 1978).
The two Mono Q resolved activities were shown to differ in 
their responsiveness to cyclic GMP, with one activity (the later eluting 
activity) being potently inhibited by cyclic GMP and the other showing 
insensitivity. The former activity was presumed to be the 'dense -  
vesicle' phospodiesterase on the basis of it’s inhibition by cyclic GMP, 
it’s sensitivity to the inhibitor ICI 118233 and from an analysis of it’s 
kinetic characteristics where it was shown that the for cyclic AMP 
hydrolysis for this Mono Q resolved activity was very similar to that of 
the purified protein (0.5 pM compared to 0.3 pM) (Pyne, et al., 1987a). 
The cyclic GMP -  insensitive activity was not characterised in detail.
These studies confirmed then, the ability of the a n ti-se ra  DV1 
to detect native 'dense-vesicle' phosphodiesterase. Attempts to elute 
bound 'dense-vesicle' enzyme, indicated that only under extreme
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conditions, that were likely to denature the an ti-se ra , could 
polypeptides corresponding to the presumed molecular weights of the 
proteolysed ’dense-vesicle' phosphodiesterase (57 -kD a and 5 1 -k D a) be 
observed. Further to this, these were the only two polypeptides that 
were attached to the a n ti-se ra  indicating that the interaction was both 
specific and of high affinity.
Analysis of total liver homogenates shows quite clearly that the 
antibodies PM1 and DV1 detected the native 5 2 -k D a  and 6 3 -k D a  
subunits of the 'peripheral’ and 'dense-vesicle’ phosphodiesterases 
respectively. Indeed, that single bands were obtained indicated that 
these antibodies did not cross-react with other species of 
phosphodiesterase that are found in the liver. The single band at 6 3 -  
kDa detected by immunoblotting analysis of a liver homogenate 
corresponds to the 63 -  kDa species that could be immunoprecipitated 
with DV1 from cholate* extracts of liver membranes (Pyne, et al., 
1987a). There was no evidence of the high molecular weight species 
that was observed upon immunoprecipitation from detergent treated 
membranes either upon Western blotting or from an analysis of the 
polypeptides retained upon the immunoaffinity matrix D V 1-Sepharose. 
This high molecular weight species appears to be an aggregated species 
of the 'dense-vesicle' enzyme as indicated by tryptic peptide mapping 
analysis (Pyne, et al., 1987a) that may arise as an artefact of either the 
cholate treatment or immuoprecipitation protocol.
These two phosphodiesterases were not found exclusively in liver 
however. Analysis of homogenates of heart, white (epididymal) fat and 
kidney showed that both of these enzymes were expressed in all these 
tissues. Using standard curves to estimate the jigs of these two enzymes 
in tissue homogenates, it was possible to calculate the level of expressed 
protein per mg of homogenate protein. When this was done it was 
apparent that the levels of these two enzymes varied between the 
tissues examined. In order to assess that this relative distribution of 
these activities corresponded with activity it was necessary to determine
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the contribution of these two activities to the total phosphodiesterase 
activity in tissue homogenates.
In the case of the 'dense-vesicle' phosphodiesterase, the 
inhibitor ICI 118233 was found to be a selective and potent inhibitor of 
this activity. Data presented in Chapter 3 show that this inhibitor did 
not inhibit any of the five peaks of phosphodiesterase activity prepared 
from the soluble fraction of hepatocytes. In this section of work, ICI 
118233 was shown to be a reversible and competitive inhibitor of 
partially purified preparations of the cyclic GMP -  inhibited 
phosphodiesterase prepared by Mono Q chromatography ('dense-vesicle ' 
phosphodiesterase). Given the selectivity of this inhibitor for the 
'dense-vesicle' phosphodiesterase, the amount of inhibition of cyclic 
AMP phosphodiesterase activity elicited by ICI 118233 in tissue 
homogenates might be presumed to reflect the activity of this enzyme. 
This approach makes the assumption that the compound acted similarly 
in other tissues, both in terms of it’s specificity and in it’s ability to 
inhibit the 'dense-vesicle' enzyme homologues. This analysis revealed a 
very similar distribution of the 'dense-vesicle' phosphodiesterase in 
these tissues to that found using the specific antisera DV1.
Using these values of total protein/mg of homogenate and total 
activity/mg of homogenate it was possible to calculate a specific activity 
for the 'dense-vesicle' phosphodiesterase in the different tissues. In 
liver this value was estimated to be 5333 pmol/min/mg at 0.1 pM cyclic 
AMP. The specific activity of the purified pro tease 'clipped' form of 
the enzyme has been estimated to be 17,553 pmol/min/mg (Pyne, e t al., 
1987a). In kidney, the estimated specific activity of the enzyme was 
estimated to be 7857 pmol/min/mg, whilst in heart it was 
3,446 pmol/min/mg. All of these values were somewhat lower than the 
estimated values for the purified 'dense-vesicle ' phosphodiesterase from 
rat liver determined by Pyne et al., (1987a). The reasons for these 
differences is not apparent. It is possible that they reflect the fact 
that in measurements of total homogenate activity, the activity 
determined in the presence of ICI 118233 is that of the holoenzyme
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attached by it’s membrane anchor to it’s native membrane. Upon 
proteolytic release this anchor is removed and this may result in a
change in the catalytic activity of the solubilised (purified) species. 
This situation is somewhat analagous to the situation in the bovine 
brain form of the Ca2+/Calm odulin-stim ulated phosphodiesterase 
where limited proteolysis has been proposed to remove an inhibitory 
domain of the enzyme that either is or is closely associated with the 
Calmodulin binding domain (Kincaid, et al., 1985) resulting in an 
activity that is both activated and insensitive to Ca2+/Calmodulin 
(Tucker, et al., 1981; Kincaid, et al., 1985).
If such a domain exists in the ’dense-vesicle* phosphodiesterase, 
this data suggests that it would act to maintain the activity in a lower 
catalytic form when attached to the membrane and that protease action 
either removes or partially destroys it. In suppport of this proposal, 
Loten et al., (1980) have shown that solubilisation of the activity from 
liver membranes caused a modest activation of the activity and indeed
have also suggested the presence of an inhibitory fragment of the 
enzyme when attached to the membrane. The range of estimated 
specific activities observed in the tissues might also suggest that these
enzymes, although immunologically related, might possess intrinsically 
different specific activities suggesting the presence of tissue specific 
isozymes of the 'dense-vesicle' phosphodiesterase. Alternatively, some 
of the enzyme in the tissues may be sequestered in some way so that 
they would not be detected in a functional assay, but would be upon 
Western blotting. This would also explain the lower specific activities 
that are encountered in these analyses.
The 'dense vesicle' enzyme thus appears to account for a major 
fraction of the total cyclic AMP phosphodiesterase activity in heart and 
adipose tissue. Part of insulin’s major anti -  lipolytic action on white
adipose tissue is believed to be exerted through an effect on cyclic 
AMP metabolism (Loten and Sneyd, 1970; Fain, 1980; Londos, et al., 
1985; Wong and Loten, 1980; Lonroth and Smith, 1986; Kather and 
Scheurer, 1987; Wong and Loten, 1981; Belfrage, et al., 1984). At
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least part of this effect on cyclic AMP metabolism is believed to be
due to the activation, by insulin, of cyclic AMP phosphodiesterase
activity (Lonroth and Smith, 1986; Kather and Scheurer, 1987; 
Manganiello and Vaughan, 1973; Zinman and Hollenberg, 1974).
Therefore the ’dense-vesicle' phosphodiesterase may provide _ a  
physiological target for insulin’s action in this tissue. The observation 
that this activity provides a very substantial proportion of the total 
cyclic AMP phosphodiesterase activity in fat tissue may account for 
reports by various investigators that insulin elicits a very marked 
stimulation of cyclic AMP phosphodiesterase in this tissue
Rat adipose tissue has been shown to possess an activity that 
resembles the rat liver ’dense-vesicle’ phosphodiesterase. Like the rat 
liver enzyme this activity is activated by insulin (Kono, et al., 1975), has 
a high affinity for cyclic AMP, is associated with the P2 fraction 
(Manganiello and Vaughan, 1973; Sakai, et al., 1974; Zinman and
Hollenberg, 1974). Cyclic AMP hydrolysis can also be inhibited by 
cyclic GMP (Weber and Appleman).
This activity has been purified from rat adipose tissue by a 
number of workers (Saltiel and Steigerwelt, 1986c; Degerman, et al., 
1987). The most convincing purification of this activity was obtained 
by Degerman, et al., (1987). The enzyme isolated by these workers was 
shown to be sensitive to inhibition by cyclic GMP, Cilostamide and
Cilostamide derivatives and possesses high affinities for both cyclic AMP
and cyclic GMP but shows selectivity for cyclic AMP as substrate. In
agreement with this study, the subunit molecular weight of the enzyme 
was 64 -kD a. One point of difference that occured between this 
purified preparation and that of the rat liver 'dense-vesicle ' PDE lies 
in the kinetics of hydrolysis of cyclic nucleotides. Whilst the rat liver 
'dense-vesicle' phosphodiesterase exhibited anomalous kinetics, the rat 
adipocyte cyclic GMP -  inhibited phosphodiesterase demonstrated linear 
kinetics and also exhibited a much larger specific activity (Pyne, et al., 
1987a; Degerman, et al., 1987). Whether this difference reflects the 
occurence of tissue specific isozymes of this activity is uncertain but
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the data presented here would suggest that this is not the case. 
Alternatively, the difference in properties may reflect the fact that 
purified adipocyte phosphodiesterase is probably the holoenzyme, whilst 
the rat liver purified enzyme is a proteolytically 'clipped' version of the 
holoenzyme. This is a consequence of the fact that the adipocyte 
phosphodiesterase is not released from it’s membrane environment by a 
hypotonic shock (Loten, et al. , 1980) method as was the liver enzyme 
(Loten, et al., 1978; Loten, et al., 1980; Pyne, et al., 1987a).
It has been shown by numerous workers that heart tissue 
contains a cyclic GMP -  inhibited phosphodiesterase. For example this 
activity has been identified in human (Reeves, et al.„ 1987), bovine 
(Donnely, 1978; Harrison, et al., 1986a; Harrison, et al., 1986b), canine 
(Weishaar, et al., 1987a; Weishaar, et al., 1987b; Weishaar, et al., 
1987c), guinea pig (Weishaar, et al., 1987a; Weishaar, et al., 1987b; 
Weishaar, et al., 1987c) and rat (Weishaar, et al., 1987b) hearts.
This study suggests that the rat heart cyclic GMP -  inhibited
phosphodiesterase is related to the rat liver 'dense-vesicle ' 
phosphodiesterase both immunologically and in terms of it’s sensitivity 
to ICI 118233 and it’s molecular weight. It appears to contribute a 
large proportion of the cyclic AMP phosphodiesterase activity in the rat 
heart. This has also been shown to be true of this activity in the 
hearts of other species (Weishaar, et al., 1987a; Weishaar, et al., 1987b; 
Weishaar, et al., 1987c). These activities are different however in terms 
of their subcellular distribution. Whilst the bovine and canine activities 
are membrane bound, the activities in rat and guinea pig hearts are 
both soluble (Weishaar, et al., 1987b). This might imply that there are 
isozymes of this activity which differ in terms of their subcellular 
location. The molecular weight of the cyclic G M P-inh ib ited  
phosphodiesterase in rat heart appears to be identical to that observed 
in other tissues, namely about 63 -kD a. In contrast the molecular 
weight of the bovine cardiac cyclic GMP -  inhibited phosphodiesterase 
has been shown to be 110-k D a  by immunoblotting with monoclonal
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antibodies raised to highly purified (but proteolysed) preparations of
the enzyme (Harrison, et al., 1986b).
Similarly, the subunit molecular weight of the human platelet
enzyme has been shown to be 110-k D a  by two groups (MacPhee, 
et al., 1986; Grant, et al., 1988). It is of interest to note that the
human platelet 110-k D a  subunit containing enzyme is also soluble as 
the guinea pig and rat cardiac activities are (MacPhee, et al., 1986; 
Grant and Colman, 1984; Weishaar, et al., 1987a; Weishaar, et al., 
1987b; Weishaar, et al., 1987c). It seems unlikely then that a soluble 
location is correlated with the smaller subunit molecular weight. The 
observations that the molecular weight of this activity in rat tissues 
appears to be uniform between all tissues examined (63-kD a) whilst 
the bovine and human tissues demonstrate an activity that has a much 
larger molecular weight (110-k D a ) does however suggest that species-  
specific isozymes of this activity exist.
The observation that about 12% of the total cyclic AMP 
hydrolysis in the homogenates of kidney appears to be due to the 
’dense-vesicle' like activity agrees with the observation that about 90% 
of the total cyclic AMP phosphodiesterase activity in kidney 
homogenates is soluble (Hoey and Houslay, 1990). In this tissue the 
cyclic GMP -  inhibited phosphodiesterase is membrane bound (Hoey and 
Houslay, 1990) and this study would suggest that it forms nearly all of 
the membrane bound cyclic AMP phosphodiesterase activity in kidney 
homogenates.
The 'peripheral' plasma membrane phosphodiesterase can be 
distinguished from the 'dense -  vesicle' phosphodiesterase by a number 
of crteria including it’s insensitivity to cyclic GMP as an inhibitor of 
cyclic AMP hydrolysis (Pyne, et al., 1986b; Pyne, et al., 1987a). Such 
cyclic GMP -  insensitive phosphodiesterases have also been observed in a 
number of tissues in addition to liver and hepatocytes namely heart 
(Weishaar, et al., 1986; Weishaar, et al., 1987a; Weishaar, et al., 
1987b), kidney (Thompson, et al., 1979; Thompson, et al., 1988) and
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adipose tissue (Weber and Appleman, 1982). For example, heart tissues
from a number of species have been shown to possess such an activity.
It has, however, been suggested that, unlike the cyclic cardiac G M P -
inhibited 'dense-vesicle' like phosphodiesterase, these are not observed 
in all species. Guinea pig cardiac tissue for example has been suggested 
not to contain a cyclic GMP -  insensitive phosphodiesterase (Weishaar, 
et al., 1986; Weishaar, et al., 1987b). In these studies the cyclic 
GMP -  inhibited phosphodiesterase was the major cyclic AM P-specific 
activity observed after chromatography of the soluble fraction on D E -
52. This view has been questioned, however, since work from Reeves, 
et al., (1987) has shown that using the higher resolving power of
DEAE -  Sepharose, it is possible to identify an activity that has
properties which are similar to the cyclic GMP -  insensitive subclass of 
phosphodiesterase in soluble extracts of guinea pig cardiac tissue. 
Interestingly, this activity appeared to have a molecular weight of
approximately 45,000 upon gel filtration which is very similar to the 
52-k D a  subunit molecular weight of the rat liver 'peripheral' 
phosphodiesterase (Marchmont, et al., 1981b; Pyne, et al., 1986b; 
Houslay, 1988) which is also cyclic GMP -  insensitive. Similarly, the rat 
heart has been found to possess a soluble cyclic GMP -  insensitive 
phosphodiesterase (Weishaar, et al., 1987b). Whilst the relationship 
between this activity and the 52-k D a  species identified upon Western 
blotting of rat heart homogenates is not clear, it is tempting to 
speculate that these activities are the same.
A soluble cyclic A M P-specific phosphodiesterase has been
purified from canine kidney by Thompson and co-w orkers which has 
properties that are similar to the rat liver 'peripheral1 plasma membrane 
phosphodiesterase (Thompson, et al., 1979; Thompson, et al., 1988). 
However this activity has a subunit molecular weight of 82-k D a  on 
SD S-PA G E (Thompson, et al., 1988), which is clearly different to that 
of the 52-k D a  suggested for this activity in rat kidney. Whether this 
is due to the existence of species -  specific isozymes of this activity is 
uncertain. It should be noted, however, that there appear to be
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multiple forms of this activity in rat kidney. Hoey and Houslay (1990) 
have identified two soluble cyclic AM P-specific phosphodiesterase 
activities in rat kidney that are insensitive to inhibition by cyclic GMP. 
Either one or both of these activities may be related to the rat liver 
'peripheral' phosphodiesterase and equally as well to the canine 82 -  kDa 
subunit containing form.
A number of distint cDNA clones have been isolated from brain 
and testis cDNA libraries (Davis, et al., 1989; Swinnen, et al., 1989; 
Colicelli, et al., 1989) that have been shown in some instances to
encode cyclic -  AMP specific phosphodiesterases that are insensitive to 
inhibition by cyclic GMP (Henkel -  Tigges and Davis, 1990). The 
predicted molecular weights of these activities range from 60-k D a  to 
68 -  kDa (Davis, et al., 1989; Swinnen, et al., 1989; Colicelli, et al.,
1989). As yet no clone has been isolated capable of encoding a 52 -  
kDa protein. This study implies then that the number of cyclic A M P - 
specific phosphodiesterases of this type may include even further 
members than have been identified by cloning analyses.
The difficulties that I observed in reproducing the previously
published procedures for the purification of the rat liver 'dense-vesicle1 
phosphodiesterase (Pyne, et al., 1987a) are difficult to explain. Whilst I 
could clearly identify this activity in hypotonic extracts by Mono Q 
chromatography and it was possible to follow it’s purification by at
least one of the methods (the Guanine -  Sepharose method), the yields 
from this procedure were very low. This could in part be explained by 
the instability of the 'dense -  vesicle' phosphodiesterase particularly at 
the later stages of the preparation. This variation in properties from 
the published procedure may be related to the proteolytic release of 
the activity from it’s membrane location. The rat liver 'dense-vesicle '
phosphodiesterase can be solubilised either by the endogenous proteases 
(Loten, et al., 1978; Loten, et al., 1980; Pyne, et al., 1987a) or by the
exogenously added proteases such as trypsin, chymotrypsin and papain 
(Loten, et al., 1980). It was observed by Loten, et al., (1980), that the 
particulate activity was much less labile than the 'hypotonically' -
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released activity, whilst the chymotrypsin -  released activity was even 
more labile still. The trypsin -  released activity was intermediate in 
labililty between these latter two species. These results suggest that the 
stability of the enzyme depends on the precise proteases used to cleave 
the membrane bound activity. The hypotonic shock method will 
release a number of proteases and it may be that more than one 
protease can act on the enzyme to produce a slightly different clipped 
activity with increased lability. This may also alter the chromatographic 
properties so that the activity does not bind to A ffi-ge l Blue. Altered 
chromatographic properties on Affi -  gel Blue have been reported for 
the bovine brain Ca2+/Calmodulin -stim ulated phosphodiesterase 
(Tucker, et al., 1981) although in this instance proteolysed and n o n -  
proteolysed phosphodiesterase could bind to this matrix. Indeed A ffi-  
gel Blue is presumed to bind to the nucleotide binding site of this 
enzyme since it can act as a competitive inhibitor of cyclic nucleotide 
hydrolysis (Morril, et al., 1979) so proteolysis would not be expected to 
directly affect the ability of this enzyme to bind to this matrix. Whilst 
the mechanism by which the 'dense-vesicle* phosphodiesterase binds to 
A ffi-gel Blue is not known it may be that it does not bind through 
the catalytic site so that proteolysis may remove or partially destroy the 
A ffi-gel Blue binding site.
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CHAPTER 5: FINAL DISCUSSION.
This work presented in this thesis has involved the identification and 
characterisation of the soluble phosphodiesterase species contained in 
the soluble fractions derived from both rat liver and hepatocytes as well 
as an assessment of the tissue distribution of activities immunologically 
related to the insulin -  sensitive 'peripheral' and 'dense-vesicle '
phosphodiesterases. It is becoming apparent that the multiplicity of 
phosphodiesterases previously observed in several tissues is even more
complex than originally envisaged. This multiplicity is observed both
within a single tissue and between different species. From both
purification and cloning analyses the number of distinct forms of 
phosphodiesterase that have been identified has increased from the 
original three types that were observed by workers such as Russell 
et al., (1973) and Thompson and Appleman (1971). What is also 
becoming apparent is that different cell/tissue types exhibit different 
multiplicity of forms from each other. The work presented here
demonstrates the existence of at least five soluble phosphodiesterases in 
the soluble fractions of rat liver and hepatocytes. These were identified 
by the use of high resolution anion -  exchange chromatography. This 
system, in addition to providing a much greater resolution of forms, is 
also more rapid than conventional chromatography on matrices such as 
D E -5 2  or DEAE -  Sepharose, which have been used by numerous 
workers in this type of study (Russel, et al., 1973; Thompson and 
Appleman, 1971; Reeves, et al., 1987; Turnbull and Hickie, 1984; 
Weishaar, et al., 1987b; Hidaka and Asano, 1976; Grady and Thomas, 
1986; Lugnier, et al., 1986; Emeux, et al., 1980).
The five soluble activities that have been described are,
PDE M Q -I , a cyclic AMP and cyclic GMP hydrolysing activity,
PDE M Q -II, a cyclic G M P-specific activity that contains at least the
Ca2+/calm odulin-stim ulated phosphodiesterase, PDE M Q -III  a cyclic
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GMP and cyclic AMP hydrolysing activity that is the soluble cyclic 
GMP -  stimulated phosphodiesterase and PDE M Q -IV  and PDE M Q - 
V which are both specific for cyclic AMP as substrate. One of the
aims of phosphodiesterase research is to identify and characterise the 
individual isozymes contained in a particular cell or tissue and this is a 
necessary prelude to the eventual purification of all of the individual 
species.
A largely unanswered question concerning this occurence of 
multiple forms of cyclic nucleotide phosphodiesterase in single cell
types such as hepatocytes is, what role do the individual isozyme forms 
play in controlling the levels of cyclic AMP and cyclic GMP in 
unstimulated and stimulated cells ? Furthermore, if all of the
phosphodiesterase activities do hydrolyse cyclic AMP and cyclic GMP in 
vivo why is such a diversity of species needed ?
It is well documented that the individual phosphodiesterae
isozymes are compartmentalised in the cell. For example, in 
hepatocytes, phosphodiesterase activity is observed in both the
particulate and soluble fractions (Heyworth, et al., 1983d).
Furthermore, within the particulate fraction, activity is observed in 
subcellular fractions containing the plasma membrane (Marchmont,
et al., 1980a; Marchmont, et al., 1980b), the endoplasmic reticulum
(Cercek and Houslay, 1983a; Wilson and Houslay, 1983), the
mitochondria (Cercek and Houslay, 1983b), and another unidentified 
location that has been called the 'dense-vesicle ' (Heyworth, et al.,
1983d). No activity is observed in the nucleus, lysosomes or
peroxisomes however (Heyworth, et al., 1983d). The soluble fraction of 
cells is usually considered to be a single compartment, within which
molecules are freely diffusable. However, it is quite conceivable that
some or all of the soluble phosphodiesterases identified here may not 
be free to move but may be associated, albeit very weakly, with
s
membrane bound organelles so that they are in effect constrained.
This compartmentalisation of phosphodiesterase activity within the cell 
raises the possibility that cyclic AMP/cyclic GMP may also be
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compartmentalised within the cell as well. If this is the case this would 
suggest that a number of different activities are required to control 
these functionally discrete pools of cyclic nucleotide.
There is some evidence to suggest that discrete functionally 
distinct pools of cyclic AMP do exist in cells. Studies on the ability of 
the inotropic agent imazodan to produce an inotropic response in rat, 
guinea pig and canine hearts have indicated that subclasses o f 
phosphodiesterase exist and that these may be 'coupled' to functionally 
distinct pools of cyclic AMP. In species such as the dog, where the 
imazodan -  sensitive cyclic AM P-specific PDE (cyclic GMP -  inhibited 
PDE) is membrane bound (Weishaar, et al., 1987a; Weishaar, et al., 
1987d), then agents that inhibit this activity such as imazodan (C I -  
914), C l-930  and amrinone exert positively inotropic effects, whilst 
agents such as R o - 20-1724 and rolipram which are weak inhibitors of 
this activity but potent inhibitors of the soluble imazodan -  insensitive
(cyclic GMP -  insensitive) cyclic AMP -  specific PDE, do not. In rat 
and guinea pig hearts, where the imazodan -  sensitive PDE is soluble
rather than membrane bound (Weishaar, et al., 1987a; Weishaar, e t al., 
1987d), then these agents were found to exert either a small or no 
positive inotropic effect (Weishaar, et al., 1987b; Weishaar, et al., 
1987d)). This localisation of the imazodan -  sensitive phosphodiesterase 
in cellular compartments other than the sarcoplasmic reticulum
(Kaufman, et al., 1986) has been suggested (Weishaar, et al., 1987b) to 
have the effect of partially 'uncoupling' the enzyme in terms of it’s 
ability to regulate contractility. Such 'uncoupling' would mean that the 
increases in cyclic AMP that result from inhibition of the cyclic G M P - 
inhibited phosphodiesterase would produce lesser increases in 
contractility than would otherwise occur since such increases would not
be in the most appropriate compartments within the cardiac cell. 
Implicit in this model is the hypothesis that cyclic AMP is somehow 
compartmentalised in the cell and that a distinct pool is intimately 
involved in regulating contraction.
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Similarly, studies on 3T 3-L 1  adipocytes have suggested the 
presence of at least two functionally distinct pools of cyclic AMP.
Elks and Manganiello (1984a) showed that the cilostamide -  sensitive 
subclass of cyclic AMP specific phosphodiesterase (cyclic G M P -
inhibited PDE) may be more important in regulating lipolysis in 3T3 — 
LI adipocytes than the Ro -2 0  -1724 -  sensitive form (cyclic G M P - 
insensitive). These workers have also reported that both the n o n -  
selective phosphodiesterase inhibitor IBMX and R o - 20-1724 (selective 
for the cyclic GMP -  insensitive subclass of cyclic AMP -  specific
phosphodiesterase) enhance cellular differentiation, whereas cilostamide
(selective for the cyclic GMP -  inhibited subclass of cyclic A M P - 
specific phosphodiesterase) had no effect on differentiation (Elks and 
Manganiello, 1985). These results once again imply that distinct pools 
of cyclic AMP exist within the cell that are regulated by distinct
phosphodiesterase isozymes and that they are involved in mediating
discrete effects on cellular processes.
Whilst there is not the same evidence that compartmentalisation 
of cyclic nucleotides may occur in hepatocytes there is some evidence 
to suggest that there are two types of hormone -  responsive adenylate 
cyclase in the rat liver (Yamatani, et al., 1987). These workers showed 
that one of these, the less abundant form, is linked to glycogenolysis
and the other is not. Glucagon stimulates mainly the glycogenolysis -
linked fraction, whilst secretin stimulates the other adenylate cyclase 
that is not linked to glycogenolysis. On this basis these workers have 
suggested that there is a functional compartmentalisation of cyclic AMP 
either within the hepatoctye or among distinct hepatocytes.
Whilst compartmentalisation of cyclic nucleotides and cyclic 
nucleotide -  mediated processes may be considered to be one possible 
role of the multiple forms of phosphodiesterase it is also possible to 
hypothesise, in addition, that such multiplicity of phosphodiesterases 
allows the cell to control cyclic nucleotide levels in response to a 
number of factors. A number of different phosphodiesterases that are 
individually regulated by different mechanisms would suit this purpose
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very well. This study has suggested that, in both hepatocytes and liver, 
cyclic AMP disposal can be rapidly increased by the presence of low
(pM) concentrations of cyclic GMP. The abundance of the cyclic
GMP -  stimulated phosphodiesterase in both the soluble and particulate 
fractions provides a means whereby cyclic AMP metabolism can be 
controlled by the levels of cyclic GMP. In addition, raised cyclic GMP 
will inhibit the activity of the membrane bound 'dense-vesicle* 
phosphodiesterase allowing for an increase in the cyclic AMP levels 
surrounding the membrane location of this activity. This picture is 
further enhanced by the observation that the cyclic GMP specificity of
the soluble Ca2+/calm odulin-stim ulated phosphodiesterase allows for a 
potential control of cyclic GMP levels themselves by an alteration in 
Ca2+ levels. Thus the presence of the Ca2+/calm odulin-stim ulated
phosphodiesterase and the cyclic GMP stimulated phosphodiesterase 
may allow for a direct control of cyclic AMP metabolism by cyclic 
GMP (through the cyclic GMP -  stimulated phosphodiesterase) and an 
indirect modifying control by levels of intracellular Ca2+ (through the 
Ca2+/calm odulin-stim ulated phosphodiesterase).
Further factors that control cellular phosphodiesterase activity 
have been identified both in hepatocytes and other cell types. For
example, it is well documented that the 'dense-vesicle '
phosphodiesterase and activities that are related to it (cyclic GMP -
inhibited phosphodiesterases) can be controlled by hormones such as 
insulin, glucagon, isoproterenol and PG EX (Loten, et al., 1978; 
Heyworth, et al., 1983d; MacPhee, et al., 1988; Makino and Kono, 
et al., 1980; Alvarez, et al., 1981). The latter hormones have been 
suggested to activate this enzyme by means of a cyclic A M P -
dependent phosphorylation (MacPhee, et al., 1988; Reifsnyder, et al., 
1987; Kilgour, et al., 1989; Gettys, et al., 1988). In hepatocytes this 
has been suggested to be a means by which raised cyclic AMP levels 
can negatively feed-forw ard to promote a return to basal levels of 
cyclic AMP (Corbin, et al., 1985). The observation that this activity is 
also expressed in tissues such as heart, fat and kidney may also imply
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that one such role of this enzyme is to provide these tissues with this 
control mechanism. Other phosphodiesterases have also been shown to 
be under the control of hormones, in particular in hepatocytes, the 
insulin -  stimulated ’peripheral' plasma membrane phosphodiesterase. 
This enzyme, although unable to decrease cyclic AMP levels in intact 
hepatocytes following glucagon challenge, can do so if hepatocytes are 
first challenged with PIA (an adenosine analogue). This effect of PIA 
seems to involve a reversal of the glucagon -  induced block on insulin’s 
ability to activate this enzyme (Heyworth, et al., 1984a). All these 
observations suggest that depending on the 'hormonal status' of the 
hepatoctye, different phosphodiesterases can be activated by insulin to 
promote decreases in the intracellular levels of cyclic AMP in the 
activated hepatocyte.
Other classes of phosphodiesterases may also be regulated, for 
example, the activity of the Ca2+/calm odulin-stim ulated 
phosphodiesterase can be regulated by phosphorylation, as has been 
shown for the isozymes in brain. It has been demonstrated, in vitro, 
that the 60-k D a  isozyme is a substrate for the cyclic AMP -  dependent 
protein kinase (Sharma and Wang, 1985; Sharma and Wang, 1986c), 
whilst the 6 3 -k D a  isozyme is a substrate for the auto-phosphoiylated 
form of Ca2+/calm odulin-dependent protein kinase II (Sharma and 
Wang, 1986a; Sharma and Wang, 1986c; Hashimoto, et al., 1989). 
Both of these events lead to a decrease in the affinity of the enzyme 
towards calmodulin and have been suggested to occur in vivo. It is not 
known if the isozyme of the Ca2+/calm odulin-stim ulated 
phosphodiesterase in hepatocytes undergoes a similar phosphorylation 
however.
All these different mechanisms of regulating phosphodiesterase 
activity provide a potential explanation for the occurence of multiple 
forms of phosphodiesterase within a single cell type. In order to be 
able to examine the mechanisms by which regulation of distinct species 
is achieved it is necessary to identify, purify, characterise and determine
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the amino acid sequence of, each of the individual species present in a 
single cell type.
This work described in this thesis has provided the first detailed 
identification and characterisation of the soluble phosphodiesterases 
present in hepatocytes. The PDE M Q -I  species appears to be an 
unusual activity that is very similar to an activity that has been purified 
from pig liver by Helfman and his collea^ges (Helfman, et al., 1981). (V 
In order to be able to assess this for certain it is necessary to purify 
this activity from rat liver. It should be possible to do this, based on 
the properties determined in this study, namely by chromatography on 
D E -52 , the use of A ffi-ge l Blue as a negative step .to remove other 
nucleotide binding proteins, gel filtration and Mono Q chromatography.
If an affinity step is required it should be possible to use 8 -  
H 2N(CH2)2N H -cyclic AMP Sepharose since the pig liver enzyme has 
been shown to bind to this matrix (Helfman, et al., 1981). Other 
potential affinity steps such as other dye ligand columns and cyclic 
AMP derivatives may also be tried and, given the ability to rapidly 
isolate this activity from other phosphodiesterase, matrices can be 
readily screened for their ability to bind this activity. It would be 
hoped that a specific a n ti-se ra  could then be prepared in order to 
allow an immunological comparison of this activity both with the pig 
liver enzyme and with the other soluble and particulate
phosphodiesterases in hepatocytes. A purified preparation of this
enzyme could then be used to obtain partial amino acid sequence it 
should be possible to obtain partial amino acid sequence so that 
cloning of the enzyme from an hepatocyte cDNA library could be 
achieved. If one assumes that the specific activity of the purified 
PDE M Q -I  phosphodiesterase is similar to the pig liver enzyme
(6,565 pmol/min/mg), one can estimate using the figures of the total 
activity of PDE M Q -I  in one rat liver (at 1 jiM  this was
1570 pmol/min) that one rat liver should contain approximately 240 pg 
of this enzyme. This would be more than sufficient to carry out the 
suggested studies.
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An alternative method for the production of antibodies that 
would be applicable to all of the hepatocyte -  derived PDE MQ species 
would be the production of monoclonal antibodies against the 
individual activities. This could be achieved either by using the Mono 
Q fractions as they were or further purifying them further by various 
affinity steps. In the case of the Ca2+/calm odulin- stimulated 
phosphodiesterase this could be achieved by chromatography on 
calmodulin -  Sepharose which has been used by other workers to purify 
the enzyme from brain or heart (Ho, et al., 1977; Sharma, et al., 1980) 
or calmodulin derivatives such as 3 -  (2 -  pyridylithio) propionyl -  
substituted calmodulin linked to thiol -  Sepharose (Kincaid, et al., 1984). 
The cyclic GMP -  stimulated phosphodiesterase could be similarly 
chromatographed on a column of cyclic GMP -  Sepharose as has been 
shown for both the soluble and particulate forms of this enzyme from 
rat liver (Pyne, et al., 1986a). Whilst little is known about the 
chromatographic properties of the two soluble cyclic A M P-specific 
activities, if these activities are related to the membrane -b o u n d  
'peripheral' phosphodiesterase, then an affinity step such as A ffi-g e l 
Blue or Theophylline -  Sepharose could be used. These two steps have 
been used with some success for the purification of this activity either 
from rat liver plasma membranes (Marchmont, et al., 1981b) or a total 
particulate fraction derived from rat liver (Pyne, et al., 1986b).
Since it is unlikely that these activities would be pure after such 
steps it would not be possible to screen for monoclonal antibodies 
using purified protein. One possible method of screening would be to 
assess the ability of antisera to affect the phosphodiesterase activity of 
the various species. This could result in antisera that were inhibitory, 
activatory or affected the ability of Ca2+/calmodulin or cyclic GMP to 
stimulate their target enzymes. Alternatively, the ability of antisera to 
precipitate phosphodiesterase activity from the PDE MQ fractions could 
also be used as a potential screening method.
Recent purification and cloning analyses have indicated that 
there are multiple isozymes of each of the individual phosphodiesterase
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classes. For example, it has been demonstrated that the 
Ca2+/calm odulin- stimulated phosphodiesterase in bovine brain can 
exist as either a dimer of 61 -k D a  subunits or 6 3 -k D a  subunits 
(Sharma, et al., 1984; Sharma, et al., 1986c; Wang and Sharma, 1990) 
and that the bovine heart 59 -  kDa isozyme is a distinct species from 
these two activities (LaPorte, et al., 1979). Similarly, cloning analyses 
have indicated the existence of a number of similar, but distinct, 
clones encoding high affinity cyclic AM P-specific phosphodiesterases in 
both rat brain and rat testis (Davis, et al., 1989; Swinnen, et al., 1989; 
Colicelli, et al., 1989; H enkel-Tigges and Davis, et al., 1990; Davis, 
1990; Conti and Swinnen, 1990).
This study has suggested that there are also multiple isozyme 
forms of the soluble phosphodiesterases in rat hepatocytes. In 
particular, the existence of two soluble high affinity cyclic AMP — 
specific phosphodiesterases, a Ca2+/calm odulin-stim ulated activity that 
is highly selective for cyclic GMP and a form of the cyclic GMP — 
stimulated phosphodiesterase which appears to have a different substrate 
selectivity than the soluble rat liver derived form, have all been noted. 
It is important that the relationship between these identified activities 
and cloned phosphodiesterases be established in order for comparisons 
to be drawn between them. This can be achieved initially by 
comparing their immunoreactivities but ultimately will involve cloning 
of each of the individual species.
The production of specific anti -  sera to these activities should 
also answer some unresolved issues concerning the precise molecular 
weight of rat liver derived activities compared to the bovine activities. 
For example, the cyclic GMP -  stimulated enzyme from bovine tissues 
(liver, adrenals and heart) appears to have a molecular weight of 
between 102 -  kDa and 107 -  kDa (Beavo, et al., 1982; Martins, et al., 
1982; Yamamoto, et al., 1983a), whilst those of the rat liver derived 
activities have smaller molecular weights (66 -  kDa to 67 -  kDa) (Pyne, 
et al., 1986a). Whether this is related to the observation that the rat 
hepatocyte -  derived activity is different to the liver -  derived activity is
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uncertain but is worthy of attention. Whilst the bovine heart and 
human platelet homologues of the 'dense-vesicle ' phosphodiesterase 
appear to have much larger molecular weights (110-k D a ) than the rat 
liver activity (Harrison, et al., 1988; Grant, et al., 1988), the study on 
the tissue distribution of the 'dense-vesicle ' and 'peripheral' 
phosphodiesterases has shown that the molecular weight of these two 
activities (63 -kD a and 52-k D a  respectively) is invariant between the 
rat tissues examined (heart, liver, fat and kidney) suggesting that the 
difference in molecular weight is due to a species difference rather than 
a tissue difference. This issue will need to be clarified however by 
cloning of the 'dense-vesicle’ phosphodiesterase from each of these rat 
tissues.
Previous work from this laboratory has suggested the presence of 
an insulin -  stimulated phosphodiesterase that is not the 'dense-vesic le’ 
or 'peripheral' plasma membrane phosphodiesterases. The validity of
this suggestion needs to be determined. One potential method to 
identify the putative third insulin -  stimulated phosphodiesterase and 
confirm it’s existence in hepatocytes may be to assess the ability of a 
range of different phosphodiesterase inhibitors to block the insulin-  
stimulated decrease in intracellular cyclic AMP levels. This work has 
characterised the sensitivities of the soluble phosphodiesterases in 
hepatocytes to a large number of inhibitors and, coupled with the
known sensitivities of the m em brane-bound activities (Pyne, et al., 
1987a), this proposal should be a viable prospect. At the presesnt time 
it is known that this activity is sensitive to the non -  selective
phosphodiesterase inhibitor IBMX (Heyworth, et al., 1983d). If the 
ability of selective phosphodiesterase inhibitors to block the insulin 
effect on phosphodiesterase could be determined then a correlation may 
exist between this and the inhibitor sensitivity of the individual
phosphodiesterase species in hepatocytes. This would thus allow an 
identification of this insulin -  stimulated activity. This approach has 
been used by other workers in adipocytes (Kather and Scheurer, 1987), 
although these workers only assessed the ability of a limited number of
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inhibitors to abolish insulin -  stimulated phosphodiesterase activity. 
They did suggest that the insulin effect was sensitive to inhibition by 
theophylline but not by R o - 20-1724, consistent with the activted 
species being the proposed cyclic GMP -  inhibited phosphodiesterase 
(Manganiello and Vaughan, 1973; Zinman and Hollenberg, 1974;
Weber and Appleman, 1982; Degerman, et al., 1987). However, it is 
not known if, in addition to the known insulin —stimulated cyclic 
GMP -  inhibited phosphodiesterase, there are other insulin stimulated 
activities in adipocytes as there are in hepatocytes. This study has 
suggested that fat tissue contains a phosphodiesterase activity that is
immmunologically related to the rat liver 'peripheral' cyclic AMP 
phosphodiesterase. It is not known if this activity is also located at
the plasma membrane or if it is stimulated by insulin as the liver 
activity is (Tria, et al., 1976; Marchmont and Housaly, 1980;
Heyworth, et al., 1983d; Pyne, et al., 1987a).
The observation that a protein that is immunologically related to 
the 'peripheral' plasma membrane phosphodiesterase is found in tissues 
other than liver such as kidney, fat and heart suggests that this activity 
is indeed a cyclic A M P - specific phosphodiesterase. Whilst for the 
cyclic GMP -  inhibited 'dense-vesicle ' phosphodiesterase there is a 
selective inhibitor available, namely ICI 118233, no such selective
inhibitor of the 'peripheral’cyclic GMP -  insensitive activities exists.
Inhibitors of this activity such as ICI 63197 and R o - 20-1724 (Pyne, 
et al., 1986b; Pyne, et al., 1987a) also inhibit the soluble PDE M Q -IV  
and PDE M Q -V  activities. Whether these activities are distinct from 
or derived from the peripheral plasma membrane activity has yet to be 
determined. Therefore it was not possible to assess if this activity was 
also present in these tissues.
The development of suitable affinity matrices should aid in the 
purification of specific phosphodiesterases and will involve a thorough 
characterisation of the inhibitor sensitivities of individual 
phosphodiesterase types, perhaps even the identification of isozyme 
specific inhibitors is a possibility. Affinity matrices based on inhibitors
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have been used by a number of workers to purify the cyclic G M P - 
inhibited phosphodiesterase from adipose tissue (Degerman, et al., 1987) 
and human platelets (Umekawa, et al., 1984). In this respect, the 
observation that interactions of the rat liver 'dense-vesicle1 
phosphodiesterase with selective and non -  selective inhibitors, such as 
IBMX and ICI 118233, are reversible may imply that if these could be 
coupled successfully to a matrix such as Sepharose they may be used as 
an affinity step to replace the A ffi-g e l Blue with which problems were 
encountered. Other workers have shown that IBMX can be coupled to 
Sepharose, so this may be a useful approach. The lack of a primary 
amino group in ICI 118233 (see Figure 1.6(e)) precludes the use of 
Cyanogen Bromide -  activated Sepharose to couple this activity to
Sepharose, so an alternative protocol may have to be devised. An 
alternative strategy to the use of these two inhibitors would be to use
cilostamide or it’s derivatives to prepare an affinity column. This 
approach has been used successfully to prepare a 6 4 -k D a  protein that 
resembles the rat liver 'dense-vesicle ' phosphodiesterase in most of it’s 
properties (Pyne, et al., 1987a; Degerman, et al., 1987). Whilst the
’dense-vesicle’ enzyme has not been shown to be inhibited by
cilostamide, it seems certain that it is highly related to the adipose 
tissue cyclic GMP inhibited phosphodiesterase. Indeed, this study has 
shown that adipose tissue expresses an activity that it sensitive to ICI 
118233 and is immunologically related to the rat liver activity, and on 
this basis will probably found to be sensitive to cilostamide. If this is 
the case, this step would be a promising affinity step and coupled with 
the high resolution an io n - exchange system would provide an excellent 
means of purification.
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APPENDIX.
DMSO CORRECTION CURVES
Since all inhibitor studies were carried out using inhibitors diluted in the 
solvent dimethylsulphoxide (DMSO) it was decided to assess the effect of 
DMSO alone on the activity of the individual PDE MQ peaks resolved from 
both rat liver and rat hepatocytes. All inhibitors tested were diluted from a stock 
solution of 25mM in DMSO and were added at a concentration of 4x to the 
assay mixture. The standard curves can thus be used to correct for the effects 
of solvents provided that an identical dilution protocol is followed. The 
standard curves are presented as the mean % effect on the basal cyclic AMP 
phosphodiesterase activity observed over a number of different experiments. 
The SEM values are also shown on the individual standard curves.
The standard curves for the PDE MQ peaks from rat liver are shown in 
Figures I-V and those from rat hepatocyte in Figures VI-X.
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